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Foreword
This book is the English version of the text published by the Economic Commission 
for Latin America and the Caribbean in April 2008 and entitled G eneración  
y protección  d el conocim iento: p rop iedad  intelectual, innovación y desarrollo  
económ ico . 1
Since then, the year that has passed has been fraught with uncertainty but has 
also brought signs of hope.
Indeed, the past year was marked by the outbreak of the deepest and most per­
vasive financial and economic crisis since the Great Depression of 1929, a crisis 
generated in the United States but whose negative repercussions have spread at 
a phenomenal rate throughout the planet. The impact of this crisis on the peo­
ples of Latin America and the Caribbean will undermine the region’s prospects for 
economic growth, employment, and poverty alleviation.
This was the year in which United States citizens elected Barack Obama as their 
President, a clear sign of new hope. This hope was tangible at the Fifth Summit of 
the Americas, held in 2009 in Port of Spain, which marked a turning point in the 
relations between the countries that make up this hemisphere. The open posture of 
the United States and that country’s readiness to listen rather than to impose any 
particular position and its willingness to engage in dialogue on an equal footing 
were positive signs. Moreover, it was generally admitted that there is not just one 
model for advancing successfully toward development.
Both of these developments are of great significance, bearing in mind that nego­
tiations are now taking place with a view to the signing of free trade agreements 
between the United States and various Latin American countries. Intellectual prop­
erty is known to be one of the most crucial and controversial issues in the negotiation 
of these treaties.
Knowledge is a major engine of economic growth in today’s world and will play 
an increasingly vital role in ensuring the prosperity and well-being of nations. How 
can developing nations obtain access to, and ownership of, accumulated knowledge? 
What are the first steps to be taken on the long path toward the construction of the 
very bases of knowledge generation in the pursuit of higher levels of development?
' l c /M EX /G .12.
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These are some of the questions that ECLAC has been considering in its study 
of intellectual property and knowledge generation for growth. The numerous work­
shops and seminars held by the Commission attest to its concern for these topics, 
which are also dealt with in the background document for the 19th Ibero-American 
Summit of Heads of State and Government, to be held in Portugal during 2009.
ECLAC wishes to take this opportunity to express publicly its deep appreciation 
to the Canadian International Development Agency for the support and collabora­
tion that it has provided over the years to ECLAC in this area, which is so crucial 
for the development of Latin America.
Alicia Barcena 
Executive Secretary of ECLAC
Preface
Technological change is increasingly the path by which countries leave their 
peripheral condition. A profound understanding of the dynamics and contemporary 
mechanisms for the circulation, dissemination, and access to knowledge is therefore 
imperative.
The capacity to generate research, create knowledge, adapt to it, and transform 
it into new technologies is fundamental to the wealth of the developed nations, 
and largely explains their economic growth. In this regard, analysis and debate 
about how to generate knowledge and technological innovation is a subject of major 
importance for the developing countries.
The way in which economies create and use knowledge and innovation is increas­
ingly relevant. It requires efficient national innovation systems in constant renewal 
to strengthen the innovative capacities o f less developed countries and thus create 
opportunities for convergence with the developed countries. These systems must be 
sufficiently versatile in their use of all the available tools, among them, the incen­
tives and flexibilities of intellectual property laws. In national innovation systems, 
the weight of intellectual property is always on the increase, especially in open 
economies with a strong external sector. It is therefore necessary to take advantage 
of the opportunities that these rules offer and use their versatility to promote national 
innovation policies and adapt them to the type of innovation to be promoted.
Since the Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) entered into force in 1995 the architecture o f intellectual property rights 
has become more and more complex. The protection mechanism for intellectual 
property, in its diverse forms, shows two important elements: on the one hand, it 
is a mechanism of appropriation of income that generates monopolistic or quasi- 
monopolistic gains for those who hold it, and on the other hand, there is an economic 
incentive to research since it offers inventors repayments for the investments made 
until their innovation becomes a market product. Nevertheless, there is concern that 
the intellectual property of innovations work more as incentives for the protection 
of rents than incentives for innovation, which is contrary to the desired effect.
Three intersecting subjects with diverse emphases are studied in this book. First, 
whether strengthening protection of intellectual property stimulates or hinders tech­
nological learning and innovation in developing countries. The second subject treats
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the way in which knowledge is generated and how it is transformed into useful tech­
nology for markets, that is to say, how national innovation systems work. The final 
topic is the role of public policy as an instrument for innovation and for regulation 
of intellectual property.
The political economy of the systems of intellectual property involves the inter­
ests of powerful groups related to the chemical and pharmaceutical industries, 
biotechnology, software, and entertainment. These groups have endorsed free trade 
agreements promoted by the United States, which have been signed by several Latin 
American countries. Both factors have strengthened the rules of intellectual property 
in the agreements, which have been monitored ever more jealously by the United 
States.
If  Latin American countries seek to develop a dynamic competitiveness based on 
knowledge and innovation in a context of rigorous intellectual property rights like 
the present one, they will have to take a leap forward in their science and technology 
policies to generate processes and products of greater value added, move up in the 
technological scale, and improve workers’ income. In short, active public policies in 
science and technology are required to take advantage of the increasing worldwide 
market and to open paths for long-term development.
ECLAC, Mexico City, Mexico Jorge Mario Martinez-Piva
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“For to him who has will more b e  given, and he will have abundance; but from  him 
who has not, even what he has will b e  taken away. ” (Matthew 13, 12). This contro­
versial Biblical text illustrates what Economics Nobel Prize Winner Gunnar Myrdal, 
called the principle of circular and cumulative causation. According to this prin­
ciple, growth and economic development take place through interrelations among 
variables which tend to create an accumulative process, which, if this involves vari­
ables that promote development, strengthen it, and give it impetus, but if not they 
promote its stagnation. The concept is useful in understanding the importance of 
knowledge and technological capabilities in economic development.
Knowledge incorporated as a proportion of the total value of a product is increas­
ing by the day in all sectors. The capacity to generate knowledge, appropriate it, and 
transform it into new technologies lies at the root of the wealth of the most developed 
nations and largely explains their economic growth.
Development researchers agree that technical change, the introduction of new 
products and processes, the capacity to respond and to open up new market niches 
are determining factors in the patterns of growth and development of economies. 
In a context of growing trade openness and therefore of increasing exposure to 
international competition, response capacity is a determining factor for economic 
success.
The relationship between the technological capability and the capacity to 
compete successfully in global markets further explains countries’ development 
potential. The richest nations transform their production systems into more intri­
cate, interlinked, and technology-intensive frameworks. These are the nations that 
invest more in generation of knowledge and technology, which in turn transforms 
into greater capacities for technological progress and international competition, that 
is to say, they live a virtuous circular and cumulative causation process.
This process of accumulation of technical capabilities tends to advance in par­
allel with a process of change of international rules on the appropriation of the 
income generated by innovations and the protection of their property over third 
parties. Intellectual property laws strengthen the means whereby the most devel­
oped nations generate large part of their wealth, for they constitute a system that 




I f  the evolution o f production systems toward more complex structures deter­
mines the processes o f convergence between regions and countries, then Mario 
Cimoli and Annalisa Primi appear to be right by affirming in this book that tech­
nical change seems increasingly to be the road for transition from a condition on 
the periphery to a position o f leadership in the world’s economies. Hence a deep 
understanding o f the dynamics and contemporary mechanisms o f the circulation 
and dissemination o f and access to knowledge is an urgent task.
The aim o f this book is, on the one hand, to go more deeply into the analysis o f the 
interrelations between generation, access to and dissemination o f knowledge, and 
technological innovation as the foundations o f economic development and, on the 
other hand, to analyze their international regulations. That is, it delves further into 
the study o f the linkage between innovation processes, mechanisms for protection 
o f intellectual property rights, and economic development.
Three themes run across the book with different emphases. The first refers to the 
increase in protection o f intellectual property and whether this is in detriment to or 
encourages technological learning and innovation in the developing countries. The 
second is the way in which knowledge is generated and how it is transformed into 
useful technology for the market, that is to say, the functioning o f national innova­
tion systems. The third is the role o f public policy as an instrument o f innovation 
and as an instrument o f regulation o f intellectual property.
Since the rules for protection o f intellectual property embrace a wide variety of 
subjects and their recent evolution suggests that the protected subject matters will 
increase over time, it was not possible to cover all the topics protected under the 
Agreement on Trade-Related Aspects o f Intellectual Property (TRIPS). Instead, we 
chose relevant topics that serve the object o f the book, divided into four thematic 
areas.
Part I is an analytical approach to the topic o f intellectual property rights from 
an economic rather than juridical point o f view, as is usually the case. Two articles 
analyze intellectual property rights as mechanisms for appropriation o f  income and 
incentives for research, and the recent evolution o f the patents system until such 
patents become assets in themselves.
Intellectual property as a form o f protection o f  innovation shows two important 
aspects: it is a mechanism o f income appropriation that generates monopolistic or 
quasi-monopolistic earnings for the holders, but it is also an economic incentive to 
research by compensating the innovator for the investments made until the inno­
vation becomes a market product. Economic analysis shows that this mechanism, 
although conceived to encourage innovation, can stand as a barrier to the entry of 
other innovators and as an instrument to preserve monopolies, resulting more as an 
obstacle than as an incentive to innovation.
The recent evolution and transformation undergone by the system o f protection of 
intellectual property are illustrated by an analysis o f patents. Conceived as a mech­
anism of ex post appropriation o f income, patents have become assets in themselves 
whose value tends to lose its linkage to a certain extent from the innovations that 
sustain them, becoming “ liquid” assets with their own value in terms o f expectations 
on their value and their “ liquidity” in the corporate transactions market.
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In the new markets, patents take on a value irrespective o f their direct industrial 
application. Thus, they increasingly act as decisive assets in the settling o f legal 
disputes and play an important role in mergers and acquisitions between corpora­
tions, influencing market structure, and the organizational hierarchy. Patents respond 
more to defensive and competitive conducts. Thus, their rationale is being displaced 
toward markets that operate under different logics and incentives. In the knowl­
edge markets, the value o f future bets and the search for exh ran te  income become 
determining factors for seeking protection by means o f patents.
Another contribution addresses the linkage between innovation processes -  How 
is knowledge generated and what public policies promote it? -  and the mechanism  
for protection o f intellectual property. In this regard, it analyzes two economic poli­
cies closely linked to local economic development and to the processes o f protection 
o f intellectual property: local endogenous development and the attraction o f foreign 
direct investment.
The second part o f the book addresses the topic o f intellectual property within 
the purview of recent bilateral trade agreements and multilateral treaties on the sub­
ject and analyzes how the trade agreements between the United States and Latin 
American countries have strengthened protection o f intellectual property.
The architecture o f intellectual property rights has become complex, especially 
following the entry into force o f TRIPS in 1995. Intellectual property rights cur­
rently constitute an essential chapter in bilateral and regional trade negotiations. 
The recent agreements concluded by the European Union and the United States 
include specific chapters on the subject, which in many cases broaden the rights and 
obligations o f TRIPS, for which reason they are considered TRIPS Plus.
Moreover, harmonization exercises with regard to intellectual property are being 
explored in different fora, such as the World Intellectual Property Organization and 
specialized fora on rights and instruments o f access to genetic resources, their con­
servation and the equitable share o f benefits, such as the Convention on Biological 
Diversity and the FAO International Treaty on Plant Genetic Resources for Food 
and Agriculture.
For over two decades, the United States has shown constant concern over protec­
tion o f intellectual property, which has recently been accentuated. At the domestic 
level, this country has increased its protection standards and has continued to mon­
itor observance o f intellectual property rights internationally and has gone as far as 
considering, through the Trade Act, the possibility o f imposing trade sanctions on 
countries that systematically breach the U S intellectual property rights holders.
It should be recalled that the United States was the promoter o f the first multi­
lateral industrial property protection treaty (Paris Convention o f 1883) and played a 
preponderant role in including the topic in the Uruguay Round, which culminated 
in the creation o f TRIPS. NAFTA (North American Free Trade Agreement) was 
the first post-TRIPS agreement with stricter provisions on the issue, characteristics 
which were followed in other bilateral agreements.
The Free Trade Agreement between Chile and the United States includes a chap­
ter on intellectual property, following the guidelines set down by prior free trade 
agreements signed by the United States, and has served as a model for agreements
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this country has negotiated with other countries o f the region (DR-CAFTA and 
those signed with Colombia, Panama, and Peru). Likewise, the pattern o f the chap­
ter on intellectual property is reproduced and expanded in subsequent agreements, 
as was the case o f the agreements between the United States and Australia, Bahrain, 
Morocco, and Oman. For this reason a study was made o f the central aspects o f the 
most recent bilateral agreements signed by the United States, taking the Agreement 
with Chile as a model.
The second part includes analyses o f feasible spaces for the Latin American 
countries to develop their public policies on science and technology. A common 
matter in this part is that the impact o f the intellectual property rights agreed 
on depends on the public policies implemented b efore  a n d  a f te r  their entry into 
effect. The authors develop the view that a new generation o f public policies and 
post-neoliberal or post-Washington-consensus regulations could obtain important 
benefits and minimize the negative impacts o f trade agreements. The trade agree­
ments with the United States are not incompatible with an increase in the public 
sector’s presence in social policies, the expansion o f public policies in innovation 
and technological development, an increase in economic regulations in consumer 
rights, competition, workers’ rights, and environmental protection. Furthermore, 
the agreements do not stand in the way o f integration o f the Latin American 
subcontinent in a perspective o f open  reg ion alism .
The third part includes articles on particularly sensitive topics for developing 
countries: access to medicines and protection o f biological diversity, living organ­
isms, and traditional knowledge. The debate on intellectual property is based on 
broad considerations regarding the role o f these rights in the dissemination o f inno­
vations and knowledge as agents o f development. Many discussions revolve around 
the consequences that stringent intellectual property rights have in the use o f tech­
nology and access to basic instruments o f education (data bases and software, 
among others) and health care. Until not very long ago many countries exempted 
pharmaceutical and food products from the possibility o f being patented. Recent 
trade agreements include them in the chapter on intellectual property. The effect o f 
these agreements on access to medicines is analyzed in this third part.
In recent years the discussion on intellectual property has linked the topic to 
the environmental agendas. M ost o f the authors and organizations that discuss it 
consider the effects that intellectual property rights could have on biodiversity and 
indigenous and rural communities. The arguments range from the danger o f fos­
tering bio-piracy on resources and traditional knowledge, to restrictions on farmer 
keeping and exchanging seeds o f protected varieties, including the implications of 
genetically altered organisms.
A s a result o f the establishment o f an international legal framework by the 
Convention on Biological Diversity and the FAO International Treaty on Plant 
Genetic Resources for Food and Agriculture, insistence has been placed on the 
existence o f a conflict between certain trends oriented to the strengthening o f intel­
lectual property rights and the objectives o f conserving, utilizing biodiversity in 
a sustainable manner and equitably sharing the benefits derived from the use o f  
genetic resources. One chapter in this book studies whether the implementation o f
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TRIPS leaves room for appropriate synergies between trade obligations with regard 
to intellectual property rights and those o f international environmental treaties.
Also examined are the situation and prospects o f intellectual protection o f living 
organisms. This is a complex topic on which there are markedly different positions 
between developed and developing countries, companies linked to genetic engineer­
ing, universities and academic bodies, and development agencies. The interests o f  
the holders o f the technologies to commercially develop altered organisms tend to 
differ from the interests o f those who possess the biodiversity. This conflict is ana­
lyzed in the light o f  the evolution o f international law and its consequences for the 
development and protection o f living organisms.
The fourth and final part o f the book is devoted to the policy o f innovation and 
protection o f intellectual property in Mexico. The information may be useful not 
only for this country but also for the rest o f the countries o f Latin America. M exico 
is the only Latin American country that is a member o f the OECD and has a rich 
history o f  industrial policy, science and technology policy, and trade openness. This 
chapter analyzes the policy o f protection o f intellectual policy and the actions o f  the 
Mexican State to strengthen innovation capacities and com panies’ adaptation to the 
process o f international integration initiated over a decade ago.
M exico’s science and technology policies began to change in the early 1990s, 
when the country entered international markets. The change was marked by the 
transition from the supply-side approach based on support for science toward a 
market approach oriented to fostering private-sector innovation. A s o f 2000 this 
change intensified and in recent years an innovation policy has clearly emerged 
which includes a series o f instruments, following international experiences (Brazil, 
Chile, and the Organisation for Economic Cooperation and Development, OECD).
The results, however, have not been those expected so far, as the intensity o f 
research and development (currently 0.4% o f GDP) has not increased since the 
1990s, low private-sector participation in overall spending on research persists, the 
country’s competitive position dropped from 33 in 2000 to 56 in 2004 (accord­
ing to the International Institute for Management Development), and in general the 
innovative behavior o f the stakeholders is poor. Many academ ics, industrialists, and 
members o f  civil society perceive that no substantial changes have taken place in 
the field, nor in national technological capabilities.
Theoretical discussion o f the approaches to and premises o f M exico’s science, 
technology, and innovation policies is enriched by an empirical performance analy­
sis o f  some o f the instruments employed. The source o f information corresponds to 
national statistics on such instruments and the national innovation survey.
Another contribution studies the evolution o f M exico’s industrial and techno­
logical development policies during the import substitution period, the transition 
that began in the 1980s and the period o f trade liberalization. In regard to the 
latter period, it sets forth the main characteristics o f the general scheme to foster 
industrial and technological development and analyzes the functioning o f the insti­
tutions, programs, and mechanisms implemented as o f the amendments to the Law  
on Science and Technology.
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This part ends with a review o f the functioning o f the Mexican Industrial Property 
Institute (IMPI by its Spanish acronym) and its work in the registration, protection, 
and promotion o f intellectual property. IMPI has created novel programs such as 
patenting centers in various cities o f the country, and the creation o f a portal on 
patents in the public domain that provides access to technical information contained 
in patent documents (requests for patents published and patents granted), including 
information on patenting costs and plans for creating funds to support sm all and 
medium-sized enterprises under these headings.
By way o f conclusion, the main findings and suggestions o f  the studies are col­
lected. The topics currently under discussion are identified, as are the countries’ 
technological and innovation capacities and they are linked to sustainable economic 
growth and well-being. The linkage between the forms o f protection o f intellec­
tual property and promotion o f innovation is also pointed out, identifying possible 
lessons for the developing countries.
ECLA C coordinated the different articles collected in this book within the frame­
work o f a program o f creation o f trade capacities which had the financial support 
o f the Canadian International Development Agency. It is hoped that this book will 
be a useful contribution to informed debate on increasingly important issues for 
economic development and that it will serve the designers o f economic, trade, and 
innovation policy in shaping a joint development agenda.
Part I
Intellectual Property Today: 




Intellectual Property and Development: 
An Interpretation of the (NEW) 
Markets for Knowledge
Mario Cimoli and Annalisa Primi
1.1 Introduction
Patenting activity has intensified in the last few decades. Year after year, patent 
offices receive a growing number o f applications and grant more patents. This 
growth is registered on a global scale, and despite the fact that the leading economies 
in technological capacities are those that show the greatest growth, the activity has 
also intensified in emerging economies and developing countries.1 However, cer­
tain stability persists in terms o f dominant stakeholders. Today, the United States, 
Germany, and Japan account for 80% o f the patents issued by the United States 
Patent and Trademark Office (USPTO ),2 which, together with the offices o f the 
European Union and Japan, continues to be the world’s most important patent office.
However, considering the total number o f patents granted in the United States 
to non-residents we note that in the 1960s the three main countries were Germany, 
England, and France, which accounted for 58.8% o f total patents issued to non­
residents, whereas in 2003 the three main stakeholders became Japan, Germany, 
and the Chinese province o f Taiwan, which together possess 67.3% o f that total. 
Now, if we consider the cumulative share o f the five countries with the largest num­
ber o f patents issued, the degree o f concentration goes from 73.8 to 75.5%, and 
England, Switzerland, and Canada yield their places to Japan, the Chinese province 
o f Taiwan, and the Republic o f Korea. This “overtaking” is not alien to the struc­
tural changes experienced by these countries, which in the last few decades have 
radically transformed their production structures by intensifying their specialization
M. Cimoli (¡si)
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in knowledge-intensive sectors (Amsden, 1989; Wade, 1990; Jom o, 1997; Cimoli 
et al., 2005). The combination o f -  active and selective -  industrial, technological, 
and trade policies supporting the industrial sector and the gradual opening up to 
foreign trade as the productive sectors achieved international competitiveness have 
generated technological, and productive capacities, explaining the intensification o f 
patenting activity. This responds to a logic in which the production system, once 
transformed into a generator and disseminator o f knowledge, needs patents to appro­
priate the income stemming from innovative effort. Moreover, it also responds to 
the most recent pressures in world trade forums in favor o f  increasing homogeneous 
standards o f intellectual property protection.
What is in fact happening is a reconfiguration o f the stakeholders aspiring to 
participate in the markets for technology and knowledge that exert pressure on the 
dominant positions o f traditional players. The emergence o f new players -  notably 
the countries o f Southeast A sia, China, India, Brazil, and South Africa -  which aim 
or could aim to develop on the basis o f technology and engineering-intensive sec­
tors, and the growing integration o f economies, nourish the debate on international 
protection of intellectual property from different perspectives. Understanding the 
changes in patenting dynamics is a determining factor in proposing strategies for 
convergence and development in the contemporary context.
The current debate on intellectual property protection takes place in a scenario 
o f open economies in which changes in scientific and technological patterns pose 
challenges to those systems, both in terms o f their capacity to guarantee appro­
priability and in terms o f their function to encourage or discourage innovation. 
With the new technological paradigms, new sectors with diverse returns and logics 
emerge; in these paradigms many advances derive from multiple complementarities 
and innovation is more and more incremental. In this context, the intensification o f  
patenting, the new institutional framework for intellectual property management, the 
stance o f the United States jurisprudence in favor o f protection o f intellectual prop­
erty, the marginalization o f multilateralism, the proliferation o f  trade agreements, 
and the conditioned and not always proactive attitude o f the developing countries 
bring about a situation in which the role o f systems for the protection o f intellectual 
property has been completely reconfigured.
The logic and rationale for patenting have changed. In addition to the traditional 
concept o f patents as mechanisms for appropriability o f income stemming from  
investment in research and development, and as incentives for efficiency in the tech­
nology markets, there are new dynamics from which the new markets for knowledge 
derive. Among them we can identify, first o f all, the market for science, in which 
universities and research institutes patent innovations deriving from basic and exper­
imental research. Second, we can recognize what we call “ the liquid and derivative 
markets for knowledge,”  in which the traditional concept o f patents as mechanisms 
for appropriability is overcome. Patents are reconfigured as strategic assets o f com­
panies’ competitive strategies. Patents are “monetized” and their benefits no longer 
depend on the temporary monopoly o f the innovation alone, but can derive, for 
example, from the strengthening o f negotiating power among corporations, or from
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the (potential) future appropriability o f  oligopolistic rents generated by other com ­
panies, when the patent or group o f patents become determining factors for the 
production o f some good or tangible service in the future. The logic o f patenting 
seem s thus to become unlinked from the immediate incorporation o f knowledge (of 
the “ intangible” ) into “ tangible”  production, thus generating new markets and new 
challenges. How do the developing countries and those o f Latin America in partic­
ular participate in those markets? What effect can that reconfiguration o f markets 
for knowledge have on the creation o f endogenous technological capacities and on 
convergence over the long term?
In order to answer these questions, this chapter presents an interpretation o f the 
knowledge markets which goes beyond the traditional view o f  patents. First o f  all, 
it makes a brief review o f the role o f  intellectual property rights in general, and o f  
patents in particular, as mechanisms o f appropriability; second, it outlines the main 
characteristics o f the changes in the management and in the institutional framework 
o f intellectual property systems throughout the world. Third, it analyzes the ratio­
nale and functioning o f the markets for technology and the markets for knowledge. 
Then, the chapter examines the relationship between participation in those mar­
kets, the production structure specialization, and the dynamics o f  patenting from  
the perspective o f  the developing countries in general and the Latin American coun­
tries in particular. The conclusions highlight that understanding the new dynamics 
that nourish the patenting game and the factors that determine the (potential) par­
ticipation in or exclusion from the markets for knowledge is a  task that cannot be 
postponed when it comes to proposing long-term development strategies based on 
innovation that goes beyond rhetoric and good intentions.
1.2 Intellectual Property, Appropriability, and Enforcement
Intellectual property regimes include the set o f rules, regulations, procedures, and 
institutions regulating appropriability, transfer, access, and right to use knowledge 
and “ intangibles.”3 Intellectual property rights confer an exclusive and -  in cer­
tain cases, such as patents and copyright -  temporary right on the use and transfer 
o f  technologies and knowledge.4 Thus, patents create temporary monopolies on 
knowledge which respond, in principle, to the tension between the need to guar­
antee appropriability o f innovation efforts as “ intangible”  which, in their absence, 
could be easily appropriated by competitors, and the need to favor the disclosure 
o f knowledge and innovations owing to the multiplier effect o f  innovation in the 
whole economic system (Machlup, 1958; Kitch, 1977; Besen and Raskind, 1991; 
Besen, 1998, among others). However, there is a certain gap between the the­
ory and the functioning o f the system. The relationship between innovation and 
patents is neither determinist nor linear, and the discussion on the appropriability 
o f knowledge and its effects on the rate and direction o f technical change continues 
to be open in the economic literature (Machlup and Penrose, 1950; Arrow, 1962; 
Scherer, 1977; Dosi, 1982; David, 1993; Heller and Eisenberg, 1998; Mazzoleni 
and Nelson, 1998).5
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First o f all, patents are not the only mechanism for the appropriability o f income 
stemming from innovation. The pioneering empirical studies on the propensity to 
patent o f  innovations are those o f  Scherer (1965 and 1983) and Mansfield (1986). 
In these, and in subsequent studies -  despite the different definitions o f propensity 
to patent, which in general measures the percentage o f innovations in which patents 
are applied for -  we can appreciate different rates o f propensity to patent accord­
ing to sectors, generally the textile sector is the one with the lowest propensity and 
the pharmaceutical is the one with the highest rate. In general, these asymmetries 
depend on corporate appropriability strategies, which vary in terms o f the value 
assigned to the dissemination o f information to competitors and users (Horstman 
et al., 1985; Levin et al., 1987; Harter, 1993; Arundel et al., 1995; Harabi, 1995; 
Arundel and Kabla, 1998). Besides patents, companies can also protect their inno­
vations by means o f  industrial secret, temporary advantages stemming from placing 
the innovation on the market with substantial anticipation over competitors, and 
complementary manufacturing capacities, among others.
Levin et al. (1987) and Cohen et al. (2000) analyze the set o f  mechanisms that 
firms use to guarantee the appropriability o f returns deriving from innovations. In 
addition to the notable differences between sectors, to the characteristics o f  the inno­
vation process, and to the market structure, corporations use different combinations 
o f mechanisms for appropriability. According to Cohen et al. (2000), whose study 
is based on a survey applied to around 1,500 research and development labora­
tories o f manufacturing firms in the United States, patents are extremely relevant 
only in certain sectors, particularly pharmaceuticals.6 The authors find that on an 
average, patents are effective for 34% o f product innovations, whereas industrial 
secret is effective for 51%, temporary advantages for 53%, sales capacities and 
complementary services for 43% , and complementary manufacturing capacities for 
46% of product innovations.7 Furthermore, patents play a relatively more important 
role in the appropriability strategies o f  larger corporations. Considering the case of 
appropriability mechanisms o f large firms, the importance o f patents increases con­
siderably, for these turn out to be effective in 41.5%  o f product innovations, showing 
an effectiveness similar to that o f complementary manufacturing capacities, both in 
sales and services and in manufacturing companies. However, industrial secret and 
temporary advantages continue to be the most used appropriability mechanisms, for 
they are considered effective in more than 51% o f cases.
These dynamics are not exclusive to firms in the United States. In an analy­
sis based on data from innovation surveys in Germany, Belgium , Denmark, the 
Netherlands, Ireland, Luxembourg, and Norway, Arundel (2001) shows that most 
companies consider industrial secret a more effective appropriability mechanism  
than patents. Sim ilar studies have recently begun to be made in Latin American 
countries. López and Orlicki (2006) show that in Brazil -  the only country o f the 
region for which information is available based on innovation surveys on legal and 
strategic appropriability mechanisms -  industrial trademarks are the mechanism  
preferred by companies, since 21.8% of firms use them, whereas only 8.3% use 
industrial secret, 7.4% patents, 1.9% temporary advantages, and 1.4% the complex­
ity o f  the industrial design. The preference for trademarks, common in the various
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countries o f the region, reflects the type o f generally adapting innovation and the 
productive specialization o f these countries, rather than a strategic management of 
different appropriability mechanisms, as happens in the most developed countries.
Second, intellectual property rights confer the right to appropriability, but they 
do not guarantee the effective appropriability. The existence and legal recognition 
of these rights do not automatically translate into effective capacity to guarantee 
control over the intangibles and to the generation o f de facto monopolies over inno­
vations. Patents confer the right to defend the monopoly or the privilege conferred 
through legal action and, as Shapiro (2003) and Lemely and Shapiro (2005) noted 
they can be defined as “probabilistic” rights. Effective appropriability is a func­
tion o f the capacity and will o f the holder to exercise its own right (enforcement 
capacities). The costs o f lawsuits, the competence o f lawyers’ teams, the negotiat­
ing power, and the capacity to monitor the market and the competitors are factors 
that have a bearing on the possibility that legal ownership translates into effective 
appropriability. It is necessary for the patent holder to have the capacity (and the 
will) to exercise the right conferred by the title so that the patent can fulfill its theo­
retical dual function o f appropriability mechanism and circulation o f knowledge. In 
a study on patenting behavior o f small and medium-sized enterprises in the United 
States, Koen (1991) points out that the majority o f these enterprises know when 
their intellectual property rights are being breached, but that 55% of them do not 
institute any kind o f legal proceedings in their defense due to the high costs and the 
protracted length o f legal disputes.
At the same time, the possibility o f incurring in litigations might affect com­
panies’ innovative behavior by influencing decisions on investment in research 
and development in certain technological trajectories. In markets in which domi­
nant stakeholders exist by virtue o f oligopolistic or monopolistic positions derived 
from temporary advantages from entry or accumulated production and technological 
capacities, patents may discourage the entry o f new stakeholders and restrict com­
petition. A  number o f studies explore this aspect. Lerner (1995) shows that small 
and medium-sized enterprises tend to reduce investment in research and develop­
ment in technological areas and sectors where the probability o f being the object o f 
a lawsuit for patent infringement by big corporations is high. Lanjouw and Lerner 
(2001) observe that large corporations use preliminary injunction to discourage the 
research and development activities o f smaller com panies.8 The preliminary injunc­
tion can result in the legal decision to prevent both parties from using the patents 
object o f the dispute and suspend production o f the goods and services involved. 
These are costs that smaller, highly specialized firms find it difficult to bear. For the 
large firms, on the other hand, such costs are relatively minor, so they can invoke 
the judicial injunction in a strategic manner.
In sum, agents’ technological, production and legal capacities, firms’ size, and 
sectoral specialization have a bearing on the use o f patents. Recognizing that patents 
are only one o f the appropriability mechanisms used by enterprises and considering 
the increase in patenting activities leads one to question what are the new dynamics, 
rationales, and interests that make companies applying for and obtaining an increas­
ing number o f patents. In effect, the changes in the management and institutional
8 M. Cimoli and A. Primi
framework o f intellectual property, together with new technological paradigms have 
contributed, in a determining manner in the last few decades, to altering the scope 
and function o f  patents in com panies’ competitive strategies.
1.3 The Reconfiguration of Intellectual Property Systems
The transformation o f intellectual property systems has gone hand in hand with 
the different phases o f  development o f modern economies.9 From regulations of 
national scope, during the beginning o f industrial development and the “ inward” 
stage o f development o f the industrial takeoff o f the countries o f first industri­
alization, intellectual property systems have evolved toward regimes o f suprana­
tional scope. This transformation has taken place as foreign trade and interaction 
among countries have become more necessary, closer, and more frequent, and the 
entrepreneurial and production structure has gradually become more articulated and 
diversified, increasing the focus on know-how, technical information, knowledge, 
and the consequent value o f  its appropriability.10
However, beyond the transformation deriving by the change in social and produc­
tion systems and pushed by the new technological paradigms, as o f the 1980s we 
have seen radical changes in the management o f intellectual property. Such changes 
have occurred in the context o f growing trade integration and as a result o f  the 
transition to a  system o f open economies and have aimed, in general terms, at the 
strengthening and alignment o f intellectual property rights on an international scale. 
In this regard, two major transformations can be identified:
1) The changes in the institutional framework and strengthening o f protection of 
intellectual property in the United States, which have originated the changes 
in the rest o f  the countries in various ways. Broadly speaking, the reconfigura­
tion o f the system o f  intellectual property in the United States as o f the 1980s 
is characterized by a) expansion o f the patentable frontier (Hunt, 2001); b) pre­
dominance o f a legal stance oriented to strengthening o f protection o f intellectual 
property;11 and c) the transition from a model o f open science to one that is more 
proprietary and oriented to commercialization (Dasgupta and David, 1994).
2) The adoption o f the Agreement on Trade-Related Aspects o f Intellectual 
Property Rights (TRIPS) and the inclusion o f  intellectual property in bilateral 
trade negotiations. Intellectual property became a central element in trade nego­
tiations, first multilateral and then bilateral, as part o f a strategy o f support to 
firms’ competitiveness, whose dominant position can be eroded by the lack of 
uniform intellectual property protection systems in global markets. Although 
recent bilateral agreements tend to reduce the spaces for intellectual property 
management for the developing countries, the latter have not pushed strategic 
intellectual property management by including the topic in a  broader indus­
trial and technological development strategy; the use o f the flexibilities provided 
by TRIPS has been scarce, not to say almost non-existent. Instead, the coun­
tries have favored the search for preferential access to market for the products 
in which they possess comparative advantages, thus bringing about a situation
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in which they easily yield to the new provisions on intellectual property in 
exchange for concessions in the markets for traditional exports. The changes in 
the intellectual property protection regimes in contexts o f  obvious asymmetries 
between north and south pose challenges to the creation o f scientific, techno­
logical, and production capacities, their costs, time frames, and viability, and 
as regards the role played in that process by intellectual property mechanisms 
(Fink and Reichenmiler, 2005; Abbot, 2006, 2006, Moncayo, 2006, among 
others).
1.4 Transactions in the Markets for Technology
The idea o f markets for technology has been explicitly explored in the economic 
literature in a relatively recent period (Eaton and Kortum, 1996; Arora, Fosfuri and 
Gambardella, 2001). According to the definition proposed by Arora, Fosfuri, and 
Gambardella (2001), when the knowledge necessary for production (know-how) or 
the right to use it is separated from the product or service which embodies it, a line 
o f demarcation emerges between the market for “ tangibles”  and the market for the 
technology necessary to the production. This concept o f  the markets for technology 
assigns a determining role to intellectual property rights, especially to patents, since 
they represent the basic institutional infrastructure for their functioning.
In this framework, patents define the conditions o f use and transfer o f knowledge, 
allowing specialization according to comparative advantages, and maximization o f 
the system ’s efficiency. Patents guarantee the appropriability o f the innovative effort 
by technology providers and represent the mechanism through which the prof­
itability o f  the innovation is captured. In this regard, the market is assumed to be 
composed by a set o f firms with different comparative advantages, some specialized 
in technology and the provision o f intermediate technological inputs, but without 
productive and market-access capacities, and others with complementary manu­
facturing capacities that enable them to use the patented technologies to carry out 
the production processes and incorporate the technology into products or processes 
and reach the consumers’ market. Patents would thus act as an incentive for “effi­
ciency” in the technology markets, favoring specialization and the division o f labor 
in keeping with comparative advantages (Arora, Fosfuri, and Gambardella, 2001).
In the markets for technology, the ultimate aim o f intellectual property protection 
is to incorporate the patented innovation into present or future tangible production. 
That is, the value and the market itself arise because there are firms specialized in 
the provision o f “ technology” and firms that demand for their production processes 
and their end products and services. In this context, innovation is generated and dis­
seminated according to a “ soft”  and continuous process in which there is a series o f  
companies that, starting from an existing pool o f knowledge, carry out research and 
development activities, patent scientific and technological advances, and have the 
dual possibility o f incorporating them into production, or license them in exchange 
for royalties to another company that will devote itself to production and commer­
cialization o f the good or service in question. This approach presents an interesting
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framework for describing the dynamics o f specialization and the division o f labor 
in the generation, production, and transfer o f some technologies. Nevertheless, over 
the last few decades, entrepreneurial behavior has undergone transformations that 
escape that logic and give rise to new markets for knowledge in which the rationale 
o f patenting turns out to be completely reconfigured.
1.5 Liquidity and Derivatives in the Markets for Knowledge
A number o f studies show the growing importance o f patents and the increase in the 
use o f technology licenses in terms o f transfers, acquisitions, and cross-licensing 
among companies (Grindley and Teece, 1997; Thurow, 1997; Granstrand, 1999; 
Guellec, Martinez, and Sheenan, 2004).12 At the same time, transactions in intangi­
ble goods and services have grown constantly starting from the 1980s. International 
payments for royalties and licenses as a share o f total world imports tripled from 
the mid-1980s to 2002 (Cimoli, Coriat, and Primi, 2006). However, the importance 
o f markets for technology and the increase in worldwide transactions o f intangible 
goods explain only some o f the dynamics related to the recent explosion in patenting 
and new trends in firms’ strategies.
In fact, according to us, patents are becoming progressively unlinked from tangi­
ble production. Changes in the patent regime and in firms’ behavior have generated 
markets in which the value o f patents is increasingly independent from their direct or 
indirect incorporation into current production. Patents play new roles and respond to 
logics that differ from the traditional view o f appropriability mechanisms o f  income 
deriving from innovation. Their value derives increasingly from future expectations, 
that is, (i) from the possibility that the patented innovation becomes a determining 
factor for production or for a set o f  future patents; (ii) depending on the role that 
the patent itself may have in the hierarchical repositioning among companies, in 
technology transfers agreements, in settlement o f legal disputes; and (iii) in the case 
o f patent portfolios and patent pools, in terms o f the value and relevance o f other 
patents.
Three markets coexist in this scenario, which operate under particular logics and 
incentives and in which patents play different roles: 1) the market for technology, 
in which patents guarantee the appropriability and allow the specialization and the 
division o f labor between technology producers and users; 2) the market for sci­
ence, in which universities and research institutes patent innovations derived from  
basic and experimental research and development activities, and 3) the liquid and 
derivative markets for knowledge, in which patents are reconfigured as strategic 
assets in com panies’ competitive strategies. Figure 1.1 presents a taxonomy o f this 
reconfiguration o f the markets for knowledge.
In this reconfiguration o f the markets for knowledge, the dynamics o f the mar­
kets for technology persists. Companies invest human, financial resources, and time 
in research and development, and they seek to protect the investment by means 
o f patents and to generate rents through the direct sale o f products, processes, or
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to characterizing the dynamics o f  the markets for technology and science, nourish the dynamics o f 
the liquid and derivative markets for knowledge.
services that incorporate the innovation or through the license o f  the patented inno­
vation to other companies which incorporate the technological advances in their 
processes or products.
However, the transactions in this market explain only one part o f current patent 
dynamics. The study by Cohen, Nelson, and Walsh (2000) shows that compa­
nies can receive additional benefits (whether monetary or not) from their patents 
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direct sales o f the good, product, or service that incorporates the technology, or 
from technology licensing. Indeed, companies also patent to block the entry o f 
competitors into markets, to increase their negotiating power in cross-licensing 
agreements, and to protect themselves from lawsuits on intellectual property 
infringements. In our view, the changes in the institutional framework and in the 
management o f intellectual property regimes and the new technological paradigms 
contribute to generate additional spaces and markets for knowledge that are even 
more unlinked from tangible production. The current scenario has become more 
complex due to a series o f transactions in which patents operate under different 
incentives, logics, and institutional frameworks favoring the exponential growth o f  
patenting.
The extension o f patentable subject matter and o f the range o f parties eligi­
ble as patents’ holders derived from the changes in intellectual property systems 
has altered the traditional conception o f open science, giving rise to incentives for 
the creation o f a market for science in which the universities apply for and obtain 
patents relative to innovations stemming from basic and experimental research and 
development activities. Thus, a “prior”  market to that o f technology has emerged, to 
which companies must recur when they need innovations deriving from the research 
patented by the universities.
The adoption o f the Bayh-Dole Act in the United States in 1981 represents an 
important institutional change in this regard (Jaffe, 2000; Mowery et al., 2004). This 
act regulates the granting and transfer o f patent rights to the parties that develop 
federally funded inventions, that is to say, it regulates the protection o f intellectual 
property relative to research activities developed mainly by universities and research 
centers.13
After the Bayh-Dole Act, patenting activity in United States universities has 
intensified. According to Mowery and Sampat (2005), the share o f patents issued 
to universities in relation to the total o f those issued to residents in the USPTO has 
grown from 1% in the 1960s to 3.5% in the early 1990s. According to the USPTO  
data, in 1990 the universities received 1,182 patents, whereas in 2003 they received 
3,259. That year, the number o f patents issued to local universities represented 4.5%  
o f the total o f invention patents granted to companies. In ju st over a  decade, the 
number o f patents issued annually to universities has tripled. The phenomenon of 
universities’ patenting is not limited to the United States; universities are the holders 
o f 2.4% of applications for patents presented to the European Patents Office (EPO) 
between 2001 and 2003 (OECD, Patent Database, 2006).
In the market for science, universities (and some technology-based companies) 
carry out basic and experimental research and development activities and patent the 
advances obtained without these necessarily being incorporated into the production 
o f goods and services. Formerly, the scientific advances made by the research and 
development laboratories o f universities contributed to the pool o f knowledge avail­
able to the production agents, and the filter for access to that knowledge, mainly 
derived from com panies’ technological and productive capacities, from firms’ rou­
tines, from the tacit component o f knowledge, and from the capacities for decoding 
the technical knowledge embodied in companies.
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The market for science reconfigures the setting in which companies operate and 
introduces intellectual property in a phase prior to that o f the markets for technology, 
thus reshaping the spaces for action and the incentives for firms and the universities 
themselves. This market differs from the market for technology basically according 
to the category o f intellectual property holders and to the patent subject-matter,
i.e., innovations derived from basic and experimental research developed by public 
research laboratories and universities. The introduction o f the Bayh-Dole Act and 
the increase in the number o f patents applied for and obtained by universities pose 
challenges to the model o f open science and nourish the discussion on proprietary 
science and its potential effects on long-term technological dynamism (Rai, 2001; 
Dasgupta and David, 1994; Mowery et al., 2004). In short, the market for science, by 
standing as an ex-ante market with respect to the market for technology, introduces 
an initial degree o f complexity to the functioning o f the contemporary markets for 
knowledge.
However, on analyzing the behavior o f firms and universities, the current scenario 
takes on an even greater degree o f complexity. In the new technological paradigms -  
characterized by innovation processes which are increasingly intensive in interrela­
tions between companies and networks, and cumulative in nature, in which scientific 
and technological advances multiply and, consequently, the patents on which sub­
sequent innovations are based -  the rationale o f patenting changes. Firms patent 
to reduce the probability that their counterparts will reinforce their position in 
cross-licensing agreements and to increase their own negotiating power. Companies 
carry out defensive patenting strategies and build patent portfolios, with sleeping 
and blocking patents. According to a survey on the value and use o f invention 
patents in European firms based on the cases o f Germany, France, England, Italy, 
the Netherlands, and Spain, the share o f inactive patents -  i.e., sleeping and block­
ing patents -  varies between 18% in small enterprises and 40% in large corporations 
and universities (Cesaroni and Giuri, 2005).
In this regard, it may be stated that a liquid market for knowledge emerges; 
patenting responds to com panies’ strategies that go beyond the need to protect the 
innovation. Patents become a liquid asset in the portfolios o f the companies that use 
them, for example, to increase their negotiating power vis-à-vis other companies, to 
increase their value and reputation, and to facilitate settlement o f legal disputes.
The attribute o f “ liquidity” o f patents derives from the fact that these markets and 
their transactions are disentangled from the incorporation o f the patented innovation 
into tangible production. In this regard, the patent as such acquires value, even if  it 
cannot be incorporated into the current production o f a company; its value depends 
and is a function o f other patents o f the company, or the patents o f other firms that 
need it, o f the value o f the patents portfolio, or the importance it may acquire in a 
cross-licensing agreement.
Patents are “ liquid” in the sense that they constitute assets that are exchangeable 
among firms, without the counterparts necessarily having the scientific and tech­
nological capacities to incorporate the respective innovations into production. In 
fact, a market is liquid when there is facility o f circulation o f the assets exchanged. 
Patents are liquid because they lose the density and weight o f the technological
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component and can circulate fluidly in the market without necessarily having to be 
embodied in some end product or service; these dynamics characterize transactions 
in the technology markets. The liquid market for knowledge takes place in a dif­
ferent context in which the strategic utilization o f patents prevails. In that market, 
the rationale behind patenting is different; companies tend to increase the num­
ber o f patents’ applications since their value increasingly depends on that o f other 
patents.14
The decision to patent innovations, even those that have no direct and immediate 
industrial application, has been compared in the literature to the purchase o f lottery 
tickets (Scherer, 2001; Lemely and Shapiro, 2005). Even though the probability of 
winning is very low, the reward in playing is sufficiently high to encourage agents 
to bear the costs o f patenting. In fact, the current scenario is even more complex 
than that o f the lottery, since the probability o f “ winning” and the prize associated 
with the patent are uncertain. In this regard, it may be affirmed that a market for 
knowledge emerges, in which patenting is a function o f expectations relative to the 
uncertain potential future value o f patents. In that market, companies patent for 
various reasons independently to the incorporation o f the patented innovation in 
tangible production. Thus, patents are obtained in order to raise entry barriers to 
potential competitors, ensure a share o f possible income derived from subsequent 
discoveries related to incremental evolutions o f the innovation or because o f the 
possibility o f including the patent at a particular time in a patent pool, among other 
reasons.
These markets may be defined as “derivative” markets for knowledge. This cat­
egory o f markets is extremely peculiar, since no transactions take place between 
companies. The transactions correspond to the firms’ decisions to patent their inno­
vations, without having the willingness to license them. Thus a “derivative” market 
is created, in which patents do not circulate among companies but remain in their 
portfolios waiting for their future potential value.15 That market includes sleeping 
patents, those that block the entry o f  new stakeholders or competitors (blocking 
patents), and those stemming from the expectation o f their inclusion in future 
transactions in other markets (technology, science, and liquid markets).
The expectation o f the (potential) future value o f the patent, the threat o f the 
fact that competitors might obtain the patent, and the possibility that its value does 
not depend on protected innovation, but on the value o f  additional patents o f  the 
company itself or others, encourage aggressive patenting strategies. So  this gives 
rise to “derivative” markets in which the decision to patent is based on expectations, 
depending on firms’ risk aversion or propensity.
The scenario, in which these markets coexist, explains the exponential growth in 
patenting, even though the distribution o f the value o f patents is skewed. Despite 
some sectoral and specific tendencies in some industrial sectors, in general there is 
a very limited series o f significant patents o f high value, followed by a whole series 
o f patents o f lesser value, which acquire value in terms o f future expectations of 
profitability, as an instrument for defending a dominant position and as a mecha­
nism for barrier to entry o f other players in a particular paradigm or technological 
trajectory. In the chemical industry, for example, it is a common strategy to patent
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advances and incremental innovations around the patent that protects the main inno­
vation in order to reduce the probability o f competitors entering that research space. 
In the electronics sector, companies build up portfolios o f a wide range o f patents to 
defend their dominant positions and raise barriers to the entry o f new competitors. 
In those reconfigured markets for knowledge, firms and universities patent not so 
much to appropriate the income derived from their innovating efforts, but to increase 
the possibility o f appropriating, today or in the future, a share o f the oligopolistic 
rents stemming from the present or future research and development efforts o f  other 
stakeholders (Levin et al., 1987; Cohen et al., 2000).
Corporate strategies do not follow linear patterns in innovation nor in the search 
and management o f profitability. The effect o f the exponential growth in patenting 
and the favorable attitude o f the courts toward raising protection standards might 
have perverse effects in the markets for knowledge, in which an excess o f patents 
can become a barrier to the entry o f new actors in specific technological devel­
opment trajectories. This is the case o f the patent thicket, a situation in which a 
series o f intellectual property rights on complementary technological components 
coexist and overlap, subjecting the interested parties to the obligation to obtain 
licenses or establish agreements with several intellectual property rights holders 
when they wish to market new technologies based on those technological com­
ponents (Shapiro, 2001). According to Llobet (2003), in contexts o f cumulative 
inventions, excessive protection and legal rulings in favor o f intellectual property 
rights holders in lawsuits for patent violation can inhibit com panies’ research and 
development efforts.
Hence, markets for knowledge turn out to be conflicting scenarios in which costs 
and barriers to entry o f new players, the costs o f potential violations o f patent rights, 
legal defense costs, and those associated with the decisions are extremely high. 
In the hierarchies o f entrepreneurial networks, com panies’ position is increasingly 
determined in terms o f the patents portfolio, with the consequent pressure toward 
market concentration and strengthening o f dominant positions. At the same time, 
there are spaces so that new stakeholders impose themselves as leaders in certain 
technological sub-trajectories as a result o f strategic use o f intellectual property. 
Nevertheless, the institutional capacity to guarantee the appropriability o f income 
derived from intangibles continues to be crucial, especially in the new technological 
paradigms.
1.6 Participation and Exclusion in the Markets for Knowledge
Intellectual property regimes represent a key controversial issue in current 
economies. The intensification o f patenting activity, the new and diverse forms 
in which firms use patents, the new technological paradigms, the context o f open 
economies, the growing global integration o f economies, institutional modifica­
tions in intellectual property systems, and the coexistence o f diverse markets for 
technology and knowledge reconfigure the rationales and the leeway for action of
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companies and governments. The management o f intellectual property systems and 
an understanding o f their relationship with the creation o f scientific and technolog­
ical capabilities is an urgent challenge for the countries o f Latin America and the 
developing countries in general.
A  parallel can be drawn between the “North-South” asymmetry in the dynamics 
o f patenting and the “North-South” asymmetry in the technological intensity o f the 
production structures and patterns o f  specialization. That is, the countries’ participa­
tion in the dynamics o f world patenting and its changes is not alien to the dynamics 
o f production structures and the processes o f technical change. The industrialized 
countries are specialized in knowledge- and technology-intensive activities and sec­
tors and invest more resources in research and development activities; it therefore 
comes as no surprise that they are also leaders in the number o f patents applied for 
and granted. The developing countries, on the other hand, are specialized in tra­
ditional sectors that are more intensive in labor and natural resources, invest scant 
resources in research and development, and their patenting activity is less intense 
(Aboites and Cimoli, 2002; Cimoli, 2005; Montobbio, 2006). The geographical con­
centration o f the patents applied for and granted (see Table 1.1) corresponds to the 
concentration o f research and development activities. The United States and Canada
Table 1.1 Geographical concentration o f main USPTO patent holders. Evolution 1963-2003
1963 1973
1983
(% ) 1993 2003
Quota o f 90.5 83.7 82.9 83 83.8
patents (United States, (United States, (United States, (United States, (United States,
issued to the Germany, Germany, Japan, Japan, Japan,
three main 
stakeholders
U K ) Japan) Germany) Germany) Germany)
Quota o f 58.8 59.1 67.5 67.9 67.3
patents (Germany, (Germany, (Japan, (Japan, (Japan,












Province o f 
Taiwan)
Quota o f 73.8 74.5 79.7 80 75.5
patents (Germany, (Germany, (Japan, (Japan, (Japan,
issued to the UK, France, Japan, UK, Germany, Germany, Germany,





Canada) Canada) Switzerland) Canada) Province o f 
Taiwan, 
Republic o f 
Korea, 
France)
Source: Prepared by the authors based on data from USPTO, Technology Monitoring Division 
Report, Utility Patents Report.
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Chart 1.1 The knowledge curve: production specialization and patenting 
Note: In the abscissas we measure the indicator o f  relative specialization in technology-intensive 
activities based on United States and Canada =  1. The relative specialization indicator for geo­
graphical areas is calculated as a simple average o f  countries. The emerging economies o f  Asia 
include India, Republic o f  Korea, and Singapore. The European countries are Finland, France, 
Ireland, Israel, Norway, Sweden, and the U.K. For Latin America, Argentina, Brazil, Chile, 
and Mexico are considered. The ordinates measure the accumulated share o f triadic patents 
applications.
carry out 41.9%  o f  world spending on research and development, the European 
Union 28.2%, A sia 27.3%, Latin America and the Caribbean only 1.3%, Oceania 
1.1%, and Africa 0.2% (RICYT, 2004).
The asymmetry in patenting reflects profound structural differences among coun­
tries. Chart 1.1 orders the countries in terms o f their production specialization and 
the intensity o f their patenting activity. A “ knowledge curve” is built in which 
19 countries are ordered, grouped into seven geographical areas, according to their 
relative technological specialization and their patenting activity. The United States 
and Canada are considered the technological frontier on account o f  their participa­
tion in knowledge-intensive sectors in the total manufacturing value added. In terms 
o f relative specialization in technology-intensive sectors they are followed for by 
the Republic o f Korea, India, and Singapore,16 then Japan, the European countries, 
Australia and New Zealand, and finally, Latin America, and South Africa.
If we order the countries by the relative technological intensity o f  the manufac­
turing industry, the “ knowledge curve” shows that those with a production structure 
similar to that o f the technological frontier (Japan and the European countries)
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are also those that have the largest share o f patents applications. In the United 
States, Japan and the European countries there is a relationship between their 
knowledge-intensive production structure and their relatively more intense patenting 
activities. In other words, the economies in which the knowledge-intensive sectors 
contribute to generating a significant share o f the total manufacturing value added, 
patent more. The exceptions to this tendency are the emerging Asian countries, 
the Republic o f Korea and Singapore in particular, where the process o f structural 
change and transition toward more knowledge-intensive productive frameworks is 
recent. Therefore, the dynamics o f patenting, however much it may have acceler­
ated, continues to be residual. This leads us to reflect on the temporary dynamics o f 
technical and structural changes and com panies’ competitive behavior in terms of 
patenting.
The dynamics o f patenting derives from production specialization; the creation 
o f production and technological capabilities is a long-term process influenced by 
path-dependent dynamics and by sectoral and temporary public-policy choices. In 
the past 30 years, the Republic o f Korea and Singapore have intensified their special­
ization in technology-intensive sectors. In the 1970s, engineering-intensive sectors 
generated 10% o f the industrial value added in the Republic o f  Korea; in 2000 they 
generated 63%, surpassing the United States. Singapore is a similar case in point: 
those sectors’ quota has risen from 34 to 65% over the same period. At the same 
time, these countries invest considerable resources in research and development (2.8 
and 1.9% of GDP, respectively, on an average, between 1996 and 2002). In parallel, 
these countries have notably intensified their patenting activity.
The introduction and use o f  the intellectual property protection system go hand 
in hand with the creation o f industrial productive capabilities. Specialization in 
knowledge-intensive sectors, technological development, and investment efforts in 
research and development favor technical change, increase the absorption capac­
ity o f the production structure, and lead to generate a structure that demands more 
knowledge. Hence, the intensification o f patenting emerges as those capacities are 
developed and built. When certain technological capacities have been accumulated, 
the production system requires a patents system and can benefit from it.
How to achieve convergence and the development o f technological capabilities, 
that is, how to move on the knowledge curve in contexts characterized by high 
levels and standards o f intellectual property protection, remains an open question. 
Understanding the dynamics o f  patenting in the current context is the first step in 
that direction.
The patents game is increasingly costly in terms o f the necessary human and 
financial resources needed to convert the “probabilistic” right conferred by the 
patent into an effective right and in terms o f the necessary time to carry out research 
and development activities, create a patentable innovation, and obtain the correspon­
dent intellectual property right. The firms that possess a certain accumulated level 
o f technological capacities are the ones that dominate the scenario. In the current 
reconfiguration o f markets for knowledge, the game is, in our view, increasingly 
competitive among companies, posing serious challenges to designing development 
strategies based on knowledge and innovation.
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In the countries o f the technological frontier, especially the United States, the 
discussion on intellectual property follows a double track. Foreign policy defends 
the raising o f standards o f protection for intellectual property rights. It aims at the 
standardization o f those rights, since the weakness o f protection and the asymme­
try between the systems o f the developed countries and those o f the developing 
ones is viewed as a systemic failure which prevents the knowledge dissemination 
and technical progress derived from trade liberalization. Investing in research and 
development and trading knowledge in a context o f scarce protection o f intellectual 
property is a risk that few are prepared to take. In the internal debate, on the one 
hand, pressure groups, large corporations from sectors such as pharmaceuticals and 
chemicals, and jurisprudence, which advocate growing standards o f protection and, 
on the other, academics and the members o f organizations o f civil society, which 
express concern over the proliferation o f patenting and their potential adverse effect 
on the capacity to innovate o f the economic system in the long term.
In Latin America, the inclusion o f intellectual property issues in trade nego­
tiations has raised the topic in political discussions. The discussion is mainly 
characterized by the paradox o f adopting favorable positions on trade liberalization 
in tangible sectors and, at the same time, promoting the adoption o f protection mea­
sures in the area o f intellectual property and intangibles. The stances are varied, but 
in general a lack o f strategic perspective prevails on the role that intellectual property 
in general, and patents in particular, can play in the development and construction 
o f endogenous technological capabilities.
At international level, in both multilateral and bilateral negotiations, the debate 
is characterized by a double standard in which there is a push for free trade in 
goods and services and a pressure to increase protection o f intellectual property 
and “intangibles.” These circumstances redefine the scenario and policy spaces in 
which less developed and developing countries have to define their strategies toward 
convergence, thus posing new challenges for catching up strategies. In this context, 
recognizing that the rationale for patenting is moving away from the traditional mar­
kets for technologies and heading to the new markets for science and the liquid and 
derivative ones, in which transactions and the role o f  patents are completely new and 
uncertain, is the first step in proposing a pragmatic development agenda capable of 
going beyond good intentions and declarations.
1.7 Conclusions
Almost all Latin American countries aim toward a development based on knowl­
edge, at least in plans and declarations. Innovation, science, and technology policies 
have begun to appear again in politically correct discourses. However, the search and 
need for access to markets in traditional sectors lead to cede on potential dynamic 
advantages in intellectual property. In general, marginal stances prevail which advo­
cate for “ adding value” in the natural resources-intensive sectors, rather than for 
selective policies o f creation o f new sectors. In the discourse on intellectual prop­
erty rights, attention to the development o f the legal and institutional infrastructure
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prevails over the concern for generating productive and technological capacities that 
could benefit from the regulations themselves. The modernization o f patents offices, 
institutional reforms, design o f public-policy instruments o f support for the protec­
tion o f intellectual property are current topics in political debates. Nevertheless, 
these efforts could become sterile unless they are accompanied by a deep under­
standing o f the effects o f the new dynamics o f patenting on the construction of 
production and technological capacities and on the need to implement policies to 
support the technical and structural change.
Lack o f strategic vision and short-term demands can come into conflict with 
learning processes and the development o f scientific and technological capacities, 
which are localized and are built up gradually in a continuous process o f trial, error, 
and feedback (Atkinson and Stiglitz, 1969). Prioritizing traditional sectors with 
comparative advantages in the present without considering the strategic relevance of 
capacity building in more knowledge-intensive sectors, the effects o f spillover and 
linkage these may have on the economy and the role played by intellectual property 
protection systems in that process may turn out to be a  short-sighted strategy that 
does not sufficiently value knowledge and technology management.
Firms use patents not only as incentives and mechanisms for appropriability o f  
innovation but also as strategic assets for the generation and maintenance o f domi­
nant positions. Transactions in the technology markets -  basically patent licenses -  
are but one o f the components o f the (new) markets for knowledge. Nowadays 
there is a former market, the science market, in which new players (universities) 
patent innovations stemming from basic research and basic development which were 
previously not classified as patentable material.
At the same time, additional markets are also created in which patents acquire 
the role o f strategic asset, beyond the effective utilization o f protected innova­
tion in present or future tangible production. On the one hand, patents become a 
determining asset in redefining com panies’ strategic and hierarchical position and 
increasing their negotiating power. Patents become “ liquid” assets, easily transacted 
between companies, which make it possible to settle legal disputes and facilitate 
cross-licensing agreements.
A s in a competitive game, expectations on the value o f a patent and the possibility 
o f combining patents o f  little or no value in patent pools or patent portfolios encour­
age companies to develop aggressive patenting strategies. Thus, a “derivative” 
market for knowledge emerges, in which, in contrast to other markets, companies 
apply for patents for the explicit purpose o f not using them in transactions with 
other companies. In that market, patents possess a value in themselves, based on a 
series o f future expectations, whether by means o f their inclusion in a patent pool, 
in the possible importance o f the patented innovation for future incremental innova­
tions, or in the desire to block the entry o f new competitors. Patents act as a signal, 
without the need for them to circulate among companies. In this market, the theo­
retical balance between the two basic functions o f patents, those o f protection and 
appropriability versus the disclosure o f knowledge, fades away. Patents lose their 
traditional attribute o f a mechanism to facilitate the disclosure o f knowledge (dis­
closure function) and remain sleeping, block the entry o f other players (blocking), or
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simply increase the value o f the company by indicating its (potential) technological 
capacities.
In this type o f scenario, clearly the Latin American countries and the developing 
countries in general are residual actors. However, once the firms in developing coun­
tries acquire the technological capacities to enter those markets, they will operate 
under the same logics, will use mechanisms o f appropriability in a strategic manner, 
and will play in the various markets -  the technology, science, liquid and derivatives 
markets -  the same as their competitors in the most advanced countries. Therefore, 
in the current discourse on intellectual property and development it is important to 
recognize that the present dynamics show completely novel traits. It is fundamental 
to refocus the debate in the countries o f the region, leaving behind the conventional 
view of patents. Recognizing the existence o f the different markets for knowledge 
and understanding the variety o f functions and roles performed by patents in com­
pany strategies is essential (i) in understanding how the region could enter the new 
global knowledge game and (ii) in formulating public policies to support industrial 
development and innovation beyond the rhetoric.
Notes
1. Several studies analyze this increase in patenting activities. See Kortum and Lerner (1997); 
Hall (2004); Guellec, Martinez, and Sheehan (2004), Montobbio (2006), among others.
2. In the 1960s, the degree o f concentration -  the percentage o f  patents issued to the three 
main countries -  was 90%. The analysis o f patterns o f application and issuance o f  patents 
in the USPTO prevents capturing the intensity and dynamics o f  the phenomenon in the dif­
ferent national offices and can lead to underestimating their activity. Nevertheless, since the 
USPTO is the major office worldwide, its activity is a reliable indicator for studying the phe­
nomenon in a global and comparative perspective. In order to avoid the bias toward the United 
States stemming from USPTO data, the analysis o f patenting dynamics in the other countries 
considers the total o f patents applied for or issued only to non-residents.
3. These systems define a set o f  rights that are interlinked in different legal regimes o f vast 
scope, which range from patents on inventions, copyright on original forms o f expression 
(such as artistic and literary productions) and the marks protecting the symbols that identify 
goods and services, among others.
4. Since their origin, the intellectual property protection systems are associated with the creation 
and recognition o f  privileges. The etymological root o f  the term patent derives from the Latin 
litterae patente, “ manifesto”  or “ open letter,”  a document that publicly declared the granting 
o f a special privilege. The guilds in the Middle Ages used in order to concede exclusive rights 
may be considered as an embryonic system o f protection o f  intellectual property. The first law 
on patents goes back to the Republic o f Venice in 1474. The British statute o f  1623 eliminated 
all monopolies and privileges, exclusively recognizing the monopolies created by the first 
inventor o f  manufacturing methods in the field. For an analysis o f the historical evolution o f 
protection systems for intellectual property, see David (1993) and Drahos (1999).
5. The discussion on intellectual property is an old debate. Plant (1934) puts forward a skeptical 
position as to the need for a system o f protection o f  intellectual property. Kitch (1977) under­
scores the importance o f patents as an incentive for investment in research and development. 
The debate on the duration and optimum scope o f patents is also extensive. See, among oth­
ers, Gilbert and Shapiro (1990), Klemperer (1990) and Lerner (1994). Fora review o f  patents 
as indicators o f  economic phenomena, see Grilliches (1990).
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6. The peculiarity o f  the pharmaceutical sector in the use o f  patents is a topic widely debated 
in the literature (see Mansfield, 1986; Levin et al., 1987; Mazzucato and Dosi, 2006, among 
others).
7. The authors show that patents and legal instruments are also the least effective instruments for 
guaranteeing appropriability o f  process innovations, a case in which industrial secret appears 
as the most adequate instrument for appropriability.
8. The study analyzes 252 lawsuits in courts o f the European Union between January 1990 and 
June 1991.
9. See Machlup and Penrose (1950); David (1993) and Moncayo (2006), among others.
10. The 1883 Paris Convention on protection o f  industrial property and the 1886 Berne 
Convention, which regulates protection o f  original forms o f expression, such as artistic and lit­
erary works, represent the first stages o f the internationalization o f  intellectual property rights. 
Those two conventions were followed, always with an approach o f international protection, 
by the 1891 Madrid agreement on industrial marks and the 1925 The Hague agreement on 
industrial design. In 1893 the Office for the Protection o f Intellectual Property (B IR P I) was 
created, an antecedent o f  the World Intellectual Property Office, established in 1967, under 
whose administration today are various international treaties for the protection o f intellectual 
property.
11. See the studies by Adelman (1987); Merges (1992); Mazzoleni and Nelson (1998); Jaffe 
(2000); Hall and Ziedonis (2001); Cohen and Lemely (2001); Gallini (2002); Bessen and 
Hunt (2004); Hall (2003); Graham and Mowery (2003).
12. Grindley and Teece (1997) underscore the growing use o f technology licenses by large 
corporations such as IBM , Hewlett-Packard, and A T& T  during the nineties decade.
13. Assessing the consequences o f  the Bayh-Dole Act goes beyond the scope o f the present study, 
but it is interesting to highlight that one section -  204 indicates that the right to patent and 
the faculty o f transferring the right to utilization in an exclusive manner applies only if the 
product or service incorporating the invention or the process carried out through the invention 
is manufactured principally in the United States. Section 204 introduces a preferential mech­
anism for the local manufacturing industry and corresponds to a utilization strategy o f the 
instrument to protect domestic industry at international level. This reflects one o f the asym­
metries in the management o f  intellectual property between countries on the technological 
frontier and the developing countries (Cimoli, Coriat, and Primi, 2006).
14. The identification o f  that potential market for patents and the change in attitude o f  agents and 
courts in favor o f raising protection standards for intellectual property contribute to explaining 
the exponential increase in patenting activities in recent decades.
15. In the financial derivative markets parties acquire the right to buy or sell a particular asset 
at a particular price at a particular future moment, as is the case o f  options contracts, or to 
purchase or sale an asset at a future date at a pre-established price, as in the case o f  futures 
contracts. In those markets, present costs and obligations are assumed according to future 
expectations. It is in this sense that the “derivative”  market for knowledge is defined.
16. In fact, the weight o f technology-intensive sectors in the total manufacturing value added 
o f  Korea and Singapore is higher than that o f  the United States. However, the values o f the 
indicator o f relative specialization are calculated as simple averages, and the inclusion o f 
India reduces the indicator to a value below the unit. In any event, the group o f  emerging 
Asian countries is the one that possesses the most similar productive structure to that o f  the 
frontier.
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Knowledge embedded as a proportion o f the total value o f a product grows by the 
day in all sectors. Technological development is not only present in industrial goods 
but also in agricultural processes and in services.
Capabilities for research, creation, and appropriation of knowledge and its trans­
formation into new technologies form part o f the foundations o f wealth in the 
most developed nations and largely explain their economic growth. In this regard, 
analysis and debate on how to generate knowledge, technological innovation, and 
development is a topic o f utmost importance for the developing countries.
As o f the entry into effect o f the Agreement on Trade-Related Aspects o f 
Intellectual Property Rights (TRIPS) in 1995, the architecture o f Intellectual 
Property Rights (IPR) has gradually become more complex. TRIPS has been pro­
moted mainly by the most developed nations, and bilateral trade agreements have 
progressively incorporated diverse complementary rules, some o f them known as 
TRIPS Plus for extending intellectual property beyond the original TRIPS.
The mechanisms for intellectual property protection -  patents, trademarks, geo­
graphical indications, copyright, breeder rights, etc. -  present two important aspects: 
on the one hand, they are forms o f appropriation o f income that generate monopolis­
tic or quasi-monopolistic gains for their holders and, on the other, they are financial 
incentives for research inasmuch as they remunerate the innovator for the invest­
ments carried out until succeeding in turn their innovations into market products. 
Both aspects are examined in this chapter.
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Economic analysis shows that if  not correctly formulated, IPR protection mech­
anisms can become a barrier to the entry o f other innovators and an instrument to 
preserve monopolies, resulting in a further obstacle rather than as an incentive for 
research and for economic development.
Finally, two economic phenomena are analyzed which are closely linked to 
economic development and to intellectual property protection mechanisms: local 
endogenous development and attraction o f Foreign Direct Investment (FDI).
2.2 Innovation and Endogenous Development
The concept o f decreasing returns is a pillar o f economic theory since its founding 
by David Ricardo. It refers to the fact that the rate o f return on investment and the 
growth rate o f the per capita product are normally decreasing functions o f the level 
o f per capita capital stock. The logic o f this argument is simple: initially, when the 
per capita capital stock increases, per capita production will rise at a proportional 
rate, but if  the capital stock continues to grow, there will be a point as o f  which per 
capita returns will have declining rates.
This argument leads to the conclusion that among countries with different endow­
ments o f per capita capital and therefore different productivity and income, the 
country with the lowest capital/labor ratio will be the one that obtains the high­
est productivity and income growth rates. Therefore, the countries with the least 
income should show a tendency to converge with the rents o f the countries with the 
highest income.
By this reasoning, as Romer (1986) indicated that initial conditions or current 
distortions should not have long-term effect on the level o f production and consump­
tion. However, according to Romer, the evidence does not back up the conclusions 
o f the principle o f  decreasing returns. Madison (cited by Romer, 1986) shows that 
the countries that have had the highest productivity indices since 1700 have achieved 
increasing and not decreasing rates o f productivity. On the other hand, it has been 
proved that the most developed countries benefit more from periods o f growth 
and suffer less the periods o f crisis o f the external economy than the developing 
countries (Reynolds, 1983, cited by Romer, 1986).
Two assumptions make the analysis o f convergence among countries predict dif­
ferent results from those shown by the evidence: the first is that technological change 
is exogenous to the growth process o f and the second is that the same technology 
is available all over the world. The assumption is, then, that there is free access to 
the technology on the market and therefore, investment decisions in one country 
are determined by the relative prices o f  the factors o f production, technology being 
a given factor, that is, exogenous. According to this approach, changes, improve­
ments, and technological leaps are external to countries, which take them for their 
investments (Lucas, 1988; Romer, 1986).
Although it is true that investment rates in rich countries are higher than in poor 
countries, the variation between them is not so high as to explain the difference in
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growth. The assumption that the level o f available technology is the same for all 
countries has been identified as the key to the error.
To model the fact that developed countries maintain higher growth rates than less 
developed ones -which is indicated by the empirical evidence- it would be nec­
essary for each investment unit in capital to increase not only the stock o f physical 
capital but also the level o f  technology for all companies. This redefines the relation­
ship between technology and the rest o f the economic variables, since investments 
in capital or labor have external effects on it. The latter is therefore neither constant 
nor the same for all countries. Long-term growth would be determined mainly by the 
accumulation o f knowledge -  know-how, knowing how to use technology, knowing 
how to improve technology, all o f which is self-reinforcing -  in the agents that m ax­
imize benefits by constantly introducing improvements. The most important part o f  
this is that knowledge accumulates and grows, so that if we look on production as a 
function o f knowledge, in addition to other functions, it will have growing returns.
The statement by Romer, Lucas, Rebelo, and others has given rise to a  great deal 
o f  literature on this topic, whose essence is expressed in the following equation:
Y =  A K ,
where Y is national production, A  represents diverse factors affecting technology, 
and K  includes human capital and physical capital.
Through K , knowledge and technological development become endogenous. The 
current study o f economic development necessarily includes analysis o f the inter­
relation between the factors o f endogenous growth, that is to say, how human 
capital, physical capital, and other factors that influence technology have a bear­
ing on growth. In this regard, protection o f IPR, that is, the economic incentives for 
innovation and the exclusion o f competitors, is an element o f  growing importance 
for countries’ economic development.
2.3 Local Endogenous Development and Innovation
The study o f local development indicates that all regions possess cultural, histori­
cal, physical, and institutional characteristics that represent their own development 
potential (Vázquez and Garofoli, 1995). The regions possess knowledge, tech­
niques, preferences, etc., which are the fruits o f their own historical legacy. Over 
time, communities develop their own culture, beliefs, and values which impregnate 
all their activities, including economic ones. For the theory o f local development, 
these aspects endow each community and region with a potential o f  resources which 
also constitute their development potential.
Analyses o f local development consider three aspects, on which potential o f 
development is largely based: a sp e c ific  know -how , which has evolved from forms 
of accumulation o f agricultural surpluses to craft and subsequently industrial 
production; lo c a l  p ro d u ctio n  lin k ag es, which generate and encourage productive 
specialization, strengthening local know-how; and e n trep ren eu ria l c a p a c ity  itself.
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The latter is usually pointed to as the decisive element for promoting local 
development (Vázquez, 1988).
Local economic development occurs in delimited geographical areas where there 
is a critical mass o f micro and small enterprises vertically or horizontally inte­
grated in specific production processes (Vázquez, 1988). Such characteristics give 
the region organic interdependence to which other enterprises and the public admin­
istration provide complementary services, creating a homogeneous, specialized, and 
integrated economic and social framework.
In addition to these elements are those characteristic o f endogenous develop­
ment, i.e., making knowledge endogenous -  through the variables o f human and 
technological capital -  such as forms o f generation o f value, improvements in 
productivity, and in local production processes. Since the analysis o f local devel­
opment explicitly incorporates the knowledge variable, we talk o f local endogenous 
development.
In the developing countries, much the same as in many developed countries, 
the majority o f enterprises are small and their market objective is strictly local 
or national, and therefore improvements in the living standards o f the population 
require the modernization and improvement o f these small enterprises’ productiv­
ity and growth. In recent years, the Latin American countries, as many developing 
countries around the world, have opted for a model o f development based on the 
promotion o f exports and the attraction o f FDI, which in principle has relegated 
local endogenous development to second place.
This model has implied new priorities, new institutions, capabilities, organiza­
tion o f resources, etc. Governments have promoted exports -  some small enterprises 
have successfully benefited from this model -  and the attraction o f foreign invest­
ment. The mode] has also implied processes o f accumulation o f knowledge, 
capacities, and resources more linked to the international economy. Today’s econ­
omy is increasingly knowledge based, a determining factor o f productivity. The 
contribution o f knowledge-intensive sectors to the world economy’s value added 
and employment is growing continuously, and innovations have become a decisive 
element in competitiveness. The logic o f development based on exports and attrac­
tion o f FDI leads to competing internationally, and rewards the firms which at the 
time o f opening up national markets already had sufficient maturity to produce with 
international standards.1
However, by means o f policies and strategies that act on the necessary basic 
levels o f development, the local production can also be promoted so contributing 
to national development (Alburquerque, 1997). In a context o f open economies 
in which the technological component and knowledge are increasingly relevant 
to firms’ competitiveness, it is essential to design local endogenous development 
strategies that promote the use o f knowledge, the use o f useful innovations, and 
improve productivity rates.
The developing countries that have opted for full integration into the world econ­
omy face the challenge o f designing and implementing policies o f technological 
innovation as an essential part o f the model they should follow.
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Four levels have been identified in which public policy should act to promote 
local endogenous development (Alburquerque, 1997):
M a cro e co n o m ic  lev e l, to assure the necessary conditions o f stability for 
economic accumulation and reproduction.
M icro eco n o m ic  level, in which the production units improve their techniques 
and their entrepreneurial management, and the necessary technological 
changes are made.
M eso eco n o m ic  level, in which institutions create and maintain the innovative 
setting so that companies grow and multiply.
M e ta  level, in which a generalized commitment to investment, risk, and growth 
derived from the capacity for community development and strategic con­
certed agreement take place. In a local economy that is articulated or aims to 
articulate its production, it is essential that the actors participate in the inten- 
tionality and they bet on development. Given that all are part o f the same 
production environment, quality, effort, and growth affect its setting, which 
is why the level o f concerted agreement for development becomes essential.
2.4 National Innovation Systems
The concept o f National Innovation System (NIS) refers to the network o f  insti­
tutions and organizations in the production structure and in social institutions 
that import, develop, and disseminate new technologies or knowledge. This con­
cept incorporates the knowledge element in the function o f production and places 
innovation and the learning process at the center o f analysis. An NIS seeks to under­
stand how knowledge is generated, how it is disseminated, and how it becomes 
transformed into technology.
The ways in which each society produces knowledge are diverse and complex. 
Every system depends on factors that change slowly (culture, technological path, 
systems o f governance). N ISs are no exception. For this reason it is said that they are 
systems o f actors, interactions, and structural conditions that produce knowledge, 
disseminate it, and eventually incorporate it into useful technology for the market.
Edquist (2004) and Chaminade (2005) indicate that N ISs are made up o f two 
elements: (a) the so-called components, and (b) the relationship between them, as 
occurs in any system. In the components it is common to distinguish between orga­
nizations (firms, universities, public research centers, NGOs, etc.) and institutions 
(rules, routines, laws, etc.). It is precisely the relationships between the com po­
nents o f the system, that is, between organizations and institutions, which define the 
functioning o f an NIS.
Placing emphasis on a single element o f the NIS (intellectual property rights, 
public or private research, public incentives, etc.) does not make much sense. What 
is decisive is the system as a whole to ensure that the region or the country has the
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capacity to generate knowledge (through the organizations), transmit it (through the 
relations among organizations), and develop it (by organizations and institutions).
From the point o f  view o f local endogenous development, the analysis o f inno­
vation systems explains the manner in which a region generates and incorporates 
knowledge into its production. It thus contributes information on how to build up 
the functioning o f the system by means o f public policies in order to generate 
more knowledge, increase productivity, and improve the capacity to incorporate 
knowledge into local production.
2.4.1 Determining factors for innovation processes
A number o f studies have analyzed the factors at play in innovation processes, that 
is, the activities related to the creation, dissemination, and development o f techno­
logical innovations, without so far reaching consensus on the determining factors 
(Liu and White, 2001; Johnson and Jacobsson, 2003; Rickne, 2000).
Every country or region can have determining factors depending on the series and 
functioning o f its organizations and institutions and therefore, each system tends to 
be unique and unrepeatable. Even so, any country or region that strives to identify 
the said factors must base itself on the yardstick that the system ’s main function and 
the object o f study is the innovation process: development, dissemination, and use 
(exploitation) o f the innovations.
A s Edquist (2004) states, almost certainly any satisfactory explanation o f inno­
vation processes will find multiple causes -  reinforcing one another -  and therefore 
should specify the relative importance o f each one o f them. In any case, the exercise 
should be pragmatic: identifying the important activities that have a bearing on the 
innovation process. Thus action areas can be identified for public policy on science 
and technology (see Box 2.1).
Box 2.1 Determining factors of innovation systems
1. Availability o f  Research and Development (R& D ) centers that produce 
new knowledge, especially in the areas o f  engineering, medicine, and 
natural sciences.
2. Creation o f competences or capabilities (availability o f education and 
training, creation o f human capital, production, and reproduction o f  
skills).
3. Creation o f markets for new products.
4. Exacting demand for the quality o f new products.
5. Creation and evolution o f the necessary organizations for the develop­
ment o f new fields o f  innovation, i.e., improvement o f  entrepreneurial 
capacity to create new enterprises and diversify existing ones.
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6. Relations through lhe market and oilier mechanisms, including inter­
active learning processes among organizations participating in the 
innovation process.
7. Creation and renewal ol' institutions -  i.e., intellectual property laws, 
fiscal incentives, environmental and security regulations, practices o f  
investment in research and development, etc. -  which influence orga­
nizations and processes.
8. Incubation activities with access to adequate facilities, administrative 
support, etc.
9. Financing for innovative processes and other activities that facilitate the 
marketing and adoption o f knowledge.
10. Availability o f  relevant consultancy services for innovation processes, 
i.e., technology transfer, commercial information, legal advice.
Source: Prepared by the author based on Edquist (2004).
2.4.2 National innovation systems in Latin America
Regardless o f the indicator used to analyze and compare the N ISs o f developing 
countries to those o f the developed ones, there are major quantitative differences 
(number o f patents registered per year, relative weight o f expenditure on research 
and development in GDP, number o f people working on research projects, etc.) and 
qualitative ones (types o f patents, relevance o f their use, etc.), which places the 
developing countries at a serious disadvantage in competing and promoting policies 
o f technological convergence and innovation.
Although the data for measuring and rating N ISs may not be very solid in the 
sense that they do not necessarily reflect the countries’ innovating capacities -  i.e., 
number o f patents registered or number o f scientists in the universities -  this section 
presents the most commonly accepted indicators.
One initial fact is the innovation index designed by Warner (2000), which is 
based on replies from company executives by means o f surveys on sources and 
results o f innovating processes, evaluation o f the quality o f scientific research insti­
tutions, higher education, teaching o f mathematics and sciences, and incentives for 
innovation.
The index is on a scale o f —2 to +2 (close to —2 means low innovation and close 
to 2 supposes greater innovation). The average for Latin America is —0.99. On an 
average the industrialized countries have an index o f 0.89 and the countries with the 
highest indexes are the United States and Finland with 2.02, which shows that the 
Latin American lag is very significant and o f concern if compared with the average 
o f the countries o f Southeast A sia (—0.25) or with South Korea, whose index is 0.33. 
For countries such as Costa Rica and El Salvador, the index is —0.21 and —1.35, 
whereas larger countries such as Mexico, Brazil, and Argentina show indexes o f 
— 0.76, —0.52, and —0.95, respectively.
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Table 2.1 Latin America and selected countries patent registration -  PCT*
Patents registered per year
Country/region 2002 2003 2004 2005
Europe (EPO ) 42,447 43,205 44,010 47,239
United States 41,294 41,026 43,342 46,019
Japan 14,063 17,414 20,263 24,815
Republic o f  Korea 2520 2949 3556 4685
Brazil 201 219 279 280
Mexico 132 131 118 140
Colombia 36 24 22 23
Argentina 9 15 11 21
Cuba 11 20 18 11
Source: W IPO, Statistics Division, 2005 Yearly Review o f  the 
PCT.
*Patent Cooperation Treaty (PCT), W IPO.
If we analyze production o f innovation based on patents registered, we also find 
a great difference between the Latin American region and other regions o f the world 
(see Table 2.1). It should be noted that in the entire Latin America region, including 
M exico and Brazil, where the indicator is higher, it is the transnational corporations 
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Chart 2.1 Latin America: patents registration B Y  Category.
Source: Prepared by the author based on R IC Y T  (2004)
Spending on science and technology as a percentage o f GDP also indicates that 
the Latin American countries are a long way from investing the proportions that 
countries such as the United States invest under this heading (2.67% o f GDP as 
against Nicaragua’s 0.14%  and El Salvador’s 0.84%). Interestingly, countries like 
Brazil, Costa Rica, and Cuba make more investment in science and technology in
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relation to GDP than countries like Spain, but with mediocre results in production 
o f marketable knowledge (measured by the number o f  patents). This fact is relevant 
as regards the type o f relations between the organizations and the institutions that 
constitute their national innovation systems.
Finally, it is important to underline two characteristic elements o f  protection o f  
innovations in Latin America which make it difficult to measure innovation capac­
ity: (a) most innovations are incremental and adaptive (important to the economy 
and firms, but not patentable) and (b) the most often used mechanisms o f protection 
for inventions are industrial secret and trademarks.
Whichever the indicator used to analyze investment and development o f  inno­
vations in Latin America, the region suffers a considerable lag in comparison with 
other regions o f the world, which is evident with respect to the developed countries, 
but also to other developing countries, such as those o f East Asia. Latin America 
has made considerable progress in its absolute indicators, but in relative terms it is 
increasingly far removed from its competitors.
2.4.3 Characteristics of NISs in Latin America
According to Melo (2001), N ISs in Latin America are “open,”  which means that 
their sources and principal agents o f  innovation are foreign technology flows and 
that foreign economic actors -  especially transnational firm s- are the main agents o f 
domestic innovation processes. This is illustrated by the ownership o f locally reg­
istered patents, which largely belong to foreign corporations in the region, 84.4%  
(see Chart 2.1). Similarly, the growing share o f technological industries in the 
region’s industrial exports is contributed by transnational firms.
Foreign technology flows through three main channels: ( 1 ) foreign direct invest­
ment; (2) imports o f  capital goods and intermediate goods; and (3) transfer by means 
o f purchase o f technology not incorporated into goods, but in the form o f patents, 
licenses, and technical assistance, among others.
This characteristic o f  Latin American N ISs brings to mind that in terms o f 
innovation policy there is a need to improve the transfer channels from foreign 
to national agents. If a country or region does not have high levels o f investment 
in research and development, it should seek the capacity to absorb the knowledge 
generated in other places, adapt it to its needs, and develop it. An example o f a 
country without research capacity some decades ago which turned into an innovator 
is Republic o f Korea. Other countries o f East A sia are attempting to improve their 
N IS by following Korea’s model.
Another characteristic o f Latin American N ISs is their heterogeneity, which 
means that the differences within the region may be greater than with regard to 
other countries. Depending on the indicator used, the differences between coun­
tries such as Uruguay, Cuba, or Brazil compared to others such as Bolivia, Peru, 
or Nicaragua are greater than the differences the former countries have with more 
developed countries. It has been calculated that 73% o f Latin America’s researchers 
are concentrated in Brazil, Argentina, and Mexico.
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Finally, another characteristic o f  Latin American N ISs is the role o f private firms 
in the innovation process. Unlike the majority o f the developed countries, where 
innovative efforts are concentrated in the private sector, in Latin America they are 
concentrated in the public sector. In the 1990 s decade, 60% o f spending on science 
and technology was carried out by the public sector as against less than 30% by 
the business sector. It is also significant to point out that the links and therefore the 
flows o f knowledge between firms and research institutions -  including universi­
ties -  are weak. This shows that the relations between the centers that concentrate 
research and the firms in charge o f applying and marketing innovations are not 
effective.
It should also be highlighted that Latin America has a low coefficient o f  patent 
generation with respect to its investment in research, but its production o f  scien­
tific articles is considerable (see Alvaro Diaz in this book, in Chapter 5). M exico’s 
National Researchers’ System  uses the publication o f scientific articles as an indi­
cator o f scientific production and instead o f other type o f innovative product (i.e., 
patents or utility models). Many university systems in the region reward scientific 
publication, not patent registration. Many companies use forms other than patents 
(industrial secret, utility model and, in software, copyright) as forms o f protection 
o f intellectual property. The number o f scientific articles reflects significant efforts 
in the Latin American region, which should work to connect such efforts to tech­
nological development. Thus, it is not a matter o f lacking “ innovative culture,”  but 
rather that the scarce use o f patents is basically the result o f  the type and scope of 
their innovative activities and protection models.
These characteristics common to the Latin American N ISs serve as a guide for 
the work every country should do to analyze and strengthen their respective sys­
tems. The relations between the organizations and institutions that make up N ISs  
are different in each country and it is therefore important for each one to draw up 
national research and development plans by identifying the most appropriate public 
policies.
2.4.4 Public innovation policies
The developing countries’ lag as regards the processes o f creation, dissemination 
and use o f the developed countries’ innovations should be the object o f concern and 
should give rise to public policies to close the gap. Innovation promotion policies 
should be understood as part o f the development policies o f  a country or region. Just 
as development improves the living standards o f the population o f poor countries, 
public innovation policies should be a strategy to attain levels o f creation, dissem ­
ination, and use o f the knowledge o f the most developed countries (catching up 
strategy).
The role o f  productive policies is to help create the conditions for developing the innovation
process, in the widest sense, and advance in the complementarity o f  the production structure
( . . . )  in contrast to the developed world, innovation in the developing countries is frequently
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m ore related to the process o f  adopting and adapting new technologies or form s o f m arket­
ing than to creating new technologies or processes. In the developing countries, therefore, 
innovation (defined in the broadest sense) is basically related to investment, but since the 
“discovery” is not fully appropriable, due to the im possibility o f  patenting it, the appearance 
o f  new activities or processes is less than socially  optim al (M achinea and Vera, 20 0 6 ).
Carlota Pérez (1992) identifies several levels in which Government can act to 
boost the competitive restructuring o f knowledge and technology-generating agen­
cies and institutions. An initial level is the elimination o f obstacles, hindrances, 
and mechanisms inherited from former systems. A second level is supplying facil­
itating resources in the form of financing, human resources, and infrastructure. A  
third level is the promotion and guidance o f the technological change. This last 
level is related to systemic competitiveness and the forming o f an NIS as such. At 
present, firms do not compete alone, but find support from the synergies created 
by N ISs.
In som e developing countries there might be sufficiently strong econom ic groups to attempt 
to com pete alone, but m ost enterprises in most o f  the countries would find it difficult to 
act in an isolated manner. The two necessary conditions -sy n ergy  and dynam ic evolution- 
would most likely be attained on the basis o f  the establishm ent o f  a powerful ‘national 
innovation system ’2 (Pérez, 1992).
Public policies to promote technological change and innovation processes should 
act on the three levels identified, but it is in the third where Governments 
can be more proactive, specifically in two major areas: (1) policies aimed at 
modifying market incentives and (2) those aimed at providing public goods 
(Melo, 2001).
In general, policies aimed at modifying market incentives have to do with fis­
cal and financial measures. The first o f these include public financing for research 
projects, joint projects between public and private sectors, and use o f public- 
sector procurement to induce innovation. The second are credit policies, risk capital 
policies, and others.
In regard to policies directed at supplying public goods, Melo (2001) highlights 
five policies (1) policies aimed at the dissemination o f technology (particularly 
important for countries that do not create technology but adapt it); (2) policies aimed 
at the development o f human resources; (3) direct production o f scientific and tech­
nological knowledge by means o f government financed research and development 
in public universities and research institutes; (4) initiatives in which the government 
plays a special role in organization and convening, such as promotion and creation 
of clusters o f innovating companies; and (5) policies related to regulations and the 
setting o f standards.
Each o f these policies in which the public sector can be proactive has given rise 
to debates and analysis which are not addressed in this chapter. Institutional func­
tioning, internal political relations, and the interaction between State and market 
adopt different forms in each country. In this regard, the preeminence o f one policy 
over others should be appraised depending on the case.
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2.5 Protection of Intellectual Property Rights (IPR)
The analysis o f N ISs includes intellectual property as an important institution. In 
some cases, intellectual property can be a powerful incentive for innovation, but 
in others, such as adoption o f technology, the use o f foreign technology, and the 
catching up processes can be an obstacle, although not always. Over and above this 
distinction, however, what must be kept in mind is that the weight o f intellectual 
property in N ISs is increasing by the day.
Innovation is costly, uncertain, and generates externalities, since the appropria­
tion o f its results tends to be incomplete and is easily appropriable by agents that 
have not invested in it. Although uncertainty -  the success or failure o f a research 
project or the usefulness o f its results -  is always present, the public sector can 
promote mechanisms to reduce it by means o f the right incentives.
The private sector also intervenes in innovating activities and profit is its main 
motivation. Since innovating activities are essential for creating new technologies, 
which create more productivity, competitiveness, and growth, it is o f prime interest 
that the greatest number o f private and public agents become involved in them.
In order to increase the supply o f knowledge and innovations it is necessary to 
provide private agents with the appropriate incentives so that they can cope with 
the high costs, the uncertainty, and the incomplete appropriability o f knowledge 
implicit in the results o f the research. Such an incentive is monopolistic power 
over the invention to ensure returns on the investment and encourage the risk of 
undertaking subsequent innovations. In view o f the imperfect nature o f the appro­
priability o f knowledge and related technical inventions, monopolistic power can 
only be exercised by means o f an adequate institutional framework.
The institutional mechanisms o f monopolistic power over innovations are 
diverse, but the most common are the secret, commercial mechanisms, and intel­
lectual property rights (IPR).
The secret is a mechanism based on asymmetric information in favor o f the cre­
ator o f a  product or technology. It is based on non-disclosure o f the invention, not 
even before the authority, which guarantees de facto monopolistic power o f the pro­
prietor over the invention. The main risk for the proprietor is that if its formula is 
discovered it will be left without protection.
Commercial mechanisms are based on firms’ own attributes -  leadership, pres­
tige, tradition, cultural or historical legacy, productive capacity, market knowledge, 
distribution, logistics, etc. -  in competing with producers o f similar goods. Thus, 
such firms can benefit more from the intrinsic or aggregate value o f the good than 
from the value o f its use. Their market edge helps them to remain as productive 
leaders and innovators.
IPR “ the legal rights which result from intellectual activity in the industrial, sci­
entific, literary and artistic fields ( . . . ) .  Intellectual property law aims at safeguarding 
creators and other producers o f  intellectual goods and services by granting them 
certain time-limited rights to control the use made o f those productions” (WIPO, 
2004). Thus, IPR grant appropriability to goods which the latter do not possess. In 
this manner, economic attributes o f appropriability are assigned to knowledge and
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innovation through a legal institution. Unprotected goods are subject to open com­
petition with similar goods whose quality and price determine their demand. But 
when a good receives legal intellectual protection it acquires a category similar to 
a non-replaceable good, for its production becomes an exclusive right of the holder 
(Box 2.2).
2.6 Local Endogenous Development and Geographical 
Indications
As has been explained above, every region possesses specific knowledge, local 
production linkages, and its own entrepreneurial capacity. Historically, this has 
given rise to its own techniques, preferences, etc., all of which constitutes human 
resources, institutional, and production potential, which is also regions’ potential 
for development.
The regions with a critical mass of micro and small enterprises vertically or hor­
izontally integrated in specific production processes for which they have generated 
certain knowledge, production methods, and organic interdependence are living a 
process o f local endogenous development.
In many cases, local endogenous development creates products whose prestige 
and specific qualities are socially recognized and related to their geographical ori­
gin. Such products can be protected from the competition of “similar” products of 
different origin. This type of protection, like the rest of IPR, is a method of appro­
priation of extraordinary income generated in this case by prestige, local know-how, 
and geographical location.
Geographical indications and protected designation of origin are mechanisms 
of protection of local production that can be used to promote agricultural or tradi­
tional craft production and stimulate its variety, protect producers from imitators, 
and provide certainty to consumers regarding the quality and origin of the product.
This form of protection is regulated by the TRIPS agreements of the World Trade 
Organization (WTO) (Annex 1C of the Morocco Agreement whereby the WTO is 
established, signed in Marrakech on April 15 1994). Attempts to legislate these 
mechanisms date back to the end of the nineteenth century at the Paris Convention 
for the Protection of Industrial Property, signed on March 20, 1883 and revised and 
amended on repeated occasions. In WIPO, appellation of origin is protected by the 
Lisbon Agreement.3
At present, effective protection of geographical indications differs among the 
regions, that of the European Union being the most effective.
Box 2.2 Mechanisms for protection of intellectual property
The types of protection of the international juridical system for IPR are the 
following (WIPO):
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a) Inventions (patents). A patent is an exclusive right granted for an inven­
tion, which is a product or a process that provides, in general, a new way of 
doing something, or offers a new technical solution to a problem. It is the 
most widespread and consolidated mechanism worldwide. This category 
includes utility models, which are exclusive rights granted to the holders 
of inventions and which prevent commercial use to third parties without 
authorization for a limited period. It has differences in form with regard to 
patents, but its content is similar, which is why they are also called “ petty 
patents” or “ innovation patents.”
b) Trademark. A distinctive sign which identifies certain goods or services as 
those produced or provided by a specific person or enterprise.
c) Industrial design. The ornamental or aesthetic aspect of an article. The 
design may consist of three-dimensional features, such as the shape or 
surface o f an article, or two-dimensional features, such as patterns, lines, 
or color.
d) Copyright. The right granted to creators to protect their literary and artistic 
works.
e) Geographical indications. A sign used on goods that have a specific geo­
graphical origin and possess qualities or a reputation that are due to that 
place of origin.
In addition to these mechanisms there are new figures created by free 
trade agreements. DR-CAFTA (Free Trade Agreement between the United 
Status, the Dominican Republic and Central America) includes recognition 
of rights of deposit of microorganisms, the agreement on the distribution of 
program-carrying satellite signals, the international convention for the protec­
tion of New Varieties of Plants (UPOV),4 domain names on the Internet, and 
copyright-related rights.
Source: Prepared by the author with WIPO and DR-CAFTA data.
2.6.1 Protected Designation o f Origin in the European Context
Within the framework of its agricultural policy, in 1992 the European Union cre­
ated the quality-control systems Protected Designation o f  Origin (PDO), Protected 
Geographical Indication (PGI), and Traditional Specialty Guaranteed (TSG) to 
promote and protect certain agro-food products (EEC Regulation No. 2081/1992), 
thus unifying the standards in France, Italy, and Spain under the name Appellation 
d ’Origine Contrôlée (AOC) -  the first created by the Institut National des 
Appellations d ’Origine in 1935 -  the Denominazione di Origine Controllata (DOC), 
and Denominación de Origen (DO).
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The European Union distinguishes between Protected Designation of Origin 
and Protected Geographical Indication. In the former “all the productive processes 
(production, processing and preparation) must be carried out with recognized and 
proven specific knowledge,” whereas in the latter the link with the geographi­
cal milieu is manifested in “at least one stage in the productive process” (Art 2. 
Regulations (EEC) No. 2081/1992).
The procedure for registering Protected Designation of Origin and Protected 
Geographical Indications is under the tutelage o f the European Commission. The 
application for registration is done first before local governments, which process 
it before the Commission. The latter grants the designation after compliance with 
the requirements o f the case and the non-objection of the other members of the 
European Union. One of the requirements is forming a group of producers and an 
inspection agency, which can be a public entity, generally the ministry of agro-food 
resources, with the participation o f organized farmers.
In view of the lack of similar protection structures in other regions, the 
European Union recently initiated registration o f Protected Designation of Origin 
and Protected Geographical Indications of third countries (Regulation EC No. 
510/2006), whose products would thus be protected in the territory of the European 
Union.
2.6.2 Geographical Indications: Advantages and Risks
Geographical indications can create advantages for the protected regions and sec­
tors, but they also involve risks. Common advantages and risks are summarized 
below:
2.6.2.1 Advantages
The European experience shows that the regions to which designation of origin 
have been authorized have succeeded in “ .. .harmonizing productive efficiency 
in ‘traditional’ activities with technological innovation and growth of firms and 
employment.” (Quintar and Gatto, 1992).
The successful cases show the development o f networks of producers who com­
bine cooperation and competition. In a simple representation of game theory, the 
creation of these networks is possible when the producers assume that the cost of 
competing is greater than that of cooperating.
The designation of origin creates singular income for local producers of particu­
lar products by assigning them exclusivity of origin with the regulatory requirements 
(climatic conditions, type of product, process, and ingredients, among others).
The designation of origin implies making the characteristics of the product homo­
geneous, as well as its subjection to quality and hygiene standards which in the 
long term make it more distinctive. Monopoly in conditions of association enables 
farmers to have a certain control over the sale price, which increases their ben­
efits. Although this monopoly may on principle seem to be disadvantageous for
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consumers, in fact it can be a benefit as long as the rise in price reflects an increase 
in product quality. Another advantage for consumers is the certainty that they are 
purchasing the product with particular characteristics and an increase in the variety 
of goods at their disposition.
Monopolistic rents and the dynamics of protection of the designation of origin -  
farmers’ associations, strict quality controls, increasing production standards, etc. -  
can generate endogenous innovative processes.
Designation of origin contributes to improving farmers’ competitive and inno­
vative capacities, which motivate the transformation o f local productive systems, 
stimulating the forming of a territorial culture (Silva, 2005). This transformation 
does not involve the substitution of forms and techniques of production, but their 
appraisal and the introduction of innovative production processes which make local 
tradition compatible with the competitive environment. The advantage of combin­
ing micro ambits (local farmers) with macro settings (external competitiveness) is 
based on an endogenous vision of development, in which public-private association 
is a necessary element for promoting development.
2.6.2.1 Risks
The adoption of geographical indications in regions where the distribution of the 
means of production and technological capacities is very uneven can give rise to 
greater concentration o f wealth. In this regard it is interesting to study the case of 
agave tequila in Mexico (see Box 2.3).
Box 2.3 Economic and social consequences of protection 
of Agave Tequila in Mexico
The Denominación de Origen Tequila (DOT), instituted in 1974 and currently 
regulated by Mexican Standard NOM-006-SCFI-2005, is Mexico’s oldest. 
This protection was gradually expanded in agreements signed by Mexico with 
the United States, the European Union, Canada and Japan, the main markets 
for this beverage.
The appellation covers the entire state of Jalisco (124 municipalities) 
and municipalities o f Nayarit (8), Michoacán (29), Guanajuato (6), and 
Tamaulipas (11). This concentration is explained by the Jalisco origin of 
Tequila in the municipality of the same name, as well as by the concentra­
tion of plantations o f tequilana Weber blue agave, which cover approximately 
90% of all the DOT in the said region.
The economic effects o f DOT have been contradictory. On the one hand, 
thanks to public policies of protection for private initiative, the value of overall 
production of this beverage (without distinguishing sales categories or terms) 
rose in the last decade to reach the record of 2,240 million pesos in 2004
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(SAGARPÀ). This result evidenced not so much the increase in production 
of the beverage in liters, which actually fluctuated, but the final sale price 
(see Chart 2.2)
Chart 2.2
t e q u il a : Ev o l u t io n  o f  p r ic e s
AND PRODUCTION,
Chart 2.3
Some authors attribute these results to the increase in the competitiveness 
of the tequila industry, but this is not reflected in certain key indicators of 
the production chain. In fact, the production o f tequilana blue agave, the raw 
material of tequila, has been constant over time (see Graph 2.3). Likewise, 
the average quantity of agave plants used to distill one liter o f tequila and the 
proportion of labor (agricultural workers) in total production have gradually 
decreased (see Charts 2.4. and 2,5), which has an effective social impact in 
terms of demand for inputs and employment. In addition, the marked fluctua­
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This fluctuation led to the so-called Agave War o f  1996 due to oversup­
ply which sank the price o f agave to 0.75 pesos per kilo and ruined farmers. 
In 1999 scarcity raised the price to 14 pesos a kilo and this time it was the 
industries who suffered the consequences.
At present, three producers (Cuervo, Sauza, and Herradura) concentrate 
almost 60% o f production and have plans for self-supply, which has resulted 
in agave planting being deconcentrated from the original region toward 
others with agave at a lower price. There is no doubt that the dispute 
between agaveros and tequilems, and unequal power relations in the indus­
try do not favor the region’s harmonious development, despite the industry ’s 
considerable growth.
Source: Prepared by the author with data from Consejo Regulador del Tequila 
(CRT), SAGARPA, Llamas, Jorge (1999).
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Geographical indication should be defended from its possible infringers -  
producers from other areas, producers who violate the standards and characteristics 
of the product -  in search o f the benefits of public recognition and price of the 
original product. This defense has costs which can be very high. In cases in which 
protection benefits a small group of farmers of medium or small size, the costs can 
exceed the benefits and discourage regional productive organization.
One threat against successful geographical indications is unfair competition from 
farmers alien to the area delimited by the designation of origin, who, given a 
product’s reputation, find incentives in its illegal production. The consequences of 
unfair competition, in addition to the direct loss o f income caused to the legiti­
mate producers and the costs of litigation, harm the quality and good name of the 
product. The cost of preventing such competition is a disincentive for the creation 
of geographical indications. Effective public mechanisms to minimize this risk are 
essential.
Finally, it is important to bear in mind that the knowledge underpinning geo­
graphical indications is in the public domain, and therefore its appropriation is not 
regulated, much less prohibited. In this regard, geographical indications should be 
considered one of various measures of protection of traditional knowledge. This 
opens the possibility of other IPR, such as distinctive signs, trademarks, or tech­
nical ideas on how to make some products, regulating the matter in a overlapping 
manner (Rangnekar, 2004).
2.6.3 Endogenous development policies based on local 
innovation
Endogenous local development policies based on regional characteristics and on 
the assessment of their capabilities identify a strategy that would make it possible 
to integrate local production with the national and international spatial locations 
(UNDP/ILO/UNOPS/EUR, 2002). Following Bianchi’s (1992) view, two areas of 
action can be differentiated in public policies for intellectual protection o f industrial 
production: a macro level which defines entitlements and a micro level that defines 
capabilities.5
It is on this latter level that intellectual protection faces the greatest difficulties 
in Latin America. In contrast to European enterprises with well-defined institutional 
ambits, Latin America’s production units face problems derived from an insufficient 
educational, research, and production structure and the inability to enforce existing 
legislation. Another difference is that the competitiveness of small European firms is 
based on structures of cooperation, as is the case with the Italian industrial districts 
and the Spanish and French clusters, which are absent in Latin America’s tradition. 
Nor should one underestimate the importance of the macro level in which entitle­
ments are defined. Suffice it to recall that few Latin American countries regulate 
geographical indications.
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Public policy can help to create favorable conditions for the emergence of 
local endogenous development activities. On a macro level (Bianchi, 1996), the 
Government can provide the legal framework to facilitate the organization of pro­
ducers’ networks in certain regions and regulate the creation, registration, and 
protection of geographical indications.
Local know-how, supported by protection granted by trademarks and geograph­
ical indications, can be strengthened and evolve toward greater diversification and 
product reassessment. Financial policies -  access to credit -  and policies of support 
for innovation -  science, technology, education, etc.- are fundamental in making 
local processes gradually incorporate useful innovations.
Local innovation arises as a result of traditional knowledge and its appli­
cation to production. Local innovative processes can receive impetus from the 
demand side (demand for greater quality standards, regulations, and specifica­
tions) and from the supply side (improvements by firms to processes or products). 
In both cases, the elements described in Box 2.1 structure a supply of services 
that has proved to be very useful in introducing innovations into local productive 
systems.
Another important element is the dynamics o f forming capital stock. As illus­
trated by the case of Turrialba cheese in Costa Rica, local identity and capital 
stock, in addition to being the result of its own geographical and historical fac­
tors, are also built up constantly in spaces o f concerted agreement and trust among 
the stakeholders. These spaces can also be built or promoted by public policies 
(see Box 2.4).
Box 2.4 T\irrialba Cheese (Costa Rica)
The case of Turrialba Cheese of Costa Rica serves to analyze current lim­
itations of small-scale and informal production in contrast to organized 
and legally protected production. This cheese is produced in the vicinity 
o f the Turrialba Volcano, in the district of Santa Cruz de Turrialba. The 
dairy production involves around 175 production units, basically o f two 
types:
a) Family operated firms with informal production (60%), on a small scale, 
lacking o f strict standards of hygiene, without registration of trademark 
or marketing structure, which limits the marketing o f their products. In 
the year 2000, some of them formed the Asociación de Productores 
Agropecuarios de Santa Cruz de Turrialba (ASOPROA).
b) Agroindustrial mini-plants organized in general as cooperatives (some 25). 
Their origin goes back to 1989 through the Program of Rural Cheese mak­
ers promoted by public entities and international cooperation (Cascante, 
2003). Now they have more competitive technology which enables them
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to produce, in addition lo the cheese, sour cream, pasteurized cheeses, 
and butters. Moreover, hv operating in the formal sector, they benefit from 
trademarks and registers.
With regard to production strategy, whereas family operated firms tend 
to carry out “backward" vertical integration, since they are the producers 
o f the milk they use for cheese production, the mini-plants have special­
ized in processing by means o f “ forward" integration, including the stages 
o f transport and marketing. Cascante (2003) remarks that one of the ele­
ments that the development o f these rural agroinduslry mini-plants has 
achieved is the forming o f a capital stock manifested in the “capacity for 
transmission of information through the conglomerate."
Despite the advantages of formal enterprises, these suffer inconve­
niences similar to those o f the family-operated firms, among them the lack 
of industrial protection regulations and unfair competition. The latter takes 
place within and outside the organization and is harmful lo consumers, 
which is explained by the lack of process regulation, characteristics, and 
price margins so that the product has protection based on geographical 
indication.
In 2002 a second association o f dairy producers was created in 
Turrialba: the Asociación de Miniplantas de Turrialba (ASOPLUT). 
which has made it possible lo broaden the positive effects of association 
in the region.
Recently, ASOPROA took steps to obtain the designation of origin for 
Turrialba Cheeses at the Ministry of Agriculture and Livestock (MAG). 
Administrative procedures are in place since new regulations for Law 7978 
(Law on Trademarks and Other Distinctive Signs) have been recently put 
in place (2007). In parallel, the creation o f a Cheese Expo-Fair has been 
promoted, an annual event for marketing and publicity for the product 
(Cascante, 2003).
Source: Prepared by the author with data from Cascante (2003).
2.7 Foreign Direct Investment (FDI)
The determination showed by the majority o f the developing countries to attract FDI 
indicates their high expectations in its contribution to development. As Paus (2005) 
points out, on the macroeconomic level FDI is expected to generate greater invest­
ment, employment, and fiscal revenues. On the microeconomic level, spillovers 
in technology, marketing, and good business practices are expected. Faced with 
the regional weakness in capital formation, it is expected that these investments
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will replace the lack o f national investment and thus cover the cost o f the mod­
ernization of equipment and machinery necessary to compete in the international 
market.
Latin American economic performance shows weak capital formation which has 
not grown significantly in the last 15 years, remaining well below the 25% mini­
mum that the United Nations Conference on Trade and Development (UNCTAD) 
indicates as necessary for maintaining a process of sustained growth in the less 
developed countries (UNCTAD, 2003).
With regard to innovation, it has traditionally been maintained that NISs are 
based on the mobilization and development of a country or region’s endogenous 
economic potential. However, a number of authors (Asheim and Vang, 2006) indi­
cate that, due to limitations with regard to capital, training, formal education, and 
industrial knowledge, the developing countries often depend on exogenous sources 
of capital, technology, and knowledge.
Transnational corporations have always been a controversial source of capital, 
knowledge, and technology. Although FDI can be a source of financial capital that 
replaces the lack of domestic savings, increases local competition, and links local 
producers in some cases, it is also true that frequently its localization in particu­
lar countries is only a cost-reduction strategy. In such cases, its presence does not 
entail technology transfer nor support for or linkage to local firms or to training and 
research centers.
The possibility that a hosting economy can take advantage of FDI and embark on 
endogenous innovating processes furthered initially by exogenous sources depends 
on a number of factors. Absorption capability and the national strategy to link 
transnational corporations to the local productive system require special attention. 
In both cases the types o f protection for knowledge -  patents, utility models, indus­
trial secrets, among others -  are determining factors for transfer of knowledge and 
technology.
2.7.1 Absorption Capabilities
In order for a developing region to initiate a process o f systematic generation of 
knowledge and technological improvements by taking advantage of foreign invest­
ment, initially there is a need to develop capabilities for absorption of knowledge 
and technology.
Absorption capabilities are routines, habits, skills etc., that allow a company or its 
regional environment to benefit from the knowledge and information of the setting 
in which it finds itself, process them, and apply them so as to upgrade its capabilities.
For authors such as Cohen and Levinthal (1990), absorption capability is a func­
tion of original domestic knowledge -  prior to the arrival o f any foreign investment -  
and of the institutional context. The latter refers to the way in which the capital 
stock transmits and disseminates the knowledge contributed by a foreign com­
pany (spillovers) and the manner in which organizations support and promote this 
dissemination.
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The capability of a region to make the best use of the knowledge developed 
in other regions by foreign firms will largely depend on prior and continuous 
investment in human capital (ongoing training, curricular improvements, etc.). But 
it will also depend on the interaction between the transnational corporations and 
their environment: suppliers, universities, other transnational corporations, research 
foundations, etc.
Although to a large extent they existed prior to the arrival of foreign investment, 
absorption capabilities can also be created and reinforced with the passing o f time. 
However, it is also true that the rules with regard to appropriability of knowledge 
and technique are currently more restrictive than a few decades ago due to the reg­
ulations on intellectual property. For this reason, authors such as Chang (2002) 
indicate that by means of their stringent rules on intellectual property, the devel­
oped countries have kicked away the ladder they themselves went up, thus avoiding 
latecomers.
Moreover, the circumstances of the international market and investment attrac­
tion policies have changed a great deal over the past two decades. Until the early 
1980 s, Latin America applied import-substitution policies which discouraged inno­
vative FDI. In many cases FDI was viewed as a counterproductive competitor 
as regards local industry, which is why it was often faced with restrictions and 
adverse regulations. In many cases, restrictions on imports of inputs did not per­
mit the development of competitive industries at international level, and therefore 
the transnational corporations located in Latin America did not generally develop 
their export potential and remained as suppliers for the domestic market. By con­
trast, countries such as Korea and Hong Kong attracted FDI whose main purpose 
was achieving competitive prices in order to export. The circumstances enabled 
such countries to obtain certain performance conditions from those corporations, 
such as linkage to local firms, and activities to facilitate technology transfer, among 
others. Now it is very difficult to do the same due to the strong competition to attract 
FDI, so the host countries lack the negotiating muscle to obtain specific conducts to 
facilitate the transfer o f knowledge and technology.
For the above-mentioned reasons, the potential of FDI to transfer technological 
capabilities largely depends on domestic factors in the hosting economy that facili­
tate its absorption. Although IPR restrict certain activities that would facilitate that 
absorption, they also offer opportunities that countries should study and incorpo­
rate into their national innovation plans, i.e., greater disclosure of patent contents, 
expired patent data banks, exceptions to intellectual property rules for academic 
research centers, etc.
2.7.2 National Strategy o f Linkage to Transnational 
Corporations
Whatever the reason for which transnational corporations choose a particular region 
for their operations, the greater or lesser transfer of knowledge and technology they 
spill over will depend on the local strategy for linkage to them.
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Direct or indirect spillovers by transnational corporations tend to be scarce 
(Narula and Marin, 2005; Fosfuri et al., 2001) and, in many cases, these firms have 
explicit policies to reduce knowledge spillovers. Nevertheless, for many developing 
countries, basing a technological development strategy exclusively on endogenous 
capabilities can be a sentence for the strategy itself. Therefore, in many cases 
national innovation strategies go through a stage of attraction of FDI and linkage 
mechanisms to obtain the greatest contribution to national development.
Strategies for linkage to transnational enterprises tend to require the following 
elements:
a) Absorption capability of local firms
This element is fundamental and depends on the capabilities developed before 
the arrival of transnational corporations. However, as has been explained, 
absorption capabilities can be strengthened by means of specific actions: invest­
ment in physical and human capital, movement of employees and professionals 
between firms, and access to the international market and to high-quality inputs. 
The potential spillovers o f transnational corporations will only be taken advan­
tage of if local firms are capable o f absorbing them. This is also true for 
institutons other than companies: universities, research centers, and others.
b) Public programs that promote production linkages
The arriving of transnational corporations in a region does not automatically lead 
to the search for local suppliers or to local companies seeking to link themselves 
to them. Public programs that provide incentives and offer resources, generate 
personal contacts, etc., have proved useful for creating links between companies. 
One example is the Program Costa Rica Provides,6 which promotes production 
linkages between multinationals and small and medium-sized local firms. Its 
objective is to support the latter so that they become suppliers of the former. 
Among its actions are keeping a national register of local suppliers, lobbying, 
and making contact with multinational corporations and following up on the 
linkages achieved.
When they set up their business in some country, transnational corporations 
already have international suppliers that comply with their quality standards 
and extended services. Some local firms should begin by finding the niches in 
which they can supply transnational corporations and show that they can do so 
with identical or higher standards than their competitors. Local firms will often 
require certifications, substantial improvements in their productive processes, 
human capital, new knowledge, and significant investment for which public 
programs can be important allies.
c) Quality local teaching institutions with the capacity to adapt
Human capital with the skills required by transnational corporations is an impor­
tant factor in their investing decisions. But once the investment has been made, 
the country’s capacity to upgrade the skills and knowledge of its human capital 
can determine increases in the value chain of the firm itself.
In some sectors, especially those linked to Ieading-edge technologies, changes in 
the market and in technique tend to occur with increasing rapidity, which means 
that labor and educational programs must adapt quickly.
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The quality of training and teaching institutions and research centers is crucial 
for a region to be able to offer increasingly sophisticated links to transnational 
corporations. Such links in turn raise the company’s exit costs, which can result 
in greater links.
Laboratories can offer quality services, especially to local firms, so that they 
improve their products and services, as well as certifications and research 
programs suited to their needs.
The costs of graduating professionals and technicians whose knowledge and 
skills respond to the state of the art in their field are high for the developing coun­
tries. But it is a question o f a long-term goal so as to take growing advantage of 
potential FDI transfers,
d) Infrastructure
Some requirements that local firms have to comply with in order to link them­
selves to transnational corporations have their limits in national infrastructure: 
laboratories with sophisticated services, energy services, transport, telecom­
munications, hazardous wastes treatment, etc. Some of these services can be 
provided by the private sector, but if the latter is struggling to modernize, 
the assistance could come from the public sector as the main provider of 
infrastructure for development.
2.8 Final Considerations
As a development strategy, putting emphasis on local know-how and its production 
relations (linkages) is a means of support for endogenous processes of strengthening 
entrepreneurial capabilities and useful local knowledge.
Local endogenous development is a way to promote the market based on local 
knowledge and also to encourage continuous improvement of processes and prod­
ucts. In a market in which knowledge incorporated into tradable goods is increasing, 
the generation and incorporation o f domestic knowledge and its useful incorporation 
into the market becomes important.
In the current context, the rules regulating trade and industrial property pose 
challenges for small-scale producers and for strategies to promote local develop­
ment. Restrictions on copying and technological adaptation also curb the capacity 
for technological absorption and make it difficult to take technological leaps to reach 
the most advanced countries. Other than this, mechanisms to protect local knowl­
edge have been used little in Latin America and therefore their potential value is 
difficult to assess. Equally important but not much studied is the entry into new 
areas o f protection o f knowledge that could suit the countries of the region, for 
example, forms of protection of collective knowledge, mechanisms for access to the 
protection of that knowledge, etc.
Local endogenous development is one of the many public-policy options for 
supporting existing knowledge and strengthening its development. Equally impor­
tant can be a strategy of selective attraction of FDI, complemented by national 
efforts of support for the capacity of its utilization: absorption of its advantages 
and production linkages.
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The way in which a country or region creates or uses knowledge and inno­
vations is highly relevant in the current context. There is a need for a national 
innovation system which is constantly reinforced in order to boost local innova­
tive capabilities. These systems should use all the available tools, among them the 
incentives of intellectual property rules. As part of national innovation systems, the 
weight of standards of protection of intellectual property is ever greater, especially 
in open economies with a strong weight of foreign trade. It is therefore essential to 
seek the opportunities that these rules offer, use their flexibility for the promotion 
of national innovation policies, and adapt them to the local reality one wishes to 
protect.
Notes
1. These processes have led to the largest firms being rewarded, which is why in countries such 
as Costa Rica, which has successfully entered international trade currents -  exports rose from 
21.7% of GDP in 1985 to 47.4% of GDP in 2005 -  distribution of wealth has worsened, mea­
sured on the Gini index, from 0.3512 (1985) to 0.4567 (2004) (INEC, National Survey on 
Household Income and Expenditure, 2004).
2. Author’s own translation into English.
3. Its members are Algeria, Bulgaria, Burkina Faso, Congo, Costa Rica, Cuba, Czech Republic, 
France, Gabon, Georgia, Haiti, Hungary, Israel, Italy, Mexico, Moldova, Peru, Portugal, 
Republic of Korea, Serbia and Montenegro (before their division), Slovakia, Togo, and Tunis.
4. UPOV (Union for the Protection of New Varieties of Plants). Agreement on protection of intel­
lectual property of the process of plant improvement to encourage the creation of new plant 
varieties (WIPO).
5. According to Bianchi (1996), “the macro level defines the entitlements of those who can take 
part in the game, creates the regulatory system governing the behaviour of the stakeholders and 
sanctions ‘evaders’ and the abuses of those who occupy dominant positions” ( . . . )  “The micro 
level defines the capabilities of the stakeholders in the economic arena, which means that micro 
policies include not only local firms, but also educational institutions, infrastructure, etc.”
6. See web site: www.crprovee.com
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Chapter 3
T h e  F le x ib i l i ty  o f  T R I P S  a n d  I t s  P o s s ib le  
E r o s io n  in  B i la t e r a l ,  M u l t i l a t e r a l ,  
a n d  R e g io n a l  N e g o t ia t io n s
Andrés Moncayo von Hase
3.1 Introduction
The architecture o f intellectual property rights has become increasingly complex, 
especially since the entry into force o f the 1995 Agreement on Trade-Related 
Aspects of Intellectual Property (TRIPS) reached during the Uruguay Round of 
GATT which ended in the establishment of the World Trade Organization (WTO).
Certain important issues have arisen over time, such as the need to estab­
lish an adequate interaction between intellectual property rights and public health 
needs expressed in the Doha Declaration of November 14, 2001. Likewise, at 
present, intellectual property rights constitute an essential aspect o f bilateral and 
regional trade negotiations, to the extent that trade agreements signed recently by 
the European Union and the United States with various countries include chapters 
on the matter, many of which expand the rights and obligations provided for in 
TRIPS. In addition to this are the exercises in alignment of patent laws in the World 
Intellectual Property Organization (WIPO) and the negotiations and instruments on 
access to genetic resources, their conservation, and the fair and equitable benefit 
sharing at the Convention on Biological Diversity and the Treaty on Plant Genetic 
Resources for Food and Agriculture in effect since mid-2004. All of this poses the 
challenge to the developing countries of adopting the complex framework of intel­
lectual property as a tool for their development objectives and not as an end in itself. 
Currently there is a sort o f permanently open negotiations agenda in this field.
Some o f the issues that have been the object of discussion in various bilateral 
and multilateral forums will be dealt with in this chapter, namely ( 1) patentability,
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(2) patents and public health, (3) undisclosed test or other data, and (4) exhaustion 
of rights and parallel imports. Many recently signed trade agreements, especially 
bilateral ones, tend to limit and fade the flexibility margin of TRIPS. Below 
we will cover the aforementioned issues and the international negotiations tak­
ing place around them, considering the possible impacts at national and regional 
levels.
3.2 Patentable Subject Matter
3.2.1 Introduction
Article 27 of the TRIPS Agreement, under the title “Patentable Subject Matter,” 
evinces the importance and growing weight o f immaterial goods in the economy 
and in companies’ strategies, particularly in the most developed economies.
This provision sets a broad standard of patentability based on non-discrimination, 
in terms o f the technology or the place from where it originates and specifies the spe­
cific cases and grounds for which the Members may exclude certain developments 
of patentability.
Article 27 states
1. Subject to the provisions of paragraphs 2 and 3, patents shall be available for 
any inventions, whether products or processes, in all fields o f technology, pro­
vided that they are new, involve an inventive step, and are capable of industrial 
application.1 Subject to paragraph 4 of Article 65, paragraph 8 of Article 70, and 
paragraph 3 o f this Article, patents shall be available and patent rights enjoyable 
without discrimination as to the place of invention, the field of technology, and 
whether products are imported or locally produced.
2. Members may exclude from patentability any inventions, o f which the prevention 
within their territory of commercial exploitation is necessary to protect ordre 
public or morality, including to protect human, animal, or plant life or health or 
to avoid serious prejudice to the environment, provided that such exclusion is not 
made merely because the exploitation is prohibited by their law.
3. Members may also exclude from patentability:
(a) diagnostic, therapeutic, and surgical methods for the treatment of humans or 
animals;
(b) plants and animals other than microorganisms, and essentially biological 
processes for the production of plants or animals other than non-biological 
and microbiological processes. However, Members shall provide for the pro­
tection o f plant varieties either by patents or by an effective sui generis 
system or by any combination thereof. The provisions o f this subparagraph 
shall be reviewed 4 years after the date of entry into force of the WTO 
Agreement.
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3.2.2 The Non-discrimination Principle
Paragraph 1 of Article 27 enshrines as a basic principle that patents shall be available 
for any inventions, whether products or processes in all fields of technology, without 
discrimination as to the place of invention and the field of technology, provided that 
they are new, involve an inventive step, and are capable of industrial application.
On interpreting the notion of “ non-discrimination” in the case of “Canada Patent 
Protection of Pharmaceutical Products” contemplated in Article 27.1, the Special 
Group instituted in the sphere of the dispute settlement mechanism of WTO, within 
the framework of TRIPS, in some way advised to avoid the use of the term “dis­
crimination” in the cases in which other more precise standards should be available. 
Thus, certain TRIPS provisions referring to discrimination -  such as national treat­
ment (Article 3) and that of most favoured nation (Article 4) -  were drafted in a 
more precise manner without alluding to the concept of “discrimination,” which has 
a potentially broader interpretation than any other specific definition and pejorative 
connotations in the sense of unjustified imposition of differentially disadvantageous 
treatment (de jure discrimination). Discrimination may be due to an ostensibly 
identical treatment but which, due to existing differences in circumstances, has 
differentially disadvantageous effects, which at times is called “defacto  discrimina­
tion.” In view of the “infinite complexity” of the term, the Special Group deemed it 
advisable to dispense with it when possible, or interpret it cautiously, in order not to 
give it more precision than that which is intrinsic in this concept.2
The Special Group recalled that diverse panels of the General Agreement on 
Tariffs and Trade (GATT) and the WTO had been dispatched as regards de notion 
of de jure and defacto  discrimination. These recommendations have analyzed mea­
sures that were in conflict with various rules of GATT or WTO and have tended 
to prohibit various forms of discrimination. However, as the Appellate Body has 
emphasized on repeated occasions, the said recommendations have been based on 
the questioned legal text, in such a way that it is not possible to treat them as con­
crete applications of a general concept of “discrimination.” Therefore, the Special 
Group decided to dispense with any prior general definition of such a concept and 
opted definitively for first analyzing the issues debated in the case and defining the 
concept of discrimination only to the extent that it were necessary.
It is interesting that the Special Group established particular guidelines and clari­
fications on the principle of non-discrimination in Article 27.1 on the measures that 
Members may adopt under Articles 7 and 8 and the “limited” exceptions to the 
rights of patent holders in Article 30 of TRIPS.3 In this regard, the Panel states that 
“ it is not true that Article 27 requires all Article 30 exceptions to be applied to all 
products. Article 27 prohibits only discrimination as to the place of invention, the 
field of technology, and whether products are imported or produced locally. Article 
27 does not prohibit bona fide exceptions to deal with problems that may exist only 
in certain product areas.”
From this reasoning one can infer that a national policy based on Articles 7 (pro­
motion of technology transfer) and 8 (public health and nutrition and needs) can
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result in exceptions in good faith for rights that could have effect on specific prod­
ucts. What is to be avoided with the principle of non-discrimination of Article 27.1 
is that the public authorities succumb to domestic pressures so deliberately "limit 
exceptions to areas where right holders tend to be foreign producers. ”4
3.2.3 The Concept o f Invention Under TRIPS and Positive 
and Negative Conditions o f Patentability:
The Case o f Computer Programs
The TRIPS Agreement does not define the concept of invention. It does, however, 
stipulate that patents be granted to any product or invention process , as long as they 
are new, involve an inventive step, and are susceptible to industrial application. 
Nor are these three requirements defined, which means that their interpretation and 
application remains in the Members’ judgement.
Some Members have established in their laws a general definition to the concept 
of invention (although this practice is tending to disappear) and others distinguish 
the invention o f the discovery itself. Thus, inventions are associated with human 
creations that transform matter or energy for its utilization by man.5 Other regula­
tions, such as those of the United States and Canada, conceptually characterize the 
“patentable subject matter” by providing for the possibility o f patenting “any new 
and useful process, machine, manufacture, or composition o f  matter. ”
Aside from these differences, national laws in general define the essential 
legal components o f the invention in accordance with the three requirements for 
patentability specified in Article 27.1 of TRIPS. Obviously, the pertinence of the 
patents will depend on how the Members define and interpret the so-called con­
ditions or positive requirements for patenting, that is, novelty, inventive step, and 
industrial application. A lax interpretation of such conditions can result in the grant­
ing of trivial patents which will not benefit society by blocking new research and 
not generating genuine incentives for research and development.
In any event, the fact that TRIPS has not legally defined the notion of inven­
tion, nor specified the scope and content o f the positive requirements or purpose of 
patentability, has conferred on the Members a margin for action to continue with 
a practice prior to TRIPS, which consists of establishing “negative conditions of 
patentability.” In fact, the current patent laws are not limited to establishing the pos­
itive and objective conditions of patentability of inventions, but set forth the cases 
in which legislators consider a priori that the invention does not exist.
Now, it is worth asking how the right of defining “negative conditions of patent­
ing” combines with the principle of non-discrimination set down in paragraph 1 of 
Article 27, which prescribes that patents may be obtained and their rights enjoyed 
without discrimination with regard to the field and the technology. Can a national 
legislator, for example, decide that computing programs are not a “technology” or 
do not constitute a patentable invention?
Contemporary practice shows that many WTO Members are unwilling to inter­
pret that the principle o f non-discrimination of Article 27.1 entails the obligation to
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recognize the patentability of computer programs. Thus, for example, the European 
Patent Convention does not consider computer programs inventions “as such” 
(Articles 52.2 and 3), although the European Patent Office (EPO) has been increas­
ingly inclined to interpret the said provision in a restrictive manner by accepting 
patents for programs that display a “technical effect.” This would be the closest 
intermediate position to the traditional public perception of what a patent means 
and seeks to protect. The most extreme position is that of the United States and 
Japan, which tend to protect computer programs and their effects, not necessarily 
technical, by extending patent protection to business methods (Lind-Edlund, 2003).
In any event, beyond possible interpretations, the legislative practice of WTO 
Members in general has not expressed the legal conviction that Article 27.1 obliges 
them to authorize patents for computer programs. Thus, for example, France’s 
national legislation prohibits them, although this country is a Member of the 
European Patent Convention which has granted numerous patents to computer 
programs that have the effect of a national patent (Le Toumeau, 2003).
To be sure, in the current state of affairs, and without prejudice to the obli­
gation o f granting computer programs protection under copyright regulations, the 
Members have the right to define the legal concept of invention and the negative 
conditions of patentability in order to open or close the path to patenting com­
puter programs, without reaching the extreme o f denying them protection for the 
sole reason that they are inventions of an computer nature, or come from that 
industry.
3.2.4 Patenting Exclusions in TRIPS
3.2.4.1 Ordre Public, Environment and Health
Paragraphs 2 and 3 of Article 27 contain the patenting exclusions permitted to the 
Members o f WTO. The first permits excluding the patentability o f inventions whose 
commercial exploitation in the territory o f the interested Members should be pre­
vented to protect ordre public or morality, including to protect human, animal, or 
plant life or health or to avoid serious prejudice to the environment. The exercise of 
this right is subject to the exclusion not being made merely because the exploitation 
of the patent is prohibited by national legislation.
Thus, Members can deny patentability, for example, for food and pharmaceuti­
cals which in their view are harmful to health. This provision is also important for 
genetically modified organisms, whose use has been criticized by sectors of civil 
society in many countries owing to the dangers they can entail for the preservation 
of the environment and biodiversity by transferring genes to the microorganisms 
present in the soil, genetic recombination, and the appearance o f new pests and 
diseases. However, it is also true that many o f them have contributed to the develop­
ment of agriculture without it being possible to determine the specific damage they 
could cause.
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In any case, the legal importance of this provision should not be underestimated, 
for it could be a link to the Convention on Biological Diversity (CBD) into force 
since 1993. CBD puts forward the following objectives: (i) conservation of biologi­
cal diversity, (ii) sustainable use of its components and organisms, and (iii) fair and 
equitable sharing of the benefits arising out the utilization of genetic resources. In 
few words, it could be said that Members have the right to exclude inventions from 
patenting (e.g., genetically modified organisms) contrary to the objectives of CBD. 
All of this without ignoring the practical difficulties that could stem from apply­
ing exclusions o f this nature to biotechnological inventions, as many national laws 
consider that the objective o f patents is to encourage innovation, reserving for other 
branches of law, such as environmental law, to consider the risks and remedies to 
avoid them, including o f course, prohibiting the exploitation, or marketing o f the 
patented invention.6
3.2.4.2 The Right to Prohibit Diagnostic, Therapeutic, 
and Surgical Methods
Article 27.3(a) of TRIPS confers the right on Members to also exclude from patents 
“diagnostic, therapeutic and surgical methods fo r  the treatment o f  persons or 
animals. ”
This exclusion, together with the absence of greater specifications on the differ­
ence between invention and mere “discovery,” makes it possible to infer that there 
could be discrepancies on the level of protection that Members can grant to what is 
known as second use of substances or known products. This is particularly impor­
tant for the pharmaceutical industry. Thus, bearing in mind that Article 27.1 makes 
it mandatory to grant patents for products or procedures, it says nothing, by con­
trast, about their uses. The same occurs with Article 28, which refers to exclusive 
rights that Members are obliged to recognize for patents’ holders of “products” and 
“procedures.”
In such a regulatory context, it is logical for differences to appear among 
Members. Some of them have not used the right to exclude from patentability 
diagnostic or therapeutic methods, stipulated in Article 27.3.a). Canada, for exam­
ple, admits the patentability of diagnostic methods. The United States admits, in 
addition to patents on therapeutic methods, those of second pharmaceutical indi­
cation as “method o f  use. ” This means that in “discoveries” or “inventions” of 
a method to cure sicknesses with known substances, the method itself may be 
patented.
The situation in the field o f the European Patent Convention is more complex, 
for it does not consider methods for treatment of the human or animal body as 
inventions susceptible to industrial application. It only admits one exception for 
pharmaceutical patents, limited to the first therapeutic indication. However, the 
European Patent Office (EPO) has admitted patents of second use or pharmaceu­
tical indications indirectly by means of the “ Swiss formula,” that is to say, as a 
claim for a procedure in the form of “Use o fX  in the manufacture o f  a medicine fo r  
the treatment o f  Y. ”
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Others understand that the claim for a new use of a product or a known sub­
stance is equivalent to a therapeutic method that Members of WTO can exclude from 
patenting. If patents protect inventions, finding a new application o f a known prod­
uct would be comparable to a discovery not susceptible o f patentability. This is the 
direction taken by the Andean Community, whose Common Intellectual Property 
Regime (Decision 486) establishes in Article 21 that “products or processes already 
patented and included in the state o f  the art ( . . . )  will not be the subject o f  new 
patents on the mere ground o f  having been put to a use different from  that originally 
contemplated by the initial patent. ”7
Argentina’s patent law only recognizes this type of titles for products and pro­
cesses, but says nothing about the patenting o f new or second use of known 
substances or products, on which diverging opinions exist. Chilean laws, on the 
other hand, expressly provide for them.
As a consequence of the flexibility or lack of express regulation for second uses 
of products, known substances, or compounds, the solutions vary among countries, 
whether industrialized or developing. This means that under TRIPS, Members are 
free to adopt any of the stances provided for according to considerations based 
on protection o f public health, the level of economic development, or the need to 
encourage innovation. These differences among legislations seem to take advantage 
of the flexibility of TRIPS and the Doha Declaration on TRIPS and Public Health 
of November 14, 2001.
3.2.4.3 The Process of Review of Paragraph (b) of Article 27
This provision authorizes Members to exclude the following from patentability:
b) plants and animals other than microorganisms, and essentially biological processes for 
the production o f plants or animals other than non-biological and microbiological pro­
cesses. However, Members shall provide for the protection of plant varieties either by 
patents or by an effective sui generis system or by any combination thereof. The provi­
sions o f this subparagraph shall be reviewed four years after the date of entry into force of 
the WTO Agreement.
i) The process o f  gathering information. In its meeting of December 1988, the 
TRIPS Council agreed to begin the anticipated process of review through the 
gathering of information from the Members which should inform how they were 
applying Article 27.3 (b) in their jurisdictions. There was agreement in this 
regard, but not on how the process of review of Article 27.3 should be carried 
out. Countries such as India, Brazil, Egypt, and the Philippines sustained that the 
process of review to be carried out by the TRIPS Council should be substantial. 
The United States proposed revoking all exclusions permitted in the provision. 
The European Union initially insisted on changes, but finally accepted that it was 
not necessary to undertake a process of review and reform, but that it was suf­
ficient to carry out the informative process on implementation of the article in 
question.
At present, it seems to be an emerging tendency or consensus toward leaving the 
article as it is. For developing countries, it would be a way to maintain the delicate
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balance of interests in an area characterized by major differences between the 
Members of WTO. Developed countries, particularly the United States, have taken 
steps to reduce the margin of flexibility provided for in Article 27.3 (b) in their bilat­
eral and regional trade agreements, which stipulate adherence to the International 
Convention for the Protection o f New Plant Varieties (UPOV, 1991) and to the 
Budapest Treaty on International Recognition of the Deposit of Microorganisms 
for the Purposes of Patent Procedure (1980), demanding also a future commitment 
of the Parties to make efforts to provide patent protection for plants. In general, the 
developed countries have begun to place emphasis on the exercise of harmonization 
of patent right undertaken several years ago by WIPO.
ii) Positions on patenting o f  plants and animals. There was a clearly favorable posi­
tion for broad patent protection for inventions related to animals and plants,
which may be summarize as follows:
-  Inventions relative to animals and plants should receive patent protection, in 
the same way as inventions in other fields, in order to promote private sector 
investments in innovation activities that contribute to solving problems in 
areas such as agriculture, nutrition, health, and environment in all countries 
(Japan and Switzerland).
-  To that end, it is necessary to have international regulations to protect 
inventions in animals and plants and not depend on national regulations 
(Singapore).
-  Patents facilitate technology transfer and dissemination of the state of the art 
and provide an incentive to the private sector to establish contract licensing, 
thus avoiding confidentiality (Australia).
-  The requirements of disclosure and the control conferred on patent holders 
can facilitate the implementation o f laws designed to protect public morality, 
health, and the environment (Switzerland) (Table 3.1).
Against these positions, various developing countries expressed their concern 
for the growing tendency of developed countries to grant patents to different forms 
of life due to the negative impact this could have on development, food security, 
culture, and morality (India), namely
-  The granting of patents for plants may have a strong impact on access, cost, 
reuse, and exchange o f seeds among farmers, displace traditional varieties, 
and affect biodiversity (Kenya).
-  The granting of excessively broad patents that do not satisfy patentability 
requirements has a negative impact on genetic material, traditional knowl­
edge, and the cost associated with revocation of the said patents, while at the 
same time encourages “biopiracy.”
-  Another cause for concern is that international agreements mainly protect 
the interests o f innovators, unlike those o f countries and communities that 
contribute the genetic material and traditional knowledge that serve as the 
basis for innovations, for which reason agreements should be “rebalanced” in 
order to render more efficient the principles of CBD relative to prior consent 
and equitable benefit sharing.9
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Table 3.1 TRIPS council: process of gathering information under Article 27.3 information on 
25 Members of WTO8
Illustrative list of questions (patent systems) Yes No
Did not 
answer
Is there any basis for denying a patent on an 
invention consisting of an entire plant or 
animal?
17 6
Does the patent regime exclude entire plants or 
animals as inventions?
Is it possible to obtain a patent claim that:
2 13 8
Is not limited to a specific animal/plant variety? 
Is expressly limited to one plant or animal
13 5 5
variety?
Is expressly limited to a group of plants or
9 11 3
animals?





Is it possible to obtain a patent on an essentially 
biological process?
5 17 1
Is it possible to obtain a patent for matter 
identical to that found in nature?
1 17 6
Does the national law contemplate a “sui 
generis" protection?
22 2 2
The form adopted conforms to UPOV 1978 or 
1991
Is prior authorization from the right holder 






For research to develop new varieties? 22 2
To commercially exploit a variety different from 
the protected one, but sharing its essential 
characteristics?
13 8 3
Can a farmer harvest seeds from his planting of a 
protected variety legitimately obtained, store 
it, and replant it in his plantation?
1 20 3
If prior authorization is not required, are there 
mechanisms for remuneration to the right 
holder?
7 12 5
Source: Prepared by the author with WTO data.
In this context, the suggestions made in the discussions on the review of Article
27.3 (b) were the following:
-  Exceptions to patentability authorized by Article 27.3 (b) are unnecessary and 
protection should be granted to all inventions relative to plants and animals 
(United States).
-  The provision should be kept as it is (Australia), without diminishing the 
level of protection (Japan). The rule provides a balance by preserving 
Members’ right to decide whether they exclude plants and animals from 
patenting according to their own needs and interests. There should only be a
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process of assessment of the implementation of the rule at the national level 
(Japan).
-  Article 27.3 (b) should be made more precise to prohibit patentability o f all 
forms of life, especially plants and animals, microorganisms and their parts, 
including genes and natural processes that plants, animals, and other living 
organisms produce (India). Some followers of this position suggested that the 
rule be modified in accordance with the general exceptions and those linked 
to security in other WTO agreements (Kenya). It was proposed to modify 
the article in such a way that it prohibits patenting o f inventions based on 
traditional knowledge and of those that violate Article 15 of CBD, which 
recognizes the sovereign right of States over their natural resources (India). 
It was also suggested that the obligation o f the developing countries to imple­
ment Article 27.3 (b) should have a term of 5 years after the review process 
has been concluded (Kenya on behalf of the African Group).
-There were also proposals on the requirement of disclosure and dissemination 
of genetic material and traditional knowledge used in inventions.
iii) Scope o f  the exceptions to patentability in Article 27.3 (b). First of all, it was 
emphasized that the absence of definitions for the terms “plants,” “animals,” 
“microorganisms,” and others specified in this provision gave rise to doubts as 
regard the scope o f patenting (Brazil).
With regard to the definition of the terms “plants” and “animals,” it was suggested 
that the parts of plants and animals that are excluded from patentability should be 
clarified (India), and there should also be a prohibition on patenting of cells, lines 
of cells, genes, and genomas (Kenya).
With regard to microorganisms, it was stated that there are no scientific reasons 
for distinguishing between plants and animals, on the one hand, and microorgan­
isms, on the other. Both should be excluded from patentability on account o f being 
living matter, which can be discovered, not invented (Kenya). It was also expressed 
that there is no scientific consensus on the meaning of the term “microorganism” 
(Brazil). For example, it has been questioned whether cell lines, enzymes, plasmids, 
and genes qualify as microorganisms (Brazil).
In response to these positions from developing countries, various developed 
countries expressed that the distinctions contained in Article 27.3 (b) are in keep­
ing with the generally accepted scientific classification of organisms (Switzerland) 
and that the practice of classifying life forms into plants, animals, and microor­
ganisms is widely accepted in international agreements, including CBD (Japan). It 
was maintained that the fact that TRIPS does not define the term “microorganism” 
only reflects that it has not been defined by patent experts in other fora such as 
the Budapest Treaty on International Recognition of the Deposit of Microorganisms 
for the Purposes of Patent Procedure and the meetings of experts on biotechno­
logical inventions at the headquarters of WIPO between the years 1984 and 1988. 
A document prepared by the United States patent office, Japan and Europe (EPO) 
stress that none of the laws administered by them contains a formal definition of the
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term “microorganism.” The administrative patent guidelines do not define either, 
and only identify specific microorganisms in a non-exhaustive list of organisms that 
can be included within such a term. As the EPO has noted, it would not be very 
practical to adopt a definition subject to frequent updates due to the rapid evolution 
of knowledge in microbiology. Therefore, if the definition was not made before, it 
would not be wise for the TRIPS Council to do so now.
In regard to the actions that should be adopted in WTO on treatment of 
microorganisms, the following opinions were expressed:
-  Microorganisms and other living or biological organisms should be excluded 
from patentability (Kenya).
-  The scope of the term “microorganism” should be clarified to exclude cell 
lines, enzymes, plasmids, cosmics, and genes (Kenya).
-M embers may determine and apply the term individually in their own national 
jurisdictions in accordance with Article 1.1 o f the Budapest Treaty, without 
trying to define it. Since the subject is a complex one, its interpretation should 
be left to patent offices and experts (Korea).
-  The subject should be left to national policies so that they decide whether 
microorganisms are patentable (India).
-  It is important to know the path taken by each Member within the framework 
of its own legal provisions in order to have a collective understanding of the 
terms under discussion (Australia).
Regarding microbiological and non-biological processes, the concern was voiced 
that Article 27.3 (b) should incorporate specific patenting obligations, but that it 
should not propose any definition (India). It was suggested that the artificial distinc­
tion between essentially biological processes, on the one hand, and microbiological 
and non-biological processes, on the other hand, be suppressed and both processes 
be given the same treatment (Kenya) or that the distinction be clarified (Brazil).
iv) Conditions o f  patentability in Article 27.1 and inventions relative to plants and 
animals. In the review process there were discussions about the manner in which 
novelty requirements, inventive step (not obvious), and industrial application 
(utility) are applied in microorganisms, microbiological processes, and other 
inventions related to plants or animals that may be patentable under national 
laws. In this regard, emphasis was placed on the lack of clear definitions of the 
notion of “ invention” and the scope of patentable microorganisms, microbio­
logical processes, and non-biological processes (India). Thus it was expressed 
that the national patent offices are the ones which should define these questions 
(Venezuela), although leaving them to the sole discretion o f the Members could 
cause inconveniences (India).
One of those inconveniences would be laxity in the appreciation of requirements 
for novelty, inventive activity, and industrial application, which would question the 
credibility of the system (Brazil).
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During the discussions the problem of the distinction between discoveries and 
inventions also arose, in particular the requirements to satisfy the test o f inventive 
step or non-obviousness. It was stated that by stipulating that microorganisms and 
microbiological processes are patentable, TRIPS violates a basic premise of patent 
law which establishes that discoveries, in contrast to inventions, are not patentable 
(Kenya on behalf of the African Group).
The response to this approach was that life forms in their natural state do not 
satisfy the criterion of patentability of TRIPS. However, phenomena that occur 
naturally such as chemical substances and microorganisms that have been arti­
ficially isolated from their natural environment can indeed constitute inventions. 
When the patent subject matter involves sufficient human intervention, such as iso­
lation or purification, and turns out to be matter whose existence was unknown until 
then, it can be considered a patentable invention (Japan, Switzerland, United States 
and Malaysia). To meet the criterion of patentability, plants, animals, or microor­
ganisms and other genetic resources should be altered by the hand of man and 
produced by means of technical processes (Japan, European Union, United States, 
and Switzerland).
As regards the requirement o f novelty, it was mentioned that some Members 
define it in such a way that they do not recognize information that is available to the 
public and that is used and transmitted orally beyond their jurisdictions (India and 
Kenya). Thus, much traditional knowledge becomes the object o f patents without 
benefiting the communities that develop and transmit it.
It was also sustained that it was not clear whether certain patents of microorgan­
isms adequately satisfy the requirement of industrial application, bearing in mind 
that its usefulness is doubtful even for the applicant himself (Brazil). Furthermore, in 
relation to patents involving genetic sequences, some Members demand describing 
its function and others do not (Pakistan).
In the face of these concerns, it was argued that the system provides for reme­
dies such as opposition or revocation of the patent (Switzerland). The concern 
expressed by some developing countries is that such processes are very costly, 
especially those which do not admit opposition prior to the granting of the patent 
(India).
v) Sui generis protection for plant varieties: Regarding this point, developed 
countries held that plant varieties should be protected since this makes it 
possible to develop new technological solutions in the field of agriculture. 
The progress on the subject includes the development of new crops with 
greater productivity and resistance to pests and diseases (Japan and United 
States).
A group of developing countries voiced its concern over the adverse impact that 
protection of plant varieties can have on food security and the development of rural 
communities whose traditional knowledge has produced common varieties, includ­
ing many valuable ones for medicine and biodiversity (Kenya). Concern was also
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expressed that protection systems should hinder cooperation between neighboring 
farmers, a frequent situation in many developing countries (India).
In any case, some Members expressed that Article 27.3 (b) provides Members 
with flexibility to interpret the meaning of sui generis protection of plant varieties 
and that therefore, their status should not be modified (Brazil, Egypt, Malaysia, 
Mexico, Peru, and Venezuela). Some proposed to leave Article 27.3 (b) as it is, 
adding some clarifications on the meaning of “effective protection” (Brazil). The 
following points were proposed:
•  Making reference to the UPOV Convention (European Union).
•  Including a footnote after the phrase relative to the protection of plant varieties, 
stating that any system of sui generis protection o f plant varieties can establish 
( 1) protection for innovations of indigenous communities and local farmers in 
developing countries that are consistent with CBD and the International Treaty 
on Plant Genetic Resources for Food and Agriculture, in force since June 29, 
2004; (2) continuation of traditional agricultural practices that include the right 
to retain and exchange seeds and to sell farmers’ crops; and (3) prevention of 
anticompetitive practices.
The Members also held discussions as to whether there is a criterion to judge the 
effectiveness of a sui generis system. The United States maintained that there was 
and that it was already being applied in other areas of real and intangible property. 
This consists o f the following: (1) defining the nature o f the protective subject mat­
ter; (2) providing a clear difference between the protected subject matter and the 
excluded matter; (3) determining who is entitled to request protection; (4) clearly 
expressing the circumstances under which rights exist and limitations appear; (5) 
specifying the term of the rights and the circumstances that determine their loss, 
expiry, and extension; and 6) identifying legal actions and proceedings to guarantee 
observance of rights.
The opposite position was expressed by India, which maintained that TRIPS had 
no criterion whatsoever to judge the effectiveness o f sui generis systems.
Nor was there agreement on the subject matter to be protected by the sui generis 
system. To be effective, the system should include the whole of the plant kingdom 
(Uruguay). By contrast, some countries expressed that Article 27.3 (b) refers only 
to a sui generis system, without specifying details of the plant varieties to be pro­
tected (Peru). It was also emphasized that some farmers’ privileges have been left 
to national legislators (Switzerland). In response to this, it was argued that farmers’ 
privileges should not be limited to keeping and reusing (plantation) of the subject 
matter of protection within their plantations (Kenya).
There were also discrepancies regarding the term of rights. One stance assigned 
them 20 years from the date o f granting to prevent the marketing of the protected 
matter or the preparations for this by third parties without authorization of the patent 
holder. The term of protection of new varieties o f trees and wines should be 25 years 
as their development and marketing need more time (United States). Counter to this
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opinion, other delegations considered that a sui generis system does not require a 
term of protection similar to that of patents, as Article 27.3 (b) does not specify it. 
Effective sui generis methods o f protection such as UPOV admit a different duration 
(India).
vi) UPOV: a system o f  ‘‘sui generis” protection effective under Article 27.3
(b)? The Members also analyzed whether the protection of plant varieties 
by means of the UPOV regulations could be considered effective sui generis 
protection in the light of Article 27.3 (b) of TRIPS. In this regard, it was 
said that
1) TRIPS does not compel Members to follow the UPOV model of protection, 
but the latter satisfies the requirement of effectiveness of Article 27.3 (b) 
(Switzerland, Japan, United States, Uruguay, and the European Union).
2) The UPOV system is the most suitable for favoring and stimulating the 
development of new varieties in all the WTO Member (United States).
3) With regard to the concerns about the impact o f UPOV on the right of farm­
ers and plant breeders in developing countries, the flexibility of the system 
for satisfying national needs, such as the exception that protects farmers, was 
underscored.
4) Some delegations recognized the difficulties of creating and managing sui 
generis systems to protect plant varieties, but they maintained that the quickest 
and most effective way of implementing Article 27.3 (b) was to depend on sys­
tems of protection o f varieties aligned flexibly to satisfy special national needs 
(European Union).
In answer to these opinions, other countries considered:
1) Article 27.1 (b) should not make any reference to UPOV, nor commit Members 
to use that system (Norway), although it is admitted that this is an important 
reference (Brazil). The Members can choose between other models of protection, 
such as that of the CBD and the International Treaty on Plant Genetic Resources 
for Food and Agriculture (Brazil, India, and Zambia).
2) Incorporation o f references to UPOV could alter the delicate balance o f Article
27.3 (b) (Brazil).
3) There is no authorized interpretation as to whether UPOV satisfies the require­
ments of Article 27.3 (b) (India and Thailand).
4) UPOV is based on the protection of plant breeder in industrialized countries, 
not on the needs of the developing countries, despite the fact that UPOV 1978 
recognizes farmers’ privilege to replant stored seeds from previous harvests 
(India).
Finally, different points of view were expressed on the value and merit of the 
various Conventions o f UPOV in the light of Article 27.3 (b). An important group 
of developed countries expressed that UPOV 1991 establishes a suitable balance
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of interests, rights, and obligations. Emphasis was placed on the fact that this 
instrument does not permit Members to limit the varieties to be protected. This 
means that the new varieties not included in UPOV 1978 are included in the 1991 
Convention. It was stressed that a growing number of States had adhered to UPOV 
1991 and many others that signed UPOV 1978 were in the process of adhering 
(Switzerland).
In view of this, some developing countries stressed that although it is true that 
the number of Member States of UPOV 1991 had increased, a significant number of 
developing countries refuse to sign it to preserve the flexibility of UPOV 1978.10 In 
this regard, it was underscored that UPOV 1978 allows farmers to store, exchange 
and, to a certain extent, sell seeds of protected varieties, whereas UPOV 1991 trans­
forms those rights into privileges and exceptions, whose exercise will depend on the 
discretion of the governments that will only be able to permit the use of seeds by the 
farmer on his own plantations, subject to “reasonable restrictions” and bearing in 
mind the “ legitimate interests” of the plant breeder. UPOV 1991 only allows the use 
of seeds in the same plantation. This would affect the food security of many com­
munities in developing countries that depend on the storage, sharing, and replanting 
of seeds from former harvests (Kenya). The prospect of now having to pay royalties 
to be able to carry out these activities affects small farmers (Brazil). It was also held 
that UPOV 1991 only limits the right to sell or market the seed of the protected 
variety in the territory of the contracting Party, which constitutes an upsetting of 
the balance established by Article 6 of TRIPS, which allows States to choose the 
exhaustion of rights regime they prefer (Brazil).11
The debate at WTO on the scope of the notion of patentable subject matter 
and the exceptions to patentability has been extended to the deliberations of the 
Committee on Patent Rights regarding the Draft Substantive Patent Law Treaty 
of WIPO, whose purpose is to harmonize the substantive principles of patent 
law. In the absence of consensus, some developed countries, specially the United 
States and those of the European Union, have advanced by signing free trade 
agreements with developing countries that extend patent protection beyond the stan­
dards provided for in TRIPS. That is, the flexibility of TRIPS has gradually been 
eroded.
3.3 Patents and Public Health
On account of the public health crisis of the mid-1990s in South Africa and the 
difficulties in guaranteeing access to essential medicines for the majority of the 
population, the developing countries began to put forward the question of the rela­
tionship between patents and access to medicines in different international fora, 
beginning by the World Health Organization (WHO).
The conflicts between safeguarding access to medicines and international obliga­
tions derived from the WTO Agreements raised two important questions. The first 
is the conviction that the combination of competition in generic pharmaceuticals
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and the ability to recur to the safeguards of TRIPS (e.g., compulsory licenses) had a 
pro-competitive effect on the price of medicines, as was evidenced by the reduction 
o f more than 95% of the annual indicative price o f the triple antiretroviral ther­
apy from 10,000 dollars in 1996 to 140 dollars in 2003. This reality was confirmed 
when Brazil embarked on negotiations after announcing its intention to impose a 
compulsory license on the “antiretroviral patents” of two important transnational 
laboratories (Velázquez, Correa and Balasubramanian, 2004). A consequence of this 
announcement was a significant reduction in the prices of these medicines in Brazil 
without actually imposing compulsory licenses. One precedent that contributed to 
the idea of reconciling access to medicines and patent rights was the speed with 
which Canada and the United States considered issuing compulsory licenses to bring 
down the price of cirpofloxacin faced with the fear of dissemination of anthrax after 
September 11, 2001 (Velásquez et al, 2004).
This background paved the way for the Declaration on the TRIPS Agreement 
and Public Health adopted in Doha on November 14, 2001 (“ Doha Declaration”).12
As a consequence o f the mandate conferred in paragraph 6 of the Doha 
Declaration to the Council for TRIPS, and after almost 2 years of negotiations, the 
Members of WTO agreed on a solution to the problems that could be faced by 
the countries with insufficient or non-existent capacity to manufacture the products 
protected by patents upon issuing compulsory licenses.
Thus, on August 30, 2003 the General Council adopted the Decision on 
“Implementation o f  paragraph 6 o f  the Doha Declaration on the TRIPS Agreement 
and Public H ealth” (WT/L/540), a mechanism known as the “Paragraph 6 
Solution.”
In the negotiations that resulted in the Doha Declaration it was made clear that 
the countries with little or no capacity for the manufacturing of generics drugs that 
recurred to compulsory licenses would obtain very little advantage. Indeed, two 
requirements of Article 31 of TRIPS that regulate the conditions to grant compul­
sory licenses raised a number o f problems, in the Members’ view, for the effective 
use of the system by the Members with no capacity to produce medicines, namely:
1) Subparagraph f )  which permits use of the patent without authorization from 
the owner “predominantly fo r  the supply o f  the domestic market o f  the Member 
authorizing such use. ”
2) Subparagraph h) which establishes that “the right holder shall be paid ade­
quate remuneration in the circumstances o f  each case, taking into account the 
economic value o f  the authorization. ”
If strictly applied, the first o f these requirements would make it difficult to import 
the product needed by the country issuing the compulsory license (“ importing coun­
try”), since if the latter has to acquire the product from a foreign manufacturer of 
generics other than the patent owner, the foreign manufacturer would need to obtain 
a compulsory license in his own country (“exporting country” ) if the product in 
question were protected there by a patent, and also this latter compulsory license
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could only be granted in the exporting country “predominantly fo r  the supply o f  the 
domestic market” of that Member [Article 31 (f) o f TRIPS],
Following the above example, subparagraph h) of Article 31 of TRIPS demands 
paying remuneration to the patent owner. This would cause a double payment for, 
according to subparagraph f), “adequate remuneration” should be paid in the export­
ing country and in the importing country, which would cancel out the purpose of 
acquiring the product at a lower price. To provide for this eventuality, the so-called 
Paragraph 6 Solution authorizes exemption of the obligations established in sub- 
paragraphs f) and h). This means that only the beneficiary of the license of the 
exporting country should remunerate the patent owner, making the commitment to 
export only the amount o f products requested by the importing country. The solu­
tion provides for a special procedure to prevent re-exportation o f the product from 
the importing country to third countries, and a mechanism of notifications to ensure 
control of the circulation of the products, among other safeguards.
Box 3.2 describes the main characteristics of the Paragraph 6 Solution applicable 
only to pharmaceutical products, as this concept is defined in the above-mentioned 
Decision of the General Council.
Paragraph 11 of the Decision establishes that the Paragraph 6 Solution, includ­
ing exemptions, will be invalidated once an amendment to replace these TRIPS 
provisions enters into effect. It also establishes that the TRIPS Council will begin 
preparatory work for this amendment at the latest by the end o f 2003, for adoption 
within the following 6 months (June 2004).
This has not yet occurred. In recent meetings of the TRIPS Council, Members 
have put forward diverging positions on implementation o f the amendment. In 
the meeting held on July 19, 2004 it was decided to postpone the conclusion of 
the work until the end of March 2005, an aim that has not been complied with, 
either.
Recent free trade agreements signed by the United States with developing coun­
tries contain provisions contrary to the Paragraph 6 Solution, or can at least hinder 
its implementation. An example is the provisions that make it mandatory to rec­
ognize data exclusivity for pharmaceutical, chemical, and agrochemical companies 
before the regulatory authorities of the States that demand prior authorization to 
market this type of products. As will be seen, this makes it more difficult to issue 
compulsory licenses, since to obtain authorization to sell a product subject to prior 
authorization, the licensee must have the patent owner consent to use the data of the 
product registration and thus, exercise the powers provided for in the compulsory 
license. Unless the member States of these recent agreements make the legal adjust­
ments to facilitate an orderly and transparent interaction and reconciliation between 
data protection and the Paragraph 6 Solution, the application o f the provision runs 
the risk of being obstructed, if not annulled.
In view of this tendency, it can be important for developing countries that could 
need the Paragraph 6 Solution to ensure that the Decision o f the General Council 
that adopted it be embodied into the TRIPS Agreement, with a reference, if possible, 
to its supremacy over any other international agreement having a contrary effect 
(Abbott, 2004).13
Box 3.2 Paragraph 6 Solution
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Any pak'iited product or product manufactured through a patented pro­
cess needed to address the public health problems. Includes active 
ingredients necessary for its manufacture and diagnostic kits needed 
for its use
Any least-developed country and any other Member that has made a noti­
fication to the TRIPS Council o f its intention to use the system as an 
importer. Such a Member may notify at any time that it will use the 
system in whole or in a limited way (e.g., the system may be used for 
national emergencies or in cases of public non-commercial use)
Any Member that uses the system to produce pharmaceutical products 
and export them to an eligible importing Member
Article 31 (f) of TRIPS is temporarily suspended. It demands that what 
is produced with a compulsory license should predominantly be for the 
supply of the domestic market in order to allow the exporting country 
to produce and export to meet the needs of the importing member.
The requirement of “adequate remuneration” (Article 31 (h) of TRIPS 
must be fulfilled only in the jurisdiction of the exporting Member. 
Therefore, its application is suspended in the importing country.
The importing Member should notify the TRIPS Council Of the following 
information:
Name and quantities of the product needed.
Proof that it is a less advanced country or that it does not have the capac­
ity to manufacture.
Confirmation that a compulsory license has been or will be granted.
The exporting Member should grant a compulsory license under the fol­
lowing conditions:
a) Only the amount required by the importing Member can be produced;
b) Products manufactured under license should be clearly identified with 
special packing, color, and shape;
c) Before shipping the products to the importing Member, the licensee 
should publish the amount and characteristics o f the product on its 
Internet site; and
d) The exporting Member should notify the TRIPS Council that it issued 
a compulsory license.
To ensure that the products imported under the system are used exclu­
sively for the public health purposes provided for, the importing 
Member shall take reasonable measures to prevent re-exportation. The 
measures should be proportional to its administrative capacity.
Source: Prepared by the author.
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3.4 Protection of Undisclosed Information Against Unfair 
Competition
Article 39.1 of TRIPS provides that by guaranteeing effective protection against 
unfair competition in accordance with Article 10 bis of the Paris Convention (1967), 
the Members will protect undisclosed information consistent with paragraph 2 and 
the data that have been submitted to governments or to official agencies, in line with 
paragraph 3.
Paragraph 2 clarifies and broadens protection against acts of unfair competi­
tion or dishonest use to which Article 10 bis o f the Paris Convention alludes and 
describes a series of features of the information to be protected. Whereas Article 
10 bis of the Paris Convention describes acts that involve confusion and mislead 
for consumers, Article 39.2 of the TRIPS Agreement specifies the subject matter 
to be protected (the confidential information) and expands the list of behaviors and 
dishonest uses such as breach of contract, breach o f confidence, and inducement to 
breach and includes the acquisition of undisclosed information by third parties who 
knew or were grossly negligent in failing to know that such practices were involved 
in the acquisition.
Paragraph 3 o f Article 39 is the one that has given rise to the most problems 
among Members, and its implementation has generated wide debate due to the 
repercussions that the protection of data has on public health. It has been the 
object of consultations between the United States and Argentina, as the former 
considers that the latter does not guarantee adequate protection for data, without 
reaching any agreement so far (WT/DS196 of July 5, 2001). The field of protec­
tion of data used to obtain health registration or government approval has been 
extended and specified in various recently signed free trade agreements between the 
United States and several developing countries. Such agreements recognize exclu­
sivity o f data submitted by pharmaceutical, chemical, and agrochemical companies 
before regulatory authorities of the States in which prior authorization is required 
in order to market those products in their territories. This provision has established 
a link between the undisclosed information and the patents regime, even though it 
does not always entail data on innovative products. The recent generation of free 
trade agreements protects the exclusivity of data relative to “new products,” under­
standing by such those that are presented for the first time in a country for their 
registration and approval. In other words, the information and data submitted to reg­
ulatory authority may be protected with respect to a product that is protected by 
a patent and those relative to an old product (not covered by any patent), which 
is considered new since it is the first time that authorization is requested for its 
marketing.
Thus, the protection of data is no longer warranted only by unfair competi­
tion but, aside from it being a patented product or not, its registration gives rise 
to the obligation of the State to recognize exclusivity and control to whomever 
has requested the first authorization in the country for 5 years for pharmaceutical 
products and 10 years for chemical and agrochemical products.
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The main interest behind this type of protection is to preserve the confidentiality 
and economic value o f the data and tests that have been necessary to obtain the first 
approval of the product. Simply put, it can be said that a new drug must undergo 
a long, complex process of selection, tests, and development in order to prove its 
effectiveness and minimize collateral effects. After a series of computer-simulated 
initial tests, laboratories have to carry out pre-clinical research so as to then make 
experiments in animals and finally make tests in humans. This process demands 
considerable effort and investment. In practice, the enormous financial resources 
and the time demanded by the collection and generation of the data necessary for 
approval of a new drug creates in itself a very high market barrier which is difficult 
for manufacturers o f generics drugs to cross. And it is precisely this barrier that 
is at the center of the debate on to what extent the exclusivity of the data affects 
the balance and market position among research and development pharmaceutical 
companies and those devoted to the production of generics drugs (Pugatch, 2004)
The exclusivity term of data was an initiative by the United States and other 
developed countries at the Uruguay Round, which did not prosper. It is now advanc­
ing through the bilateral and regional free trade agreements. The effect is that the 
authorities could not base themselves on prior registration to approve pharmaceu­
tical, chemical, and agrochemical products for 5 years since their first approval in 
the first case, and for 10 years in the case of chemical and agrochemical products, 
unless the applicants obtain the consent of the patent owner of first authorization. 
This could delay the entry of new competitors into the market and even exclude 
the competition’s products with inevitable consequences on prices of medicines 
(Correa, 2004).
Another effect of this provision is that Members will not be able to register 
generic pharmaceuticals for non-commercial use in public hospitals (Abbott, 2004).
Added to this is the extension o f the patent term to compensate for unjustified 
delays incurred in the procedure to approve marketing of the product.
In the same way as the FTA between the United States and Chile, DR-CAFTA14 
does not mention the “unfair commercial use,” which is the main condition for deter­
mining whether an act is permitted or prohibited according to Article 39.3 of TRIPS. 
The agreement also contains the prohibition on authorizing the marketing of phar­
maceutical products for 5 years and agrochemicals for 10 years without the consent 
of the holder of the previous approval [Article 15.10.1(a)].
DR-CAFTA extends the scope of this obligation by providing that a third party 
(a producer of generic drugs) will not be able for 5 or 10 years, depending on the 
case, to base its request for authorization to market a product in a prior approval 
granted in another country or on information relative to the security and effective­
ness previously issued to obtain approval in the territory of another country. It will 
only be able to do so with the consent o f the holder of the authorization in the other 
territory, otherwise, it will have to wait for the above-mentioned exclusivity terms 
to expire.
If they spread, these new provisions should be smoothed out and regulated in 
greater detail in the light of national law, regardless of whether they are included 
in free trade agreements, for if the latter do not annul the stipulations of TRIPS,
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it may be considered that they are implementing the obligations stemming from 
Article 39.3 of this agreement through the principle of freedom o f methods for 
their application provided for in Article 1.1. In other words, countries may and it 
would be advisable for them to adopt internal measures to make the data exclusivity 
regime compatible with that of compulsory licenses, “Paragraph 6 Solution” o f the 
Doha Declaration and the right of defense of the competition to achieve an adequate 
balance between protection of immaterial goods and access to health.
3.5 Exhaustion of Rights and Parallel Imports
It is well known that the territorial nature of intellectual property laws can lead to 
use the exclusive rights recognized to patent holders (or to owners o f other intellec­
tual property rights) to prevent the free circulation o f products within a territory or 
between countries in detriment to free trade. This is why for a long time courts of 
various industrialized countries developed the principle of “exhaustion of intellec­
tual property rights” to limit abuse of exclusive rights on the part of patent holders 
and other owners of diverse intellectual property rights. This principle establishes 
that intellectual property rights cannot be invoked once the right holder has placed 
the protected good on the market or authorized a third party (licensee, distributor) 
to do so, since the right holder could have had economic benefits.
This principle was later used and developed by the European Court of Justice 
since the mid-1960s to reconcile protection of intellectual property with the free 
circulation of goods and services in the community area. The Court considered that 
the sale made by the holder of an exclusive intellectual property right, or by a third 
party authorized by him in one of the Member States of the European Community 
exhausted the intellectual property rights in the countries where parallel protection 
had been obtained. It was considered that otherwise, markets would be at the mercy 
of the distribution policies of patent holders, with the consequent damage to trade 
flows between the member states and the harm to the consumers, who would thus 
see their free choice restricted by being deprived of healthy price competition of 
products protected by any intellectual property right.
Article 6 of TRIPS leaves it up to the Members to adopt the systems of exhaustion 
of rights they consider advisable by simply providing that for the effects of dispute 
settlement, subject to the provisions of Articles 3 (national treatment) and 4 (most 
favoured nation), use will not be made of any provision of the present Agreement in 
relation to the issue o f exhaustion of intellectual property rights.
This means that this principle could be applied on the basis of “ territory” 
(national or territorial exhaustion), in which case, the first sale of the patented prod­
uct in country A only exhausts the rights in that territory. The holder of a patent in 
A may then invoke its exclusive rights of importation in A to prevent importation 
of the product if its sale was made in country B. This principle may be also applied 
on a “ regional” basis. This being so, the sale in the territory of a country that is a 
member o f a free trade area, customs union or common market, exhausts the rights
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in the other member States. That is to say, after the first legal sale of the product, 
the holder “exhausts” his right to control successive re-sales in the regional market. 
However, the holder of a intellectual property right can invoke his exclusive rights 
to halt the importation of a product he himself put on the market in a non-member 
country of the free trade zone, customs union or common market. And finally, the 
exhaustion can be o f “ international” nature, which means that the first sale made in 
any country “exhausts” the rights of the holder to control successive re-sales and 
distribution of the protected product.
Adoption o f any system is o f great significance, for on that will depend the legal­
ity of so-called “parallel imports.” This type of operations involves the importation 
o f one product into a country (State A) where such a product is patented, coming 
from another country (State B), where the product was placed in the market by the 
holder himself, or by a third party with his consent. It will thus depend on the system 
of each country, whether the holder can invoke his exclusive right to block imports 
from another country. We talk about parallel trade or imports because the “paral­
lel importer,” although selling genuine products, trade them on the sidelines of the 
official distribution network established by the patent holder. In other words, it can 
be said that the activity o f the free or non-authorized reseller consists in acquiring 
genuine products in markets where their price is lower due to greater competition 
or exchange differences, in order subsequently to resell it at higher prices where the 
holder of the patent or the manufacturer, distributor or licensee generally operates, 
favored by a territorial exclusivity right.
In any event, TRIPS assumes a neutral position on the system of exhaustion of 
rights by clarifying in two footnotes that: i) the Members are not obliged to apply 
the so-called border measures to prevent parallel imports (note, Article 51), and
ii) that the right o f importation is subject to Article 6 (that is, to the system of 
exhaustion that the Member has implemented in its national legislation) (note 6 of 
Article 28). Freedom to determine the system of exhaustion that is most suitable for 
the Members was reaffirmed by the Doha Declaration on TRIPS and Public Health.
The Paragraph 6 Solution (described in Section 3.3, see Box 2.2) would seem 
to reaffirm the idea that exhaustion does not occur with any licit sale of the prod­
uct, but only as long as the first sale has been made by the patent holder or by a 
third party authorized by him. This is so because in order to export to the import­
ing Member, the holder of a compulsory license should recur to the mechanism 
of product notification and identification established in Paragraph 6 Solution and 
should adopt measures to avoid its re-exportation. That is, should the sale be made 
by the holder of a compulsory license, there will be no exhaustion of rights. On 
the contrary, exportation of the product will be done by means of a sort of ad hoc 
distribution network and specially authorized through the procedure provided for in 
the Paragraph 6 Solution to the effect of satisfying a specific need of the importing 
Member.15
Developed countries are inclined to adopt territorial exhaustion with regard to 
patents. The possibility o f blocking parallel imports makes it possible to adapt 
product prices to market elasticity and thus repay research and development costs 
incurred by the patent holder. The defenders of parallel imports (who are opposed to
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territorial exhaustion) argue that such imports do not stand in the way of maximizing 
earnings, but only reduce the margin, which will benefit consumers. The question 
is, knowing as o f what moment the holder o f a patent can estimate that his level of 
earnings is no longer sufficient and that it is not worth continuing to distribute the 
product in a particular market. Such a product would be removed from the market 
when the marginal cost o f production is higher than the profits it generates.
3.6 Conclusions
Many developing countries initially imagined that TRIPS would set a ceiling of 
standards and demands for intellectual property rights. Reality has surpassed this 
illusion, for various recent bilateral and regional free trade agreements between 
developing and developed countries, mainly the United States and the European 
Union, provide higher and more demanding protection standards than those of 
TRIPS. The new agreements significantly reduce the margins of flexibility of TRIPS 
with regard to patentable subject matter, its exceptions, access to compulsory licens­
ing, access to medicines by consumers, and access to generic drugs markets by firms 
located in developing countries.
Recent trade agreements move away from the principles of flexibility and from 
the need to prevent intellectual property from standing as an obstacle for guarantee­
ing full access to medicines set forth in the Doha Declaration on TRIPS and Public 
Health.
The tendency to protect test data relative to chemical, agrochemical, and phar­
maceutical products in last generation free trade agreements, besides going well 
beyond the standard of protection stipulated by TRIPS, poses new and highly com­
plex problems. Unless appropriate national regulations are established, undisclosed 
test data may raise the cost of the process of approval of pharmaceutical, chemical, 
and agrochemical products. It can also make it more difficult, if not impossible, to 
authorize compulsory licenses which TRIPS admits under certain conditions.
Nor do multilateral systems prevent the erosion of that flexibility in all cases. 
One example is the solution agreed on by the United States and Argentina, whereby 
the latter country substantially reduced the scope of the exception of exhaustion of 
rights provided for in its patent law, even though the topic is alien to the dispute 
settlement system provided for in TRIPS.
Consequently, the diversity of bilateral, regional, and multilateral trade agree­
ments overlapped or seeking to coexist and containing regulations on intellectual 
property, has opened an ongoing agenda of international negotiations which obliges 
the developing countries to place emphasis on effective interaction o f the different 
levels and regulatory scenarios and their different objectives.
Finally, this determines that from now on, national legislations on the matter take 
note of this objective and of the need to fill the spaces and inconsistencies derived 
from the multiple objectives and standards of protection of diverse international 
rules.
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1. For the purposes of this Article, the terms “inventive step” and “capable of industrial appli­
cation” may be deemed by a Member to be synonymous with the terms “non-obvious” and 
“useful” respectively.
2. Section 7.94 of the Report of the Special Group “Canada-Protection by means of Patents for 
Pharmaceutical Products”, WT/DS114/R, of 17 March 2000.
3. Article 30 of TRIPS establishes that “Members may provide limited exceptions to the 
exclusive rights conferred by a patent, provided that such exceptions do not unreasonably 
conflict with a normal exploitation o f the patent and do not unreasonably prejudice the 
legitimate interests of the patent owner, taking account of the legitimate interests of third 
parties. ”
4. Section 7.92 of the Report of the Special Group in the Canada-Pharmaceutical Products case.
5. Argentine patents law No. 24.481 (Article 4, paragraph a) which in this aspect, has followed 
the Spanish invention patents’ law of 1986.
6. Cfr. decision T 356/93, Plant Genetic Systems, paragraph 17.3 of the Chamber of Resources 
of the European Patent Convention.
7. The Court of Justice o f the Andean Community has made a statement in this regard. It has 
declared the non-compliance by the Republic of Ecuador and Peru with the prohibition on 
granting patents for second uses prohibited by Article 16 of the former Common Intellectual 
Property Regime (Decision 344) conceived in identical terms to the current Article 21 of the 
current Decision 486 and has called upon both countries to desist in such non-compliance and 
invalidate the corresponding patents. In both cases it involved a second use patent relative 
to the product “Pirazolopirimidones for the treatment of impotence” , PROCESO 34-AI- 
2001 OF 21/08/2002 and PROCESO 89-A1-2000 of 28/09/2001, respectively. See rulings 
in www.comunidadandina.org.
8. Explanatory list of questions to the Members: WTO document 1P/C/W/122 and 1P/C/W/I26, 
Information from 25 Members in WTO document: IP/C/125 and Addl-24: Australia, 
Bulgaria, Canada, Czech Republic, European Community and Member States, Hong Kong, 
China, Hungary, Iceland, Japan, Korea, Lithuania, Moldova, Morocco, New Zealand, 
Norway, Poland, Rumania, Slovenia, South Africa, Switzerland, Thailand, United States, and 
Zambia.
9. See Note from the WTO Secretariat which summarizes the positions regarding the rela­
tionship between the TRIPS Agreement and the CBD, iP/C/W/368, 8 August 2002 
(www.wto.int.)
10. To June 30, 2004, 25 States were members of UPOV 1978 and 28 had signed UPOV 1991 ; 
only two remain adhered to the 1961 version (modified by the 1972 act), UPOV Publication 
No. 437 (E).
11. For further details on the process of review of Article 27.3(b) and the issues linked to the 
relation between TRIPS and CBD, see Notes of the Secretariat IP/C/W/369 and IP/C/W/368, 
of 8 August 2002.
12. WT/MIN(01)/DEC/2 of November 20, 2001 (www.wto.int)
13. See the discussions on the decision relative to the Paragraph 6 Solution and the form the 
TRIPS amendment should take in the document of the session of the TRIPS Council of July 
19, 2004 (IP/C/M/44).
14. United States Free Trade Agreement with the Dominican Republic, Honduras, Nicaragua, El 
Salvador, Costa Rica, and Guatemala.
15. There are views to the effect that the Paragraph 6 Solution limits the margin of freedom with 
regard to exhaustion recognized in Article 6 of TRIPS and in the Doha Declaration, since the 
whole system implicitly presupposes the existence of territorial exhaustion (González Perini, 
Lowenstein and Wegbrait, 2004).
N o t e s
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Chapter 4
I n te l le c tu a l  P r o p e r t y  a n d  th e  N e w  G e n e r a t io n  
o f  F r e e  T r a d e  A g r e e m e n ts :  T h e  A g r e e m e n t  
B e tw e e n  C h i le  a n d  th e  U n i te d  S ta te s  o f  A m e r ic a
Pedro Roffe
4.1 Introduction
The Free Trade Agreement between Chile and the United States (hereinafter the 
FTA or the Agreement), signed in 2003 and in force since January 1, 2004, marks 
an important stage in the new generation of bilateral trade agreements. The incorpo­
ration of a chapter on intellectual property, following the format of previous agree­
ments signed by the United States, has served as a model for subsequent negotia­
tions particularly with Latin American countries (DR-CAFTA, Colombia, Panama, 
and Peru).
For the United States, the protection of intellectual property has been a constant 
concern. At the domestic level it has increased protection standards and systemati­
cally monitors their enforcement internationally through Special Report 301, which 
includes a list of countries that, in the view of the trade authority of that coun­
try, are not up to their international commitments on the subject. The said report 
is part of the Trade Act, and the list is the step that precedes the imposition of 
trade sanctions on the countries that infringe the rights of United States patent hold­
ers. The United States was the promoter of the first treaty on industrial property at 
the end of 19th century (Paris Convention of 1883) and has played a preponderant 
role in raising levels of protection, especially since the Uruguay Round and then 
with the Agreement on Trade-Related Aspects of Intellectual Property (TRIPS). 
NAFTA was the first post-TRIPS agreement with a Latin American country includ­
ing robust provisions on the matter. This intent of the United States is also articulated 
in the protracted negotiations for a Free Trade Agreement for the Americas, whose
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chapter on intellectual property resembles the model that this country has followed 
in various bilateral agreements.
The purpose of this chapter is to analyze the central aspects of these agreements, 
taking the agreement between Chile and the United States as a reference and com­
paring with other free trade agreements negotiated by the United States, particularly 
with Latin American countries.
4.2 Objectives of the Agreement: The Preamble
The aims of the Agreement with Chile on intellectual property are set forth in the 
Preamble to Chapter 17, which states that its main objective is “ to reduce distortions 
and impediments to trade between the Parties.” This objective would be fulfilled by 
ensuring that the “measures and procedures to enforce intellectual property rights 
do not themselves become barriers to legitimate trade” by means, among others, of 
greater efficiency and transparency in the administration of the system.
The purpose o f transparency is detailed in the body o f the Agreement. “Each 
Party shall ensure that all laws, regulations, and procedures concerning the protec­
tion or enforcement of intellectual property rights, and all final judicial decisions 
and administrative rulings o f general applicability pertaining to the enforcement of 
such rights, shall be in writing and shall be published or where such publication is 
not practicable, made publicly available, in a national language in such a manner as 
to enable the other Party and right holders to become acquainted with them, with 
the object of making the protection and enforcement of intellectual property rights 
transparent. Nothing in this paragraph shall require a Party to disclose confidential 
information the disclosure of which would impede law enforcement or otherwise be 
contrary to the public interest or would prejudice the legitimate commercial interests 
of particular enterprises, public or private” (Article 17.1.12).
The provision on transparency is similar to that of TRIPS (Article 63). The FTA 
clarifies in a footnote that the requirement of publication may be met by simply 
making available a written document to the public via the Internet. The princi­
ple o f transparency is generally accepted in international law. In the context of 
international trade, the transparency of national legislation on intellectual property 
serves the objective of making foreign economic operators familiar with domestic 
regulations, thus making international transactions more predictable.
The Preamble also stresses that the Agreement builds on the foundations o f the 
international architecture of intellectual property agreements, reaffirming, among 
others, “the rights and obligations set forth in the TRIPS Agreement.”
The Preamble makes further explicit reference to the principles established in the 
Doha Declaration on TRIPS and Public Health.1 The Declaration, among others, 
confirms that . .  the TRIPS Agreement does not and should not prevent Members 
from taking measures to protect public health ( . . . )  and should be interpreted and 
implemented in a manner supportive o f WTO Members’ right to protect public 
health and, in particular, to promote access to medicines for all” also “reaffirms the 
right of WTO Members to use, to the full, the provisions in the TRIPS Agreement, 
which provide flexibility for this purpose.”
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Another clause of the Preamble is similar to the general objectives of Article 7 of 
TRIPS by underscoring that the protection and enforcement of intellectual property 
rights is a .. fundamental principle of this Chapter that helps promote technologi­
cal innovation as well as the transfer and dissemination o f technology to the mutual 
advantage of technology producers and users, and that encourages the development 
o f social and economic well-being.”
The Preamble acknowledges the importance of public and private investment 
and the role of the business community in research, innovation, and transfer of 
technology.
The Agreement includes two other objectives. The first refers to anticompetitive 
practices that can be associated with intellectual property rights, without deviating 
from similar principles in the TRIPS Agreement, leaving the Parties free to legislate 
in this regard. DR-CAFTA and the recent agreements between the United States and, 
respectively, Colombia, Panama, and Peru contain identical provisions. The second 
objective refers to bilateral technical cooperation, which can be useful in fulfilling 
obligations between parties with different degrees of development.
In the case of DR-CAFTA, the agreement links technical cooperation to the 
Committee for the Creation of Trade-Related Capabilities, a committee instituted 
by the agreement itself. The FTAs signed with Colombia and Peru make no direct 
reference to technical cooperation, but include a novel section on promotion of inno­
vation and technological development to encourage public and private partnerships 
and initiatives in the area of intellectual property.
The FTAs address in detail the entry into force of its provisions and the necessary 
amendments to be made to domestic legislation. As of its entry into force and as a 
matter of general principle, each Party, in the case of Chile, will give effect to the 
provisions on intellectual property rights of the Agreement, including their adher­
ence to various international treaties administered by the World Intellectual Property 
Organization (WIPO). A report of February 2006 by the Advisory Industrial Group 
to the US Trade Representative (USTR) on intellectual property emphasizes the 
need not only to strictly monitor the implementation of free trade agreements but 




The first provision of Chapter 17 of the FTA with Chile reiterates the principle 
of minimum standards, a pillar of the system established by TRIPS. This provi­
sion is reproduced in an almost identical manner in all the free trade agreements in 
the region. The FTA states “ [e]ach Party shall give effect to the provisions of this 
Chapter and may, but shall not be obliged to, implement in its domestic law more 
extensive protection than is required by this Chapter, provided that such protection 
does not contravene the provisions of this Chapter” (17.1.1).
The provision is similar to that o f Article 1 of TRIPS, but does not include the 
important qualification that the Members may establish the method they consider
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most adequate to apply the provisions of the Agreement within their own legal 
system and practice. The following should be stressed in relation to this general 
principle:
a) The requirement to implement international agreements is implicit in the obliga­
tion to perform it in good faith (“pacta sunt servanda”), an obligation recognized 
in the Vienna Convention on the Law of Treaties (VCLT)3 and by customary inter­
national law. The Agreement points out that each Party shall “give effect to the 
provisions” of the Agreement, reiterating the basic international legal obligation.
b) The FTA reaffirms the minimum standards principle that the Parties may, but 
need not, adopt more extensive protection of IP than is required by the FTA. In 
fact, the FTA goes beyond the minimum standards provided in TRIPS. This by 
itself is perfectly consistent with TRIPS, which left members with the freedom 
of adopting higher standards of protection, precisely on grounds of the minimum 
standard principle.
c) However, as pointed out, the FTA does not make reference to the “freedom 
of implementation method” recognized under TRIPS. In TRIPS each WTO 
Member decides whether it will adopt specific statutes or administrative rules for 
its implementation, or instead rely on the text of the Agreement as if it was part 
of national law. More importantly, TRIPS authorizes each Member to implement 
the rules in the manner it deems most appropriate, provided that implementation 
is in accord with the terms o f the agreement.
d) In light of the non-derogation principle, discussed subsequently, it must be con­
sidered whether the Parties retain the “freedom of implementation” principle 
referred to above. One simple explanation for the omission in the FTA of this 
important principle o f TRIPS is that the FTA sets forth specific modalities for 
the implementation of some of its provisions, without much freedom for the 
Parties to decide on its method of implementation. In other words, the freedom 
of implementation recognized by TRIPS is constrained but not removed from 
the agreement.
4.3.2 The Non-derogation Clause and the International 
Architecture o f Intellectual Property
An important principle of the FTA with Chile that governs the way it should be 
interpreted states that
Nothing in this Chapter concerning intellectual property rights shall derogate from the obli­
gations and rights of one Party with respect to the other by virtue of the TRIPS Agreement or 
multilateral intellectual property agreements concluded or administered under the auspices 
of the World Intellectual Property Organization (WIPO).4 (17.1.5).
This is the first time that the principle of non-derogation appears in a trade agree­
ment signed by the United States. It is not in NAFTA or in the agreements with 
Jordan, Singapore, and Australia, but it is found in DR-CAFTA5 and in the recent
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agreements signed with Colombia, Panama, and Peru, although using different 
terminology. One consequence of this principle is its extension to all matters relative 
to intellectual property and not only Parts I to IV of the TRIPS Agreement (general 
provisions and basic principles, rules relative to the existence, scope and exercise of 
intellectual property rights, observance of intellectual property and acquisition and 
maintenance of related inter parties procedures).
The principle also extends to “rights” and not only to “obligations,” to the mul­
tilateral intellectual property agreements agreed on or administered by WIPO, in 
addition to the TRIPS Agreement, and points to the non-derogation of any right 
or obligation of one Party with respect to the other stemming from those interna­
tional agreements. Unless otherwise provided for in the FTA, the non-derogation 
principle should permit the Parties to preserve all rights and obligations referred to 
in the TRIPS Agreement in present and future conventions concluded or adminis­
tered under the auspices o f WIPO to which both the United States and Chile are 
Parties. Thus, for example, limitations provided under the TRIPS Agreement on the 
granting of compulsory licenses, not explicitly referred to in the FTA, are preserved, 
consistent with other provisions of the Agreement. The reaffirmation that compul­
sory licensing is preserved is the reference made to Article 31, TRIPS, in the FTA 
Chapter on investment.
4.3.3 The Principles o f National Treatment 
and Most Favored Nation
National treatment (NT) has been a guiding principle of the international trad­
ing legal system, including the General Agreement on Tariffs and Trade o f 1947 
(GATT, 1947) and the TRIPS Agreement. This is also one of the basic aspects 
of the treaties administered by WIPO since the 1883 Paris Convention for the 
Protection of Industrial Property. According to the FTA, this principle guarantees 
non-discrimination between Chilean and US nationals with regard to intellectual 
property. In TRIPS, the principle of national treatment has exceptions which are 
incorporated into the Agreement (Roffe, 2004).
The principle o f Most Favored Nation (MFN) applies to third parties that are 
Members of WTO. Its validity in the Agreement is a consequence o f the principle 
of non-derogation discussed earlier. In general, application o f the principle of MFN 
to the protection of intellectual property rights is an innovation in the multilateral 
context. TRIPS provides for the immediate and unconditional extension to nationals 
of all WTO Members of any advantage, favor, privilege, or immunity granted by a 
Member to nationals of any country.
The TRIPS Agreement recognizes exceptions to the MFN principle. One o f these 
exceptions relates to any advantage, favor, privilege, or immunity deriving from 
international agreements related to the protection of intellectual property rights 
entered into force prior to the entry into force o f the Agreement establishing the 
WTO.6 Two additional conditions should be met in this case: the said agreement
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shall be notified to the WTO7 and shall not constitute “an arbitrary or unjustifiable 
discrimination against nationals o f other Members.”8
The clear meaning of this principle is that any advantage, favor, privilege, or 
immunity accorded by a WTO Member to nationals o f any other country (not nec­
essarily a WTO Member), after January 1, 1995, needs to be immediately and 
unconditionally extended to nationals of any other WTO Member.
In brief, as a result o f the MFN -  a “cornerstone” principle of the international 
trading system -  the advantages, favors, privileges, or immunities contemplated in 
the FTA between Chile and the United States will be accorded “immediately and 
unconditionally,” in the terms prescribed in the TRIPS Agreement, to nationals of 
all other WTO Members. This general conclusion applies to other trade agreements 
signed by the United States, including DR-CAFTA and those signed more recently 
with Colombia, Panama, and Peru.
4.4 Substantive Intellectual Property Standards
4.4.1 Introduction
The FTA with Chile deals with certain intellectual property disciplines, setting 
standards of protection generally higher than those in the TRIPS Agreement. The 
following sections describe their main features. For other intellectual property dis­
ciplines not dealt with explicitly in the FTA, the standards o f the TRIPS Agreement 
as well as other international instruments in which both Parties are Members would 
prevail. For instance, the FTA is silent on industrial designs, as well as on layout 
designs of integrated circuits covered in the TRIPS Agreement. On these issues and 
in light of the principle of non-derogation, discussed above, the standards of TRIPS 
prevail. Furthermore, the FTA, -  as well as the other trade agreements signed by 
the United States with countries of the Americas -  not only sets higher standards of 
protection than in TRIPS but also governs disciplines not covered at all by the lat­
ter, e.g., domain names, protection against circumvention of effective technological 
protection measures, and limitations on liability of Internet service providers (ISPs).
4.4.2 Patents and Regulated Products
4,4.2.1 Patents
Compared to TRIPS, the FTA section on patents is relatively brief. However, an 
important section on regulated products (pharmaceuticals and chemicals) comple­
ments it. The section on patents deals mainly with issues of patentability, limited 
exceptions, plant protection, derogation, and delays in their granting. The limited, 
but significant, treatment of patents in the FTA is explained by the fact that on mat­
ters not dealt with, the principles and standards of the TRIPS Agreement govern the 
relationship of the Parties.
On the exhaustion of patent rights, the FTA is silent, leaving the Parties the free­
dom to adopt the most appropriate system. The Chilean law on implementation of
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the Agreement opts for international exhaustion of rights. On its part, the Unites 
States has traditionally advocated for a national exhaustion regime and in its bilat­
eral agreements signed with Singapore, Australia, and Morocco the possibility of 
parallel imports may at least be restricted by contract. DR-CAFTA and the recent 
agreements with Colombia, Panama, and Peru follow the model of the FTA with 
Chile.
On the important issue of patentability, the FTA practically reproduces a par­
allel provision in the TRIPS Agreement (Article 27.1) and even incorporates into 
the main text its footnote. But, compared to TRIPS, the FTA does not fully repro­
duce the relevant TRIPS provision, by omitting the reference that patents shall be 
available and patent rights be enjoyable without discrimination as to the place of 
invention, the field of technology, and whether products are imported or locally 
produced.
The FTA contains the overriding requirement that patents shall be available 
for all types of product and process inventions. It prohibits distinctions about 
the field of technology to which the invention belongs. In addition, the FTA 
with Chile does not explicitly obligate Parties to protect the “second use” of a 
product.
Any patent application must satisfy the basic criteria of novelty, inventive step, 
and industrial applicability, without altering the criteria already explicit in TRIPS. 
The FTA, as in the case of TRIPS, does not define what an “ invention” is; it only 
specifies the requirements that an invention should meet to be patentable. This leaves 
Parties considerable freedom to determine what should be deemed an invention and, 
if they so desire, to exclude from patentability any substance which exists in nature 
as being a mere “discovery” and not an “ invention.” The FTA also did not define, 
unlike in DR-CAFTA, the meaning of “ industrial application.” DR-CAFTA, import­
ing concepts from US law, specifies that “Each Party shall provide that a claimed 
invention is industrially applicable if it has a specific, substantial, and credible util­
ity.” The agreements signed between United States and Colombia, Panama, and 
Peru, respectively, adopt a similar approach.
The FTA with Chile qualifies that novelty or inventive step is not affected 
by authorized public disclosure or derived from the patent applicant, provided it 
occurred within 12 months prior to the filing of the patent application. This approach 
is common to DR-CAFTA and to the agreements signed with Colombia, Panama, 
and Peru.
One of the controversial provisions of the free trade agreements is the protection 
of life forms. In this regard, the FTAs introduce different rules to those of TRIPS. 
Some countries provide patent protection for all kinds of plants regardless of their 
method of reproduction, while others (e.g., Republic of Korea) protect under patents 
only those plants that are asexually reproduced.
The FTA with Chile does not contain an explicit obligation to protect plants 
under the patent system. But, it provides for a “best effort” clause in order for each 
Party to undertake reasonable efforts, through a transparent and participatory pro­
cess, to develop and propose legislation -  within 4 years from the entry into force 
of the Agreement -  to make available patent protection for plants which are new, 
involve an inventive step, and are capable of industrial application. This provision
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does not contain any limitation on the type of plants that should be protected under 
the patent system (sexually and/or asexually reproduced). According to this obliga­
tion that in practice applies only to Chile, the latter is not obliged to consider plants 
as a patentable subject matter, but to engage in a process to legislate to that effect. 
Similar provisions are contemplated under DR-CAFTA. Nevertheless, in the latter 
agreement any Party that does not provide patent protection for plants by the date of 
entry into force of the Agreement shall undertake all reasonable efforts to make such 
patent protection available. In addition, according to the same agreement, any Party 
that provides patent protection for plants and animals as of, or after, the date of entry 
into force of the Agreement shall maintain such protection. This latest approach 
is followed in the FTAs signed by the United States with Colombia, Panama, 
and Peru.
Patents confer an “exclusive” right, that is, the right to prevent others from using 
the invention, without the authorization of the patent holder. The market power con­
ferred by patents and the benefits the patent owner may obtain constitute one of 
the essential elements of patent grants. However, the conferred rights are not abso­
lute. Under most patent laws, such rights may not be exercised over certain acts 
performed by third parties. This means that under certain specified circumstances, 
there may be exceptions to the exclusive rights.
Exceptions can be invoked by third parties at any time during the term o f the 
patent as a defense against alleged infringements. The FTAs allow the establish­
ment of exceptions to patent rights, but imposes conditions on such exceptions. As 
in the case of TRIPS, exceptions to patent rights are subject to three conditions: the 
exception must be “ limited” ; the exception should “not unreasonably conflict with 
the normal exploitation” of the patent; and the exception should “not unreason­
ably prejudice the legitimate interests” of the right holder and of third parties. This 
provision is reproduced generally in subsequent free trade agreements, including 
DR-CAFTA.
Article 17.9.4 o f the FTA with Chile makes it possible to invoke the “Bolar 
exception” (so called for the name of the laboratory that set the precedent) or “regu­
latory exception” under the following circumstances: “If a Party permits the use by 
a third party o f the subject matter o f a subsisting patent to support an application 
for marketing approval or sanitary permit of a pharmaceutical product, the Party 
shall provide that any product produced under such authority shall not be made, 
used, or sold in the territory o f the Party other than for purposes related to meeting 
requirements for marketing approval or the sanitary permit, and if export is permit­
ted, the product shall only be exported outside the territory o f the Party for purposes 
of meeting requirements for issuing marketing approval or sanitary permits in the 
exporting Party.”
The purpose of the Bolar exception is to accelerate the introduction of generic 
medicines into the market, as soon as the term of protection of the patent of 
an original drug expires. Otherwise, the generic producer would have to wait 
until the patent expires to begin considering the production of a copy of the 
original product and just then ask for the approval of the drug by the health 
authorities. This would amount to a de facto extension of the patent term, as the
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competing drugs would have to wait for a number of years to make it into the 
market.
In this matter the Agreement provides for two situations. One allows a third Party 
to use the subject matter of a patent for purposes of obtaining the sanitary permit or 
marketing approval of a pharmaceutical product. The other allows the third Party to 
use the subject matter of a patent when the product will be exported, but only to meet 
requirements for issuing marketing approval or sanitary permits in the exporting 
Party. The Bolar exception is reproduced in similar terms in DR-CAFTA9 and in 
the agreements signed with Colombia, Panama, and Peru.
Among its selected patent provisions, the FTA with Chile deals with revocation 
or cancellation of patents: “A Party may revoke or cancel a patent only when grounds 
exist that would have justified a refusal to grant the patent.” (Article 17.9.5).
Apparently, the only grounds for revocation or cancellation of a patent would be 
that the invention protected by the patent was not new, was obvious, or not useful. A 
footnote clarifies that fraud in obtaining the patent may also be cause for revocation. 
One should ask if these are the only causes for revocation or the Parties would be 
allowed to establish different grounds for such cancellation, such as inequitable con­
duct or misrepresentation. In fact, other trade agreements have been more explicit 
and have broadened the causes for revocation recognized in the FTA. For instance, 
the DR-CAFTA10 and the United States Agreement with Peru allow for these other 
two causes of revocation.
Another aspect o f the FTA with Chile, common to free trade agreements signed 
by the United States, such as with DR-CAFTA11 , is the provision for the extension 
o f patent terms to compensate for unjustified delays during the granting process.12
The Agreement also provides for extension of the patent term to compensate for 
“ unreasonable curtailment of the patent term as a result of the marketing approval 
process.” However, the FTA with Chile does not define what “unreasonable” is leav­
ing each Party to determine this term. These provisions on the extension of the 
patent terms are reproduced in DR-CAFTA and the original agreements signed with 
Colombia, Panama, and Peru. It is appropriate to note that in the case of Peru and 
with respect to pharmaceutical products these provisions have been amended with 
the view of introducing some flexibility in their implementation.13
4.4.2.2 Regulated Products
This is one o f the most controversial aspects of the free trade agreements. They refer 
mainly to the protection and possible use of undisclosed information concerning the 
safety and efficacy of pharmaceutical and agricultural chemical products, which uti­
lize a new chemical entity. Since NAFTA negotiations, the United States has been 
interested in introducing in its trade agreements special provisions for data exclu­
sivity related to agricultural chemical and pharmaceutical products. In NAFTA, the 
provisions apply to “undisclosed test or other data” necessary to determine safety 
and efficacy of “products that utilize new chemical entities” when the generation 
of these data “ involves considerable effort.” No person other than the one that has 
submitted the data may rely on such data to support an application for the marketing
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approval of the product concerned, during a reasonable period of time, of no less 
than 5 in the first case and 10 years in the second.
The United States has not followed the same approach on protection of undis­
closed information with its different trade partners (Box 4.1).
The Agreement with Chile states, for example: “If a Party requires the submis­
sion o f undisclosed information concerning the safety and efficacy of a pharmaceu­
tical or agricultural chemical product which utilizes a new chemical entity, which 
product has not been previously approved, to grant a marketing approval or sani­
tary permit for such product, the Party shall not permit third parties not having the 
consent of the person providing the information to market a product based on this 
new chemical entity, on the basis o f the approval granted to the party submitting 
such information. A Party shall maintain this prohibition for a period of at least five 
years from the date o f approval for a pharmaceutical product and ten years from 
the date of approval for an agricultural chemical product. Each Party shall protect 
such information against disclosure except where necessary to protect the public” 
(Article 17.10.1).
In the absence of such provision, it has been a practice that information 
concerning safety and efficacy o f products subject to marketing approval or 
sanitary permit is normally submitted by the first applicant for such an autho­
rization or permit. Subsequent applicants regarding the same or similar products 
will benefit from the information submitted by the first applicant and the com­
petent authorities will base their decision for granting the marketing approval 
or the sanitary permit on the undisclosed information provided by that first 
applicant.
The purpose of the FTA provision is precisely to avoid such a practice and to 
oblige any person who applies for marketing approval or sanitary permit to submit 
to the competent authority, its own confidential information related to the safety and 
efficacy regarding the pharmaceutical and agro-chemical products which utilize a 
new chemical entity for which marketing approval or sanitary permit is requested. 
These provisions have been the subject of criticism for their possible impact on 
access to generic medicines whose prices are in principle largely lower than those 
of the original product. As a result of these criticisms the recent FTA with Peru 
includes a number of safeguard mechanisms.14
Box 4.1 Regulated products in recent trade agreements 
signed by the United States
The free trade agreement with Jordan (Article 4.22.) requires the protection 
of undisclosed test or other data submitted to obtain marketing approval for 
agricultural chemical and pharmaceutical products that utilize new chemi­
cal entities, the origination o f which “ involves a considerable effort,”  There
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is no reference to prohibiting the use of such information for a market 
approval application in favor of a third Parly. The agreement provides that 
new chemical entities could allow new uses for products, for which purpose 
protection will be extended for 3 years. In cases in which the non-disclosed 
information is supported by an approval in another country, Jordan will protect 
it from unfair use for at least the same period.
The Singapore agreement (Article 16.8.1) goes a step further by recogniz­
ing that ‘‘[l]f a Party requires the submission o f information concerning the 
safely and efficacy of a pharmaceutical or agricultural chemical product prior 
to permitting the marketing of such product, the Party shall not permit third 
parlies not hav ing the consent o f the parly providing the information to market 
the same or a similar product on the basis of the approval granted to the parly 
submitting such information for a period of at least live years from the dale of 
approval for a pharmaceutical product and ten years from the date of approval 
for an agricultural chemical product." Note that the protection is not limited 
to products with new chemical entities.
The agreement with Australia contains a set of complex provisions which 
differentiate between pharmaceutical and agricultural chemical products. The 
agreement provides that “ |i |f  a Party requires, as a condition of approving the 
marketing o f a new pharmaceutical product, the submission o f undisclosed 
test or other data concerning safety or efficacy of the product, the ParLy shall 
not permit third persons, without the consent o f the person who provided such 
information, to market a same or similar product on the basis of ( 1) such 
information or (2) the approval granted to the person who submitted such 
information for at least five years from the date o f marketing approval in the 
Party." (Article 17.10.1(a))
For agricultural chemical products the agreement states that “ [i|f a Parly 
requires, as a condition of approving the marketing of a new agricultural 
chemical product, including certain new uses of the same product, the sub­
mission of undisclosed test or other data concerning safety or efficacy of that 
product, the Party shall not permit third persons, without the consent of the 
person who provided such information, to market a same or similar product 
on the basis of ( 1) such information or (2) the approval granted to the person 
who submitted such information for ten years from the date of the market­
ing approval of the new agricultural chemical product in the Party." (Article 
10. 10.1(b)).
The agreement with Australia defines a new product as “ . .  .one that does 
not contain a chemical entity that has been previously approved in the Party” 
(Article 17.10.1(d)). The agreement also contains provisions on the protection 
of “new clinical information (other than related to hioequivalcncy)" and “evi­
dence of prior approval o f the product in another territory which is essential 
to the approval of the pharmaceutical product.” (Article 17.10.2).
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The DR-CAFTA provides for the following:
1 (a) If a Party requires, as a condition o f approving the marketing o f a
new pharmaceutical or agricultural chemical product, the submission 
o f undisclosed data concerning safety or efficacy, the Party shall not 
permit third persons, without the consent o f the person who provided 
the information, to market a product on the basis o f ( 1) the information, 
or (2) the approval granted to the person who submitted the informa­
tion for at least 5 years for pharmaceutical products and 10 years for 
agricultural chemical products from the date o f approval in the Party.
(b) If a Party permits, as a condition o f approving the marketing o f a new 
pharmaceutical or agricultural chemical product, third persons to sub­
mit evidence concerning the safety or efficacy o f a product that was 
previously approved in another territory, such as evidence of prior mar­
keting approval, the Party shall not permit third persons, without the 
consent o f the person who previously obtained such approval in the 
other territory, to obtain authorization or to market a product on the 
basis o f ( 1) evidence o f prior marketing approval in the other territory, 
or (2) information concerning safety or efficacy that was previously 
submitted to obtain marketing approval in the other territory, for at least 
5 years for pharmaceutical products and 10 years for agricultural chem­
ical products from the date approval was granted in the Party’s territory 
to the person who received approval in the other territory. In order to 
receive protection under this subparagraph, a Party may require that the 
person providing the information in the other territory seeks approval 
in the territory of the Party within 5 years after obtaining marketing 
approval in the other territory.
(c) For purposes o f this paragraph, a new product is one that does not con­
tain a chemical entity that has been previously approved in the territory 
of the Party.
(d) For purposes o f this paragraph, each Party shall protect such undis­
closed information against disclosure except where necessary to pro­
tect the public, and no Party may consider information accessible 
within the public domain as undisclosed data. Notwithstanding the 
foregoing, if  any undisclosed information concerning safety and effi­
cacy submitted to a Party, or an entity acting on behalf of a Party, 
for purposes o f obtaining marketing approval is disclosed by such 
entity, the Party is still required to protect such information from unfair 
commercial use in the manner set forth in this Article.
2 Where a Party permits, as a condition o f approving the marketing 
o f a pharmaceutical product, persons, other than the person origi­
nally submitting safety or efficacy information, to rely on evidence or 
information concerning the safety and efficacy of a product that was
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previously approved, such as evidence o f prior marketing approval in 
the territory o f a Party or in another country, that Party (a) shall imple­
ment measures in its marketing approval process to prevent such other 
persons from marketing a product covered by a patent claiming the 
previously approved product or its approved use during the term of that 
patent, unless by consent or acquiescence o f the patent owner; and (b) 
shall provide that the patent owner shall be informed o f the request and 
the identity of any such other person who requests approval to enter the 
market during the term o f a patent identified as claiming the approved 
product or its approved use.
Under the regulated product provisions, the FTA with Chile establishes a more 
detailed regulation than that to be found in TRIPS and NAFTA, and for this reason 
it has been taken as a model for subsequent free trade agreements signed by the 
United States. DR-CAFTA establishes more extensive rules on regulated products, 
covering aspects not dealt with in the Agreement with Chile, such as confirmation of 
sanitary permits obtained in the other country and extended terms to validate those 
permits (see Box 4.1). Following the criticisms referred earlier these provisions on 
regulated products, in the case of pharmaceutical products, have been revised in the 
recent approved FTA between the United States and Peru.15
The FTA with respect to regulated products includes three additional important 
obligations to the Parties about pharmaceutical products, which are subject to a 
patent: (a) as noted earlier, an extension o f the patent term to be available to com­
pensate the patent owner for unreasonable curtailment of the patent term as a result 
of the marketing approval process; (b) the identity of any third Party requesting 
marketing approval of a patented pharmaceutical product shall be available to the 
patent owner, during the term of the patent; and (c) a Party shall not grant “mar­
keting approval” to any third Party prior to the expiration of the patent term, unless 
by “consent or acquiescence” of the patent owner. In fact, this means an exten­
sion of the protection afforded to the patent owner, which goes beyond the TRIPS 
Agreement. This “ linkage” between market approvals and the consent or acquies­
cence of the patentee creates a number of ambiguities and might bring into question, 
among others, the ability to actually exercise the flexibilities in TRIPS, such as the 
granting of compulsory licenses to facilitate access to medicines.16 The bilateral 
trade agreements signed by the United States with Australia, DR-CAFTA, Jordan, 
and Singapore do not differentiate between “marketing approval” and “sanitary per­
mit” as in the case of the FTA.17 The most serious aspect of this linkage relates 
to extending to the sanitary authorities obligations on the existence and validity of 
patents that fall normally under the portfolio of other agencies.
In DR-CAFTA, this “ linkage” is made more explicit and even includes references 
to market approvals “ in another country” -  an extension not provided for in the FTA 
with Chile. The linkage provision is made less stringent in the FTA with Peru.18
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4.4.3 Copyright and Related Rights
4.4.3.1 Copyright
The FTA with Chile is the first signed by the United States in which copyright 
is treated separately from the related rights. The United States agreements with 
Singapore and Morocco and DR-CAFTA treat the subject as a whole, reflecting 
the legal philosophy of the United States and the preferences of its industry.
The DR-CAFTA model is not reproduced in the agreements with Peru and 
Colombia, which follow the approach used with Chile.
On protectable subject matter, the FTA with Chile does not innovate with respect 
to the Berne Convention or the TRIPS Agreement. Thus, the FTA applies to literary 
and artistic works, as understood by the Berne Convention, including computer pro­
grams and compilations of data in accordance with TRIPS and the WIPO Copyright 
Treaty of 1996 (WCT).
The Agreement with Chile provides further that authors “ . .  .have the right to 
authorize or prohibit all reproductions of their works, in any manner or form, per­
manent or temporary (including temporary storage in electronic form)” (Article 
17.5.1).
This reproduction right builds upon the Berne Convention which establishes a 
right of reproduction of the author’s work “ in any manner or form,” and on the 
Agreed Statement concerning Article 1(4) of the WCT, which provides that the right 
o f reproduction set in Berne “fully appl(ies) in the digital environment, in particu­
lar to the use of works in digital form.”  Though the Agreed Statement adds that 
the storage of a protected work in digital form in an electronic medium constitutes 
a reproduction, it says nothing about temporary copies, such as those made in the 
RAM memory of a computer, an issue that was extensively discussed during the 
negotiations of the WCT, but did not make it into the final text. Here the FTA go 
beyond Berne and the WCT in that they make clear that temporary copies in elec­
tronic form are subject to the right o f reproduction. But, the FTA with Chile, in 
a footnote to the main text, allows for the application of specific exceptions and 
limitations in the digital environment:
For works other than computer software, and other subject matter, such exceptions and 
limitations may include temporary acts of reproduction which are transient or incidental 
and an integral and essential part of a technological process and whose sole purpose is to 
enable (a) a lawful transmission in a network between third parties by an intermediary; or 
(b) a lawful use of a work or other subject matter to be made; and which have no independent 
economic significance. (Note to Article 17.7.3)
Because o f the fundamental importance o f temporary copies in the digital envi­
ronment, the explicit possibility o f exempting temporary copies from the right of 
reproduction, subject to the traditional “three-step test,” 19 may be important at the 
moment of devising appropriate intellectual property policies. The rapid evolution 
o f emerging technologies in this field explains the need for the creation of excep­
tions for temporary copies. For instance, the United States has dealt with this issue
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by creating limited exceptions, such as allowing the making of copies for machine 
maintenance or repair of a computer, or by exempting small copies incidental to 
web casting called buffer copies. Therefore, other temporary copies, besides those 
explicitly exempted, must follow the fair use test of Section 107 of the US Copyright 
Act. The European Union, on the other hand, has included a broad exception in its 
Directive20 with a similar wording to the quoted footnote in the FTA.
Neither DR-CAFTA nor the agreements signed by the United States with 
Australia, Singapore, Morocco, and Jordan have a provision similar to that of the 
FTA with Chile on exception of temporary copies to the right of reproduction.
The FTA deals with the right o f communication to the public, in the same 
terms as the WCT. Therefore, this right covers all kinds of works communi­
cated to the public by wire or wireless means, without prejudice to related Berne 
Convention provisions. This broad right of communication is not fully covered 
by TRIPS.
However, the FTA with Chile establishes that authors have the right to autho­
rize or prohibit the communication to the public o f their works in such a way that 
Members of the public may access these works from a place and at a time individ­
ually chosen by them (Article 17.5.2). This means that the Parties should recognize 
an exclusive right for interactive, on-demand communications. This provision does 
not include private communications such as electronic mails with contents protected 
by copyright.
With regard to the right of distribution, the Chilean FTA practically reproduces 
the provision of WCT but omits the exhaustion of rights provided for therein, which 
prescribes that: “Nothing in this Treaty shall affect the freedom of Contracting 
Parties to determine the conditions, if any, under which the exhaustion of the right in 
paragraph ( 1 ) applies after the first sale or other transfer of ownership of the original 
or a copy o f the work with the authorization of the author.”
However, Parties are free to determine whether they will apply a national or inter­
national regime of exhaustion o f rights. This conclusion is based, among others, on 
the application of the non-derogation principle, discussed above. While Chile in its 
FTA implementing legislation, together with establishing the right of distribution, 
provided for a system of international exhaustion of rights, the United States has 
traditionally applied a national exhaustion regime.
The distribution right in the FTA with Chile applies only to fixed copies that can 
be put into circulation as tangible objects. It does not provide for the distribution 
o f electronic copies. Some have argued that limitations to the right of distribution, 
such as the doctrine o f exhaustion or the first sale doctrine, do not apply to the digital 
transmission of lawful electronic copies, because the sender would always retain a 
copy of the work. One may ask whether the Parties, under the FTA, still have leeway 
to apply limitations to the distribution right for electronic copies, when together with 
sending an electronic copy, the sender deletes or destroys the original copy in the 
computer. This could be considered a transfer of ownership altogether, the same as 
selling a book in the analogue world. It seems that because this particular provision 
and its footnote are limited to the distribution right (limited to tangible objects), 
Parties could provide for a digital first sale.
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Consistent with the Berne Convention (“countries of the Union may grant a term 
of protection in excess o f those provided” in the Treaty), the FTA extends copyright 
by 20 years for most works, to life of the author plus 70 years -  up from the life of 
the author plus 50 years after death term of protection set in TRIPS for the majority 
of works. In cases where the term o f protection of a work is calculated on a basis 
other than the life’s span of a natural person, such as those whose author is a legal 
entity, the term was set at a minimum of 70 years from the end of the calendar year 
of the first authorized publication of the work, or failing such authorized publication 
within 50 years from the creation of the work, at a minimum of 70 years from the 
end of the calendar year of the creation o f the work. In general, United States’ 
industry welcomed the approach taken in the FTA with Chile and subsequently by 
DR-CAFTA, Colombia, Panama, and Peru.
For photographic works, the general rule for most countries is still the 25-year 
protection from the making of the work, provided for in the Berne Convention. 
Parties to the WCT agreed to modify the Berne/TRIPS standard by stating that 
they would “not apply the provisions of Article 7(4) of the Berne Convention.” 
Therefore, the term of protection of photographic works went from 25 years from 
the making of the work to life of the author plus 50 years, which is the general rule 
in the Berne Convention. The FTA with Chile, in the same way as DR-CAFTA and 
those signed with Colombia, Panama, and Peru, extended protection on the term 
established in WCT by 20 years. Hence, photographic works are protected by the 
general 70-year rule. While the United States already protected this type o f work 
by the standard in the FTA, Chile protected them only for the life of the author plus 
50 years.
4.4.3.2 Related Rights
As for the duration o f rights, in a similar provision to the one on the copyright, 
performers and producers of phonograms are granted a minimum of 70 years from 
the end of the calendar year of the first authorized publication of the work, or failing 
such authorized publication, within 50 years from the fixation o f the performance 
or phonogram, a minimum of 70 years from the end of the calendar year of the 
fixation of the performance or phonogram. This provision applies when the terms 
are to be calculated on a basis other than the life of a natural person. This would 
normally be the case of collective works, works commissioned in the United States, 
and computer and cinematographic works in Chile. These terms are identical in 
DR-CAFTA and in the agreements signed with Colombia, Panama, and Peru.
The fact that related rights are treated separately from copyright does not mean 
that there are no similarities between them. Indeed, for the right o f reproduction and 
the right of distribution (making available to the public) they are treated in the same 
manner for authors, performers, and producers of phonograms. With regard to the 
rights of reproduction and distribution for performers and producers, the wording is 
drawn from WIPO Performances and Phonograms Treaty of 1996 (WPPT).
As regard the right of communication to the public,21 the standard in the 
FTA with Chile is the same as for copyright, as discussed above. Together with
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establishing the right of communication of fixed performances22 or phonograms23, 
including the interactive on-demand communications, the FTA preserves some 
exceptions and limitations authorized under previous treaties. Parties are allowed 
to provide for exemptions for “radio broadcasting or communication to the pub­
lic o f performances or phonograms through analogue communications and free 
over-the-air broadcasting, and the exceptions or limitations to this right for such 
activities shall be a matter of domestic law. Each Party may adopt excep­
tions and limitations, including compulsory licenses, to the right to authorize 
or prohibit the broadcasting or communication to the public or performances or 
phonograms in respect of other non interactive transmissions in accordance with 
Article 17.7(3). Such compulsory licenses shall not prejudice the right of the per­
former or producer of a phonogram to obtain equitable remuneration.” (Article
17.6.5 (b)).
Less explicitly than in DR-CAFTA or the agreement between the United States 
and Australia, the FTA with Chile reduces the asymmetries between copyright and 
related rights. Prior to the implementation of the FTA in December 2003, Chile’s 
Copyright Law provided that when the interest of an author in a phonogram con­
flicted with the interest of the producer o f the phonogram, regarding the public 
performance of the phonogram, the author would always prevail over the producer. 
After the implementation law was enacted, this was amended in order to remove 
such hierarchy.
The FTA, in what again seems to be a bridge between copyright and related 
rights, provides for freedom of contract with respect to economic or patrimonial 
rights, as opposed to moral rights. It also states that the licensee and the employer 
in the case of commissioned works will be able to fully exercise the same rights as 
the original creator of the work (licensor or employee).24
However, despite the apparent freedom to contract and the general rule that 
the employer can freely exercise such rights, the Agreement adds that the Parties 
may establish “which contracts of employment underlying the creation of works 
or phonograms shall, in the absence of a written agreement, result in a transfer of 
economic rights by operation of law; and reasonable limits to the provisions . . .  to 
protect the interests o f the original right holders, taking into account the legitimate 
interests o f the transferees.” (Author’s emphasis).
The FTA with Chile permits limitations and exceptions to rights when their use 
does not conflict with a normal exploitation of the work, performance, or phonogram 
and do not unreasonably prejudice the legitimate interests o f the right holder, similar 
to the “three-step rule” established in TRIPS (Article 13), the Berne Convention 
(Article 9.2), WCT (Article 19), and WPPT (Article 16).
With regard to the exceptions and limitations in the digital environment, the FTA 
reproduces the Agreed Statements to Articles 10 and 16 of WCT and WPPT, but 
goes further by explicitly allowing temporary copies which are transient or inciden­
tal and an integral and essential part o f the technological process and whose sole 
purpose is to enable a lawful transmission in a network between third parties by an 
intermediary or the licit use of a work or other protected subject matter that has no 
independent economic significance.
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The FTA confirms that government use of computer software should take place 
as duly authorized. To that end, the Parties shall issue appropriate legal instruments 
to actively regulate the acquisition and management of software for government 
use. Such measures may take the form of procedures for the preparation and main­
tenance of inventories of software present on agencies’ computers and inventories 
of software licenses. DR-CAFTA and the FTA with Peru contain similar provisions.
4.4.3.3 Evasion of Effective Technological Measures and Information 
on Rights Management
The FTA with Chile provides for very strict rules against the circumvention of tech­
nological protection measures (TPMs) used by authors, performers, and producers 
o f phonograms or any protected material to protect their works, performances, and 
phonograms, protected by copyright and related rights.25
The provisions on TPMs go beyond the WIPO treaties of 1996, which only state 
that Parties “shall provide adequate legal protection and legal remedies” against the 
circumvention of TPMs, leaving it to each Party to decide the way in which it will 
implement the provisions and whether it will apply civil and/or criminal sanctions 
to infringers. In a key provision, Parties are committed to
provide that any person who knowingly circumvents without authorization of the right 
holder or law consistent with this Agreement any effective technological measure that con­
trols access to a protected work, performance, or phonogram shall be civilly liable and, in 
appropriate circumstances, shall be criminally liable, or said conduct shall be considered an 
aggravating circumstance of another offence. No Party is required to impose civil or crimi­
nal liability for a person who circumvents any effective technological measure that protects 
any of the exclusive rights of copyright or related rights in a protected work, but does not 
control access to such work (Article 17.7.5).
Very limited exemptions to the FTA detailed provisions -  aimed at providing 
adequate legal protection and effective legal remedies to fight against circumven­
tion of effective technological measures -  are permitted for cases such as reverse 
engineering to achieve interoperability between computer programs; analyzing and 
identifying flaws of encryption technologies; preventing access o f minors to inap­
propriate online content; correcting security of a computer; disabling a capability 
to collect and disseminate personal information; lawful activities of government 
employees; and, access to works by non-profit libraries, archives, or educational 
institutions for the purpose of making acquisition decisions.
The provisions on TPM have a 5-year term for application in Chile, one of the 
longest term allowed by the FTA in its transitional provisions. In DR-CAFTA the 
terms for the implementation o f the TPM vary according to the countries, but 
the average is of 3 years.
The FTAs also protect Rights Management Information (RMI)26 in terms similar 
to those in the WIPO treaties of 1996 (WCT and the WPPT). The difference is that 
it provides for civil sanctions and for criminal sanctions when the prohibited acts 
are done willfully and for commercial advantage.
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4.4.4 Protection o f  Satellite S ign als
The FTA with Chile binds the Parties to ratify a number of international treaties of 
the so-called international architecture of intellectual property. In this respect the 
FTA obliges the Parties to ratify before January 1, 2009, the Convention relating 
to the Distribution of Program-Carrying Signals Transmitted by Satellite, agreed in 
Brussels on May 21, 1974 (the Brussels Convention)27 , which entered into force on 
August 25, 1979. In the case of the DR-CAFTA it stipulates the same obligation to 
be complied with before January 1, 2008. This obligation is stricter in subsequent 
free trade agreements. In those of Colombia and Peru, for example, adherence must 
coincide with the entry into force of the agreements.
The Brussels Convention provides that each contracting Party shall take adequate 
measures to prevent the unauthorized distribution in or from its territory o f any 
program-carrying signal transmitted by satellite. The said Convention (Article 8) 
permits specific reservations to Members, under special circumstances, which are 
not excluded from the FTAs.
In addition to the obligation to become a Party to the Brussels Convention and the 
obligations deriving from that treaty, the FTAs provide for further complementary- 
related enforcement obligations: first, acts such as the manufacture, assembly, 
modification, import, export, sale, lease, or distribution of a tangible or intangible 
device or system may be considered either a civil or a criminal offence if the person 
concerned knows that the principal function of the device or the system is solely to 
assist in decoding an encrypted program-carrying satellite signal without being duly 
authorized. The knowledge of the principal function of the device or system may be 
demonstrated through reasonable evidence, taking into account the facts and cir­
cumstances surrounding the alleged illegal act. Also the wilful reception or further 
distribution of an encrypted-program-carrying satellite signal knowing that it has 
been decoded without the authorization of the lawful distributor shall be considered 
either a civil or a criminal offence.
In the case of DR-CAFTA28 and the FTA with Peru, the infringement is assumed 
to be a criminal offence and do not allow, optionally, for civil or criminal offences 
as in the FTA with Chile.
4.5 Identification Signs: Marks and Geographical Indications
4.5.1 Tradem arks
Because of both Parties particular interest in this category of protection, the provi­
sions on trademarks were thoroughly discussed during the FTA negotiations with 
Chile. Great emphasis was given in the discussions to certification and collective 
marks and to the different trademark systems in place in Chile and the United States. 
Difficulties did arise in the negotiations with respect to geographical indications 
(GIs), because in the United States geographical indications are generally protected 
under trademark law.
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According to the FTA, trademarks shall include collective, certification, and 
sound marks and may include geographical indications and scent marks. This means 
that there are at least three categories of marks that should be protected, namely col­
lective, certification, and sound marks. But, there are two further categories of signs 
for which protection as a trademark is not mandatory, i.e., geographical indications 
and scent marks. This is a TRIPS-plus and even NAFTA-plus standard because 
the protection of certification marks is not mandatory under those agreements. In 
the recent United States agreement with Australia, protection for collective and 
certification marks is also mandatory and geographical indications are eligible for 
protection as a mark. Sound and scent marks are not included in this latter agree­
ment. However, the United States agreements with Jordan, Singapore, DR-CAFTA, 
and Peru have a similar provision to the FTA with Chile. In the latter FTA, certifi­
cation marks do not need to be recognized as a separate category of trademark, but 
the sign as such should be protected as an ordinary trademark.
Consistent with TRIPS, the FTA with Chile provides that the trademark owner 
shall have the exclusive right to prevent others, without his consent, from using in 
the course of trade identical or similar signs. Nevertheless, there are two important 
differences when compared with the TRIPS Agreement.
First, trademark owners shall have the right to prevent third parties without their 
consent, from using in the course of trade identical or similar signs, .. including 
subsequent geographical indications.. This addition makes sense, as geographical 
indications are capable o f constituting a trademark, according to the FTA. Second, 
the right of the titleholder is not only extended to products or services which are 
identical or similar to those for which the trademark is registered but also extended 
to goods or services “ ... that are related to those goods or services in respect of 
which the trademark is registered, where such use would result in a likelihood of 
confusion.” Likelihood of confusion is a matter to be determined by the domestic 
trademark law.29
No parallel provision to that in the TRIPS Agreement on the minimum duration 
of a trademark and its renewal is found in the FTA. This is not the case in the 
agreements of the United States with Australia, Morocco, and DR-CAFTA30 , which 
provide for a minimum of 10 years instead of 7 years as provided for in TRIPS. This 
is also the case of the recent agreements signed with Colombia, Panama, and Peru.
Reportedly, an additional issue discussed during the negotiations was the prohi­
bition of the requirement to record trademark licenses to establish the validity of 
such a license. While both TRIPS and the FTA with Chile say nothing about record­
ing of trademark licenses, a provision of this nature is found in the trade agreements 
of the United States with Australia, Jordan, Morocco, and Singapore and FTAs with 
Colombia, Panama, and Peru.
The FTA with Chile contains a number of provisions about the trademark regis­
tration system to establish basic formal requirements affecting decisions and notifi­
cations; modernize the registration system by using electronic means; and encourage 
the use o f the International Classification contained in the Nice Agreement. No 
similar provisions are found under the NAFTA or in the United States agreements 
with Jordan and Singapore, but they do appear in the agreements with Australia and
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DR-CAFTA31. The substance of the obligations regarding the registration of trade­
marks contained in the FTA is already included in the enforcement provisions of 
the TRIPS Agreement; however, the latter provisions are less burdensome and more 
flexibly drafted than those in the FTA.
According to the FTA with Chile, in cases where the full implementation of the 
obligations requires a Party to amend its domestic legislation or additional financial 
resources, those amendments and additional resources should be in force or avail­
able as soon as practicable, as in the case of the trademarks provisions of the FTA 
and in no event later than 2 years from the date of entry into force of the bilateral 
agreement.
4.5.2 Sp ecial Protection f o r  Well-Known Tradem arks
As in TRIPS, the level of protection for well-known trademarks is the same as that 
provided under the Paris Convention for the Protection of Industrial Property ( 1967), 
but covering both products and services. In the FTA with Chile non-registered well- 
known marks also benefit from such protection against dilution. A  similar provision 
is found in the United States agreements with DR-CAFTA, Jordan, Singapore, 
Morocco, and Australia and more recently in the FTAs signed with Colombia, 
Panama, and Peru.
The FTAs also go beyond the TRIPS Agreement in various respects when provid­
ing for additional measures of protection of well-known trademarks. They provide 
that according to the respective domestic legislation, Parties shall provide for appro­
priate measures to prohibit or cancel the registration of a trademark, identical or 
similar to a well-known trademark, if the use of that trademark by the registrant 
applicant: a) is likely to cause confusion; or b) to cause mistakes; or c) to deceive; 
or d) risk associating the mark with the owner of the well-know trademark; or e) 
constitutes unfair exploitation of the reputation of the trademark.
4.5.3 G eographical Indications
Although Chile and the United States have advocated similar positions and sub­
mitted joint proposals on geographical indications in the WTO, some differences 
remain between both countries over the scope and the means o f protection available 
for geographical indications. The United States protects geographical indications by 
means of collective marks. The Agreement tries to accommodate both forms.
Besides the framework of protection under the section on geographical indica­
tions, to protect their own indications, Chile and the United States agreed to follow 
the same approach as provided for under the NAFTA and protect them as distinc­
tive products. Thus, Chapter Three of the FTA dealing with “National Treatment 
and Market Access for Goods” governs particular geographical indications such as 
Bourbon Whiskey of the United States and Chilean Pisco. One superficial reading
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of this mutual obligation is that recognition of specific geographical indications in 
the Market Access Chapter instead of listing the same specific indications in the 
Intellectual Property Rights Chapter is to ensure that listed geographical indications 
will be granted only market access, respectively, to the United States and Chile. 
However, the provisions of the Market Access Chapter go beyond access and pro­
vide a strong protection to the listed geographic terms. In fact, besides allowing 
for the importation of the listed products, the Parties committed themselves to ban 
the sale of the unauthorized products bearing those geographical indications within 
their territories.
As to the definition of “geographical indications,” the FTAs adopt the one 
provided in TRIPS. Nevertheless, a second sentence was added to the relevant 
provisions of the FTAs which broaden the TRIPS concept to allow the protection 
of geographical indications under the trademark system. This extends the possi­
bility that a trademark -  in the approach followed by the United States, which 
includes collective and certification marks -  could be protected as a geographical 
indication. In doing so, part of the definition of trademarks has been included by 
providing that
. .  .Any sign or combination of signs (such as words, including geographical and personal 
names, letters, numerals, figurative elements, and colors) in any form whatsoever shall be 
eligible for protection or recognition as a geographical indication (Article 17.4.1, Chile 
FTA).
The new given definition is extremely broad and might produce some unexpected 
consequences. Any WTO Member could request, for example, Chile or the United 
States, according to the most favored nation principle, to extend protection to signs 
or combination of signs as geographical indications. While the trademark elements 
added to the geographical indication definition might broaden the scope of denom­
inations protected via GIs, this may be at the expense of indiscriminate filing and 
registration of geographical indications. Because the standard of protection for geo­
graphical indications in TRIPS is rather objective, in the sense that the good must 
have originated in a certain territory and a given characteristic of the good must be 
attributable to that origin, it could be assumed that the registration should be more 
or less automatic. Yet geographical indications protected through trademarks must 
still be subject to the distinctiveness or secondary meaning test, because they are 
essentially descriptive terms (i.e., non-inherently distinctive).
A  new distinction concerning the legal means that each Party should provide to 
the other to protect geographical indications was introduced in the FTA with Chile.32 
The latter shall provide the legal means to identify and protect geographical indi­
cations of “United States persons” that meet the criteria contained in the common 
definition. However, the United States shall provide the legal means to identify and 
protect Chilean geographical indications that meet the criteria contained in the com­
mon definition. The difference lays in the use of the concept “person” contained in 
the obligation by Chile. Because the United States protects geographical indications 
through a system of collective and certification trademarks, the owners of the those
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indications are usually legal persons. For all purposes, the FTA defines “person”33 
as “a natural person or an enterprise.” On the contrary, Chile protects its geograph­
ical indications through specific laws and regulations, and technically, the owner is 
the Chilean State because -  at least in the wine and spirit sectors -  they are created 
through Presidential Supreme Decrees.34 Thus, for purposes of the geographical 
indications provisions, a footnote states that -  besides natural persons and enter­
prises -  “persons of a Party shall also mean government agencies” which means 
that in the case of Chile (and eventually the United States), government agencies 
may file for geographical indications on behalf o f the Chilean State.
Due to these considerations, a special provision was included in the FTA for those 
geographical indications related to wines and spirits. It means Chile shall provide to 
geographical indications of the United States the same recognition as Chile accords 
to wines and spirits under the Chilean regime. This provision might be considered 
redundant because of the national treatment principle in the Agreement. The United 
States shall provide to Chilean geographical indications the same recognition as 
it grants to wines and spirits under the Certificate of Label Approval system as 
administered by the United States Department of the Treasury Alcohol and Tobacco 
Tax and Trade Bureau or any successor agencies, notwithstanding the provisions of 
the US Trademark Act.
Other provisions of the FTAs are intended to simplify the formalities of registra­
tion and protection of geographical indications; provide publicity and transparency 
of the relevant regulations; and establish opposition procedures and guidelines 
regarding the processing of application or petitions and special grounds for refusing 
protection by favoring pre-existing trademarks.
Excluding the special measures on wines and spirits in the case of Chile, the 
provisions on geographical indications are similar in subsequent agreements, e.g., 
DR-CAFTA, Colombia, Panama, and Peru.
4.6 Enforcement and Settlement of Disputes
Measures related to the enforcement of rights and obligations are key components 
of trade agreements. The existence of a dispute settlement mechanism also provides 
guarantees to the Parties that the problems that may arise due to the implemen­
tation and enforcement of commitments will be resolved in an orderly manner. 
In the FTAs, as in the WTO system, the respective Intellectual Property Rights 
Chapters have specific enforcement rules, and in a separate chapter there is an 
FTA mechanism for the settlement of all disputes related to the agreements. This 
model is followed in all subsequent FTAs subscribed by the United States including 
DR-CAFTA and the agreements with Colombia, Panama, and Peru.
The enforcement provisions of the FTAs present the same structure as the TRIPS 
Agreement. Accordingly, they contain provisions on General Obligations, Civil and 
Administrative Procedures, Provisional Measures, Border Measures, and Criminal 
Procedures. For the United States, probably the most relevant achievement in this
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area has been to make mandatory many of the discretionary remedies included under 
TRIPS. The important novelty of the FTAs, as far as TRIPS and the WIPO Internet 
Treaties are concerned, is that it provides for “Limitations on Liability of Internet 
Service Providers.”
The FTA with respect to civil and administrative procedures and measures pro­
vides that each Party shall make available to right holders civil judicial procedures 
concerning the enforcement of any intellectual property right (Article 17.11.7).
This was practically transcribed from TRIPS (Article 42) with the difference 
that the FTA prescribes that civil procedures shall be applied to present and future 
intellectual property rights that are recognized by the legislations of both countries.
The FTAs complement TRIPS (Article 50.2) in the sense that provisional mea­
sures inaudita altera parte (without hearing the other Party) must be acted upon 
expeditiously in accordance with judicial procedural rules o f each Party. It seems 
also that the FTAs allow authorities to request evidence from the applicant only 
when the infringement of the right is imminent, not when it is already being 
infringed, as provided in TRIPS (Article 50.3). What the FTAs add to TRIPS is 
that reasonable security or equivalent assurance must be in an amount sufficient; 
not only to protect the defendant and to prevent abuses but also not to unreasonably 
deter recourse to such procedure.
With regard to border measures, the FTAs go beyond TRIPS particularly in one 
aspect. The latter provides for border measures, including ex officio actions, only for 
the importation of counterfeit trademarks or pirated goods. The application of border 
measures to goods being exported and to goods in transit is optional. The FTAs are 
TRIPS-plus in the sense that they provide for ex officio measures for goods being 
imported, as well as for those destined for export or moving in transit.
As in TRIPS, the FTAs provide for criminal measures at least for cases of wilful 
trademark counterfeiting or copyright piracy on a commercial scale. But they go 
beyond TRIPS by broadening the scope of what is considered a willful infringe­
ment on a commercial scale for two specific situations that probably had in mind 
copyright infringement in the digital environment. The first, in the case of the FTA 
with Chile, relates to the obligation of the Parties to ensure that “willful infringe­
ment of copyright and related rights for a commercial advantage or financial gain, 
is subject to criminal procedures and penalties.” This provision seems to disregard 
the quantitative “commercial scale” requirement in TRIPS and replaces it with the 
notion of a “commercial advantage or financial gain” element, which focus more on 
the purpose of the infringement, even if it is not made at a commercial scale.
The second is the establishment of rules on limitation of responsibility for 
Internet service providers (ISP). The FTA provides for detailed rules on the limi­
tation of responsibility for Internet service providers (ISPs). These provisions are 
based on the United States Copyright Act. In the case of Chile, the issue was 
extensively discussed during the negotiations, mainly because of its novelty in intel­
lectual property negotiations. Initially it was to be incorporated in the FTA as a 
side letter, but finally it was included in the Intellectual Property Chapter itself. 
No such provisions can be found in NAFTA or in the trade agreement signed with 
Jordan.
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The FTA provides specific and detailed rules on liability of and limitation of the 
liability of services providers for infringing content that is transmitted or stored in 
their networks when they perform certain functions, such as hosting, caching, or 
linking.
4.6.1 The D ispute Settlement M echanism
Under the WTO system the dispute settlement mechanism is based on the principle 
that any Member can challenge trade measures taken by any other Member, so that 
even those countries that are economically weak can challenge the more econom­
ically powerful trade partners. However, the practical application of this important 
principle is not necessarily straightforward.
The need for dispute settlement arises whenever a Party considers that benefits 
accruing to it under commitments in a trade agreement are being impaired through 
measures taken by the other Party. Since the free trade agreements are based on 
the idea of reciprocal and mutually advantageous economic benefits through trade 
liberalization, it is the principal objective of a dispute settlement to reinstall, as 
quickly as possible, a situation in which each Party can fully enjoy the benefits it is 
entitled to under the agreement.
The United States has long advocated greater transparency in the WTO dispute 
settlement system. According to that perspective, experience shows that the dis­
pute settlement body recommendations and rulings can affect large segments of 
civil society. Furthermore, the increase in WTO Membership has given rise to a 
larger number of governments and their citizens being interested in its recommen­
dations and rulings. Yet civil society and non-Party Members have been unable even 
to observe the arguments or proceedings resulting in those recommendations and 
rulings.
The dispute settlement mechanism of the FTAs applys to almost all the different 
matters covered by the agreements, except, in the case of Chile, for some provi­
sions related to Competition Policy, Designated Monopolies, and State Enterprises 
(Chapter 16). In addition, some special proceedings are included for financial ser­
vices, environment, and labor issues, where technical consultations are established.
The dispute settlement mechanism under the FTAs includes namely consul­
tations, good offices, conciliation, and mediation and the establishment of an 
Arbitration Panel. For the latter, the FTA with Chile obliges the Parties to estab­
lish and maintain, within 6 months after the entry into force of the Agreement, a 
roster of at least 20 individuals who are willing and able to serve as panelists in the 
various disputes that could arise, appointed by mutual agreement of the Parties. Six 
of these Members shall be non-Party nationals. The roster remains in effect for a 
minimum of 3 years and panelists may be reappointed.
Finally, the dispute settlement mechanism applies broadly to disputes related 
to the avoidance or settlement of all disputes between the Parties regarding the 
interpretation or application of the Agreement; whenever a Party considers that a
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measure adopted by the other Party is inconsistent with the obligations of the FTA 
or the Party has failed to carry out its obligations; and, whenever a Party considers 
that a measure of the other Party causes nullification or impairment.
As noted, the FTAs mechanisms include non-violation complaints as a com­
ponent of the dispute settlement mechanism. In the WTO system, the difference 
between violation and non-violation remedies is that, under former, the competitive 
relationship is upset through the violation by one Member of a WTO obligation, 
whereas under the second situation, this competitive relationship is upset through 
“WTO-consistent” action on the part of one Member, rendering the results of cer­
tain market access concessions made by that Member less beneficial for other 
Members. It is considered a valid cause of action if a Member by some purely 
domestic measure frustrates the legitimate expectations of other Members as to the 
competitive advantages their products can draw from a negotiated tariff conces­
sion. However, such legitimate expectations may not be invoked if the complainant 
could “anticipate,” at the time of negotiating the concession, the possible adoption of 
future domestic measures by the respondent that would cancel out the complainant’s 
competitive advantage resulting from the negotiated concession. This requirement 
ensures that non-violation complaints are actually used in case of the frustration of 
legitimate expectations and not merely on grounds of a negative economic develop­
ment. This distinction and rationale for non-violation complaints extend to the case 
of the FTAs.
In the FTA, there are exclusions in the case of intellectual property rights to non­
violation complaint cases; therefore, non-violation situations could be the source 
o f differences between the parties and give rise to a dispute following the general 
principles outlined above. However, the automatic application of non-violation com­
plaints to intellectual property cases is not so obvious. In TRIPS, it was recognized 
that this was a subject deserving further consideration and transitional arrangements 
were devised to that effect. In the Council for TRIPS this continues to be an out­
standing question. The FTAs have gone no doubt beyond the present state of affairs 
in the TRIPS Agreement making countries parties to those agreements potential 
subjects of unforeseeable situations that according to the other Party might frustrate 
its legitimate expectations. This, according to some views, could make countries 
more vulnerable to pressures regarding the use and modalities of implementation of 
the flexibilities allowed in international agreements35 (South Centre/CIEL, 2004).
4.7 Conclusions
The TRIPS Agreement signaled a major change in international economic rela­
tions. For the first time intellectual property entered in full into the international 
trading regime36. This, in a way, reflected the approach of the United States that 
since the Trade Act o f 1974 established in its commercial relations a link between 
trade and adequate protection of intellectual property. The reasons for including 
intellectual property rights in the framework of the multilateral trading system dur­
ing the Uruguay Round of Multilateral Trade Negotiations that concluded with the
4 Intellectual Property and the New Generation o f Free Trade Agreements 111
creation of the WTO are complex. The attempt was originally resisted by a number 
of developing countries which advanced reservations, among others, on social inter­
est grounds, about subjecting, for example, inventions related to public health and 
nutrition to strict patenting rules under a new trading regime.
While TRIPS introduces minimum standards of protection, albeit with some flex­
ibilities, recent trends suggest a more complex picture characterized as a TRIPS-plus 
phenomenon. It has elicited concerns as it goes beyond the minimum standards of 
TRIPS by seeking to harmonize intellectual property regimes in developing coun­
tries with those of economically and technologically more advanced countries. This 
harmonization trend is being encouraged in bilateral, regional, and new multilat­
eral initiatives. The concerns advanced by some developing countries relate to the 
curtailment of their policy space in an important area of their economic develop­
ment. In brief, the perception by many is that TRIPS-plus requirements will inhibit 
countries from using fully the flexibilities implicit in the TRIPS Agreement and to 
resort to industrial policies with laxer systems of intellectual property protection, 
which were followed in the past by developed countries and until recently by newly 
industrialized countries (e.g., cases of Republic of Korea and Chinese province of 
Taiwan).
The TRIPS-plus phenomenon responds to the view that the Agreement is con­
sidered as not adequately reflecting the highest standards of intellectual property 
protection needed to promote global trade and to respond to the requirements of 
the digital age. As a result, in recent years, the United States has followed a clear 
and explicit bilateral trade policy going beyond the TRIPS Agreement by includ­
ing TRIPS-plus provisions in its free trade agreements post-NAFTA, which was, 
by the way, concluded almost in parallel with the Uruguay Round Negotiations. 
This bilateral agenda has included issues raised, with minor degrees of success, 
by the United States in various international fora, namely the extension of cover­
age of copyright, trademark, and patents protection; the need to ratify and enforce 
certain intellectual property-related treaties; patent protection for life forms; limita­
tions in granting compulsory licenses on patents; specific implementation of TRIPS 
provisions in areas such as undisclosed information; rules concerning the exhaus­
tion of intellectual property rights; and strengthened rules on enforcement. Recent 
trade agreements of the European Free Trade Association (EFTA) and the European 
Union with Latin American countries (Chile and Mexico) include provisions that 
oblige the parties to provide effective protection to intellectual property according 
to the highest standards, including effective means of enforcement. The bilateral 
agenda of the United States has proven to be more ambitious compared to that 
from Europe. However, recent initiatives from the European Union predict a more 
vigorous agenda on intellectual property matters particularly with respect to the 
enforcement of intellectual property rights.
Closer study of the FTA with Chile is a stimulating incursion into this TRIPS- 
plus world. At this stage, it is difficult to assess the overall impact of the intellectual 
property rights provisions of the FTA and even more to extrapolate results of such 
evaluation to other countries. The FTA is comprehensive treaty, which in Chile’s 
perception, together with a broad network of trade agreements with a multifarious
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group of trade partners, constitutes a dynamic feature of its economic policy geared 
at the promotion of exports o f services and products. Thus, the impact of these 
agreements cannot be assessed in isolation of these considerations.
One tentative conclusion that one can derive from the FTA with Chile is that the 
level of its intellectual property rights protection and enforcement provisions are 
less stringent than those negotiated by the United States -  simultaneously -  with 
Singapore and subsequently with DR-CAFTA, Australia, Bahrain, and Morocco; 
however, it includes a number of key provisions that constitute important precedents 
for incorporation in future bilateral and multilateral agreements.
The provisions dealing with pharmaceutical products have elicited a number of 
criticisms. In this regard, it should be noted that the expanded protection of phar­
maceutical products is in some respects conditioned to the Ministerial Declaration 
of the Doha Round on TRIPS and Public Health of November 14, 2001, which is 
expressly mentioned in the Preamble to Chapter 17 of the FTA with Chile. The DR- 
CAFTA agreement has included a letter of understanding to specify the relationship 
between intellectual property and access to health. The Preamble of the Agreement 
with Chile is innovative in comparison with other agreements signed recently by 
the United States. The relationship between the Preamble and the general principles 
of the Agreement, such as the non-derogation clause and provisions on pharmaceu­
tical products, is at least ambiguous and leave room for creative implementation. 
As noted in this chapter, the recent agreement signed by the United States with 
Peru has introduced important changes to the provisions on pharmaceutical prod­
ucts amending, among others, the linkage between sanitary and marketing approval 
with the validity of a patent, linkage that does prevail in the Agreement with Chile 
and DR-CAFTA.
Among the areas not covered in the FTAs signed by Latin American countries is 
the granting of compulsory licenses to allow for the use of the subject matter of a 
patent. In this area, as well as in others not covered by the FTAs, the latter do not 
innovate with respect, for example, to the provisions o f the TRIPS Agreement.
The trade agreements do not address the whole gamut of intellectual property 
issues. For example, a number of developing countries have claimed that interna­
tional intellectual property regimes fail to account adequately for the protection of 
traditional knowledge, but free trade agreements do not provide guidelines and do 
not innovate with respect to current debates in WTO and WIPO.
At the same time, the free trade agreements signed by Latin American countries 
do not address either the issue of the exhaustion of intellectual property rights in 
areas such as patents and trademarks. In this respect, the Doha Declaration on the 
TRIPS Agreement and Public Health of November 14, 2001, reaffirmed the right of 
WTO Members to use, to the full, the provisions in the TRIPS Agreement, which 
provide flexibility by leaving each Member free to establish its own exhaustion 
regime. The United States Free Trade Agreement with Australia, however, allows 
for the possibility that in the case of patents, the patent owner may contractually 
restrict the importation of patented products that it has placed on the market. Free 
trade agreements with Latin American countries leave Parties with the full flexibility 
contemplated in TRIPS.
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Finally, as underlined in this chapter, the recent bilateral agreements promoted 
by the United States add an unchartered page in the history of intellectual prop­
erty rights. TRIPS has been one important event in this history but not the 
concluding one.
Notes
1. See text of Declaration at http://www.wto.org/spanish/thewto_s/minist_s/min01_s/mindecl_ 
trips_s.htm
2. The Industry Trade Advisory Committee on Intellectual Property Rights (ITAC-15), with 
respect to the FTA recently signed with Peru, stated “ITAC 15 urges the US not only to moni­
tor very closely the implementation by Peru (and other FTA partners) of their FTA obligations 
but also to ensure that Peru and other FTA partners have in place, before the entry into force 
of the FTAs, national legislation that faithfully reflects their FTA obligations. ...IFAC-15 
commends the US for working with FTA partners to secure fully-compliant national legisla­
tion before each agreement enters into force. ITAC-15 considers it essential that, if need be, 
entry into force be postponed until full compliance is achieved.” Cited by P. Roffe (2006), 
Intellectual property provisions in bilateral and regional trade agreements: the challenges of 
implementation, C1EL.
3. See Article 26 of the Vienna Convention on the Law of Treaties.
4. Twenty-three agreements have been concluded or administered under the auspices of WIPO 
with regard to Intellectual Property. See the text of these agreements at http://www.wipo.int/ 
treaties/es/index.html
5. The reference in DR-CAFTA to agreements concluded or administered by WIPO is limited 
to those where both parties are members (see Article 15.1.6).
6. The TRIPS Agreement entered into force on January 1, 1995.
7. The 41 notifications made so far by different WTO Members regarding Article 4(d) of the 
TRIPS Agreement are available at the WTO web site http://www.wto.org/english/tratop_e/ 
TRIPS_e/intel7_e.htm
8. For some of the notifications made so far under Article 4(d) of the TRIPS Agreement, see 
UNCTAD/ICTSD Resource Book, Part One, Chapter 1.4.
9. See Article 15.9.5.
10. Article 15.9.4, CAFTA: “Without prejudice to Article 5.A(3) of the Paris Convention for the 
Protection of Industrial Property ( 1967), each Party shal I provide that a patent may be revoked 
or cancelled only on grounds that would have justified a refusal to grant the patent. However, a 
Party may also provide that fraud, misrepresentation, or inequitable conduct may be the basis 
for revoking, cancelling, or holding a patent unenforceable.” The US industry reacted to this 
provision in the following terms: “CAFTA restricts, in Article 15.9.4, the grounds for the 
revocation of a patent to those limited to the patentability of the invention. Notwithstanding 
that IFAC-3 is disappointed that it does not require CAFTA countries to also provide that 
fraud, misrepresentation or inequitable conduct may be the basis for revoking, cancelling 
or holding a patent unenforceable, it urges the U.S. Government to work with the CAFTA 
governments in the implementation of this provision to ensure that it is consistent with U.S. 
practice. For example, the possibility of preventing enforcement of a patent due to actions 
that are found to constitute inequitable conduct should be limited to acts that are material to 
the patentability of the invention. Since CAFTA countries are already members of the Paris 
Convention, IFAC-3 notes that the reference to the obligations contained in Article 5.A (3) of 
the Paris Convention does not add or detract from the obligation contained in the FTA Article 
15.9.4.” See IFAC-3-CAFTA.
11. See Article 15.9.6 (a).
12. This provision has its origins in the US Drug Price Competition and Patent Term Restoration 
Act of 1984 (Hatch-Waxman Act), which together with granting an extension of the patent
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term for administrative delays in the FDA, awarded extensions for delays during the granting 
of the patent.
13. See Pedro Roffe and David Vivas, “A Shift in Intellectual Property Policies in US FTAs?”, 
Bridges, Geneva, Year 11,5, August (2007).
14. Ibid.
15. See Roffe & Vivas, op. cit.
16. Correa, 2004.
17. In fact, there are two provisions in the FTA dealing with regulated products. The first pro­
vision (Article 17.10.1) states that the protection is awarded to undisclosed information for 
the grant or marketing approvals or sanitary permits. The second provision (Article 17.10.2) 
establishes the relation between regulated products and patents referring exclusively to “mar­
keting approvals.” A logical interpretation should lead to the conclusion that the parties 
probably meant different things in the use of the terms “marketing approval” and “sanitary 
permits.” One expression of this might be the interpretation that if a Party grants only sani­
tary permits (i.e., to certify the safety and efficacy of the product), the provisions of Article 
17.10.2 (that refers to marketing approval) would not apply to that Party. However, as stated 
in this study, the provisions of the FTA in this area derive from Article 39, TRIPS, and these 
refer only to marketing approvals.
18. See Roffe & Vivas, op. cit.
19. The so-called three-step test allows Parties to “confine limitations or exceptions to exclusive 
rights to certain special cases which do not conflict with a normal exploitation of the work 
and do not unreasonably prejudice the legitimate interests of the right holder”. See Article 13, 
TRIPS.
20. See Article 5 of Directive 2001/29/EC of the European Parliament and of the Council of 
May 22, 2001, on the harmonization of certain aspects of copyright and related rights in the 
information society.
21. According to the FTA “Communication to the public of a performance or a phonogram means 
the transmission to the public by any medium, otherwise than by broadcasting, of sounds of 
a performance or the sounds or the representations of sounds fixed in a phonogram. For the 
purposes of Article 17.6(5) ‘communication to the public’ includes making the sounds or 
representations of sounds fixed in a phonogram audible to the public.”
22. Under Article 17.6.8(c) of the FTA: Fixation means the embodiment of sounds, or of the 
representations thereof, from which they can be perceived, reproduced, or communicated 
through a device.
23. Phonogram means, according to the FTA, the fixation of the sounds of a performance or of 
other sounds, or of a representation of sounds, other than in the form of a fixation incorporated 
in a cinematographic or other audiovisual work.
24. For the relevant equivalent provision in DR-CAFTA, see Article 15.5.6.
25. According to the FTA: An “effective technological measure” is any technology, device, or 
component which in the normal course of operation, controls access to a work, performance, 
or phonogram or other protected subject matter, or protects copyright or other related rights 
which cannot be evaded accidentally.
26. According to Article 17.7.6 (b), FTA, Rights management information means: “information 
which identifies a work, performance, or phonogram; the author of the work, the performer 
of the performance, or the producer of the phonogram; or the owner of any right in the work, 
performance, or phonogram; information about the terms and conditions of the use of the 
work, performance, or phonogram; and any numbers or codes that represent such information, 
when any of these items is attached to a copy of the work, performance, or phonogram or 
appears in conjunction with the communication or making available of a work, performance, 
or phonogram to the public. Nothing in paragraph 6(a) requires the owner of any right in 
the work, performance, or phonogram to attach rights management information to copies of 
the owner’s work, performance, or phonogram or to cause rights management information to 
appear in connection with a communication of the work, performance, or phonogram to the 
public.” In the case of DR-CAFTA, see equivalent Article 15.5.8 (c).
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27. In no other bilateral trade treaty recently negotiated by Chile (with Mexico, EFTA, 
EU, or Korea), there exists a similar obligation to become member of the Brussels 
Convention.
28. See Article 15.8.
29. Footnote 4, FTA.
30. See Article 15.2.9 of DR-CAFTA.
31. Article 15.2.6, CAFTA.
32. Articles 17.4.2 and 17.4.3, FTA. These two provisions are not found in CAFTA or the U S- 
Morocco FTA
33. Article 2.1, FTA, on general definitions.
34. See Article 27 of Chile’s Law 18.455, which “Sets Rules on Production, Elaboration, and 
Commercialisation of Ethylic Alcohols, Ethylic Beverages and Vinegars.” Article 27: “The 
President of the Republic, by supreme decree issued through the Ministry of Agriculture, 
may establish vine-producing zones and denominations of origin for wines and spirits in 
certain areas of the country, where conditions of weather, soil, varieties of grapes, cultural 
and oenological practices are homogeneous” (non-official translation).
35. South Centre/CIEL, 2004. The report acknowledges that “Nonetheless, these bilateral agree­
ments establish some limitations for non-violation complaints that must be taken into account. 
In the United States-Chile FTA, for instance, benefits expected under the intellectual property 
chapter cannot be invoked with respect to measures taken under the general exceptions pro­
visions. That is, measures taken under Article XX of GATT 1947 (along with its interpretive 
notes, into the agreements mutatis mutandis) cannot be challenged on the basis of annulment 
or impairment of benefits expected under the intellectual property provisions.”
36. Previous to the TRIPS Agreement, there were references to intellectual property rights in 
the GATT-1947. For instance, Article IX deals with Marks of Origin; both Article XII 
on Restrictions to Safeguard Balance of Payments and Article XVIII on Governmental 
Assistance to Economic Development state that Parties may not apply restrictions which 
would prevent compliance with patent, trade mark, copyright, or similar procedures. Finally, 
Article XX, which provides for general exceptions, allows for exceptions necessary to secure 
compliance with laws or regulations which are not inconsistent with the provisions of this 
Agreement, including those relating to the protection of patents, trade marks and copyrights, 
and the prevention of deceptive practices.
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Chapter 5
Free Trade Agreements and Intellectual 
Property: Impacts and Challenges
Álvaro Díaz
5.1 Introduction
A decade after having adhered to the agreement of the World Trade Organization 
(WTO) concerning Trade-Related Aspects of Intellectual Property Rights (TRIPS), 
10 countries of Latin America and the Caribbean have signed free trade agree­
ments (FTA) with the United States, which contain extensive chapters on intellectual 
property which go beyond the TRIPS Agreement o f 1994.
The agreements have given rise to heated debate in all the signatory countries. In 
Costa Rica, the country with the longest democratic tradition on the continent, DR- 
CAFTA was subject of strong controversy and therefore, the Legislative Assembly 
agreed in September 2007 to carry out a referendum which was won by the gov­
ernment by a short margin. In the United States the process was not easy either. 
DR-CAFTA was approved by only one vote, and the defeat of the Republican 
Party in the 2006 parliamentary election -  and the current recession in the United 
States -  postponed for an uncertain future the agreements with Colombia and 
Panama.1
If these obstacles are overcome, almost the entire Pacific coast of Latin America 
will have FTA’s with the United States. Including Mexico, this means 11 countries 
of the region which represent almost 30% of the subcontinental territory and 45% 
of the population and of the regional GDP.
Nevertheless, the free trade agreement wave has ended for the foreseeable future. 
The Colombia and Panama FTA’s are stalled in Congress. In the case of Ecuador, 
the negotiations were first interrupted in 2006 by the Bush Government and then 
suspended by President Rafael Correa.2 Most importantly this FTA wave failed 
to incorporate Brazil and Argentina, for it is clear that neither of them will sign 
agreements with the United States which include public purchases and intellectual
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property if the United States does not substantially reduce agricultural subsidies. 
Brazil and Argentina worked for a multilateral solution in the Doha Round, but its 
collapse in 2008 increased the uncertainty on these matters.
The ten Latin American countries that negotiated trade agreements with the 
Bush Government had very focalized goals: consolidate, diversify and increase 
exports and also promote foreign direct investment. In exchange they had to accept 
the strengthening of intellectual property rights, the opening of public purchases 
to foreign firms and the reduction of regulations for short and long term capital 
movements.
Evidently, the FTA’s will intensify the opening and export-led orientation of 
these Latin American economies. The governments of the region commissioned 
studies that estimated the effects of tariff reduction on growth and concluded that 
although the effects were positive, they were rather small. No studies were com­
missioned about the economic impact of intellectual property. Although there is 
consensus that there will be significant economic consequences, the scarcity of sta­
tistical data, uncertainty on implementation methods of the FTA’s obligations and 
the possible formulation of new public policies make it impossible to make reliable 
estimates.
In this context, there are two viewpoints. On the one hand, the orthodox view 
assures that the agreements can have transitory costs but their benefits will be 
greater, provided that the contracted obligations are fully applied and complemented 
with new reforms and deregulation to strengthen the free market. On the other, the 
heterodox view maintains that the agreements entail risks for macroeconomic sta­
bility, can generate regressive social effects and affect some branches of production, 
which may not be compensated by expansion of exports, nor by greater foreign 
investment, if any.
This chapter follows the second view, emphasizing that the consequences of the 
agreements will depend on the flexibilities achieved in their implementation and 
on the public policies put into effect before and after their entry into force. In this 
regard, the present world economic crisis which begun in the United States will 
probably favour a pos Washington consensus for a new balance between markets 
and state, between private and social control, even in the intellectual property arena. 
The recent G-20 April 2009 London Agreement is an example. This could inspire 
a new generation of public policies and regulations that maximize benefits from the 
free trade agreements and minimize their negative impact.
This could seem deceptive because it is common to establish a causal relation 
between the FTA’s, the strengthening of the market and the reduction of the State. 
However, the agreements with the United States are not incompatible with greater 
public-sector activity in social policies, the expansion of public policies in innova­
tion and technological development, the development of sound regulations in public 
utility services, the progress of legislation and the competition agencies, as well 
as the strengthening of consumer rights, labor rights and environmental protection. 
Furthermore, the agreements do not hinder the political autonomy of the countries 
in international affairs, as occurred when Mexico and Chile opposed the United
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Nations’ intervention in Iraq. Nor do they stand in the way o f the integration of the 
subcontinent in a perspective of open regionalism, which we hope will be the next 
generation of agreements.
This perspective can also be applied to intellectual property rights (IPR). To be 
sure, one should start by recognizing that the agreements broaden and strengthen 
IPR by generating important consequences for the dynamics o f technological 
innovation, as well as consumption of products intensive in information and com­
munication technologies (ICT). They will also have a powerful impact on the 
agricultural and pharmaceutical sectors.
The IPR strengthening commitments should be fully implemented toward the 
year 2010. There will inevitably be postponements, but even so, they will bring 
about a rapid institutional and regulatory change. To understand its scope, there is no 
doubt that the text of trade agreements is a starting point for analyzing the possible 
impacts of IPRs. This, however, is not sufficient. First of all, because despite their 
technical and legal complexity, free trade agreements are “ incomplete contracts,” 
that is, they make numerous explicit obligations but leave gaps and ambiguities that 
can only be filled with laws, regulations, and the jurisprudence of each country. 
Second, because other public policies related to technological innovation, compe­
tition, consumer rights, health, education, and social protection will determine the 
final balance between IPR protection and social access to knowledge and goods like 
pharmaceuticals.
One possible scenario is a strict implementation of free trade agreements caus­
ing an overprotection of IPRs, which could be combined with weak public policies 
in innovation, health, competition, consumer rights, and others. The result will be 
inevitable. There will be negative impacts in the population’s access to health and 
in the competitiveness of small-scale agricultural production, also hindering the 
dynamics of local innovation and increasing the inequality o f access to knowledge 
and information.
Another scenario is a flexible implementation of free trade agreements, creat­
ing a more adequate balance between the holders of intellectual property rights 
and the general interests of society, which could be combined with a new very 
active generation o f public policies with regard to innovation, health, competition, 
and consumer rights. In this context, the negative impacts could be minimized 
and more favorable conditions for a growth path with equity could even be 
created.
To meet these challenges, this chapter addresses two major issues. Section 5.2 
analyzes the possible impacts of free trade agreements focusing on technological 
innovation and the digital economy.3 Section 5.3 makes recommendations for a 
new treatment o f IPRs to encourage creation and innovation, spread the transfer 
of knowledge on a large scale, and maximize the dissemination of its benefits. To 
end this chapter, Section 5.4 summarizes the main challenges faced by the Latin 
American countries that ratified the FTA’s: the building of a new treatment for intel­
lectual property and the encouragement of a new generation of post-Washington 
consensus public policies.
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5.2 Impacts of Free Trade Agreements
5.2.1 Innovation
Free trade agreements devote little space to patents and most of the provisions reg­
ulate patents only for pharmaceutical and agrochemical products. There are three 
main changes: first, although they do not impose obligations, they open the doors to 
an expansion of patentable subject matter, specially in business methods, software, 
and the patenting o f plants4; second, they strengthen enforcement of intellectual 
property with administrative, civil, and criminal proceedings; and third, they make 
it mandatory to compensate during the term of the patent for administrative delays 
of more than 5 years, which in practice is not an excessive obligation.
Nevertheless, the free trade agreements have numerous ambiguities and gaps. 
Countries are not strictly compelled to broaden patentable subject matter and could 
oppose patenting business methods, software, and plants.5 Furthermore, the free 
trade agreements do not define the “height” or innovation level to assess patentable 
innovations, nor do they provide conditions for compulsory licenses and parallel 
imports. Therefore the countries keep a margin of freedom to fill these gaps with 
their laws and technological innovation policies.
But none of this is guaranteed. The political economy of implementation of the 
agreements shows that there are countries that could further harden the provisions 
of the free trade agreements. Therefore, it is necessary to reach national consensuses 
in order to effectively take advantage of the gaps in patent regulation and promote a 
new generation of technological innovation policies.
5.2.1.1 Technological Innovation and Patents
Will the strengthening of the patents regime lead to more local innovation and will 
it encourage the registration of patents by national private entities and universities? 
For some, the unequivocal answer is affirmative under the assumption that weak 
intellectual property rights do not allow Latin American firms to assure the appro­
priability of high-risk investments in innovation, causing an under-investment in 
research and development (R&D). Hence, it is believed that the strengthening of 
IPRs will stimulate technological innovation and logically increase national patent 
applications.
This is a reductionist approach that leads to erroneous conclusions of diagnosis 
and appropriate public policy design.
It is well known that technological change in Latin American countries mostly 
depends on capital goods imports. The 10 countries that ratified the FTA’s have a 
small and asymmetric scientific and technological infrastructure shown by the fact 
that for every million dollars’ invested in science and technology, there is an output 
of four times more scientific articles than patents. Moreover, investment in R&D 
is low and has little private participation. Patent registration has very slow growth 
rate and foreign companies represent 90% of total patent applications. Table 5.1 
summarizes the reality in these matters and shows that the 10 countries that signed
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- 1 - 2 - 3 (3/2) - 4 - 5 - 6
OECD 910 25,091 622,706 2.50 533,267 754,835 310,672
LAC 522 2,007 11,222 0.60 17,575 5,496 702
Brazil 180 623 6,177 1.00 7,918 3,403 246
Mexico 102 592 2,395 0.40 3,492 505 181
Argentina 38 270 1,131 0.40 3,066 753 119
10 Countries with FTA 122 287 840 0.29 1,954 491 88
Chile 16 81 499 0.60 1,370 318 34
Colombia 44 88 161 0.20 334 68 21
Costa Rica 4 17 52 0.30 88 28 9
El Salvador 7 14 11 0.10 2 9 2
Honduras 7 6 3 0.00 11 9 2
Nicaragua 5 4 2 0.00 8 6 1
Panama 3 12 44 0.40 45 10 6
Peru 27 56 58 0.10 88 28 9
Dominican Republic 9 9 10 0.10 8 15 4
Rest of LAC 83 234 680 0.29 1,138 338 72
Venezuela 25 114 384 0.30 533 87 36
Cuba 11 30 181 0.60 262 148 11
Uruguay 3 19 44 0.20 165 42 8
Bolivia 9 9 24 0.30 32 16 1
Ecuador 13 17 14 0.10 30 11 7
Guatemala 12 20 10 0.10 14 9 2
Jamaica 3 8 5 0.10 49 10 3
Trinidad and Tobago 1 9 11 0.10 46 4 3
Paraguay 6 8 7 0.10 7 11 1
FTA 10/LAC (%) 23.3 14.3 7.5 11,1 8,9 12,5
FTA11/LAC (%) 42.9 43.8 28.8 30,1 18,1 38,3
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agreements with the United States represent 23.3% of the population and 14.3% 
of GDP, but only 11.1% of scientific articles and 8.9% of national applications for 
patents in Latin America.
The above-mentioned asymmetries have deepened over time. In the 1994-2004 
period, the growth rate of foreign patent applications doubled the national one.7 At 
the same time, the scientific articles-patents coefficient increased from 1.3 in 1994 
to 4 in 2004.
Nevertheless, the above has not hindered technological change driven mainly by 
capital goods imports with embedded technology, exports, and foreign investments 
which lead to new product and process technologies, the diffusion of information 
and telecommunications technologies, and also new management methods in busi­
ness. Although most advanced companies carry out little research and development 
in the conventional sense, it is also true that they devote significant efforts to imi­
tative, adaptive, and incremental innovations. This explains the asymmetry between 
very low private R&D and the high levels of adaptive and imitative innovation. This 
is consistent with empirical studies that have concluded that innovation occurs in 
most industries despite the shortage of patents (Arundel and Kabla, 1998; Cohen, 
Goto, Nagata, Nelson, and Walsh, 2003).
But why Latin American firms invest so little in R&D and consequently have 
such low levels of patent registration? Historical comparison shows that low levels 
of IP protection is not the fundamental cause. The American, Chinese, German, and 
Japanese historical experiences show that these countries substantially increased 
R&D and patent registration before the strengthening of IPR’s.
There are other sources o f explanation. One of them is that innovative Latin 
American firms that potentially could submit a patent application are inhibited by 
the risks of litigation whose costs generally exceed the expected benefits and are 
quite superior to the initial R&D investment. This is particularly discouraging for 
innovative small and medium-sized enterprises (SMEs) which lack funds to back 
these kinds of risks. However, innovative firms have other alternative strategies to 
deal with problems of appropriability: industrial secret, market-lead time, vendor 
lock-in techniques that generate customer dependency because of high switching 
costs, among others practices (Levin et al. 1987).
Furthermore, the conditions of appropriability vary among sectors. In the chem­
ical and pharmaceutical sectors patents are very important because of high sunken 
costs of R&D that contrasts with low imitation and reproduction costs. As regards 
financial services, retail trade, and Internet services, the costs of innovation are rela­
tively low, but the advantage of being first is very important. In such cases, free-rider 
problems and waiting games are lesser problems, which reduce the importance of 
patents.
For the Latin American countries that have trade agreements with the United 
States, a significant part of their R&D -  often not computed as such -  is linked to 
national resources research: adaptation of species, mining exploration and prospect­
ing, biomass studies, identification of ecosystems, and combating forestry and 
agricultural pests. These activities attract public resources, generate scientific arti­
cles, and require continuous innovation in science and technologies methodologies
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and techniques, but they can hardly obtain invention patents because they will be 
mostly classified as discoveries. Moreover, only a few countries authorize patents 
for genes, plants, and animals. In this cases, industrial secret will generally be the 
preferred technique.
Finally, it should be borne in mind that in these countries public science and 
technology policies are concentrated on promoting technology transfer toward 
small enterprises and on supporting scientific research in universities.8 This is nec­
essary, but is definitely insufficient to encourage private efforts in research and 
development.
5.2.1.2 Lessons from the Mexican Experience
The Mexican experience after NAFTA indicates that rigid application o f the FTA 
obligations does not necessarily encourage local innovation subject to protection 
by intellectual property. Between 1995 and 2005 registration of Mexican patents 
dropped 12%, whereas that of foreign patents doubled, despite the fact that spending 
on R&D increased from 0.2 to 0.4% of GDP, a coefficient nevertheless five times 
lower than the OECD average (Chart 5.1).9
M EXICO: PATENTS' APPLICATIONS (1980-2005)
BY NATIONAL OR FOREIGN ORIGEN
I Foreign applications Mexican applications  M cxicans/To la l (% ) |
19801981 19821983 19841985 19861987198819891990 19911992 1993199419951996199719981999 2000 200120022003 20042005
Chart 5.1 Mexico: patent applications according to origin national or foreign, 1980-2005. 
Source: Diaz (2007).
This poor performance in patents also extends to models of utility and industrial 
designs, which contrasts with the notable increase in scientific articles classified 
in the Science Index. Between 1990 and 2004 Mexico almost quadrupled annual 
production o f scientific articles with a higher performance than the Latin American 
average.
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What were the causes of this post-NAFTA drop in national patent registration 
in the Mexican Intellectual Property Institute (IMPI)? As it is known, Mexico was 
deeply integrated into the North American economy as a result of the NAFTA agree­
ment. Although between 1994 and 2004 GDP only increased by 30%, exports and 
imports tripled, while foreign investment grew rapidly. This brought an economic 
and a social restructuring marked by the emergence o f new industries and the decline 
of others.
Facilitated by a stricter intellectual property regime and by the Mexican adher­
ence to the Patent Cooperation Treaty (PCT),10 the entry of foreign investment 
generated an increase of foreign patent applications, particularly in the automo­
tive, electro-electronic, machine tool, chemical, pharmaceutical, and agro industrial 
sectors. This speed-up in foreign patent applications crowded out local innova­
tors, especially where the industrial restructuring was most intense. This can be 
explained because foreign patents give rise to monopolistic rights and increased 
the costs and risks of litigation for local innovators (Jones, 1995; Kortum, 1993; 
Reinganum, 1983).
The Mexican Government did not respond with a strong Science and Technology 
Strategy. Between 1994 and 2004 Mexican R&D only rose from 0.2 to 0.4% of GDP 
and private participation did not exceed 30% of total spending under this heading, 
far from the average of the developed countries. Also, the increase in R&D spend­
ing was concentrated in universities and scientific-technological research centers, 
which explains the 160% increase in scientific articles.
This situation can change, but it will not be easy. Mexican scientists and tech­
nologists can use the growing number of registered patents to develop incremental 
innovations (Romer, 1990; Aghion and Howitt, 1992), but this can be insufficient to 
compensate for litigation costs and for the sunk costs of generating new knowledge 
as a technological opportunity (Evenson, 1993; Evenson and Kislev, 1976; Kortum, 
1996; Segerstrom, 1998). Moreover, the innovative dynamism of various Mexican 
industries does not usually require competitive strategies based on patents, but on 
the alternatives above described.
5.2.1.3 Importance of Research and Development
The evidence indicates that there is a clear association between R&D spending and 
patenting rate, as illustrated in Chart 5.2 which considers a sample of 44 countries 
for the period 2000-2004. A  Cobb-Douglas function is used, P  =  I&D^a., in which 
P  is applications for patents, I&D  the spending on R&D in constant US dollars 
o f 2000, and ft is the elasticity which links both. The regression yields a correla­
tion coefficient of 0.92, which is statistically sound, ft patents-R&D elasticity is 
0.93. A  similar correlation was observed when the dependent variables are patent 
applications in the United States Patent and Trademark Office (USPTO).
Even when the correlation between spending on R&D and patents has been 
widely documented, controversial aspects persist. Trajtenberg (2002) and Griliches 
(1990) find that although patents are clearly proportional to R&D in cross-section 
studies, in a more dynamic perspective, decreasing returns appear. In a dynamic
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Latin America and OECD: Number of patent applications as a function of total 
expenditures in R&D (44 countries) (US constant prices Mean 2000-2004)
Chart 5.2 Latin America and OECD: Number of patent applications in relation to spending on 
R&D (44 countries) (Dollars at constant prices, average 2000-2004). Source: Diaz (2007).
panel study, Bosch and others (2005) find a high correlation between both variables. 
For developed countries there is a unitary elasticity consistent with the hypothesis 
o f constant but not increasing returns, w h erea s in d ev e lo p in g  c o u n trie s they f in d  low  
e la st ic ity , w hich is  co n sisten t with d e c re a sin g  retu rn s a n d  a t  the sa m e  tim e with 
s ign ifican tly  lo w er p a te n t  return ra te s  than the d e v e lo p e d  c o u n trie s. The authors 
explain these differences in elasticity by institutional factors (education, property 
rights, and quality of innovation systems).
The experience of developed countries and the most recent of India, China, 
and Brazil indicate that the expansion of private and public R&D p re c e d e s  the 
strengthening of IPRs. For almost a century, the United States had a “weak” intel­
lectual property regime which facilitated the absorption of foreign technological 
knowledge without paying for the corresponding licenses. As United States innova­
tion and investments abroad sped up, so did the tendency toward the strengthening 
o f intellectual property rights.
The Latin American export economies are mostly based on learning systems that 
rely in knowledge and technology import and dissemination. The “weakness” of 
industrial property regimes in Latin America facilitated imitation, adaptation, and 
integration of technologies. In this context, do these countries require a significant 
strengthening of the patents system? The answer is no, for stronger IP rights will not 
encourage per se an increase in national R&D efforts and national patents applica­
tions. On the contrary, it could hinder technological development by increasing the 
cost of imitative, adaptive, and incremental innovation.
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Therefore, Latin American countries need to develop efficient private-public 
collaboration for promoting and disseminating new knowledge and state-of-the-art 
technologies. This is the key for spurring new waves of innovation. The increase of 
IPR must be balanced with the strengthening of national science, technology, and 
innovation capacities. In this context, the most coherent path is to take advantage 
of the flexibilities stipulated by TRIPS and the trade agreements, in order to design 
appropriate regulations and policies.
Only a long-term effort that efficiently increases public spending or subsidies 
in science, and technology research in universities, public institutions, and private 
firms may positively impact local innovation. This is not an easy task and there 
are many policy challenges, but we should not create unreasonable expectations: 
although innovation should there be no immediate increase in patent applications 
or private participation in R&D, except when a big Hi-Tec firm decides to invest in 
a small country like Costa Rica. For countries like Chile, Peru, and Colombia, the 
Mexican experience shows that the FTA’s can generate crowding-out effects that 
can de-incentivize local patent applications. Also firms conduct R&D for learning 
and adaptive innovation or invest in fields where patents are not the right instrument 
of protection, so they will rarely produces patentable products. And although it is 
possible that universities and science and technology laboratories emerge as sources 
of intellectual property titles, it is best not to create illusions in relation to patents. 
The United States experience indicates that few universities have enough critical 
mass to obtain a significant output in patents.
5.2.2 Copyright in the D igital Econom y11
The FTA’s will also have a strong impact on the emerging digital economies of the 
region. If the provisions are fully applied, the conditions of dissemination o f com­
puters and Internet will change, because middle- and low-income access to software 
and other digital goods has been achieved through piracy (with commercial pur­
poses) and illegitimate copies distribution (without commercial purposes). In theory, 
low-income users will be affected by the higher costs of access to software and dig­
ital contents protected by intellectual property or by electronic encryption, although 
this should not prevent them from having continued access to open code software 
and free contents.
Latin American and Caribbean countries should be very careful in the copy­
right provisions implementation. An excessive strengthening of digital property 
rights without the enforcement o f exceptions and limitations to copyright set forth 
in international treaties such as the Berne Convention will not only restrain the 
dissemination of ICTs but also encourage digital piracy and promote the illegal 
economy.
Despite the socioeconomic importance of software and digital contents, Latin 
American and the Caribbean countries paid less attention to the copyright sections of 
the FTA’s than those of patents and medicines. Three factors influenced this behav­
ior. First, governments had little knowledge of the digital economy complexities.
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Second, the software and digital-contents industry was small and had little capa­
bility in putting forward its own strategic interests. And third, the United States 
software and multimedia industries have an important influence in the region. The 
result was an asymmetric behavior: a great deal of concern in issues such as drugs 
and patents, but fairly little preoccupation for access to software and digital contents 
which have an increasing influence in the region.
5.2.2.1 The Dissemination of ICTs in Latin America and the Caribbean
The development of the Latin American and Caribbean countries has been increas­
ingly influenced by the digital revolution in the last 10 years. To 2005, the Economic 
Commission for Latin America and the Caribbean (ECLAC) estimated that in the 
ten LAC countries that signed FTA’s with the United States there were almost 
19 million fixed phone lines, 52 million mobile telephones, 33 million computers, 
and 20 million Internet users. The growth rate o f fixed lines was low during the 
period 2000-2005 but notable in the other categories, especially in Internet. Chile 
heads the tendency of broadband penetration, followed by Costa Rica and Colombia 
(Table 5.2).
Despite their lag with respect to the developed countries and the persistence of 
access gaps, a growing number of Latin American firms, consumers, and public 
institutions are using ICTs more and more. The development of the telecommuni­
cations infrastructure and the dissemination o f computers have been accompanied 
by a mass expansion of software, music, videos, and digitalized contents through 
Internet. For most of the 1990s, the dissemination of digital contents mainly took 
place via CD and DVD. In the last 5 years, it has been increasingly by Internet.
Although the countries that have signed trade agreements with the United States 
are not characterized -  with the exception of Costa Rica -  as exporters of ICT goods 
and services, they have developed important telecommunications and information 
technologies services sectors. Furthermore, all the countries register the expan­
sion of a sector that offers wide and growing diversity of contents and services via 
Internet.
However, the ten LAC countries appear to be entering a difficult stage in the con­
tinuing expansion of digital access. The urban high-income markets are beginning to 
reach their saturation point and the challenge now is to reach low-income urban and 
rural social population with higher infrastructure costs and less purchasing power. 
This will translate into a slower expansion until new wireless technologies are more 
competitive and competition invigorates the natural inertia of incumbent firms. In 
this context, public policies can facilitate and act as a catalyst in the process.
5.2.2.2 The Obsolescence of the Old Copyright Regime
Digital products and networks are proliferating in Latin America and the Caribbean. 
This produces a progressive obsolesce of the 19th century legal regime of copy­
right protection adapted for printed matter. As it is known, all digital contents can 
be copied, stored, reproduced, and distributed through the Internet any number of
Table 5.2 ICT expansion in Latin America, 2000-2005
Fixed telephones Mobile telephones Computers Internet users
Countries 2000 2005 Var. (%) 2000 2005 Var. (% ) 2000 2005 Var. (%) 2000 2005 Var. (%)
Costa Rica 899 1,389 55 212 1,101 419 600 950 58 228 1,111 387
El Salvador 625 972 56 744 2,412 224 120 401 234 70 628 797
Guatemala 677 1,132 67 857 3,168 270 130 267 105 80 1,039 1,199
Honduras 299 494 65 155 1,282 727 70 121 73 55 242 340
Nicaragua 164 221 35 90 1,119 1143 120 231 93 50 826 1,552
Dominican Republic 894 895 0 705 3,623 414 198 728 268 327 985 201
Panama 429 440 3 410 1,352 230 105 1,352 1188 90 487 441
Peru 1,717 2,251 31 1,274 5,583 338 1,050 4,113 292 800 3,638 355
Colombia 7,193 7,767 8 2,257 21,850 868 2,257 21,850 868 878 6,004 584
Chile 3,303 3,436 4 3,402 10,570 211 1,420 3,000 111 2,537 4,623 82
Subtotal 16,200 18,997 17 10,106 52,060 415 6,070 33,013 444 5,115 19,583 283
Latin America and the 
Caribbean 65,549 96,864 48 62,385 236,916 280 24,523 56,165 129 19,673 80,072 307
Share of Latin America and 
the Caribbean (%) 25 20 -2 1 16 22 36 25 59 137 26 24 - 6
Source: ITU and ECLAC estimates.
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times, all with identical quality. This poses a basic economic problem: while the 
creation and production of an original work require considerable investments, the 
marginal cost of reproduction is almost 0. This is why it is conventionally stated that 
with no technological protection measures (i.e., encrypting) and/or enforcement of 
copyright, the social benefit of an original work would be greater than the private 
benefit and there would be no incentives to creators and inventors.
For the United States Government, Latin America and the Caribbean are subcon­
tinents where digital piracy predominates. For several years, the Business Software 
Alliance (BSA) publishes annual statistical reports on software "piracy,” which are 
used by the United States Trade Representative (USTR) to ground its complaints. 
According to a BSA report for 2007, 65% of computers in Latin America had 
“pirate” software, equivalent to 4.123 billion dollars losses, less than half the United 
States figures. But the BSA report has some important flaws such as not considering 
the difference between a software copy for personal use -  which can be legiti­
mate -  and piracy as such.12 Other similar reports from associations representing 
the music industry or the audiovisual industry have equally unclear methodologies 
and sources, which creates considerable doubts about their objectivity.13 However, 
although the economic and social magnitude of the piracy and illegitimate distri­
bution phenomenon can be discussed, there is no doubt that its importance grew 
significantly in the last decade and this implies that changes have to be made in the 
national copyright regimes which were born in the 19th century.
5.2.2.3 The Debate on the New Copyright Regime
Free trade agreements strengthen the protection of copyright like never before. They 
expand the protected subject matter to ephemeral copies and interactive digital radio 
broadcast, increase the duration of protection from 50 to 70 years, increase the scope 
of technological protection of digital contents, and strengthen their enforcement by 
means of judicial and administrative proceedings.
The principal question that LAC countries face is how to apply the TRIPS and 
Berne copyright exceptions and limitations provisions that are accepted by the free 
trade agreements. The Bush Administration answer for reducing exceptions and 
limitations seems very simple: digital technologies and Internet facilitate illegal 
reproduction, making it increasingly difficult to delimit the above-mentioned lim­
its and exceptions. The answer to this difficulty in access and content control should 
be to limit the right to obtain digital copies of the works for private, non-commercial 
purposes, and restrict non-commercial reproduction of works by educational estab­
lishments, research centers, and libraries, since there is a risk of deviation toward 
illegitimate copies.
LAC countries must consider international experience in this field. I f copyright 
regulation changes are applied without considering the TRIPS and Berne multilat­
eral international treaties, there could be a negative alteration of the carefully crafted 
balances shaped during the 20th century. In particular, they could restrict the rules 
of the game which made it possible to expand the digital economy over the past 
20 years.
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In this context, LAC countries should carefully craft the exceptions to copyright, 
such as the “ fair use” right to copy for personal purposes or the reproduction of 
material for educational and scientific-technological research purposes, all estab­
lished in the Berne Convention and in the 1996 agreements of the World Intellectual 
Property Organization (WIPO). Particular attention should be brought on the limits 
and exceptions of copyright of temporary copies (temporary electronic storage) and 
the legal scope and exceptions o f the so-called Effective Technological Protection 
Measures (TPMs) used to prevent, through encrypting or devices, unauthorized 
access to software and contents.14
Although the free trade agreements allow flexible application, LAC gov­
ernments face a strong external and internal pressure to considerably increase 
protection of copyright. This could lead to a rigid implementation of the obliga­
tions incurred, restricting the exceptions and limitations to copyright, facilitating 
indiscriminate application of TPMs, could in practice annul the provisions of the 
Berne Convention, the TRIPS Agreement, and WIPO. This could make piracy diffi­
cult, but at the same time it could increase the social costs of access to information 
and knowledge, limit competition, and hinder innovation and creation.
5.2.2A The Consequences on the Digital Gap
There are two views on the possible impacts of an increase of intellectual property 
in the digital world in LAC countries. One is that experience shows that it is very 
difficult to achieve full efficiency in copyright enforcement and that the TPMs have 
not curbed the proliferation of illegal copies. This means business as usual: enforce­
ment will be possible for high-income groups and formal firms market, but piracy 
and illegal dissemination of software and contents will continue to predominate in 
low-income groups and the small informal business. The battleground will be the 
middle class and the formal small firms.
Another view is that the combination of increased IP enforcement and greater 
efficiency of technological protection measures will reduce piracy and increase the 
appropriation capacity of software and content producing companies by means of 
compulsory payment for authorized copies. This process will take time but in the 
end it could reduce the extension of illegal markets and unauthorized copy distribu­
tion. However, it will exclude small business and medium- and low-income sectors 
access, which can be partially compensated by strategies o f market discrimination, 
where versions of lower quality of software can be freely accessed or sold at a 
lower price. At the same time, the reduction in piracy will create better conditions 
for the development of markets for free and open source software (FOSS), which 
offers popular platforms and programs such as Linux and Open Office. Nevertheless, 
the network economies involved will only make this alternative possible insofar as 
public sectors and educational establishments adopt strategies of growing use of 
FOSS-type software.
In this scenario, the case of digital contents is different because it is very diffi­
cult to discriminate markets by means of reduced versions of an original work, thus 
running the risk of large segments o f the population not having access to knowledge 
and the cultural heritage of humanity. Hence, to ensure mass access to knowledge
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and information proactive public policies will be required -  for example, digitaliza­
tion of contents and dissemination by public libraries- which can be complemented 
by voluntary options such as creative commons.
This scenario can also generate an enrichment of competitive strategies for soft­
ware and proprietary contents. It is known that software firms distribute free copies 
and then sell originals of higher quality or with more functions. Other firms have 
established a relationship of alliance and competition with free and open source 
software companies (Lerner and Tiróle, 2005), because they can offer complemen­
tary services and goods in proprietary market segments. Proprietary contents firms, 
for their part, also resort to the distribution of free copies as part of their business 
strategy (Varian, 2005). They can distribute free copies of some songs with the aim 
that consumers buy the whole CD or to assure attendance at concerts and sales 
of T-shirts or other similar goods. These trends are becoming generalized and are 
bringing about deep-seated changes in the contents industries that are beginning 
to be assimilated in LAC countries. But business innovation is always accompa­
nied with some form of uncompetitive behavior, which demands a greater role 
for competition policies. LAC countries need to accelerate institutional learning in 
this field.
In any case, a careful and balanced legislation is necessary and should be com­
plemented with an explicit public policy agenda oriented toward social access to 
digital contents. This is one of the challenges of the information and knowledge 
society.
5.2.2.5 The Consequences on Innovation and Creation
Current thinking is that the strengthening of intellectual property rights will encour­
age creation, thus fostering the development o f cultural industries. But creativity 
is not only determined by private control of contents, but also determined by a 
set o f factors such as the capacity o f each author to become inspired by using, 
reusing, mixing, combining, and even copying contents that are already in the cul­
tural and scientific heritage of humanity. Creation produces new knowledge but it 
also requires inputs of pre-existing knowledge. This is why intellectual property 
ensures appropriability to encourage creation but it also considers regulations that 
assure social dissemination. Excess protection of intellectual property rights can 
restrict mass access to a nation’s cultural heritage and thus discourage creation and 
innovation.
LAC governments must consider that it is not proven that more intellectual prop­
erty protection necessarily translates into more creation and innovation. In a critique 
of the Digital Millennium Copyright Act of the United States, a group of economists 
calculated that at a discount rate of 7%, an increase from 50 to 70 years in copy­
right protection has trivial effects and its yield will not be higher than 0.33% of the 
present value of the first 50 years o f protection. It has also been discussed whether 
such broad protection terms make any sense without paying renewal rates for rights. 
In fact, only a small proportion of works has a significant market for such long peri­
ods (70 years after the author’s death). In the United States, between 1883 and 1964, 
when renewal was compulsory, only 11 % of works had an application for renewal of
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the 28-year period. Landes and Posner (2003) note that of more than 10,000 books 
published in 1930, less than 200 were being printed in 2001.
Excess protection o f intellectual property can bring about a contrary effect to the 
one pursued. Without laws that restore the balance between protection of intellectual 
property rights and free access to knowledge and culture, creators and innova­
tors could live in a jungle of restrictions and litigation threats that could curb the 
development of cultural industries.
5.2.2.6 New Roles for the Public Sector
Free trade agreements contain a set of obligations aimed at strengthening intellectual 
property rights in the digital world. In their implementation, governments should 
take care to preserve the flexibilities permitted by the multilateral agreements of 
Berne and WIPO, with the aim of not overprotecting intellectual property rights, 
since this could have negative effects on social access and innovation. At the same 
time, this brings about the need to move forward toward a new generation of public 
policies aimed at providing high-quality education, promoting universal access to 
knowledge, and fostering innovation and creation.
It should be stressed that the expansion of the digital economy in Latin America 
and the Caribbean opens up singular opportunities for production and distribution 
of digital public goods on a mass scale. On the one hand, there is an important 
development of the so-called electronic government, that is, the growing use of 
digital technology by government agencies to capture, process, produce, and dis­
tribute information and public, free knowledge through Internet. On the other hand, 
a similar process is occurring in universities, research centers, non-governmental 
organizations, and international organizations, which are rapidly expanding the sup­
ply of public, free contents through Internet. At the same time, new digital industries 
have emerged -  providers of Internet access and search engines -  where the busi­
ness is built on the basis of access to information on a mass scale. In this context, 
public policies should promote their development, applying criteria and intellectual 
property legislation in a coherent manner.
All of this expands the public domain and makes room for innovation in public 
policies, which come to light in projects such as the digitalization o f the cultural her­
itage, the placement of growing volumes of public information on the Internet, and 
the expansion of information in public libraries. As these processes become gener­
alized and the private sector develops similar initiatives, the increase in intellectual 
property protection will be harmonized with the objectives of digital inclusion and 
the promotion of innovation and creation.
5.3 Challenges of Implementation and Economic Policy
The accumulated experience in the LAC countries with free trade agreements with 
the United States show that the main challenges comes with the legislative and reg­
ulatory implementation. The experience indicates that the process is neither easy 
nor straightforward, because the FTA are incomplete contracts with many silences
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and ambiguities The implementation process is a struggle among local interests 
which was augmented by the Bush Administration decision to fully influence the 
configuration of laws and regulations in each of the region’s 10 signatory countries.
The agreements can be divided into three stages: negotiation, short-term appli­
cation, and medium-term implementation. The process will be exhausted formally 
in 2010-2012 when all stipulated obligations are to be fulfilled, but it could go 
beyond that.
The negotiation stage ends with the signing of the agreement by governments. 
The short-term application stage begins with parliamentary ratification of the 
agreement and culminates with its entry into effect. The medium-term implemen­
tation stage includes the ratification of international agreements and the parliament 
approval of more complex rules and regulations that implement FTA obligations 
(see Fig. 5.1).
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Source: Prepared by the author.
Each stage is marked by an intense political economy which comes to light with 
the crafting of new laws and regulations that implement the free trade agreements 
and that also expresses itself with the development of public policies such as health 
and competition policies, which can limit or expand the scope of the FTA intellectual 
property provisions.
Intellectual property is a complex combination of international agreements, 
laws, and regulations that affects patents, copyright, and other categories. So, 
there is not one but various political economies which determine different imple­
mentation paths. For example, in patents for pharmaceutical products there is a 
well-defined polarization: on the one hand, health ministries, generic industries, and 
non-governmental organizations; and on the other hand, the brand name pharma­
ceutical industry and the United States government. In copyright the interests of 
national and foreign industries tend to coincide in increasing enforcement, whereas 
education ministries, libraries and Internet Services Providers (ISP) emphasize the 
need for access to information and knowledge.
The ambiguities and silences of free trade agreements are the object of sharp 
controversy in short-term implementation. The United States Government has 
instruments of pressure such as delaying the entry into effect of the agreement to 
ensure that its immediate implementation is in accordance with its interests. This 
was harshly manifested in the cases of Guatemala, Honduras, El Salvador, and 
Nicaragua. l5The same did not occur with Chile, partly because as a non-permanent 
member of the United Nations Security Council it opposed the intervention in Iraq 
and the Bush Administration faced high political costs if it held back on the free
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trade agreement as a form of retaliation. Nevertheless, between 2003 and 2008 Chile 
was subject of an increase pressure by the Bush Administration and was placed 
on the “Special Watch List” of USTR’s Special 301 Report (2006), 16 years after 
having kept Chile on the “Watch List.”
In this context, LAC countries that signed trade agreements with the United 
States face a triple challenge. First, develop a new set of intellectual property laws 
and regulations that maintain a balance between incentives to innovation and access 
to knowledge and the protection of human health. Second, develop a complemen­
tary agenda or a set of public policies and legislation in innovation, education, 
competition, and consumer rights. And, last but not least, building an institu­
tional framework that facilitates Coordination within government. This is crucial. 
Intellectual property cannot be an exclusive matter for the agencies in charge of its 
protection. It is also a matter of concern for other government agencies in charge 
o f health, innovation, and science and technology. Equally important is developing 
an institutional framework that facilitates expression of the interests of intellectual 
property holders and o f the consumers and users of goods and services protected by 
intellectual property.
A  new positive agenda for the next decade should be considered that should at 
least include the following recommendations.
5.3.1 A N ation al Com m ission on Intellectual Property
In view o f the complexity of the subject matters involved, it is essential for countries 
to devise strategies that integrate intellectual property into policies for innova­
tion, competition, health, and access to knowledge and information. It is therefore 
recommendable, to set up a national commissions on intellectual property with 
representatives of the sectors involved, including international experts. This com­
mission should issue recommendations based on the commitments o f the trade 
agreements, the stipulations of TRIPS and WIPO, and on considerations related to 
policies for innovation and productive development, education, health, competition, 
and consumer rights.
The more open and informed the debate on legislation for implementation and 
the impetus of the complementary agenda, the greater the opportunities to estab­
lish a balanced legislation. The recommendations of these commissions will not 
substitute the decisions o f national congresses, but will help build consensuses on 
the most desirable legislation for implementation. If several countries set up similar 
commissions, the possibilities for cooperation will grow considerably.
5.3.2 Link the Innovation Policy to Intellectual Property
The strengthening of the intellectual property regime should be accompanied by 
a leap forward in science, technology, and innovation policies. This is essen­
tial to advance toward economies whose competitiveness is increasingly based 
on knowledge and innovation. World experience indicates that the protection
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of intellectual property is not a sufficient incentive to promote innovation, and 
overprotection discourages it.
5.3.2.1 Recommendations on Patent Regulation
Patents can encourage innovation, provided that its application is adequately delim­
ited. Trade agreements are ambiguous on the matter. On the one hand, they state that 
they accept TRIPS, which establishes exceptions to intellectual property rights, but 
on the other hand they impose some shortcuts and they establish that governments 
should make efforts to patent plants, but do not compel them.
First recommendation: governments should not accept patents for software, 
plants and animals, business methods, and second use. In such cases, patents are 
not the most appropriate instrument for promoting innovation because they can hin­
der the protection of intellectual property of subsequent innovators or small and 
medium firms that make incremental innovations.
This does not imply leaving invention and creation unprotected. Software, for 
instance, is already protected by industrial secret and copyright. Plants have UPOV 
protection and it is reasonable to permit patents of isolated DNA sequences with 
industrial application,16 although not complete genomes, which accounts for the 
cases of transgenic plants.17 On the other hand, second use patents favor the foreign 
pharmaceutical industry but nothing prevents countries from invoking the TRIPS 
clause that allows rejecting them, which could be reinforced by the exclusion of 
patentability of surgical methods.18
Second recommendation: although the free trade agreements uphold the TRIPS 
criterion of a 20-year term of a patent from the time of application, the countries can 
carefully regulate aspects not considered in bilateral and multilateral agreements, 
but which have as much economic importance as the duration of protection. Indeed, 
the definition of the requirements of novelty and the scope of a patent constitute a 
relatively unexplored dimension of regulations on industrial property.
Furthermore, experience shows that regulations on intellectual property rights 
based on technological and industrial policy can be established. In fact, if the pur­
pose were to foster original and radical innovations, the regulations should increase 
novelty requirements and broaden scope claims, although this will expand the 
monopolistic power of the first innovators and discourage subsequent innovations 
of third parties. This will favor patenting by foreign firms but will discourage that 
of national entities.
In this context, what would be the most appropriate system for developing coun­
tries with low R&D spending and low patentability rate? Although at first it could 
seem more adequate, a system that favors patents with greater scope and less nov­
elty requirements could end up discouraging imitative innovation because it would 
increase litigations risks postponing the entry of imitators into the market (Gallini, 
2002). This could discourage R&D efforts, especially in small and medium firms.
One solution could be to rigorously delimit a patent’s claim scope sphere, in 
such a way that it favors the development of subsequent innovations that adapt 
technologies to a product or process other than that originally patented. At the same
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time, they can establish more or less demanding novelty requirements that could 
be specific according to major areas of technique.19 For example, in patent appli­
cations associated with life sciences additional conditions can be required to prove 
that it is not a question of a discovery. In the chemical and pharmaceutical areas 
second use patents can be rejected, since neither the free trade agreements nor the 
TRIPS Agreement have obligations in this regard. In any event, a balanced approach 
is required with regard to novelty and scope in order to maintain incentives for 
patenting of national innovations.
Third recommendation: the countries that recently signed a trade agreement with 
the United States should pay special attention to the application of intellectual prop­
erty in life sciences and natural resources. All of them have abundant and diverse 
natural resources and genetic patrimony. It is in this area that the largest and most 
competitive companies tend to concentrate, as well as most of the scientific and 
technological personnel of universities, where full importance is placed on the 
exclusion from patentability of plants and animals, the establishment of rigorous 
novelty requirements, the delimiting of patent claim spheres, the promotion of the 
use of protection of plant varieties -  considering exceptions for plant breeders and 
small agricultural production -  as well as the promotion of geographical indications.
5.3.2.2 Promotion of the Use of Patents
Technological innovation policies should remove unnecessary obstacles to protect 
results of R&D. This implies four recommendations.
i) Use intellectual property to strengthen the results o f R&D+I financed with 
public funds. Every R&D public financing scheme should promote the use of 
intellectual property rights, particularly in R&D projects oriented toward inno­
vation developed by companies and/or universities. In this context, intellectual 
property does not run counter to the objectives of dissemination and transfer of 
technology, since public technological centers and universities can use a broad, 
flexible system of licenses that allows dissemination o f the new technologies on 
a mass scale without the risk of undue appropriation by third parties. In inno­
vation projects whose results are subject to private appropriation, the use of 
patents or other forms of intellectual protection should also be promoted. This 
will favor subsequent innovations carried out by the private sector.
ii) Incorporate applications and registers fo r patents and other forms of intellec­
tual property as an additional criterion fo r academic evaluation in universities 
and technological centers.There is already a certain amount of accumulated 
experience to incorporate this system o f incentives into existing ones. This, 
however, requires careful criteria which, for example, draw a distinction 
between patent applications and registers.
iii) Further a massive and rapid process of training of scientific personnel in 
innovation management and intellectual property. In the 10 countries that 
have signed agreements with the United States there are more than 175,000 
researchers and tens of thousands of innovating entrepreneurs who require rapid
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training in use of intellectual property in business, particularly in processes, 
utility models, industrial design, circuit layout, and plant varieties. The scarce 
culture and experience in this field points up public innovation policy,
iv) Promote technological transfer entities specializing in intellectual property 
linked to universities and technological scientific centers. These entities should 
put together multidisciplinary teams to identify business opportunities derived 
from research programs of universities and technological scientific centers. 
Experience indicates that there is a need to attain scale and scope to diversify 
the risk, but there should also be a policy that assures long-term sustainabil­
ity based on results. This policy should consider regional and international best 
practices.
5.3.3 Copyright an d  D igital Econom y
The countries with trade agreements with the United States should use the excep­
tions and limitations to copyright and adequately regulate legal protection of 
technological protection measures (TPMs), so that it is consistent with consumer 
rights and with the facilities for innovation and creation.
5.3.3.1 Treatment of Exceptions and Limitations
The countries can use the flexibilities in exceptions and limitations stipulated in the 
Berne Convention and ratified by the TRIPS Agreement. Applying these criteria can 
balance access to knowledge and culture with the interests of intellectual property 
rights holders.20
Exceptions and limitations apply to official texts, personal use, use of works 
for purposes o f science, technology, and education, reproduction in libraries and 
archives for storage and replacement, unorganized facts and data, quotes, daily news 
and press information, political and legal speeches, works for radio broadcasting, 
ephemeral recordings, reproduction and adaptation of computer source codes for 
purposes of interoperability and control of monopolistic abuse.
In the ratification o f Articles 1-21 of the Berne Convention, the signatories issued 
Agreed Statement concerning Article 1 (4) of the WIPO Copyright Treaty (WCT, 
1996) which states “The reproduction right, as set out in Article 9 o f the Berne 
Convention, and the exceptions permitted there under, fully apply in the digital envi­
ronment, in particular to the use of works in digital form. It is understood that the 
storage of a protected work in digital form in an electronic medium constitutes a 
reproduction within the meaning of Article 9 o f the Berne Convention.”
In this context, it is worth considering the following recommendations on 
limitations and exceptions on copyright in the digital environment.
First, ensure the right to a copy fo r personal use, which includes the family 
and, in some national legislations, the circle of close friends. This is a limitation 
accepted by all the developed countries, which should be kept adequately delimiting 
its application.21
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Second, maintain reproduction rights fo r educational purposes, an exception 
provided for in Article 10(2) of the Berne Convention, which includes distance 
education related to execution and reproduction rights and distribution to the 
public.
Third, the press should maintain reproduction rights fo r articles on politi­
cal, religious, and scientific topics. This includes maintaining the right to quote, 
guaranteeing freedom of expression, criticism, and information.
Fourth, maintain the exception on ephemeral recordings. This would enable radio 
broadcasting companies to conserve the content in official archives, which is current 
practice in contracts with rights management companies.
Fifth, maintain and reinforce the role o f libraries. Libraries should be important 
subjects of the exceptions and limitations due to their purpose o f collecting, pre­
serving, and disseminating knowledge, a basic function o f educational institutions. 
It will be necessary to eliminate ambiguities in many legislations by discouraging 
the presence of mass photocopying centers and reinforcing the work of reproduc­
tion for libraries’ legitimate uses, among them ensuring reproduction for purposes 
of storage and replacement.
Sixth, ensure access fo r  disabled people.
Seventh, allow copies of software to ensure interoperability. In the process of 
ensuring interoperability between software programs, copies can be obtained in 
order to modify these programs. This is a basic condition for promoting competition 
and encouraging efficiency and the development of innovative companies.
5.3.3.2 Appropriate Treatment of Technological Protection 
Measures (TPMs)
It will be necessary to achieve a balance between enforcement of effective techno­
logical protection measures (TPMs) and respect for consumer rights and the need 
to grant facilities to innovation and creation (Villaroel, 2005). TPMs are neces­
sary to protect intellectual property rights in the digital era, but by transferring 
access regulation to works protected from the public domain to the private (Okediji 
and Prosser, 2005), copyright exceptions and limitations provided for in the Berne 
Convention and the TRIPS Agreement and that were not modified by recent free 
trade agreements could be reduced (Okediji and Prosser, 2005). To preserve the 
original purpose of TPMs, avoid monopolistic abuses and ensure consumer rights, 
the following initiatives should be considered.
First, establish the compulsory requirement o f information on TPMs, a condition 
so that the user and the consumer identify the TPM of the case and know where and 
how to recur in order to obtain authorization to do without it with legitimate ends.
Second, assure the obligation o f providing interested parties with means to 
legally elude TPMj. Consumers and users should have the necessary information 
and means to benefit from the exception when merited. It should be provided 
that failure to comply with this obligation will be the object of legal com­
plaint by means of class-action suits and that this will give rise to indemnity 
obligations.
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Third, prohibit the application of TPMs fo r certain categories o f users. It is nec­
essary to establish express prohibitions of TPMs that control access or copy for 
libraries, educational institutions, researchers, and the disabled.
And fourth, competition policy should consider the risk of monopolistic abuse of 
TPMs. It should be sanctioned under the competition laws and the corresponding 
authorities should be endowed with the means to apply sanctions against those who 
use TPMs for purposes other than those provided for.
5.3 .4  Competition Policy an d  Consum er Rights
In most of the Latin American countries, particularly those that have signed trade 
agreements with the United States, there is a notable asymmetry between intellec­
tual property legislation and the lag of institutions for the defense of competition, 
especially the areas related to intellectual property. This demands an effort to create 
a new institutional framework with appropriate laws and the capacity to implement 
them. The following measures could be taken in this regard:
First, legislate and ensure budget resources to set up strong, autonomous, and 
modern antimonopoly Commissions. This also involves creating economic 
inspector’s offices with ample technical capacity, legal force, endowed with 
broad investigation powers, as well as their own budget and independence of 
action. It is necessary to ensure that the inspector’s offices and commissions 
rapidly develop capacities to investigate, analyze, and take decisions in cases 
in which there is monopolistic abuse through the use of intellectual property 
rights.
Second, promote regional cooperation to foster quick learning in competi­
tion policy and its relations with intellectual property. All the countries 
are promoting laws or reviewing their competition legislation. The TRIPS 
Agreement and trade agreements establish criteria to assure national treat­
ment, transparency, due process, but they do not specify guidelines on 
situations in which monopolistic abuse exists based on the use of an intel­
lectual property right. To that end, the countries have considerable freedom 
to establish an institutional framework that responds to their needs according 
to the best world practices and joint regional learning.
Third, promote open and democratic debate on competition policy and intel­
lectual property to identify guidelines and best practices for control of 
monopolistic abuses in cases where there are intellectual property rights. 
The document of the Federal Trade Commission and the Department of 
Justice of the United States, as well as the resolutions of the Competition 
Commission of the European Union are important precedents. Likewise, 
Canada, Australia, and Japan have shown similar efforts. “Guide” documents 
on antimonopoly legislation and intellectual property rights can be prepared 
by means of regional cooperation and the assistance of multilateral technical 
agencies.
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And fourth, strengthen and train consumer associations, particularly those 
related to intellectual property-intensive goods and services. This will prob­
ably require that national laws adopt figures such as class-action suits.
5.3 .5  Patents an d  M edicines
The free trade agreements with the United States contain provisions that broaden 
protection for medicines and agrochemical products protected by patents or undis­
closed information, but here too there is room for a flexible implementation aimed at 
reducing the terms of entry of generic medicines into the market. In this regard, some 
countries have greater freedom of action than others, but the Democrat-Republican 
agreement of May 2007 contains provisions that should make the traditional position 
o f the USTR more flexible.
5.3.5.1 Strengthening the System of Compulsory Licenses 
and Parallel Imports
Compulsory licenses and parallel imports were not the subject matter of the 10 trade 
agreements with the United States but they are stipulated by the TRIPS agreement.22 
Thus, the Central American countries and those of the Andean Community do not 
need to modify their law to authorize them.23 Chile had the possibility o f strength­
ening its system and did so. Its 1991 legislation only permitted compulsory licenses 
against monopolistic conducts. Its new law broadens the grounds to reasons of pub­
lic health, national security or national emergency, non-commercial public use, as 
well as exploitation of later patents that could not be exploited without infringement 
of an earlier patent.
Since 1994 only one Latin American country has used the compulsory license. 
We refer to Brazil in April 2007, when it applied this mechanism for the medicine 
Efavirenz made by Merck Sharp & Dohme, used for treatment against HIV-AIDS. 
This measure will make it possible to manufacture or purchase generic versions 
of the medicine at low cost, establishing the payment of a moderate royalty to 
the American company. Although it is a rarely used mechanism, there is evidence 
that the mere threat of using it brings about the desired results. To that end, the 
presence of strong health institutions and transparent and flexible administrative 
procedures are essential in order to avoid judicial proceedings that would hinder its 
use. However, for the countries without the capacity to produce medicines, compul­
sory licenses are not sufficient to ensure enough imports, for they can be the object 
o f restrictions established in TRIPS, which has given rise to intense discussions in 
the Doha Round.
Nor do the trade agreements consider parallel imports, so the TRIPS provisions 
continue to be valid, although problematical. In cases in which a country without 
productive capacity issues a compulsory license for monopolistic conduct, TRIPS
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(Article 31.31 .k) establishes that the latter can import from third countries. When 
a country without productive capacity issues an obligatory license for reasons of 
national emergency or public security, it could import the medicines from a third 
country with productive capacity, but TRIPS (Article 31.31.Í) imposes restrictions 
for that country. This can be overcome by means of laws or regulations that explic­
itly permit exporting to countries that have legally established a compulsory license, 
as well as by agreements that combine compulsory licenses for patents and parallel 
imports.24
S.3.5.2 Adaptation of Administrative Procedures in Pharmaceutical 
Patents
The administrative procedures for granting or rejecting pharmaceutical patents 
are a central component of regulations on industrial property. The following 
recommendations are made in this regard:
First, conserve or implement formal objections, allowing third parties to chal­
lenge the degree o f inventiveness, novelty, or industrial application o f patent 
applications. This would facilitate the work of industrial property offices that 
face problems of asymmetry of information due to budget shortages.
Second, regulate compensation of patent duration due exclusively to admin­
istrative delays. The trade agreements with the United States provide for 
compensating pharmaceutical patent terms when their processing exceeds 
5 years not counting the applicant’s delays. This seems reasonable, provided 
there is an application from the holder25 that is only valid for pharmaceu­
tical patents for human use and that the time consumed by objections from 
third parties is not counted as administrative delay. Since no yardstick was 
established to count the compensation time, maximum compensation terms 
could be established similar to the provisions of the Hatch-Waxman Act in 
the United States.
Third, define clear compensation procedures due to administrative delays in 
sanitary permits. In the trade agreements this provision is only in force for 
pharmaceutical products and therefore agrochemicals, foods, and medical 
devices can be excluded. Nor are strict deadlines established, which grants 
flexibility of implementation to each country. In this regard, the yardstick 
of speed of granting of sanitary permits should be subordinated to public 
health considerations. Therefore extensive terms or powers to expand the 
established terms are recommendable.
Fourth, specify the legal definitions of “undisclosed information” and “new 
chemical entity” (NCE). All the countries agreed to protect undisclosed 
information for 5 years for pharmaceutical products and 10 years for 
agrochemicals.26 Although the language of the agreements differ, they con­
tain at least three flexibilities: (i) the concept of NCE should be limited to 
new active ingredients not registered or marketed; (ii) “undisclosed infor­
mation” should be limited to clinical or field test data that were the object
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of reasonable measures to keep them reserved and that are not known by 
experts in the area; and (iii) protection should be eliminated in case of grant­
ing of a compulsory license or when the product has not been marketed in 
the national territory in a period of 12 months, an essential condition for the 
effectiveness of compulsory licenses.
Even though DR-CAFTA, Peru, Colombia, and Panama accepted that the 5 
years’ protection should be counted as of the time the NCE was registered 
in their territories and not in countries such as the United States, they could 
incorporate greater flexibilities into their legislations, such as demanding that 
the first registration of a drug in the world has a period of no more than 12 
months to be registered in their territories.27 Furthermore, if the agreement 
between Republicans and Democrats communicated in May 2007 by USTR 
becomes effective and which establishes that “ in certain circumstances” the 
protection period for test data in developing countries that have signed an 
free trade agreement with the United States “shall not exceed the period in 
which that protection is available in the United States,” which is coupled with 
a provision that encourages greater speed in approval of marketing permits. 
Although the specific proposals that USTR will make have yet to be seen, 
and this is valid only for Colombia, Panama, and Peru, there is no doubt 
that in the long run the rest of the countries will be able to incorporate these 
flexibilities into their national legislations.28
Fifth, delimit terms o f validity o f patent protection with criteria similar to those 
of the United States,29 where the effective period of validity of pharmaceu­
tical patents, including possible compensations for delays in approval of the 
product, cannot be longer that 14 years after approval.
Sixth, sanitary approval requirements should not delay the entry of generic 
medicines into the market. It should be ensured that these initiate the 
procedure to obtain sanitary approval, even though they cannot market it 
because the patented product continues to be protected. This is equivalent 
to application of the Bolar exemption provided for in US legislation.
5.3 .6  Institutional Fram ew ork an d  Intellectual Property
The strengthening of intellectual property requires a process of institutional modern­
ization. It is critical to develop strong and independent antimonopoly commissions 
with the capacity to act in cases where intellectual property rights are involved. It 
is necessary to strengthen legislation for consumer protection and foster consumer 
associations. At the same time, there is a need to improve transparency of procedures 
in intellectual and industrial property offices, as well as entities in charge of sanitary 
supervision, establishing regulations to avoid their capture by interest groups. This 
involves new challenges that did not seem important in the times prior to the free 
trade agreements, when intellectual property systems had low standards. The free 
trade agreements and their implementation will establish new regulations, but that
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will require modern, vigorous, independent, transparent, and effective institutions.
The recommendations are
First, modernize intellectual property agencies which should be autonomous 
public services with representative directorates. The governments and parlia­
ments face a problem with this type o f public entities, since they run the risk 
of being controlled by corporate interests such as lawyer’s offices specializ­
ing in the field. It is therefore advisable to establish directorates of experts 
in economics, law, and engineering, representatives of intellectual property 
associations, and consumers. It is a question o f creating a transparent vig­
ilance mechanism that is regularly informed by the agency’s director and 
technicians.
Second, assure quality management and periodic independent assessments. 
The procedures and criteria used by industrial and/or intellectual property 
agencies are not usually codified in regulations or procedure manuals. The 
dynamics of assessment and granting of patents and other categories of intel­
lectual property are deeply influenced by the idiosyncrasy of institutions that 
are not very transparent to the public and the government, which favors 
corruption. This is a chronic problem in developed countries and there is 
frequently uncertainty with regard to the novelty requirements demanded, 
the sphere o f protection granted, administrative procedures effectively car­
ried out, the rules applied to ensure that applicants for a patent turn over the 
complete technical information necessary so that someone knowledgeable 
about the subject can reproduce it, and the subject matter that will remain 
as a trade secret. All o f this needs to be regulated and clarified by means 
of written rules available to the public, for which purpose an active policy 
of cooperation with international and regional entities is necessary. Moving 
forward in these matters will reduce arbitrariness, give greater certainty, and 
limit corruption (Green and Scotchmer, 1993). At the same time and as has 
occurred in the United States, there should be periodic assessments by gov­
ernment entities in charge of public innovation policies and by the authorities 
in charge of competition policies.
Third, full autonomy o f health, environmental, and plant health agencies. The 
entities responsible for approval and regulation of medicines and agrochem­
icals protect public goods, whereas intellectual property agencies assign 
property rights in the matter. It is therefore a question of different purposes 
and functions. In this regard, it is not recommendable to apply the USTR 
proposal in the sense that sanitary agencies should perform administrative 
functions of vigilance of intellectual property rights. Even though it may 
be a question of one same drug, the types of analysis carried out in each 
of these agencies have completely different technical grounds and purposes. 
This does not exempt the sanitary agencies from the duty to be fully trans­
parent and communicate the relevant information to the public so that the 
interested parties exercise their rights. I f some owner of a patent consid­
ers that his rights have been or could be harmed, he can avail himself of
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the courts to institute civil and even penal proceedings, including stopgap 
measures.
5.4 Conclusions: Toward a New Deal
The recent free trade agreements between Latin American countries and the United 
States have embarked on a process of transformation of intellectual property 
regimes, giving rise to public policy challenges that demand to be addressed in a 
systemic manner in order to create a new balance between incentives for innova­
tion and creation with the social interest of maximizing dissemination of knowledge 
and benefiting consumers. The free trade agreements have established an agenda for 
legislation and regulations on intellectual property and this poses the challenge of 
assuring a flexible implementation that minimizes negative effects and assures the 
interests of developing countries. At the same time a process of institutional mod­
ernization of intellectual property agencies is required. But more important is the 
promotion of a complementary agenda in the fields of education, health, innovation, 
competition, and consumer rights.
This raises the need to build a new deal that includes the following public 
policies:
1) Take measures to lower piracy, understood as reproduction and illegal distri­
bution of copies for commercial purposes, without confusing it with digital 
copies for personal use, a practice that millions of Latin Americans carry out 
daily and which should not be prevented, so as not to affect rights established 
by Conventions such as Berne and WIPO. To that end judicial proceedings 
should be streamlined and strengthened, at the same time assuring respect for 
due process.
2) Expand the system of public libraries, the national network of infocenters and 
the supply of digital public information for citizens, as well as encourage the use 
o f the growing open code platforms, on which China, Japan, India, Germany, 
and Brazil are betting.
3) Assure health protection and not allow, through exaggerated protection of intel­
lectual property, increased prices of medicines or public action to be hindered in 
the face of sanitary emergencies and natural disasters. Therefore, the new laws 
should strengthen systems of compulsory licenses, authorize parallel imports, 
and establish other rules to avoid overprotection of intellectual property.
4) Strengthen systems o f competition and consumer rights, particularly in mat­
ters in which intellectual property rights are involved. The complaints against 
Microsoft in the United States and Europe, in connection with its prod­
uct Internet Explorer, are a clear indication of where the world is moving 
toward with regard to prevention of monopolistic abuses. The experience of the 
developed countries on the matter should be studied and rapidly assimilated.
5) Promote a new generation of public policies in order to advance toward 
economies that are more intensive in knowledge, innovation, and learning
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capacity. This involves increasing available budgets for scientific and techno­
logical funds and programs that increase the national effort in R&D and increase 
technology transfers to small and medium firms, also encouraging mass train­
ing o f world-class professionals and the development o f high-quality learning 
systems for life.
Laws and regulations express an architecture o f private and social interests. This 
also happens with intellectual property. The agreements contain many provisions, 
but they constitute “ incomplete contracts.” Although it is true that the 10 Latin 
American countries undertook important commitments in signing trade agreements 
with the United States, it is also true that they keep ample room for maneuver to 
adapt the intellectual property regime to their own needs, and at the same time 
they can promote a complementary agenda aimed at strengthening their innovation 
systems and ensuring a path of growth with equity.
This requires that all the stakeholders participate and express their interests and 
aspirations. The debate should incorporate the whole range of voices of civil society 
and companies. The case of Costa Rica is a significant democratic experience, but 
the referendum of September 2007 was to approve or not the DR-CAFTA already 
signed by that country’s government. The subsequent challenge -  which is faced by 
the other nine countries -  is to ensure a democratic and transparent debate on the 
implementation legislation and the complementary agenda.
In short, the new intellectual property regime should be based on a new deal for 
the 21st century, which should translate into regulations and the balanced play of 
stakeholders. Incentives for creators and innovators should be counterbalanced by 
provisions that assure maximum dissemination of knowledge, protection of human 
health, sanctions for monopolistic abuse, and a policy that promotes innovation and 
creation as sources of economic and social development.
Notes
1. The bipartite agreement between Republicans and Democrats also included new labor and 
environmental clauses and incorporated some flexibilities in pharmaceutical patents and 
undisclosed information, which until this date are only valid for Peru.
2. The wave of agreements made room for Uruguay and the United States to sign one on invest­
ment and services in December 2006, which could be expanded with chapters on public 
purchases and intellectual property, although its scope would be lesser than the rest. Uruguay 
is deeply integrated to Brazil and Argentina, and its leeway is less. A recent joint declaration 
by Presidents Lula and Tabaré Vázquez admits the possibility of a United States-Uruguay 
agreement, but the latter will remain within MERCOSUR. This could also be Paraguay’s 
course in the future.
3. The impact on the agricultural economy and the pharmaceutical market is extensively covered 
in book A. Diaz (2008) “América Latina y el Caribe: la propiedad intellectual después de los 
tratados de libre comercio”, Libro de la CEPAL, N° 94, February, Santiago de Chile.
4. El Salvador agreed to maintain plant patents; Nicaragua adopted them in the implementation 
law and Chile rejected them, but opted for patenting isolated genetic sequences that could be 
applied industrially.
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5. Chile decided not to patent plants or business methods, and its new Intellectual Property Law 
upholds the criterion that patents must have “industrial application”, thereby excluding “stand 
alone” software patents. Nicaragua and El Salvador, for their part, decided to legally permit 
plant patents. However, both countries still have margins of freedom on how they will apply 
that legislation.
6. The Caribbean countries for which information is unavailable are Antigua and Barbuda, 
Bahamas, Barbuda, Belize, Dominica, Granada, Haiti, Guyana, Suriname, Saint Lucia, Saint 
Kitts and Nevis, and Saint Vincent and the Grenadines. These countries have a population of
11.6 million inhabitants (2.2% of the regional total) and a GDP of 18 billion dollars (0.9% of 
the regional total).
7. Among the 10 countries mentioned, Chile represents more than 50% of foreign applications.
8. At the same time, the predominant system of academic evaluation encourages researchers to 
publish articles, not to register patents or other intellectual property titles.
9. The above means that R&D-patents elasticity was negative for the 1994-2004 decade, which 
would seem to contradict studies that estimate a unitary elasticity (Jaffe and Trajtenberg, 
2002; Griliches, 1990). The Mexican experience of that decade does not corroborate the study 
by Aghion and Howitt (1998) which shows constant returns for R&D taken as a percentage 
of GDP. However, it could be consistent with approaches that suggest decreasing returns in 
patents in relation to R&D spending.
10. The PCT unifies patent application procedures in the signatory countries with the presen­
tation, before the receiving office (in Mexico’s case, the IMPI) of the international “PCT” 
application, which avoids red tape in each country, lowering costs and encouraging patenting 
in countries other than that of the applicant’s residence.
11. Copyright and related rights are valid for “all productions in the literary, scientific and artistic 
fields, whichever the means or form of expression.” Both rights are protected equally because 
authors, artists, performers, producers, radio broadcasters, and others are essential elements 
of the cultural industries.
12. Business Software Alliance (BSA) and International Data Corporation (IDC), September 
2008. It should be noted that BSA has not revealed its sources and methodology. An arti­
cle in The Economist “Software piracy: BSA or just BS?” of May 19, 2005 points out that 
BSA’s methodology calculates losses based on an estimate of the stock of computers and its 
annual increase, the amount of software estimated per PC, and sales of legitimate software. 
The difference between legitimate software sold and the increase in the stock of total soft­
ware existing is assumed to be “pirate” software. To estimate sales losses, the difference is 
multiplied by the market price of the legitimate software without considerations of price and 
income elasticity, which strongly overestimates losses.
13. When Chile began negotiation of the trade agreement with the United States, BSA declared 
that Chile had 51% piracy. Twelve months later, at the end of the negotiation, it inexplicably 
declared that the figure was 63%.
14. TPMs are devices or components that restrict unauthorized access to subject matter protected 
by copyright and related rights, as well as other contents not necessarily protected. There 
are two types of TPMs: those that control access and those that ensure reproduction rights 
(anti-copy).
15. Something similar occurred in the agreement with Morocco which was signed in March 2004, 
but did not enter into force until the country complied with USTR demands in January 2006.
16. It is advisable to sign the Patent Cooperation Treaty (PCT), which only regulates proce­
dures, not substantive matters, and the Budapest Treaty on the International Recognition of 
the Deposit of Microorganisms for the Purposes of Patent Procedure ( 1980).
17. El Salvador is the only country which before the agreement with the United States already 
permitted plant patents but also established exclusions.
18. Other exclusions are a) discoveries, scientific theories, and mathematical methods; b) sys­
tems, methods, principles and economic, financial, commercial, business plans or plans of 
simple verification, and monitoring; and c) those referring to purely mental or intellectual 
activities, or games.
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19. For example, the criteria applied in life sciences can require additional conditions to prove 
that it is not a question of a discovery, in contrast to what occurs in other areas of technique.
20. This involves paying attention to the provisions of the TRIPS Agreement and Berne 
Convention with regard to the “three criteria rule”, ratified by WIPO, the European Union 
and the Free Trade Agreements. In TRIPS (Article 13) this rule states that “Members shall 
confine limitations or exceptions to exclusive rights to (i) certain special cases which (ii) do 
not conflict with a normal exploitation of the work and (iii) do not unreasonably prejudice 
the legitimate interests of the right holder” (Berne talks of authors). The rule applies to all 
categories of the Berne Convention. The criterion of “certain special cases” implies that these 
should be clearly defined, although it is not necessary to identify all possible situations. The 
concept of “normal exploitation of the work” should be delimited so as not to overestimate 
the relevant market. Finally, the concept of “unreasonably prejudice” should be considered in 
relation to the reasonable benefits of the intellectual property right holder.
21. Okediji and Prosser (2005) put forward cases in which the digital copy for personal use has 
gray areas: For example, reproduction for personal use could imply placing (the work) on a 
web page for personal use, which could be accessed by third parties, thus canceling the per­
sonal nature of the reproduction. Furthermore, placing protected material on a web page could 
affect exclusive distribution and communication rights. The sending of audiovisual material 
to private computer terminals affects the right of public performance insofar as the work can 
be accessed by persons alien to the immediate circle. Therefore, the copy for personal use 
will depend on the nature of the work and how it is accessed.
22. Compulsory licenses appeared in the Statute o f Monopolies of the United Kingdom of 1623, 
but their consolidation in the sphere of intellectual property took place with the Paris Union 
Convention of 20 March 1883, whose Article 5.A.2 permitted them to prevent patent abuse. 
Canada is the country with the greatest tradition and inclination in the use of compulsory 
licenses to guarantee medicines at affordable prices.
23. The Central American Convention for the Protection of Industrial Property of 1998 
(Guatemala, El Salvador, Nicaragua, Honduras, and Costa Rica) contains regulations on 
compulsory licenses that are consistent with the TRIPS Agreement. Decision 486 of the 
Andean Pact, incorporated in the laws of Colombia and Peru includes grounds for unjustified 
non-exploitation of patents.
24. See Abbott and Ball (2002).
25. See Roffe P. (2004).
26. Upon expiry of exclusivity, the information is not released into the public domain, but other 
applicants can base themselves on it if their product is proved to be equivalent.
27. Thus the Free Trade Agreement would be complied with and situations would be avoided 
in which an NCE, having exhausted its protection of undisclosed information in country A 
where the generic equivalent already exists, obtains 5 years in country B only because it had 
not been registered there. Thus country A could only export patented, non-generic products 
to country B, which would hinder free trade. By establishing a term of 6-12 months, this 
scenario is substantively delimited.
28. “Bipartisan Agreement on Trade Policy: Intellectual Property Provisions”, May 2007, Office 
of the United States Trade Representative (www.ustr.gov).
29. Title 35 U.S.C. § 156(3).
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Chapter 6
Intellectual Property Rights in the Agenda 
of the Developing Countries. Intellectual 
Property Laws and Access to Medicines
María Fabiana Jorge
6.1 Introduction
Agreements on intellectual property rights, and especially bilateral agreements 
signed by the United States in recent years, have led to increased levels of 
intellectual property protection where each new agreement sets higher standards 
than the previous one. Until a little over 10 years ago, several countries did not 
grant patents for pharmaceuticals and foods.1 The Agreement on Trade Related 
Aspects of Intellectual Property (TRIPS) was the first global intellectual prop­
erty agreement. It was concluded after almost 8 years of negotiations and marked 
a substantial change in the protection of intellectual property and access to 
medicines.
The Uruguay Round of the General Agreement on Tariffs and Trade (GATT), 
which included TRIPS, was concluded in December 1994. Since then, 20 year 
monopolies were granted for patents, including for pharmaceuticals. Indeed, Article 
27 specifically states that “patents shall be available and patent rights enjoyable 
without discrimination as to the place of invention, the field of technology and 
whether products are imported or locally produced.”
Although trade agreements have traditionally sought to open markets, by elim­
inating barriers to entry and thus increasing competition and benefiting consumers 
who as a result can have access to more affordable products, intellectual property 
agreements do the opposite. Instead of removing barriers to entry, they create them 
through the granting of patents; instead of increasing competition, they eliminate 
it during the term of the patent (20 years); instead of benefiting consumers with 
lower prices, the monopolies created by the patents result in higher prices, including 
pharmaceuticals, thus undermining access to affordable medicines.
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All this was done for the purpose of promoting investment and innovation in 
developing countries, although it is questionable if either goal was achieved, due 
to higher levels of protection. In fact, after Chile passed a new Industrial Property 
law during the 1990s, investments in the pharmaceutical field did not increase. On 
the contrary, international pharmaceutical companies closed manufacturing plants 
and only kept marketing offices open.2 Furthermore, a report from an Association 
of Southeast Asian Nations (ASEAN) workshop states that after the introduction of 
patents for pharmaceuticals, the experience o f countries such as Chile, Colombia, 
and other Andean countries shows that foreign direct investment (FDI) did not 
increase. There was no new investment, and various laboratories were closed down, 
since many foreign companies decided to import their products, thus substantially 
increasing the trade deficit in the region.3
The adoption of the TRIPS Agreement, which has become the standard for the 
protection of intellectual property rights for all Member States of the World Trade 
Organization (WTO), has had an enormous impact throughout the world. In some 
cases it has introduced stricter levels o f protection than those in effect in many devel­
oped countries at the time the Agreement was signed, including the most jealous 
defenders of Intellectual Property Rights (IPR). With regard to patent terms, for 
example, in the United States the patent term was 17 years from the date of the 
granting of the patent, but after the adoption of TRIPS, it was extended to 20 years 
from the date of filing of the application.
Although it is true that innovation is expensive and discovering new medicines is 
a risky and expensive business that has to be adequately paid for in order to provide 
incentives to innovators and to foster research and development, the question here is 
whether bilateral intellectual property agreements are striking the necessary balance 
between protecting the rights of inventors and those of consumers. Is the current 
agreement balanced? Where are bilateral trade agreements going? Who is promoting 
these agreements? What are the key provisions? What is their impact on consumers?
This chapter seeks to respond to those questions by providing an overview 
of what has happened in the past 12 years in the area of intellectual property 
rights, specifically with regard to pharmaceutical patents, and to reflect on the 
kind o f system that would make sense for Latin America so as to strike a bal­
ance between promoting innovation while protecting patients’ rights to access to 
life-saving medicines.
6.2 Main Provisions of the TRIPS Agreement
As mentioned above, the TRIPS Agreement has become the standard for the protec­
tion o f intellectual property rights for the member countries of the WTO. Although 
Article 1.1 of the Agreement states that “Members may, but shall not be obliged to, 
implement in their law more extensive protection than is required by this Agreement, 
provided that such protection does not contravene the provisions of this Agreement,” 
some developed nations claim that the TRIPS Agreement grants the minimum level 
o f IP protection. Furthermore, some developed countries have pressured developing
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countries not to avail themselves of the flexibilities provided in the agreement and 
since the adoption of TRIPS to adopt higher levels of protection than those that were 
agreed upon.4 As we will see later, this is consistent with the strategy of negotiating 
new bilateral agreements that take the standards set in the TRIPS Agreement as the 
basis to build on and establish higher levels of intellectual property protection.
For this analysis the TRIPS provisions have been divided into two groups: (a) 
those that seek to strengthen the rights of patent holders and (b) those that aim to 
protect consumers and/or foster technology transfer.
6.2.1 Strengthening the R ights o f  Patent Holders
6.2.1.1 Patent Term
The length of the patent term entailed a significant gain for the brand name phar­
maceutical industry, since with this agreement all members of the WTO agreed to 
grant 20 year patent protection as o f the filing date. As mentioned above, even in the 
United States the patent term had to be extended, since at the time the agreement 
was signed, patents were protected for 17 years from the date they were granted.
6.2.1.2 Patentable Subject Matter
Article 27 of the TRIPS Agreement defines patentable subject-matter and specifies 
those inventions that can be excluded from patentability if a government desires to 
do so, in the following manner: “patents shall be made available for any inventions 
whether products or processes, in all fields o f technology, provided that they are new, 
involve an inventive step and are capable of industrial application.” Furthermore, 
the definition contains three important specifications: patents shall be valid “with­
out discrimination as to the place o f invention, the field of technology, and whether 
products are imported or locally produced.” These specifications are significant 
because the developed nations wanted to make sure that countries would not dis­
criminate against the place of invention, that its field of technology would not be 
exempted, and that countries would not be forced to manufacture the products in 
specific countries. Medicines are very light products, easy, and inexpensive to ship, 
and countries negotiating the agreement wanted to ensure that they would be able to 
have full access to all markets where they could export their products from a few dis­
tribution points in the world. This would allow innovative name companies to reduce 
costs, increase exports and sales, and control markets by restricting competition for 
20 years.
More important still, the evolution of trade agreements from TRIPS to the nego­
tiation of bilateral Free Trade Agreements (FTAs) promoted by the United States 
shows the gradual expansion of the scope of patentable subject matter. In fact, many 
of them have eliminated the exclusions established in Article 27 of TRIPS.
The second paragraph has been less controversial and, in general, recent 
FTAs maintain the provision stating that members may exclude inventions to
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protect l ’ordre public or morality from patentability, although the reference rel­
ative to “avoiding serious prejudice to the environment” has been dropped from 
recent FTAs.
Finally, Article 27.3 is where the FTAs are making the biggest difference. It states 
that Members may exclude from patentability (i) diagnostic, therapeutic, and surgi­
cal methods for the treatment of humans and animals and (ii) plants and animals 
other than microorganisms, and essentially biological processes for the produc­
tion of plants or animals other than non-biological and microbiological processes. 
However, Members shall provide for the protection of plant varieties either by 
patents or by an effective sui generis system or by any combination thereof.
Although the list of exceptions is very clear, there have been strong lobbying 
efforts -in many cases successful- to eliminate or at least to start eliminating them. 
The effects of this change on pharmaceuticals, especially as regards biotechnology, 
are quite significant.
6.2.1.3 Rights Conferred
Article 28 introduces an important provision by establishing that patents may be 
granted for “products” or “processes.” Before the signing o f the TRIPS Agreement, 
some countries only patented the process of manufacturing medicines, so that if 
someone obtained the same product through a different process, the patent did not 
protect the patent owner from competition over the final product. Thus, Article 28 
was an important gain for the innovative name pharmaceutical industry.
The protection afforded by this article goes further by preventing “third parties 
not having the owner’s consent from the acts of: making, using, offering for sale, 
selling, or importing [that product] for these purposes.” This has serious implica­
tions since, for instance, a company in a country where the patent has not expired 
would be prohibited from manufacturing the product for export to a country where 
the patent has already expired.
Finally, the article reaffirms that only the patent holder has the right to transfer 
the patent by succession and to terminate licensing contracts. Clearly this article 
concentrates a great deal o f power on the patent owner.
6.2.1.4 National Treatment
Article 3 of TRIPS establishes that “ [e]ach Member shall accord to the nation­
als of other Members treatment no less favorable than that it accords to its own 
nationals with regard to the protection of intellectual property, subject to the excep­
tions already provided in, respectively, the Paris Convention (1967), the Berne 
Convention (1971), the Rome Convention or the Treaty on Intellectual Property in 
Respect of Integrated Circuits...”
Article 4 (“Most-Favored Nation Treatment” ) follows the same reasoning by 
establishing that “ [w]ith regard to the protection of intellectual property, any 
advantage, favor, privilege or immunity granted by a Member to the nations of any 
other country shall be accorded immediately and unconditionally to the nationals
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of all other Members.” Although they list some exceptions, Articles 3 and 4 seek 
to ensure that there will be no discrimination against foreign companies and that 
any concession granted to any Member must be automatically extended to any other 
Member State of the WTO.
Article 4 has additional implications for bilateral FTAs. Although these are 
negotiated between two countries, whatever is agreed upon with regard to intel­
lectual property has to be extended to all WTO members. Therefore, to a certain 
extent, this article acts as a trigger for the harmonization of new intellectual prop­
erty standards. For this reason, many question the effectiveness of these bilateral 
agreements, given that they entail additional concessions to almost 150 countries, 
although the negotiating countries receive reciprocal benefits only from each other, 
unless other countries also decide to grant such concessions, which they are not 
being forced to do.
6.2.2 Protecting Consum ers an d  Fostering  
the Transfer o f  Technology
Article 7 of the TRIPS Agreement states that “ [t]he protection and enforcement of 
intellectual property rights should contribute to the promotion of technological inno­
vation and to the transfer and dissemination of technology, to the mutual advantage 
of producers and users of technological knowledge and in a manner conducive to 
social and economic welfare, and to a balance of rights and obligations.”
It is therefore clear that this agreement seeks to achieve three objectives: (1) to 
promote innovation and foster the transfer of technology; (2) to strike a balance 
between the rights of patent holders and those of consumers; and (3) to strike a 
balance between rights and obligations. Unfortunately, new trade agreements upset 
the balance by increasing the protection that is granted to patent holders, while at 
the same time eroding or even eliminating those provisions that sought to ensure 
benefits for society and which could have expedited access to innovations.
Article 8 of TRIPS describes the key principles that should guide IP protection 
under the terms of the agreement. As in the section regarding the objectives, this 
article reveals that those negotiating the agreement sought to ensure a balanced 
system, by stating that “Members may, in formulating or amending their laws and 
regulations, adopt measures necessary to protect public health and nutrition...”
The second paragraph introduces a key concept that for the most part has 
been omitted in either the implementation of laws or in subsequent bilateral trade 
agreements, with the exception of the FTA signed between Chile and the United 
States and DR-CAFTA (Free Trade Agreement between the United States, the 
Dominican Republic and the five Central American countries) as well as the FTA 
with Colombia and Peru, which followed the Chilean example, and that refers to the 
fact that governments can implement measures to prevent the abuse of IP rights by 
patent holders. In fact, Article 8.2 of the TRIPS Agreement specifically states that, 
“ [appropriate measures, provided that they are consistent with the provisions of this 
Agreement, may be needed to prevent the abuse of intellectual property rights by
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right holders or the resort to practices which unreasonably restrain trade or adversely 
affect the international transfer of technology.”
6.2.2.1 Conditions on Patent Applicants
Article 29 of TRIPS establishes the basic conditions for the granting of a patent: 
“Members shall require that an applicant for a patent shall disclose the invention 
in a manner sufficiently clear and complete for the invention to be carried out by a 
person skilled in the art and may require the applicant to indicate the best mode for 
carrying out the invention known to the inventor at the filing date or, where priority 
is claimed, at the priority date of the application.”
Although at first glance this article seems to be quite basic, in recent FTAs there 
has been a deliberate effort on the part of the United States to limit disclosure 
requirements. For example, the reference to the “best mode” has been dropped in 
many agreements since DR-CAFTA, with the exception of the FTAs negotiated by 
the United States with Peru and Colombia, where Colombia requested that it be 
included. As we will see in more detail later on, the weakening of such require­
ments -  which are not necessarily considered to be burdensome to start with -  can 
have extremely negative consequences in the area of access to affordable medicines 
and with regard to the transfer o f technology, one of the key objectives of the TRIPS 
Agreement.
As part of the effort to reach a balanced agreement, the TRIPS included flexible 
clauses that give countries some leeway so that they can respond to the needs of 
their citizens. Such clauses are related to Paralel imports of medicines (exhaustion 
of IPR) and permit imports from any country where they are marketed in accordance 
with patent laws. For instance, if a patent holder sells a medicine that is patented in 
countries A  and B (respecting the commitments of the TRIPS Agreement), but at a 
higher price in country A, the latter could import the medicine that has been put in 
the market by the patent holder in country B without infringing on any patent rights.
Alternatively, a country could adopt the regime of national exhaustion of intel­
lectual property rights, so that even if drugs are cheaper in other countries where 
intellectual property rights are respected, country A  could not import the medicines 
(at lower prices) from country B. In other words, the international exhaustion oflPR 
is a flexibility that can provide a government with an additional tool to ensure access 
to affordable medicines. Some bilateral agreements, such as Australia-United 
States, prevent this flexibility.
6.2.2.2 Exceptions to Rights Conferred
Before addressing the issue of compulsory licensing, Article 30 of TRIPS makes 
reference to “Exceptions to Rights Conferred” : “Members may provide limited 
exceptions to the exclusive rights conferred by a patent, provided that such excep­
tions do not excessively endanger normal use of the patent and do not unreasonably 
cause damage to the legitimate interests of the patent holder, taking into account the 
legitimate interests of third parties.”
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6.2.2.3 Other Use Without Authorization of the Right Holder
Much has been written about Article 31 o f TRIPS on compulsory licensing, so this 
paper will only address the issue very briefly. This is undoubtedly one of the key 
flexibilities of the TRIPS Agreement, as it allows governments to issue compul­
sory licensing under certain circumstances and after considerable and unproductive 
efforts were made to obtain authorization from the right holder on commercial con­
ditions and reasonable terms. In any event, the patent holder must be adequately 
remunerated for the use of his/her invention, taking into account the economic value 
of the authorization.
One condition for the use of this tool is that its scope and duration must be lim­
ited to the purpose that justifies the compulsory license, which should end once 
its cause is extinguished. In addition, use of a patented invention shall be non­
exclusive, non-assignable, and shall be authorized mainly to supply the domestic 
market (this limitation was the subject of extensive negotiations that resulted in the 
Doha Declaration on the TRIPS Agreement and Public Health of November 2001, 
and the amendment to the TRIPS Agreement with the incorporation of Article 31 
bis at the end of 2005). This issue will be addressed in more detail with regard to 
the Doha Declaration.
6.2.2.4 Transition Periods
Article 65 of TRIPS provides for specific transition periods for countries according 
to their stages of development to enable them to modify their laws and regulations 
in order to comply with the commitments entered into. All signatory countries had 
I year to implement them; the developing countries were granted four additional 
years; countries undergoing transformations from a centrally planned economy into 
a free market economy had four additional years; and those countries that did not 
have patent protection for products for some areas of technology could further post­
pone their implementation for a period of five additional years. In addition, Article 
66 granted least-developed nations a transition period of 10 years which the Doha 
Declaration on the TRIPS Agreement and Public Health (paragraph 7) extended 
until 2016 for pharmaceutical patents (paragraph 7).
Although Articles 65 and 66 are very important to compensate for the major 
adjustments that the implementation of TRIPS entailed for many countries, interest 
groups and some developed countries have consistently pressured governments to 
give up this and other flexibilities, as it will be described in more detail further on.
6.3 The Doha Declaration on TRIPS and Public Health
The Doha Declaration on the TRIPS Agreement and Public Health was the result of 
a great deal of concern and frustration, especially from developing nations, which 
mostly regarded TRIPS as the result of an enormous effort to protect intellectual 
property rights, with potentially serious economic and social costs in the area of
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access to medicines. After they signed it, they found to their surprise that some 
developed countries, under pressure from powerful interest groups, were not will­
ing to fully respect it, but only to implement the provisions that best suited their 
interests.
Indeed, soon after the agreement was signed, some developed countries were 
only interested in implementing some of the provisions and started lobbying and 
pressuring other signatory countries to “unilaterally” forgo some of the flexibilities. 
Several countries such as Argentina, Brazil, and South Africa were among those 
that faced the most pressure. On June 14, 1995, only 6 months after the TRIPS 
Agreement was signed, Mickey Kantor, then United States Trade Representative 
(USTR), sent a letter to Domingo Cavallo, Minister o f Economy of Argentina, 
in which he raised his concerns regarding indications that the Argentine govern­
ment was considering a multi-year transition period (under the TRIPS Agreement 
Argentina was granted a period of transition of 10 years) and that it would “allow 
onerous clauses on compulsory licensing and provisions that would explicitly permit 
Paralel imports,” two flexibilities expressly included in the TRIPS Agreement. The 
letter also stated that “we have received no indication that Argentina will address the 
issues of pipeline protection and test data exclusivity.” In that regard, it is important 
to note that during the negotiation of the TRIPS Agreement, there were discussions 
as to whether there should be a period of exclusivity and whether pipeline protection 
should be granted, but both were excluded from the agreement, since Article 39.3 
of TRIPS only refers to protection of undisclosed information but does not establish 
any exclusivity period.
Argentina, like many other countries, is under constant pressure, especially from 
the United States, to implement “TRIPS Plus” provisions; that is, stricter intellectual 
property standards than those adopted in the TRIPS Agreement. The pressure built 
up until January 15, 1997, when the Office of the USTR sanctioned the country 
under the Special 301 Review.5 In a press release issued at the time, USTR argued 
that Argentina would not be granting patent protection for pharmaceutical products 
until 2000 (Argentina finally gave up half of the transition period that it had been 
granted due to US pressures) and was not granting an exclusivity period for test data. 
The sanctions entailed the elimination of 50% of the General System of Preferences 
for Argentine imports to the United States.
While the cases of pressures kept mounting, the HIV/AIDS crisis was steadily 
spreading. In a meeting organized in 2001 by the World Health Organization (WHO) 
and the World Trade Organization (WTO), representatives of associations of phar­
maceutical companies from Argentina and Mexico demanded that the flexibilities of 
the TRIPS Agreement be respected. During the second half o f that year, the TRIPS 
Council held a number of meetings that resulted in the Doha Declaration on the 
TRIPS Agreement and Public Health, signed on November 14, 2001.
Under normal circumstances, this declaration would not have been necessary 
since, for the most part, it just restates some of the clauses that were part of the 
TRIPS Agreement regarding the right o f Member States of the WTO to avail them­
selves of certain flexibilities in the implementation of their IPR obligations. The only 
real addition made at Doha was to address the restrictions o f Article 31 .f of TRIPS
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(that compulsory licensing should be authorized predominantly for the supply of the 
domestic market of the Member authorizing such use).
The Doha Declaration specifically states that countries “agree that the TRIPS 
Agreement does not and should not prevent members from taking measures to pro­
tect public health. Accordingly, while reiterating our commitment to the TRIPS 
Agreement, we affirm that the Agreement can and should be interpreted and imple­
mented in a manner supportive of WTO members’ right to protect public health and, 
in particular, to promote access to medicines for all.”
In addition, the Doha Declaration states that each member has the right to grant 
compulsory licenses and the freedom to determine the grounds upon which such 
licenses are granted, that each country has the right to determine what constitutes a 
national emergency, and that each member has the right to establish its own regime 
for the exhaustion of intellectual property rights.
In December 2005, an agreement was finally reached with regard to amend­
ing the TRIPS Agreement to allow compulsory licensing for countries that do 
not have medicine manufacturing capacity and need to import them from another 
country.6 The negotiations for this amendment were long and complex and not with­
out criticism from non-governmental organizations which considered the process for 
allowing trade in compulsory-license medicines burdensome.7
6.4 The Era of Bilateral Agreements on Intellectual Property
The impact of TRIPS should not be underestimated. Not only did it establish high 
standards for intellectual property protection, it also opened the door to other agree­
ments that set higher standards of protection. As mentioned above, until the adoption 
of TRIPS, many countries did not grant patents for pharmaceuticals, as these are 
considered to be an essential good for life. With the signing of TRIPS, the concept 
of monopolies on pharmaceuticals was globally accepted as necessary to provide 
enough incentives to foster innovation. Some interest groups became aware of the 
benefits of trade agreements as instruments to change countries’ laws, thus ensuring 
control of their respective markets, and what may be called the “Era of Bilateral 
Free Trade Agreements on Intellectual Property” was born.
Although bilateral agreements have been signed between many different coun­
tries, the most far-reaching in the area of intellectual property rights are the ones 
signed by the United States. Indeed, with the exception of a few agreements such 
as EFTA (European Free Trade Association)-Chile agreement, which has specific 
provisions on the protection of undisclosed information and general paragraphs 
on patent extensions, the IP section and the articles in most agreements are very 
broad and focus on areas such as observance and cooperation on intellectual prop­
erty rights and refer to the need to comply with the obligations under the TRIPS 
Agreement.8
From the US perspective, intellectual property continues to be an area where 
American industry has strong leadership and is very competitive. This, coupled
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with the lobbying efforts of the innovating brand name industry, has turned the 
intellectual property chapters into a priority in bilateral FTAs.
Such agreements have a dual purpose. The immediate one is to obtain addi­
tional access and control over the trading partner’s market, whereas the more 
far-reaching purpose is to set precedents for future agreements, as USTR has 
acknowledged in public statements. On May 8, 2003, for example, Ralph F. 
Ives, III, Assistant Secretary o f USTR for Asia, the Pacific and Asia-Pacific 
Economic Cooperation (APEC), spoke before the House Energy and Commerce 
Subcommittee on Commerce, Trade and Consumer Protection, where he said the 
following:
Also, in the FTAA, the United States is seeking to negotiate a state-of-the-art agreement. 
While some countries negotiate free-trade agreements that exclude important areas o f trade 
such as services and E-commerce, the United States seeks to negotiate the kind of ambitious 
and far-reaching commitments that one would expect to see in a 21st century free-trade 
agreement. To accomplish this, the U.S. is using bilateral FTAs as model to break new 
ground and set new higher standards. (Our emphasis).
Furthermore, speaking before the Senate Finance Committee’s Subcommittee 
on International Trade on May 13, 2003, Peter F. Allgeier, Deputy US Trade 
Representative stated that “ the United States has relatively unique interests in 
protecting the intellectual property o f its world-class entertainment, software, 
biotechnology, and pharmaceutical industries. In the Chile FTA, we have set very 
high standards o f protection in these areas and we are seeking to do the same with 
our CAFTA partners.” In fact, the bilateral agreements negotiated by the United 
States after the US-Chile FTA include increasing levels of intellectual property 
protection.
Therefore, there is a clear strategy to use these agreements as steps to gradu­
ally increase intellectual property standards. We should not make the mistake of 
thinking that the TRIPS Agreement is all there is. On the contrary, there are many 
different fronts that are operating simultaneously, including regional negotiations 
such as the one to create the Free Trade Area of the Americas (if the FTAA moves 
forward, there will be a great deal o f pressure to harmonize intellectual property 
standards at the highest levels of protection that have been set in various bilat­
eral agreements that have already been signed in the region); in global negotiations 
such as the Doha Development Round (although at the moment these negotiations 
seem to be stalled), ongoing harmonization efforts at the World Intellectual Property 
Organization (WIPO),9 and among developed nations.10
6.5 Trade Promotion Authority (TPA)
The United States Congress has the power “to regulate Commerce with foreign 
Nations” .11 However, in order to avoid a protracted and difficult process whereby 
Congress introduces changes to what has already been negotiated by the Executive, 
Congress has granted “ fast track” authority, to the USTR, giving it the power to
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conduct trade negotiations, thus only reserving the right to vote up or down on an 
agreement. These “ fast track authorizations” are granted for limited periods o f time. 
In 2002, while Chile and Singapore were negotiating free-trade agreements with the 
United States, Congress granted such authority to President Bush under the “Trade 
Promotion Authority”  section o f the Trade Act o f 2002.
Under the leadership o f Senators Edward Kennedy and Diane Feinstein and with 
the support o f various groups concerned about access to medicines, the Senate unan­
imously approved the inclusion o f the Kennedy-Feinstein Amendment, according 
to which in negotiations entered into under this mandate, the U STR  must respect 
the Doha Declaration on the TRIPS Agreement and Public Health. Thus, under 
the TPA mandate, the U STR  cannot negotiate bilateral agreements that restrict the 
flexibilities o f the TRIPS Agreement.
The Kennedy-Feinstein Amendment was supported by both political parties. In 
fact, during the debate on this amendment, Senator Grassley (R-IA), Chairman 
of the Senate Finance Committee, which has oversight o f trade negotiations, said 
that “ this amendment makes an important contribution to the underlying trade 
promotion authority bill,”  and added “During the WTO ministerial at Doha, the 
members o f the organization adopted a political declaration that highlights the 
provisions in the TRIPS agreement that provide members with the flexibility to 
address public emergencies, such as the epidemics o f HIV, tuberculosis, and malaria. 
The objectives on intellectual property, which are part o f this bill, were drafted 
before completion o f the Doha ministerial meeting. Senator Kennedy’s amendment 
updates these objectives to take into account the important declaration on public 
health made at the Doha meeting. It is a good addition to the bill. I am pleased to 
accept it.” 12
Senator Baucus (D-M T), the ranking Democrat o f the Committee, also stated that 
“ the amendment recognizes the special declaration concerning public health that 
was adopted last November in Doha. The special declaration provided assurance to 
poor countries facing the immense challenges o f dealing with public health emer­
gencies caused by pandemics o f infectious diseases like HIV/AIDS, that measures 
necessary to address such crises in these countries can be accommodated by the 
WTO TRIPS Agreement, the Agreement on Trade-Related Aspects o f Intellectual 
Property Rights” .13
Nevertheless, a review of recent bilateral agreements negotiated by the United 
States shows that U STR  negotiators have not followed this mandate. As a result, in 
February 2005 Senator Kennedy issued a clarification to the congressional record 
on this clause in which he stated the following:14
[ .. .]  Our amendment made it a principal objective of the United States to respect the Doha 
Declaration in all trade negotiations. Regrettably, in several trade agreements since then, the 
administration has refused to fulfill this obligation.
[ .. .]  Our amendment to the Trade Promotion Authority Act reinforces the Doha 
Declaration. The Bush administration should be using it to negotiate trade agreements that 
allow urgently needed access to medicines. Instead, the administration has used trade agree­
ments to promote the interests of the pharmaceutical industry at the expense of access to 
drugs in developing nations.
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Again and again, the administration has defied the Doha Declaration and imposed 
unjustified restrictions on the availability o f patented drugs. It has done so in 
trade agreements with Australia, Jordan, Morocco, Singapore and other nations. 
In these agreements, the Bush administration has undermined the very core o f the 
Doha Declaration. Now it is trying to do so in the Central American Free Trade 
Agreement.”
6,6 Key Provisions of Bilateral FTAs
The key provisions o f bilateral agreements that affect pharmaceuticals can be clas­
sified into two main groups: (A) provisions that favor patent holders and (B) 
provisions that protect consumers.
Although this chapter is focused mostly on Latin America, in this section we 
are including references to other agreements as some provisions first established in 
agreements outside the region have set precedents that have been included later on 
in FTAs negotiated in the Americas.
6.6.1 Provisions Favoring Patent Holders
The following are provisions that favor the rights o f patent holders: (a) patent exten­
sions for delays incurred by regulatory agencies, (b) patent extensions for delays 
in the patent office, (c) test data protection, (d) linkage (link between patent sta­
tus and marketing authorization), (e) elimination or reduction o f the restrictions on 
patentable subject-matter, (f) elimination o f the requirement to disclose the best 
mode for carrying out an invention, and (g) harmonization.
6.6.1.1 Patent Extensions for Delays Incurred by Regulatory Agencies
Any analysis o f  this issue must take into consideration that the TRIPS Agreement 
does not establish patent extensions, so any provision extending the term of a patent 
is clearly TRIPS Plus. In addition, there are several issues that must be looked at
(i) which are the patents subject to extensions, (ii) whether any limits are set for the 
extensions, (iii) whether there is a minimum period o f delay o f  the health authority to 
grant an extension, (iv) whether delays incurred by the patent holder could be taken 
into account in granting an extension, and (v) whether the granting o f extensions in 
one country that was used as a reference for granting a patent in another country 
means that another country should also grant such extensions.
Given the complexity o f the issue, below is a more detailed analysis o f each of 
these points:
(i) Which a re  the p a te n ts  su b je c t  to the e x ten sio n s?  According to one o f the nego­
tiating objectives o f the TPA passed by the U S Congress, negotiations in the 
area o f intellectual property rights must “reflect a standard o f protection similar 
to that found in United States law.” Nevertheless, it seems that U S negotiators
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have been picking which aspects o f the law to follow and which ones to ignore. 
For instance, under U S law, patent extensions due to delays in the regulatory 
approval process (FDA) are only granted for new chemical entities (N C E ).15 
Nevertheless, all recent FTAs fail to include this limitation, thus opening the 
door to extending patents to cover a broader range.
(ii) W hether any limits a re set f o r  the extensions. Under U S law there are very spe­
cific and clear limits on the period that a patent may be extended. For instance, 
an extension cannot be longer than 5 years, and the total effective patent term 
(EPT), which is the period from the date o f marketing approval o f the prod­
uct until the original expiration o f the patent, cannot go beyond 14 years.16 
Therefore, if a drug enters the market in the 8th year o f the patent and is granted 
a 5 year extension (its maximum) the total effective patent term would be 17 
years. Nevertheless, under U S law (due to the fact that the EPT cannot be more 
than 14 years), 3 o f the 5 years o f the extension would be automatically elimi­
nated. AH these limitations to protect consumers are not being included in the 
FTAs, even though they are part o f U S law so that extensions in the FTAs can 
be interpreted as being unlimited.
(iii) Whether there is a  minimum period  o f  time to trigger an extension. The lan­
guage o f the FTAs does not specify a time to request patent extensions during 
health approval o f a medicine (there are in cases o f delays in the approval o f a 
patent in the office o f intellectual property; see below).
(iv) Whether delays incurred by the patent holder could b e  taken into account as 
part o f  the delay to justify authorization o f  extensions. Any country negotiating 
patent extension provisions should ensure that delays that resulted from actions 
attributable to the patent holder are not eligible for patent extensions. This sort 
of language has been generally included in FTAs for the delays occurred in 
granting a patent, but not for those that occurred during the marketing approval 
process. Such limitations should be included in both cases.
(v) Whether the granting o f  extensions in a  country that was used as a  reference  
f o r  granting a  patent in another country means that the secon d  country should  
also grant such extensions. This language is serious cause for concern, since a 
delay in a reference country may not have affected at all the registration in the 
other country and yet nonetheless, based on this language, it would be granted 
an extension. This was included in the U S-Bahrain FTA (Art. 14.8.7.).
6.6.1.2 Patent Extensions for Delays in the Patent Office
Although the TRIPS Agreement only requires a period o f  patent protection o f  20 
years from the filing date, all recent FTAs negotiated by the United States since the 
U S-Singapore and the U S-C hile FTAs include extensions for delays in the granting 
o f a patent.
The language in most o f these agreements is similar, although the periods of 
delay that trigger a request for an extension varies depending on the country. For 
instance, the FTAs signed with Singapore, Australia, Morocco, Bahrain, and Oman 
establish that an unreasonable delay shall at least include a delay in the issuance o f a
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patent o f more than 4 years from the date o f filing o f the application in the territory 
o f the Party, or 2 years after a request for examination o f the application, whichever 
is later.
In the FTAs signed with Chile, Peru, and Colombia, as well as the DR-CAFTA, 
the trigger periods are 5 and 3 years instead o f 4 and 2, respectively. There is a simple 
reason for this. Although the language proposed by the United States to Chile also 
had 4 and 2 years, the Chilean intellectual property team set a good precedent for 
the Americas. The FTA with Chile includes several examples o f well negotiated 
provisions. During the renegotiation o f the FTA with Peru and Colombia in 2007 
the requirement o f  patent extensions was eliminated just for pharmaceuticals.
Finally, all FTAs from Singapore onward include similar language stating that the 
two trigger periods to request an extension o f the patent may be granted, provided 
that the periods o f time attributable to the actions o f the patent applicant need not 
be included in the determination o f such delays.
6.6.1.3 Test Data Exclusivity
This is one o f the most complex issues included in the FTAs and one which has 
serious consequences. The level o f detail and the sophistication o f the language that 
has been included in the latest agreements reveal the growing problem for access to 
medicines.
From a broader perspective, establishing exclusivity periods for test data pro­
tection is no doubt part of TRIPS Plus, even though some interest groups have 
argued that this is an obligation derived from Article 39.3 o f the TRIPS Agreement. 
However, that article does not in any way establish an exclusivity period, but only 
states that “Members, when requiring, as condition o f approving the marketing of 
pharmaceutical or o f  agricultural chemical products which utilize new chemical 
entities, the submission o f undisclosed tests or other data, the origination o f which 
involves a considerable effort, shall protect such data against unfair commercial 
u s e ...”
Data exclusivity periods entail a number o f restrictions on access to medicines. 
For instance, if a government decides to issue compulsory licenses, its effectiveness 
may be hindered if the data for the drug are protected by an exclusivity period. 
Furthermore, it has been argued that several pharmaceutical companies have weak 
pipelines, and therefore they may want to extend their existing monopolies on their 
current bestselling drugs for as long as possible, even beyond the patent term, in 
order to keep their revenues up.
(i) “A t l e a s t "  5  y e a r s . In addition, there is the concern that once a country has 
accepted the concept o f a period o f exclusivity (different from TRIPS) it is 
only a matter o f time until there is an effort to increase the period o f exclusiv­
ity. For instance, in Europe the average data exclusivity period was 6 years. 
However, in 2004 the EU  passed Directive 2004/27/EC, extending exclusivity 
to 10 years, with the possibility o f an additional year for new indications. 17 In 
Canada, the exclusivity period o f 5 years was extended to 8 years in October
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2006.18 Furthermore, all recent bilateral trade agreements establish a period 
o f exclusivity o f “ at least”  5 years, thus opening the door to longer periods in 
the future. This is another example o f the language proposed by the United 
States where it can be argued that U STR  negotiators are going beyond U S  
law requirements. Indeed, under U S law, data exclusivity for new chemical 
entities is granted for 5 years, and not 1 day more. Nevertheless, U STR  nego­
tiators have ensured that countries agree to an open-ended exclusivity period 
with a minimum o f 5 years.
(ii) Subject m atter protected  by exclusivity periods. This is a key issue that 
concerns what exactly can be protected and where there are significant 
differences between several recent bilateral trade agreements.
The text proposed by the Office o f the U STR  does not follow U S law, 
where the 5 years o f protection is only granted for new chemical entities. 
Nevertheless, the language o f some recent FTAs goes beyond that. The broad­
ening o f the scope o f  pharmaceutical products eligible for such exclusivity or 
monopoly would have a direct impact on the timing o f the entry o f generic 
competition into the market. Chile was the only country that actually made 
sure that this protection would be granted only for new chemical entities, 
even though the original U S proposal included much more ambitious lan­
guage. Unfortunately, other agreements negotiated later on, including the 
DR-CAFTA, failed to use this very important precedent.
(iii) Same or  similar. An additional and very serious problem results from the 
inclusion o f the words “ same or similar.”  Several recent FTAs establish that 
“ the Party shall not, without the consent o f  a person that previously submit­
ted such safety or efficacy information to obtain marketing approval in the 
Party, authorize another to market the same product or a similar o n e .. .” 19 
The implications o f this text are dangerous, since it basically establishes that 
if a period o f exclusivity is granted, no generic version could be authorized 
for the whole therapeutic class o f  drugs related to the one that was granted 
the exclusivity. This goes beyond what is in effect in the United States and 
has serious consequences for access to affordable medicines. Furthermore, 
by prohibiting the approval o f same or similar drugs, the approval o f generic 
versions o f biotechnology drugs would be banned which would have a very 
negative effect on access to medicines since these are the most expensive 
drugs.
(iv) Consecutive p eriods o f  exclusivity. This is one o f the most regressive data 
exclusivity provisions from the point o f view of developing nations and access 
to medicines, since it basically entails that the period o f protection in a devel­
oping country could be twice as long as the protection granted in a  developed 
country, or even more. The Central American countries (DR-CAFTA), Peru, 
and Colom bia (in the case o f the last two countries the grace period was mod­
ified in the 2007 renegotiation) accepted the granting o f a 5 year grace period 
for brand name companies to register a product in a  country once the other 
Party has registered (in this case the United States). The period o f “ at least” 
5 years o f data exclusivity goes into effect from the moment o f registration,
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and thus the CAFTA countries, the Dominican Republic, Peru, and Colombia 
could be actually granting brand name companies 10 or even more years o f  
data exclusivity, when U S consumers would only need to wait for 5 years to 
have access to more affordable medicines.
What normally occurs is that brand name companies first register the data 
in developed countries where their earnings are higher. For instance, most 
companies register their drugs first in the United States, given that, accord­
ing to IMS (Information on Pharmaceutical Markets),20 this is where about 
50% o f global pharmaceutical sales occur. However, small countries such as 
Guatemala or El Salvador may not be a high priority for pharmaceutical com­
panies in terms o f sales, so a company is likely to register its products there 
later on. In practice, this means that people in those Central American coun­
tries would be unable to have access to the drugs they need for longer periods 
o f time than the citizens o f developed nations.
In Jordan, the first country that accepted the consecutive application o f  
data protection periods in a bilateral FTA, domestic generic companies are 
reluctant to take the risk o f bringing a product to market, even if that product 
has not yet been registered in Jordan, because the brand name company could 
suddenly decide to enter the local market, thus banning the generic company 
from selling the drug for 5 years and therefore ruining the investment that 
had been made to bring the product to market. Hence, this provision is very 
regressive for those that have limited resources.
Finally, another element to look for with regard to the consecutive appli­
cation o f the protection is whether protection could go even beyond 10 years. 
DR-CAFTA states that a Party may require that the person providing the 
information in the other territory seek approval in the territory o f the Party 
within 5 years after obtaining marketing approval in the other territory. It is 
important to note that the text says that a Party “may require”  but therefore, 
it may also not require it and leave the registration o f the data in the coun­
try open ended. This could have terrible consequences for consumers whose 
access to more affordable medicines may be indefinitely delayed. This is also 
a negative provision for domestic pharmaceutical companies and as a result 
for the economy o f these nations.
(v) P e rio d  f o r  reg istra tio n  o f  con fid en tia l in fo rm ation . Although Chile accepted 
the granting o f data exclusivity for pharmaceuticals for “ at least 5 years,”  it 
rejected the consecutive terms proposed. The amendments to the Industrial 
Property Law passed by the Chilean Congress following the approval o f the 
FTA set limits on the grace period provided to brand name companies to 
register their data in the country, after which they lose such rights. Thus, Chile 
granted a 12-month grace period to register data in Chile after the data is 
first registered elsewhere. If the holder fails to register its product within that 
timeframe it loses the right to do so  later on.21
This was a positive and creative provision, as it provides an incentive 
for pharmaceutical companies to register their products in Chile soon after 
their first registration in another country, thus providing consumers with
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expeditious access to medicines and also avoiding unnecessary delays in the 
introduction o f generic competition in the market.
Som e DR-CAFTA countries and others argued that the consecutive appli­
cation o f the periods o f protection was positive, since it set a clear limit 
on how long a company could actually take to register a medicine in their 
countries. However, Central American consumers have a disadvantage with 
respect to consumers in developed countries that will have access to cheaper 
and equally effective medicines much earlier.
Chile’s legislation provides that data exclusivity will be lost if  a pharma­
ceutical product has not been traded in Chile for a period o f 12 months since 
its registration in the country.
(vi) D a ta  exclusiv ity  c an  g o  beyond the p a te n t term . Another very regressive step 
is the fact that several o f these agreements, including the FTAs negotiated 
with Peru, Colombia, Oman, Bahrain, Morocco, Singapore, and Australia, 
establish that the period o f exclusivity for the protection o f  test data could 
go beyond the term of the patent. Indeed, recent FTAs have included lan­
guage that specifically states that “ when a product is subject to a system of 
marketing approval pursuant to paragraph 1 and is also covered by a patent 
in the territory o f that Party, the Party shall not alter the term o f protection 
that it provides pursuant to paragraph 1 in the event that the patent pro­
tection terminates on a date earlier than the end o f protection specified in 
paragraph l . ” .22
Many believe that the issue o f data exclusivity is not very serious because it 
entails a period o f 5 years, whereas the period for patents is 20, thus it would 
not affect consumers because the monopoly granted by a patent remains in 
force. This is not so, given that the protection o f data can be requested for 
products that are no longer under patent. Furthermore, countries that have 
accepted to grant three more years o f exclusivity for new clinical information 
preventing the approval o f any “ same or similar” products would block all 
same or similar products approved before. It is important to underline that 
each new 3-year period will block the generic competition for the original 
product, as well as any other similar product, so that it is possible that a patent 
may expire before market exclusivity does.
(vii) “ R e q u ire ” o r  “p e rm it” . A troubling addition was recently made to the lan­
guage o f some FTAs, such as those that the United States negotiated with 
Bahrain, Oman, Peru, and Colombia (the word “ permit” was eliminated in 
2007 with regard to Peru and Colom bia with the renegotiation o f the FTA), 
with regard to regulated products (test data) which specifically states that “If 
the Party requires or permits, in connection with granting marketing approval 
for a new pharmaceutical or new agricultural chemical product, the submis­
sion o f evidence concerning safety and efficacy...” 23 This text could allow a 
company to submit information and request protection for said information, 
even though it is not required to demonstrate the safety and efficacy o f the 
product. This could potentially result in delaying new research and therefore 
innovation as well as the approval o f some generic drugs.
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(viii) Eliminating the word “undisclosed”. Another negative development from the 
point o f  view o f  access to medicines is the language regarding protected 
information. While the US-A ustralia FTA protects “ undisclosed tests or data 
concerning the safety or efficacy o f products,” the wording o f more recent 
FTAs, such as the ones signed with Bahrain, Oman, Peru, and Colom bia is 
broader, as it refers to “ the submission o f  information concerning safety and 
efficacy o f the product.”  The word “ undisclosed” was reintroduced in the FTA  
with Peru and Colom bia with the 2007 renegotiation.
There are two significant differences. First, the term “ undisclosed,”  as 
related to data, was dropped. By not including the word “ undisclosed,”  the 
information that could be protected by a period o f exclusivity is much broader 
and could include information that is already in the public domain. Second, 
the replacement o f the words “ test or data” with “ information” again broad­
ens the scope o f protection, which could delay generic competition and thus 
hinder consumers’ access to more affordable medicines.
Unfortunately, this is consistent with the most recent U STR  Annual 301 
Review published o f  April 28, 2006, where the U STR  states that a number o f 
countries do not provide adequate protection against unfair commercial use 
o f undisclosed test and other data submitted by pharmaceutical companies 
seeking approval for their products, thus widening the scope o f the data that 
they are seeking to protect.
(ix) Additional 3 years f o r  new clin ical information. Another negative develop­
ment for consumers is the fact that some FTAs, such as the ones negotiated 
with Morocco, Bahrain, and Oman, include an additional 3-year protection 
period for new clinical information submitted in support o f  the marketing 
approval process.
6.6.1.4 Linkage (Between the Health Registration Office 
and the Patents Office)
The linkage between marketing approval and patent status is a complex issue, since 
it is related to several other issues, including evergreen patents, improper filing of 
patents (frivolous lawsuits), and the misuse or abuse o f patents by right holders. 
According to this regulation, in the United States and Canada, no generic drug can 
be approved until any claim o f alleged patent infringement is decided in court or 
for a certain period o f time (30 months in the United States and 24 in Canada), 
whichever comes first. In the United States, once a patent has been granted, a com­
pany can register it in the Orange Book at the Food and Drug Administration (FDA), 
but not every patent can be registered in the Orange Book. The only patents that can 
be listed are those that claim to be (1) a drug substance (active ingredient); (2) a 
drug product (formulation and composition); and (3) a method o f use.
Recent bilateral agreements include the linkage provision, which is not part o f  
the TRIPS Agreement and which is being questioned in the United States even by 
members o f the U S Congress, as it has opened the door to a number o f abuses by 
patent holders.24 In addition, there are serious doubts as to whether the linkage is
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in compliance with Article 27.1 o f the TRIPS Agreement, which specifically states 
that patents shall be available without discrimination in the field o f technology. The 
linkage clearly applies only to pharmaceuticals, so it could be argued that it actually 
discriminates based on the field o f technology and therefore is inconsistent with the 
TRIPS Agreement.
The way it is being included in agreements goes significantly beyond U S law. 
For instance, in the United States, when a patent holder is notified by the FDA that 
a generic company is applying for a drug covered by a patent, the patent holder has 
45 days to file a lawsuit against the generic applicant or the FDA could authorize the 
generic applicant. In addition, while in the United States only a limited number o f  
patents may receive this protection, the language o f this provision in the FTAs is so 
broad that it would actually cover most if  not all patents. In fact, in the 2006 Special 
301 submission o f PhRM A25 to the U STR  regarding the 301 Annual Review, the 
association criticizes Mexico, which adopted linkage provisions through a presi­
dential decree in September 2003, due to the fact that the linkage protection is only 
granted for active substances or ingredients.
Finally, it is important to highlight that this provision shifts the responsibility 
for protecting private property from its owner to the government, thus putting an 
additional burden on the latter, which must assign resources to the implementation 
and enforcement o f  this provision. It is interesting to note that a report from the 
Department o f Health and Human Services (HHS) on drug imports stated that “ it 
is outside the scope o f H H S’ responsibility, expertise and jurisdiction to protect 
intellectual property rights.” 26 Why is it that going to the courts to solve a patent 
dispute may not be enough for patent holders?
6.6.1.5 Elimination of Requirements Regarding Disclosure of the Best Mode 
to Reproduce an Invention
Under U S law, a patent applicant must disclose what is known as the “ best mode” 
to reproduce an invention so that after the patent expires, society can benefit from 
the knowledge o f that invention.
Such information is essential for the reproduction o f biotech drugs after a patent 
expires. These drugs are the most expensive on the market -  the cost ranges from a 
few thousand dollars a year to more than a hundred thousand.27 The U STR  argues 
that it is not necessary to include the “best mode” requirement in the text o f the 
FTAs, since many countries do not have such requirements. Yet at the same time the 
U STR  is including linkage provisions, even though most countries do not have this 
type o f regulations. Therefore, the same rationale could be used to argue that the 
linkage provision should not be included in the FTAs. The only consistent element 
in all o f these provisions is that all o f them seek to favor the rights o f patent holders 
at the expense o f consumers, thus upsetting the carefully crafted balance achieved 
in the United States with the Drug Price Competition and Patent Term Restoration 
Act o f 1984, best known as the Hatch-Waxman Act, between the need to foster 
competition from generic drugs and the maintenance o f incentives to invest in the 
research and development o f new drugs.
172 M.F. Jorge
6.6.1.6 Harmonization
There are three harmonization efforts under way, one within the framework o f the 
World Intellectual Property Organization (WIPO), the second one led by the US  
Patents and Trademarks Office (USPTO), along with its counterparts in Australia, 
Canada, the European Union, and Japan, and the third within NAFTA. Indeed, dur­
ing a public hearing held in the U S House o f Representatives, John M elle, Assistant 
Secretary for North-American Affairs at the U STR, said that a review o f NAFTA  
has been launched to “ identify more ambitious disciplines than our more recent 
regional FTAs that could be candidates for incorporation into the NAFTA.” 28 The 
U STR  is currently accepting proposals from United States industry regarding which 
provisions should be included. Considering that intellectual property is one o f the 
top priorities o f the United States in the negotiation o f FTAs, it is expected that the 
U STR  will seek to include IP provisions.
Furthermore, the U S-A ustralia FTA specifically states that “each Party shall 
endeavor to participate in international patent harmonization efforts, including 
WIPO for dealing with reform and development o f the international patent 
system.” 29
6.6.1.7 Restriction of the Flexibilities of the TRIPS Agreement
A s mentioned above, the TRIPS Agreement includes some flexibilities for the 
implementation o f intellectual property provisions, some o f which are key to ensur­
ing access to medicines, such as the use o f compulsory licensing, Paralel imports, 
and restrictions on patentable subject matter. Unfortunately, several o f the FTAs 
have limited these flexibilities, despite the fact that the Trade Promotion Authority 
specifically states that the new agreements negotiated by the U STR  under this 
authority must respect such flexibilities. (Trade Act o f 2002, Title X X I, Section 
2101 (b) 4C).
6.6.1.8 Elimination of the Restrictions on Patentable Subject Matter
Article 27.3 o f the TRIPS Agreement states that “Members may also exclude from  
patentability:
i) Diagnostic, therapeutic and surgical methods for the treatment o f humans or 
animals.
ii) Plants and animals other than microorganisms, and essentially biological pro­
cesses for the production o f plants and animals other than non-biological and 
microbiological p rocesses.. . ”
Nevertheless, the Office o f the U STR  proposes the inclusion o f language in the 
FTAs that seek to limit these provisions. In the case o f patentable subject-matter, the 
U STR  included language that seeks the elimination o f these restrictions in the FTAs 
with Chile, Peru, and Colombia, as well as the countries in DR-CAFTA, stating
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that the Parties will undertake all reasonable efforts to make the patenting o f plants 
available. Other FTAs go further, like the Jordan-US FTA, which does not include 
the patenting o f  plants and animals as one o f the potential restrictions to patentable 
subject matter.
6.6.2 Provisions to Protect Consumers
These provisions include (a) Bolar, (b) compulsory licensing, (c) Paralel imports, (d) 
revocation, (e) measures to prevent abuse o f  rights by intellectual property holders, 
(f) opposition proceedings to the granting o f  a patent; and (g) side letters.
The provisions listed in this section are among those that contribute to ensuring 
access to affordable drugs. However, the language included in several o f the recent 
FTAs with regard to these clauses tends to favor in several cases the rights o f patent 
holders, leaving consumers less protected.
6.6.2.1 Bolar
This provision allows the pre-registration o f a generic drug so  that during the time 
that the patent is in force a generic applicant can conduct all the necessary testing 
and make the subm issions to the regulatory offices to obtain the pre-approval o f the 
medicine. This allows a generic company to enter the market immediately after a 
patent expires. The absence o f a Bolar-type provision entails a de facto extension o f  
the patent term beyond 20  years.
The adoption o f the Bolar provision in the United States has been one o f the 
most successful chapters in ensuring access to medicines. The text o f the law is 
very clear: “ It shall not be an act o f infringement to make, use, offer to sell, or sell 
within the United States or import into the United States a patented invention (other 
than a new animal drug or veterinary biological product ( . . . )  which is primarily 
manufactured using recombinant DNA, recombinant RNA, hybridoma technology, 
or other processes involving site specific genetic manipulation techniques) solely 
for uses reasonably related to the development o f information under a Federal law 
which regulates the manufacture, uses reasonably related to the development and 
submission o f information under a Federal law which regulates the manufacture, 
use, or sale o f drugs or veterinary biological products.”30
Despite its importance, in the trade agreements the U ST R  has chosen to water 
down the language o f certain U S laws by not requiring the inclusion o f Bolar, but 
rather only allowing it if  a  government decides to adopt it. Som e may consider that 
this is enough, but the countries that have concluded negotiations have discovered 
that once the negotiating process ends, new negotiations start on the implementation 
o f the provisions that are in the text o f an agreement. It is essential that the language 
be very clear and leaves no room for different options or for any future attempts to 
eliminate them.
A report from the United States International Trade Com mission regarding the 
U S-A ustralia FTA states that, “U .S. industry and government trade officials are
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especially concerned that the Australian Government may allow domestic drug 
producers to conduct trials and produce generic equivalents o f patented pharma­
ceuticals prior to the expiration o f the patent holders’ right to legally sold drugs. 
This would permit domestic producers’ drugs to obtain Australian regulatory mar­
keting approval in advance o f patent expiration so that generic equivalents could be 
sold immediately after the patent had expired.”31
A s the report shows, countries negotiating this type o f agreement should not 
simply agree on a text that may either allow or ban its implementation. Countries 
should demand unequivocal language, as under U S law.
6.6.2.2 Compulsory Licensing
Although compulsory-licensing provisions are at the heart o f  the flexibilities avail­
able under the TRIPS Agreement, some o f the bilateral FTAs negotiated by the 
United States such as those with Jordan, Singapore, and Australia seriously limit 
the use o f compulsory licensing, directly contradicting the TPA mandate to respect 
the Doha Declaration on the TRIPS Agreement and Public Health.
6.6.2.3 Parallel Imports
Under Article 6 o f  the TRIPS Agreement, countries could decide whether to opt 
for the national or the international exhaustion o f intellectual property rights. The 
U STR  has proposed and in some cases succeeded in including language that elimi­
nates this clause by banning imports o f legally sold patented drugs in international 
markets. The agreements that include such restrictions are the FTAs negotiated by 
the United States with Singapore, Australia, and Morocco. The United States also 
proposed similar language in other agreements, such as in the FTA with Chile, but 
was rejected on the grounds that the TPA mandate supports countries’ right to avail 
themselves o f the flexibilities o f the TRIPS Agreement. It is important that countries 
make sure that such flexibilities are fully respected in free-trade agreements.
6.6.2.4 Revocation of Patents
M ost FTAs state that a patent may be revoked only on the grounds that would have 
justified a refusal to grant the patent and also in the case o f fraud, misrepresentation, 
or inequitable conduct. Nevertheless, none o f the recent FTAs include the possibility  
o f revoking a patent if  the granting o f a compulsory license has not remedied the lack 
of exploitation o f the patent. This provision was included in NAFTA and would be 
an important option for other developing nations.
6.6.2.5 Measures to Prevent Abuse of Rights by Intellectual 
Property Holders
Article 8.2 o f the TRIPS Agreement specifically states that “ appropriate measures, 
provided that they are consistent with the provisions o f this Agreement, may be
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needed to prevent the abuse o f intellectual property rights by right holders or 
the resort to practices which unreasonably restrain trade or adversely affect the 
international transfer o f technology.”
This article is very important, since monopolies may be abused by right holders. 
Nevertheless, most recent FTAs do not include language o f this type. There are a 
few exceptions, such as the U S-C hile FTA, which included it at the request o f the 
latter, as well as DR-CAFTA, the US-Peru FTA and the U S-Colom bia FTA, which 
followed the Chilean example, and Vietnam. All the other agreements are silent 
with regard to patent abuse. In the case o f Australia, an amendment was added to 
the United States Free Trade Agreement Implementation Bill 2004 with provisions 
penalizing patent holders that abuse their rights. Among other things, the amend­
ment requires patent holders to issue a certificate when they seek to use the courts 
to block cheaper generic drugs from entering the market which must attest that the 
legal action has been commenced in good faith, has reasonable prospects for suc­
cess, and will be conducted without unreasonable delay. If the certificate is false 
or misleading, or if any undertakings given under the certificate are subsequently 
broken, the patent holders could be liable to a civil penalty o f up to $10 million for 
each contravention. This provision has been strongly rejected by PhRMA, which is 
seeking its elimination.
6.6.2.Ó Opposition Proceedings to the Granting of a Patent
There is growing concern regarding the quality o f  the patents granted. In fact, the 
Federal Trade Commission (FTC) in the United States devoted a section o f its 2003 
report entitled “To Promote Innovation: The Proper Balance o f  Competition and 
Patent Law and Policy” 32 to the problem of questionable patents. Specifically, the 
report states that “ [a] poor quality or questionable patent is one that is likely invalid 
or contains claims that are likely overly broad. Hearings participants raised concerns 
about the number o f questionable patents issued. Such patents can block competition 
[ . . . ]  and harm innovation in several ways.” 33
Therefore, it is very important to devise a mechanism to ensure that only legit­
imate patents are granted. Different countries have chosen different ways to do so. 
Some, like India, have pre- and post-granting opposition proceedings. Other coun­
tries have one o f the two. In the case o f recent bilateral agreements, the United 
States has proposed language that would only allow post-granting opposition pro­
ceedings. Not having the opportunity to challenge a patent during the application 
process poses a problem, since it would only leave the option o f resorting to costly 
litigation after a patent had been granted, in addition to the harm to consumers.
6.6.2.7 Side Letters
Given governments’ and civil society’s increasing concern over the impact o f these 
agreements on access to affordable medicines, recent FTAs including those with 
Singapore, the DR-CAFTA countries, Morocco, Australia, Bahrain, Oman, Peru, 
and Colombia (the letters in the Peru and Colom bia FTAs were incorporated into
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the main text after the renegotiation o f 2007) include side letters that seek to allay 
concerns by stating in broad terms that the obligations o f  the intellectual property 
chapters do not affect the ability o f  the Parties to take necessary measures to protect 
public health. However, in many cases the side letters are restrictive, since the lan­
guage seems to limit governments to act in the case o f certain specific diseases and 
epidemics, as well as in circumstances o f  extreme urgency or national emergency 
(CAFTA, 2004).
It is important to note that these letters fail to accomplish their intended objective, 
since their legal standing is unclear, for they are not part o f the text o f the agreement.
U STR  has failed to clarify the exact interpretation o f side letters. Therefore, 
countries that accept higher intellectual property standards because they believe that 
the letters provide a safeguard are taking a very high risk.
6.7 Concerns of US Members of Congress Regarding IPR 
Agreements
Although the U STR  has pressured other countries to adopt higher levels o f intellec­
tual property protection, other areas o f the U S government are very concerned with 
this trend. There have been a number o f letters from Members o f Congress to the 
U STR  which are very critical o f some of the TRIPS Plus provisions sought by the 
United States.
The US generic industry, which supports a balance between innovation and 
access, is also concerned about the language that is being included in these agree­
ments, since they are setting new intellectual property standards that go even beyond 
U S law and may undermine the balance achieved in the Hatch-Waxman Act.
6.8 The Role of Political Authorities 
in the Bilateral Agreements
Negotiations in the area o f intellectual property rights are very costly with regard 
to access to medicines, where the impact will be increasingly felt as time goes by. 
It is imperative that before engaging in this type o f negotiations governments be 
aware o f the potential cost to public health. I f  the decision is made to move forward, 
there are two key elements to ensure a fair and beneficial negotiation: a negotiating 
team with the necessary expertise in the area o f IP and leaders willing to leave the 
negotiating table if  it becomes clear that it is not possible to reach a compromise that 
would not undermine public health and access to medicines. One element without 
the other would make it harder to strike a balance between promoting innovation 
and ensuring access to affordable medicines.
6.9 Conclusions
The TRIPS Agreement marked the adoption o f new standards o f intellectual prop­
erty protection, when members o f the WTO attempted to reach a balance between
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the rights o f patent holders and those o f consumers. The proliferation o f bilateral 
agreements signed by the United States has gradually established precedents that are 
changing the IP laws in different countries, which may eventually result in new IP 
standards following regional or global patent harmonization efforts. Unfortunately, 
recent FTAs have failed to reach the necessary balance by increasing the rights of 
patent holders at the expense o f  consumers. In fact, many o f  these FTAs go beyond 
U S law, thus potentially upsetting the balance between access and innovation sought 
by the Hatch-Waxman Act. This trend is cause for legitimate concern.
Multilateral negotiations are likely to provide a better framework to balance the 
interests o f all countries than bilateral negotiations between unequal trading part­
ners. A s they engage in these negotiations, countries must bear in mind that in order 
to promote innovation, is it is also necessary to have a healthy competition pol­
icy. Some developed countries have been reluctant to negotiate the elimination o f  
agricultural subsidies in bilateral agreements, arguing that such negotiations should 
be conducted at the global level. Perhaps it is time that developing countries do 
the same with intellectual property issues, so that they are no longer negotiated 
bilaterally, but rather at the multilateral level.
Finally, after this chapter was submitted for publication, on May 10, 2007, the 
Ways and M eans Committee o f the House o f Representatives o f  the United Status 
Congress announced that it had reached agreement with the Office o f the Trade 
Representative (U STR ) whereby a number o f clauses negotiated in the free-trade 
agreements with Peru and Panama were amended. Such changes would also apply 
to Colombia if this country grants certain guarantees to the U S Congress regarding 
reduction o f violence and violations o f the human rights o f union leaders in that 
country.
A s indicated in the announcement, this new two-party policy represents a fun­
damental change in United States trade policy and touches areas such as labor 
rights and environment, and other new ones such as access to generic medicines. 
Regarding the latter, the changes would be as follows:
First, an amendment is made to the clause on data exclusivity (the period during 
which a generic company cannot use the test data o f an innovating company) in 
order to allow earlier entry o f generic medicines by eliminating the consecutive 
terms o f protection (the previous text established 5 years as o f registration in the 
country, granting in addition a grace period for the said registration o f up to 5 further 
years since registration in the United States). Therefore the period would be limited 
to 5 years which would run concurrently from the granting o f the first protection.
Second, an exception is included whereby if a government grants a compulsory 
license, the exclusive rights would not block effective use o f  the said license.
Third, the requirement o f linkage (link between the patent and the marketing 
permit) is eliminated.
Fourth, the requirement o f granting extensions to patents o f a pharmaceutical 
product is eliminated, even though the establishment o f an expeditious process for 
patent approval and its marketing permit is required.
Nevertheless it should be noted that the texts and final amendments to these 
agreements continue to be negotiated and therefore it is necessary to wait before 
making definitive analyses o f the same.
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Jorge Cabrera Medaglia
7.1 Introduction
The legal and institutional transformations that have accompanied free trade agree­
ments in such important areas as competitiveness, industrial development, public 
health, education, food security, environment and Intellectual Property Rights 
(IPRs) are the subject of intense discussions in various national and international 
forums.1 In relation to IPRs and the environment, and due to the emergence of an 
international body of laws within the framework of the Convention on Biological 
Diversity (C BD ) and of the FAO International Treaty on Plant Genetic Resources 
for Food and Agriculture, emphasis has been placed on the existence of a conflict 
between certain tendencies oriented toward the strengthening of IPRs and the objec­
tives of conserving, using biodiversity sustainably and equitably distributing the 
benefits derived from the use of genetic resources. Although we consider that certain 
forms of intellectual property can have negative effects, this chapter assumes that 
there is sufficient room for maneuver to create synergies between trade obligations 
in the matter and environmental treaties.
The debate on IPRs is based on certain considerations regarding their role in 
the dissemination of innovation and knowledge as factors of development. The dis­
cussion centers on the consequences that the strengthening of IPRs could have on 
technological development, access to basic instruments for education (databases, 
software, among others), health (i.e., medicines), and biodiversity. It is no sur­
prise that the environmental topic should now be added to linkage of the subject 
to development (since the mid-1960s) and trade agendas.2
Most researchers on the topic (in reference to the Agreement on Trade-Related 
Aspects o f Intellectual Property Rights; TRIPS, specifically Article 27.3.b) analyze
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and anticipate the effects of IPRs on biodiversity and indigenous and farmer com­
munities. The arguments range from the risk of fostering biopiracy of resources and 
traditional knowledge, to the prohibition on farmers to keep and exchange seeds 
of protected varieties, including the possible consequences of genetically modified 
organisms on the environment (Downes, 1999).
7.2 Biodiversity and Intellectual Property Rights:
Synergies and Opportunities. International Forums
In regard to international instruments, it is essential to consider at least the fol­
lowing. 1) the Convention on Biological Diversity (CBD ), the resolutions on 
intellectual property and biodiversity of the Conference of the Parties and the 
possible implications of the negotiation under way of an international regime on 
access to genetic resources and sharing of benefits; 2) the International Treaty 
of the Food and Agriculture Organization (FAO) on Plant Genetic Resources for 
Food and Agriculture, particularly its provisions on access to genetic resources 
(Articles 10-14), farmers’ rights (Article 9) and the impossibility of recogniz­
ing IPR for materials in the “received form” of the multilateral system of access 
(Article 12.1.d); and 3) the debate in the World Trade Organization (W T O ) and 
the TRIPS Agreement in the light of the Doha Declaration (subparagraph 19) 
and the technical aspects studied by the Intergovernmental Committee on Genetic 
Resources, Traditional Knowledge and Folklore of the World Intellectual Property 
Organization (W IPO).
7.2.1 The Convention on Biological Diversity
The progress in living organisms exploration techniques and the economic poten­
tial of biotechnology have given rise to a new consideration of the “hidden” value 
of genetic and biochemical resources. Thus, the biological wealth of tropical coun­
tries and the associated traditional knowledge have emerged as a new economic, 
scientific, and technological frontier.
According to the CBD, whose provisions will be analyzed in detail further ahead, 
there is the obligation for access to these resources and knowledge to comply with 
the following requirements:
a) Prior obtaining of the informed consent of the State and other holders of 
knowledge or the biological, genetic, and biochemical resource (PIC).
b) Agreement on the distribution of benefits derived from access to biodiversity and 
associated traditional knowledge, including the terms of access.
c) Conservation of biodiversity and creation of national capacities to give value 
added to each country’s natural resources.
In accordance with the Charter of the United Nations and the principles of inter­
national law, the CBD  reaffirms the sovereignty of States over their natural resources
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(Article 3), which entails the power to exploit and regulate their access to such 
resources and, subject the provisions of the CBD  and to national legislation, the 
fair and equitable benefit sharing among the diverse actors (Arts. 15, 16, and 19). 
The objectives of the CBD are conservation of biological diversity, sustainable use 
of its elements, the fair and equitable share of the benefits derived from genetic 
resources, among other means by the appropriate transfer of the pertinent tech­
nologies and appropriate financing. These provisions should be complemented with 
those o f Article 15 of the same convention (Access to Genetic Resources).
Article 15 recognizes the authority of governments, in keeping with their national 
legislation, to control and facilitate access to their genetic resources (subparagraph 
1), provided that their use is environmentally sound and no restrictions contrary to 
the objectives of the Convention are imposed (subparagraph 2).
Access is subject to prior informed consent of the Contracting Party, unless the 
latter provides otherwise, and it will be carried out in mutually agreed conditions 
(subparagraphs 4 and 5).
Finally, each country may take legislative, administrative, or political measures 
in accordance with Articles 16 and 19 to share fairly and equitably the results of 
research and development activities and the benefits derived from commercial and 
other use with the Party contributing such resources. This sharing will be carried out 
in mutually agreed conditions.
Access to genetic resources is complemented with Articles 16 and 19 of the CBD. 
When negotiating it, the developing countries invoked the wealth of their genetic 
resources to include rules that would allow them to acquire technology. However, 
most of that technology is now in the hands of large private corporations, whereas 
the provisions of new trade agreements tend not to compensate for contributions 
of the raw material (genetic resources) and local communities for the improvement 
of crops, animals, pest control, and natural medicine, all of which is the subject of 
concern. The stance of the developing countries was initially rejected by various 
developed countries, which sought a “more classic” convention referring to topics 
on conservation and use of biodiversity. In the process the guidelines on IPR that 
had gained importance in the Uruguay Round of GATT and the North American 
Free Trade Agreement (NAFTA) emerged.
Article 19 (biotechnology management and sharing of its benefits) is in line with 
Article 15, but restricts its scope to biotechnological research (subparagraph 1), reit­
erating the power of the Parties to adopt practicable measures to promote fair and 
equitable conditions for access to the results and benefits of biotechnologies based 
on genetic resources.
The most controversial article is 16 (Access and transfer of technology). At its 
origin is the common concern of the developing countries since the 1970s of putting 
forward the potential of their biological resources to benefit from transfer of tech­
nology, a position that would subsequently take on major importance due to the 
development of biotechnology, which is now at the center of the dispute because its 
property is essentially in private hands.
The developing countries’ access to technology will be assured or facilitated in 
fair conditions and in the most favorable terms, including the preferential conditions
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that are established by common agreement and, whenever necessary, through the 
financial mechanism of Articles 20 and 21.
Discussion of this issue was conflictive, with a clear “North-South” nuance 
and references to the obligations derived from IPRs. According to Article 16 it 
was determined that in the case of technology protected by patents and other 
IPRs, its access and transfer will take such rights into account. Article 16 permits 
each Contracting Party to take the legislative, administrative, or policy measures 
to assure, particularly to the developing countries that contribute those genetic 
resources, access to the technology that uses such material and the transfer of that 
technology, in mutually agreed conditions, including the technology protected by 
patents and other intellectual property rights. Paragraph 5 of this article recognizes 
that patents and other IPRs can influence application of the Convention and that 
the Parties will cooperate in this regard in accordance with their own laws and 
international law to ensure that those rights support the objectives o f the same.
Article 8 provides that the contracting Parties, insofar as possible, will respect, 
preserve, and maintain the knowledge, innovations, and practices of local and 
indigenous communities that involve traditional lifestyles that are pertinent for 
the conservation and sustainable use of biological diversity and will promote their 
broader application with the approval and participation of those who possess such 
knowledge, ensuring that the benefits are equitably shared.
Other important articles are 10, subparagraph c (protect and encourage the cus­
tomary use of biological resources in accordance with traditional cultural practices 
compatible with conservation or sustainable use), 17, subparagraph 2 (exchange of 
information on traditional and autochthonous knowledge), and 18, subparagraph 4 
(fostering and developing cooperation methods for the development of technologies, 
including traditional and autochthonous ones).
7.2.1.1 Resolutions of the Conferences of the Parties of the Convention 
on Biological Diversity
Decision III-5 of the Third Conference of the Parties of the CBD  (access to genetic 
resources) requested the Executive Secretary to cooperate with W TO  to explore 
links between Article 15 of the Convention and the TRIPS Agreement. Decision 
III-17 resolved that more research was required to determine such links on the 
points relative to technology transfer, conservation and sustainable use of biodiver­
sity, fair and equitable sharing of benefits, and protection of traditional knowledge. 
The Fourth Conference (Bratislava, 1999) emphasized the need to ensure con­
sistency between the provisions of CBD  and TRIPS to reconcile concerns over 
biodiversity and protection of IPRs (IV -15). Decision V-26 of the Fifth Conference 
(Kenya, 2000) requests W IPO  and the International Union for the Protection of New  
Varieties of Plants (U PO V ) to consider the provisions of CBD, including the reper­
cussions of IPRs on the conservation and sustainable use of biological diversity and 
in particular the value o f traditional knowledge. Later on it invited W TO  to take into 
account that TRIPS and CBD  are related and called upon it to explore that relation­
ship more in-depth. Resolution VI/24/C 1, “The role of intellectual property rights
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in the implementation of distribution of benefits agreements,” invites the govern­
ments and the Parties to promote the disclosure of the origin of genetic resources in 
IPR applications when the protected subject matter consists of genetic resources or 
makes use of them. Numeral 2 makes the same invitation in relation to associated 
traditional knowledge. At the Seventh Conference of the Parties, Decision VII/19 
requested the Working Group on ABS to identify the aspects relative to the disclo­
sure of the origin of genetic resources and associated traditional knowledge in IPR 
applications, including those relative to the certificate of origin/source/legal prove­
nance. It also requested W IPO  and UNCTAD to prepare studies on disclosure of 
origin in IPR applications, based on a list of topics to be addressed.
7.2.1.2 Negotiation of an International Regime and Its Implications for IPRs
In the CBD  negotiations, the developing countries strove to include the sharing of 
benefits derived from the use of genetic resources as an objective of the Convention. 
Although the convention included these nations’ positions, little has been done to 
put them into practice. The Working Group on ABS concluded its work in October 
2000 in Bonn with the document “Bonn Guides on Access to Genetic Resources 
and Distribution of Benefits,” approved by the Sixth Conference of the Parties, held 
in The Hague in 2002.3 Such guidelines were welcomed by the developed countries 
and companies with interests in these resources, but some developing countries con­
sidered them insufficient on account of being of voluntary compliance and paying 
little attention to the measures to be taken by the developed countries to fulfill their 
obligations, especially administrative, policy, and legislative measures for sharing 
benefits.
In a parallel manner the Group of Like-Minded Megadiverse Countries 
(G A P M A ) was formed through the Cancún Declaration in January 2002 (see 
www.megadiverse.com).4
At the Johannesburg Summit on Sustainable Development, G A PM A  scored 
a victory point by furthering the establishment of an international regime that 
effectively promotes and safeguards fair and equitable distribution of benefits, a 
resolution embodied in paragraph 42, subparagraph O, of the Johannesburg Action 
Plan. In its resolution 57-260 of December 20, 2002, the United Nations General 
Assembly invited the Conference of the Parties to take the necessary measures in 
relation to the commitment of the Summit to negotiate the said regime.
Decision VII/19 of the Seventh Conference of the Parties resolves that one 
of the elements of the International Regime shall be an international certificate 
of origin/source/legal acquisition of genetic resources and associated traditional 
knowledge. Point E (Measures of user countries) establishes the need to address 
the disclosure of origin as a mechanism to support compliance with access leg­
islation, prior informed consent and mutually agreed terms. Point 6 requires the 
Working Group for Access to Genetic Resources to analyze the feasibility, cost, and 
practicality of the certificate of origin.
Decision VII/19 agrees to call once again the Working Group on Access to 
Genetic Resources and Distribution of Benefits so that “.. .in collaboration with the
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Working Group of Article 8, subparagraph J, on traditional knowledge, and ensur­
ing the participation of indigenous peoples and communities, non-governmental 
organizations, industry and academic and intergovernmental institutions, it elabo­
rate and negotiate an international regime of access to genetic resources and sharing 
of benefits in order to adopt an instrument or instruments to effectively implement 
the provisions of Article 15 and 8, subparagraph J, and the three objectives of the 
Convention.”
7.2.1.3 Current Status of the Negotiations of the International Regime
The Eighth Conference of the Parties to CBD met in Curitiba, Brazil, to analyze the 
topic of the international regime. Although most of the deliberations solved aspects 
of procedure, a few important topics were agreed on.
Decision VIII/4 resolved to transmit the Annex (the results o f the Granada meet­
ing) to the Working Group on Access to Genetic Resources and Benefit Sharing 
(A BS ) at its fifth meeting so that, in accordance with Decision VII/19, it continues 
the preparation of an international regime, including the following topics:
i) The results of the Technical Expert Group on the certificate of ori­
gin/source/legal provenance.
ii) The progress report on analysis of gaps and the matrix.
iii) Other contributions submitted by the Parties related to the subject matter of the 
Working Group.
The elements of the Annex, under the title “Fair and equitable distribution of 
benefits,” include the disclosure of origin or source in IPR applications that make 
use or consist of genetic resources and traditional knowledge, including evidence of 
abidance by the law of the supplying country as regards prior informed consent and 
benefit sharing.
The paragraph on measures to support compliance with prior agreed consent and 
Mutually Agreed Terms of the Parties reaffirms that the disclosure of origin in IPR 
applications is an element of the terms of reference of the Annex to Decision VII/19 
D for the preparation of the international regime. It is recognized that the topic has 
been discussed in W IPO  and W TO  and the relevant forums are invited to address (or 
continue) the topic of disclosure of origin in IPR applications, considering the need 
to ensure that the work supports the objectives of CBD. The Executive Secretary is 
required to renew his accreditation as an observer before the Council of TRIPS.
In conclusion the following provisions of CBD are relevant to IPRs:
i) Respect for national sovereignty over biodiversity (genetic resources).
ii) Prevention of so-called biopiracy and support for the countries’ efforts to estab­
lish a system of access to genetic resources that includes the obligation to obtain 
prior informed consent and fair and equitable benefit sharing.
iii) Protection of traditional knowledge.
iv) Conservation and sustainable use of biodiversity in general.
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7.2.2 The Treaty on Plant Genetic Resources for Food 
and Agriculture5
The International Undertaking on Plant Genetic Resources was adopted by FAO in 
1983. Its objective is to “ensure that plant genetic resources of economic or social 
interest, particularly for agriculture, are explored, preserved, assessed and made 
available for improvement and scientific purposes.” It declares that plant genetic 
resources have free access and are part of the Mankind Heritage, but include in 
one same category elite lines and improved varieties, the latter protected by IPRs. 
Due to the potential conflict of this category, eight nations, most of them developed, 
expressed their reserve. Certain developing countries, for their part, questioned the 
principle of free access and the absence of benefit sharing. This gave rise to the 
negotiation and approval of clarifications regarding the scope of the Undertaking on 
the part o f FAO. Resolution 4-89 (“the Agreed Interpretation”) established that the 
rights of new plant varieties established by UPOV were not incompatible with the 
Undertaking and provided that the States should impose minimum restrictions on 
the free exchange of materials. Finally, the Free Interpretation clarified that the term 
“free access” did not mean free of cost and that the benefits under the Undertaking 
were part of a reciprocal system. That same year and as a counterpart to recog­
nition of the rights of new plant varieties, Resolution 5-89 (Farmers’ Rights) was 
adopted. It was stated that throughout history innumerable generations of farmers 
had conserved, improved, and made available plant genetic resources without their 
contribution having been recognized. Thus the concept of farmers’ rights came into 
being, those “who arise from the past, present, and future contribution of farm­
ers in the conservation, improvement and availability of plant genetic resources.” 
Such rights are attributed to the international community as trustee for the benefit of 
present and future generations of farmers.
In 1991, Resolution 3-91 of the FAO Conference recognized that the concept of 
Mankind Heritage was subject to the sovereignty of States over their plant genetic 
resources and stipulated that their conditions of access required subsequent clarifica­
tion, that farmers’ improved stock and material for improvement would be available 
at the discretion of their creators during the development time, and that farmers’ 
rights would be implemented by means of an international fund which had not been 
constituted.
It is worth mentioning Resolution 7-93, which was issued in response to the sign­
ing of CBD, in particular to Resolution No 3 of the Nairobi Act, which established 
the need to resolve, within the framework of FAO, access to collections ex situ not 
covered by CBD  and the issue of farmers’ rights. Resolution 7-93 requested the 
Director General of FAO to organize a Negotiations Forum among the governments 
to make the Undertaking with CBD  compatible,6 consider access to plant genetic 
resources on mutually agreed terms, including ex situ collections, and the manner in 
which to put farmers’ rights into practice. Since then, the Commission on Genetic 
Resources of FAO had been reviewing the Undertaking until the International Treaty 
on Plant Genetic Resources for Food and Agriculture was concluded.7 The central 
topics of this treaty are access to genetic resources, farmers’ rights, the possibility of
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authorizing IPRs on the materials of the Multilateral System, relations between the 
treaty and other international agreements, especially TRIPS, and the list of species 
to be considered.
The disputes on farmers’ rights centered on their own definition, whether as an 
abstract concept (proposed by some developed countries) or as a specific right to be 
carried out. It was agreed that the responsibility of making them a reality was the 
responsibility of national governments. Each Party, according to its own legislation, 
should adopt the following measures: protect traditional knowledge related to plant 
genetic resources and guarantee the right to participate equitably in benefit sharing 
and decision making. None of the above would limit other rights of farmers to con­
serve, use, exchange, and sell crop resources conserved in their farms (Article 9) in 
accordance to national laws and as appropriate.8
With regard to access to genetic resources and benefit sharing, a Multilateral 
System was created for the species included (some 35 crops and 29 forage species 
listed in Annex 1) to be “efficacious, effective and transparent to facilitate access 
to plant genetic resources for food and agriculture and share in a fair and equi­
table manner the benefits derived from the use of such resources” (Article 10). The 
Multilateral System should include all the resources in Annex I which are under 
the Administration and Control of the Contracting Parties and are in the public 
domain (Article 11 ). Access will be carried out under the conditions indicated in 
Article 12 and the sharing of benefits includes exchange of information, access to 
technology and its transfer, promotion of the capacity and distribution of monetary 
benefits derived from commercialization (Article 13). When the product incorpo­
rates material whose access is protected by the Multilateral System, the beneficiary 
should pay an “equitable” part to the International Fund, except when the product is 
at the unrestricted disposal of other persons for research and subsequent improve­
ment, in which case the receiver should be encouraged to make such a payment. In 
other words, if the product is protected by a patent, payment will be compulsory; 
if it is protected by plant breeders’ rights or lacking any kind of rights, payment 
will be voluntary.9 The amount, form, and type of payment should be defined 
by the Governing Body of the Treaty in accordance with commercial practice 
(Article 13).
The receivers shall not claim any IPR or of any other type that limit facilitated 
access to plant genetic resources for food and agriculture or their parts or genetic 
components in accordance with the Multilateral System (Article 12).
To date, the Commission on Genetic Resources, acting as an Interim Body of 
the FAO Treaty, has the draft of the Material Transfer Agreement with the standard 
provisions governing the transfer of genetic resources by means of the Multilateral 
Access System.
In conclusion, the main provisions of the Treaty on biodiversity are the following:
a) Restrictions on the authorization of IPRs on the material received as such by 
the Multilateral System. Nevertheless, restrictions should be incorporated into 
the Material Transfer Agreement, and therefore its drafting escapes the norms of 
intellectual property.
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b) Recognition of the right of farmers to reuse, exchange, or sell protected seeds and 
to protect traditional varieties by means of a system of exclusive rights similar 
to those of IPRs.
c) Compatibility of the Treaty with the protection of plant varieties in keeping with 
UPOV.
d) Support for conservation, sustainable use, and fair and equitable sharing of the 
benefits derived from access in accordance with the objectives of the FAO Treaty 
(Article 1).
7.2.3 Intergovernmental Committee on Intellectual Property 
and Genetic Resources, Traditional Knowledge, 
and Folklore10
The Intergovernmental Committee on Intellectual Property and Genetic Resources, 
Traditional Knowledge, and Folklore of W IPO was established in October 2000 as a 
forum for dialogue on the relationship between intellectual property and traditional 
knowledge, genetic resources, and traditional cultural expressions.11 At the session 
of the General Assembly of W IPO in 2005 it was decided to extend the mandate 
of the Committee 2 years, including the possible drafting of legally binding instru­
ments. One of the topics the Committee continues to consider is disclosure o f origin 
in patent applications and protection of traditional knowledge. The Committee has 
met on nine occasions.12
To date, W IPO ’s main work in genetic resources and traditional knowledge is the 
following:
7.2.3.1 Genetic Resources
i) Diverse analyses and creation of a database on IPR clauses in the agreements 
on access to genetic resources and benefit-sharing, including agreements on 
transfer of materials and model clauses, which are at the draft stage.
ii) With regard to access to genetic resources, W IPO  has prepared a number of 
studies on the clauses relative to IPRs in the agreements on access to genetic 
resources and benefit sharing, including agreements on transfer of materials 
and model clauses. A  database on public examples has also been created, 
with emphasis on IPR clauses. Likewise, draft guidelines on IPR clauses in 
agreements on access and benefit sharing have been prepared.
iii) Similarly, in accordance with Decision VI/24 of COP, W IPO  was invited to 
prepare a study on disclosure of origin in patent applications which should 
include, among other aspects, (a) the genetic resources used in inventions; b) 
the country of origin of the genetic resources used in inventions; c) the asso­
ciated traditional knowledge, innovations, and practices used in inventions;
d) the source of associated traditional knowledge; and e) evidence of prior 
informed consent. This Technical Study of the requirements of disclosure of
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origin in patent applications was submitted to the Seventh COP in Malaysia 
and received by the COP with appreciation (Decision VII/19/E). Furthermore, 
the Seventh COP requested W IPO  to prepare a new technical study that would 
include examining and addressing, as appropriate, aspects relative to the rela­
tionship between access to genetic resources and disclosure of origin in patent 
applications, including the following aspects, among others:
1) Options of models for disclosure requirements.
2) Suggestions for application procedures for IPRs in relation to disclosure.
3) Incentive options for applicants.
4) Identification of the implications of requirements for disclosure in treaties 
administered by WIPO.
5) Aspects of intellectual property originated by the draft certificate of ori­
gin/source/legal provenance.
W IPO  prepared the technical document “Study of the issues relative to the inter­
relation between access to genetic resources and requirements of disclosure of origin 
in applications for intellectual property rights” (WO/GA/32/8) at the request of 
the COP.
iv) Together with UNCTAD  and the Secretariat of CBD, W IPO  prepared a study 
on the role of IPRs in connection with technology transfer (February, 2006).
v) Despite the abundant information generated by W IPO and the exchange of 
opinions and positions in the sessions of the Committee, these debates have 
not translated into initiatives for national or international legal amendments 
on disclosure of origin in IPR applications.13 Some countries have questioned 
whether W IPO  and not W TO  should be the entity in charge of processing this 
topic, doubting that its steps would lead to specific normative advances.
vi) In the reviews of the Substantive Treaty on Law of Patents, disclosure of origin 
has been discussed. Pursuant to the mandate of the 2005 General Assembly 
a process of two sessions of the Standing Committee on Law of Patents was 
established, one formal and another informal, to analyze the proposals.14 The 
topic is also under discussion in the Patent Cooperation Treaty.
7.2.3.2 Traditional Knowledge
In relation to protection of traditional knowledge, W IPO  has prepared a number 
of documents on positive and defensive measures of protection and other activities 
such as the following:15
i) Systematic study and clarification of the legal options for the protection of 
traditional knowledge.
ii) Analysis of cases of the use of IPR to protect traditional knowledge, as well as 
the establishment of sui generis protection systems.
iii) Case studies and analysis of practical experiences.
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iv) Draft of the Tool Kit to document traditional knowledge associated with genetic 
resources.
v) Gradual recognition of traditional knowledge in patent systems by means of 
patent examiners, mechanisms to ensure better understanding of traditional 
knowledge as a previous art by means of links with databases and incorpora­
tion of traditional knowledge in the minimum novelty search standards by the 
authorities of the Patent Cooperation Treaty.
vi) Draft policy objectives and fundamental principles in connection with tra­
ditional knowledge. These provisions are considered compatible with CBD, 
although their scope is broader than that of traditional knowledge related to 
biodiversity. Such provisions are particularly important for establishing national 
rules.16
7.2.4 Principal Positions in WTO
7.2.4.1 Important Rules of TRIPS and Discussions of WTO
The TRIPS Agreement negotiated during the Uruguay Round of GATT establishes 
in Article 27 the obligation of the Member States to confer protection by means of 
patents in all fields of technology without any discrimination whatsoever.17
Patent rights can be obtained and enjoyed without discrimination as to the place 
of invention, the field of technology, or whether the products are imported or 
manufactured in the country.
Members can exclude from patentability any inventions whose commercial 
exploitation in their territory should be prevented to protect ordre public or morality, 
the health or life of persons or animals, preserve plants, and avoid serious damage 
to the environment, provided that such exclusion is not done merely because the 
exploitation is prohibited by their legislation.
Without an appropriate set of exceptions and limitations, this general provision 
would entail, for instance, the need for the member countries to grant protection to 
modern biotechnological inventions. Nevertheless, due to the discrepancy regarding 
the scope of protection of inventions related to plants and animals, Article 27.3.b of 
the Agreement provides the following:
“Members may also exclude from patentability:
a) ...
b) plants and animals other than microorganisms, and essentially biological pro­
cesses for the production of plants or animals other than non-biological and 
microbiological processes. However, Members shall provide for the protection 
of plant varieties either by patents or by an effective sui generis system or by any 
combination thereof. The provisions of this subparagraph shall be reviewed four 
years after the date of entry into force of the W TO  Agreement.”
According to the TRIPS Agreement, there are three options for protecting plant 
varieties: system of patents, sui generis system, or a combination thereof. This last
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option was probably drafted considering the United States 1930 Plant Patents Act. 
The best-known sui generis system is that of UPOV, which imposes less onerous 
requirements for receiving the certificate of plant breeder,18 but also greater limita­
tions and exceptions and the rights conferred have less scope than patents. UPOV  
has 1978 and 1991 versions. The countries that have not ratified the Convention 
can only accede to the 1991 version. However, TRIPS does not require member 
countries to enact laws based on UPOV, although Article 27.3.b was negotiated 
with knowledge of its provisions on the sui generis system, which is not mentioned 
either by the international treaties referred to by the TRIPS Agreement.19
So countries may establish their own sui generis systems on condition that they 
are “effective.” But their conditions and implications for being in keeping with 
W T O ’s multilateral system has no univocal answer. Other than recognition that a sui 
generis system should be based on its “own nature,” there are no other guidelines.
Article 3020 provides for limited exceptions to the exclusive rights conferred by 
the patent on condition that they do not unjustifiably endanger normal exploitation 
of the patent or cause unjustified harm to the legitimate interests of its holder. The 
most generalized exception is acts carried out for purposes of research or teaching, 
which is common in most legislations.
The TRIPS Agreement regulates in detail Enforcement of Intellectual Property 
Rights, including norms of proceedings and civil and administrative recourses in the 
face of infringement of rights, evidence, judicial orders, losses, seizures, provisional 
measures, border measures, penal sanctions, and others.
Should some country fail to comply with the provisions of the Agreement, there 
is the recourse of the dispute-settlement process pursuant to the W TO  provisions. 
This proceeding, to which recourse has been taken frequently, makes it possible 
to impose trade sanctions on countries that do not respect IPRs and to use access 
to markets to compel the adoption of legal changes in accordance with the TRIPS 
Agreement.
In view of the implications of some changes, transitory terms were established 
for application of the Agreement: developed countries, 1 year as of the entry into 
force of the Agreement, that is, January 1996; developing countries, 5 years as of 
the same date; and less advanced countries, 11 years with the right to extension to 
amend their legislation. To provide protection by means of patents to technological 
sectors that did not have them, 10 years.
7.2.4.2 The Concept of the Sui Generis System
As has been stated, the only clarifications to the sui generis system are the special 
characteristic of the system and that it should be effective. Few analyses have been 
carried out regarding the requirements of this mechanism.21
Leskien and Flitner (1997) interpret that such conditions mean:
i) Protection of all plant varieties
ii) Exclusion of third parties from use of the protected material, unless remunera­
tion is involved.
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iii) Respect for the principles of National Treatment and Most Favored Nation.
iv) The existence of procedures for the enforcement of rights.
The sui generis system can depart from the requirements of UPOV in any of its 
versions and add provisions on protection of farmers’ rights, that is, on landraces, 
whose requirements vary according to whether it is a question of benefit sharing for 
use of genetic material or of authorizing instruments such as the certificate of origin; 
and it should modify the requirements and rights granted to the holders of varieties 
and therefore the actions that require authorization.
Leskien and Flitner propose a different sui generis scheme from that of UPOV  
with more precise definitions on material that can be protected, protection require­
ments, inclusion of elements such as certificate of origin and value of crop and 
use, sphere of protection (acts that require authorization or remuneration to the 
holder), duration of rights, “interface” with other IPRs and registers, funds, and 
benefit-sharing mechanisms.
Although the provisions of sui generis systems should have been reviewed in the 
Council of TRIPS 1 1999, the Members limited themselves to compiling information 
on its compliance by the countries.22 The developing countries had until January 1, 
2000 to enact the respective laws, unless the alternative chosen was patentability of 
plant varieties, in which case the term was extended until 2005.
7,2.4.3 The Doha Round: Link Between TRIPS and CBD
The Doha Declaration that inaugurated the W TO  Round of Trade Negotiations 
under way recommended to the Council of TRIPS to examine the relationship 
between this agreement and CBD, protection of traditional knowledge and folklore, 
and the new matters submitted by the Members based on the objectives and princi­
ples set forth in Articles 7 and 8 of the TRIPS Agreement, taking the dimension of 
development fully into consideration.
One measure suggested to achieve a synergic relationship between CBD  and 
intellectual property systems (particularly TRIPS) was disclosure of origin of 
genetic resources or associated traditional knowledge in IPR applications, especially 
patents. This request has been put forward for various years in CBD, WTO, W IPO  
and in numerous forums and reports.23
Disclosure of origin in IPR applications based on the Doha Declaration has been 
discussed in W TO. The main positions of the countries or groups of countries can 
be summarized as follows:24
The African Group proposed to eliminate patents on life forms in the framework 
of the TRIPS Agreement and include disclosure of origin in IPR applications.
The United States, to a certain extent with the support of Japan, was opposed 
to including disclosure of origin in patents since it considered that this would not 
solve the problems stemming from undue appropriation of genetic resources and 
traditional knowledge and would give rise to uncertainty and practical problems in 
IPR systems. Both countries proposed improving the quality of the patent granting 
process, creating databases and other mechanisms to eliminate problems associated
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with “bad patents,” using existing systems of nullity and revocation, etc. They did 
not consider that there was conflict between TRIPS and CBD  and, to avoid undue 
appropriation, proposed strengthening access laws and the use of contracts.
Switzerland proposed modifying the Patents Cooperation Treaty since it consid­
ered the requirements for disclosure of origin formal and not substantive, together 
with its regulations for permitting (not obliging) countries to include disclosure of 
origin of genetic resources in IPR applications based directly on such resources.
The so-called “Friends of disclosure” (Brazil, China, Cuba, Dominican 
Republic, Ecuador, India, Kenya, Pakistan, Peru, Thailand, Venezuela, Zambia, and 
Zimbabwe), with occasional support of other countries, maintained that TRIPS 
and CBD  should mutually support one another.25 They suggested amending the 
TRIPS Agreement and argued that patenting of biological resources could encour­
age biopiracy and undue appropriation to the detriment of national sovereignty 
recognized by CBD. They pointed out that TRIPS did not contain elements that 
assure prior informed knowledge of the holders of biological material used in 
patented inventions nor did it permit the countries of origin to claim benefit sharing 
(Box 7.1). They therefore requested inclusion of the obligations to (i) disclose the 
source and the country of origin of biological resources and the traditional knowl­
edge used in patent applications; (ii) evidence prior informed consent in accordance 
with national laws, and (iii) prove the fair and equitable sharing of benefits obtained 
according to national regimes.
Box 7.1 Disclosure of Origin in Intellectual Property Rights
Although the idea of disclosure of origin/evidence of prior informed con­
sent/evidence o f benefit sharing has mainly been discussed within the frame­
work of the patents system, it is also applicable to plant varieties and their 
respective approval processes.
The objectives o f the proposal are:
1. Transparency: Permit national authorities that authorize access to genetic 
resources to track their use in patent applications and titles.
2. Compliance with conditions of access: Permit compliance to be tracked 
with prior informed consent and the conditions under which access was 
granted.
3. Determination of previous art: Permit a better analysis of novelty and 
inventive step by Patent Offices.
4. Relationship between the TRIPS Agreement and CBD: Prevent conflicts 
between TRIPS and CBD  and support the implementation of both.
5. Biopiracy: Control biopiracy or undue appropriation of genetic resources 
or traditional knowledge through the granting of “bad patents.”
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In the case of plant varieties, the 1991 UPOV Convention establishes that 
the requirements for granting or canceling new plant variety rights should not 
be diverted from those provided for. It specifically indicates that the rights of 
plant breeders should not be subject to additional conditions (Article 5), pro­
vided that national formalities and payment of rates have been complied with. 
Rights will not be annulled for reasons other than those indicated in Articles 
21 and 22. UPOV is riot opposed to disclosure that facilitates examination, as 
long as it is not considered an additional protection requirement.
The article provides for its own subjection to Countries’ formalities. 
Therefore, stipulating disclosure of origin as a non-substantive formal require­
ment is legally possible. If not submitted, the application will not be pro­
cessed. The second aspect to be considered is false disclosure of origin. The 
countries that demand the requirement have opted for one o f the following 
solutions: cancellation of the patent (India, Brazil, the Andean Community) 
and penal, administrative, or civil sanctions outside patent law (Norway, 
Denmark, Belgium, Sweden, and other of the European Union). Third, it is 
important to consider the particularities of origin of plant varieties and the 
extent to which the legality of access to material of domestic or foreign ori­
gin would be Safeguarded, the latter being the most probable in the case of 
imported materials.
In this regard, the Report of the Commission on Intellectual Property 
Rights stated that “the countries should provide in their legislation for compul­
sory disclosure in patent applications of the geographical origin of the genetic 
resources from which the invention derives.”
Source: Girsberger (2004) and own preparation.
The European Union accepts addressing the topic in WTO, although it con­
siders W IPO  the most appropriate forum. However, its proposal on disclosure of 
origin or source of genetic resources and associated traditional knowledge in patent 
applications submitted to the W IPO Committee (November 16,2004) includes com­
pulsory requirement to disclose the country of origin or source from which physical 
access was obtained; the invention should be directly based on genetic resources; the 
requirement would apply to traditional knowledge, a concept that requires greater 
study; of the patent applicant does not submit the information despite having been 
granted the possibility, the application will not be processed; if the information is 
incorrect or incomplete, effective, proportional, and dissuasive sanctions outside 
patent law should be provided for; a notification procedure should be introduced by 
Patent Offices to C B D ’s Information Exchange Mechanism to inform the country 
of origin of the respective application. The European Union appears to be ready to 
discuss obligatory disclosure of origin in patent applications, provided that there is 
a direct relation between the invention and the genetic resource. The consequences 
of not respecting it will be regulated outside the patents system.
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Norway does not consider that there is any contradiction between TRIPS and 
CBD  and has indicated its preference for national actions, but prefers to dis­
cuss disclosure in WTO, although possibly with more limited language consistent 
with its own national regulations (which demand evidence of previously informed 
knowledge, but not o f benefit sharing).
The Hong Kong Ministerial Meeting did not include a negotiation proposal 
despite the insistence of India, Brazil, and Peru, but took note of the work of the 
TRIPS Council in accordance with paragraph 19 of the Doha Declaration and agreed 
that the work would continue on the basis of this paragraph and the progress made 
to date. Furthermore, in accordance with paragraph 39, relative to implementation 
aspects, it was decided to address the relationship between the TRIPS Agreement 
and CBD with the participation of the Deputy Director of W TO .26
Finally, toward the end of May, six countries, among them India, Brazil, and 
Peru, submitted a proposal for changes to TRIPS to support disclosure of origin by 
means of the incorporation of Article 29 bis,27 the main provisions of which are
i) Establish a relationship of reciprocal support between CBD  and TRIPS.
ii) Include biological resources and associated traditional knowledge.
iii) Disclosure of origin in applications for patents developed with biological 
resources or associated traditional knowledge.
iv) Disclosure of country or source supplying the resources or the knowledge and 
provide evidence of compliance with requirements applicable in the supplying 
country on prior informed consent and fair and equitable sharing of benefits 
derived from use of the resources or associated traditional knowledge.
v) The Parties may require the applicant to complement or correct the information 
described above if the latter had knowledge of new information.
vi) The Members should publish the information disclosed together with the 
application or granting of the patent. The same is provided for in the case 
of information supplied to complement or correct the information initially 
disclosed.
vii) The Parties should prevent the processing of the patent or its granting, revoke 
it, or declare it non-executable when the applicant has not complied with 
disclosure obligations or has supplied false or fraudulent information.
7.2.4.4 Disclosure of Origin and Free Trade Agreements
The implications of free trade agreements signed by numerous countries with 
the United States and the European Union and their provisions on IPRs should also 
be considered. The most controversial case is the Free Trade Agreement between 
Central America, the Dominican Republic, and the United States (DR-CAFTA), 
which has been said to establish a limitation with regard to disclosure of origin. The 
language of DR-CAFTA comes from the United States law, in which each Party 
establishes that disclosure of a claimed invention should be considered sufficiently 
clear and complete if it provides information that allows the invention to be repeated 
or used by a person skilled in the art, without undue experimentation, to the date
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of submission (Article 15.9.9). The doubt that arises is whether the text prevents 
requesting further information at the time of disclosing the patent. No mention is 
made of the obligation to indicate the best mode of carrying out the invention, as 
required by many national laws.
7.3 Relations Between Intellectual Property and Biodiversity
CBD  reaffirms countries’ sovereign right over their natural resources, which is 
firmly rooted in international law. At the same time it establishes the objective of 
fair and equitable sharing of benefits resulting from the use of biological, genetic, 
and biochemical resources. None of these aspects is considered by the Intellectual 
Property System. Thus, many have seen a conflict between the intellectual property 
system (especially due to its extensions to living matter) and CBD. If such a conflict 
exists, its topic is of a high political and emotional expression.
Application of intellectual property to biodiversity entails the topic of protection 
of living matter or, as it has been called, the “patentability of life.”28 The contro­
versy, which arose with special force in the 1990s, presented the following points 
(Dutfield, 2002):
1) The moral implications of treating inventions relative to plants, animals, 
microorganisms, their components such as genes, gene sequences, proteins, 
cells, etc., as property.
2) The way in which such property endangers basic considerations of patent law 
such as novelty, inventive level, description of the invention, exhaustion of 
rights, and, in some cases, elimination of the distinction between invention and 
discovery.
3) The possibility that basic research and commercialization may be discouraged 
by broad claims of patents involving biotechnological research instruments and 
due to the conflicts between patents.
4) The possibility that IPRs on life forms support so-called biopiracy, that is, the 
appropriation of genetic material and traditional knowledge without the consent 
of the countries and communities and indigenous peoples or without adequate 
benefit sharing.
5) The way in which IPRs can hinder or limit farmers’ rights to keep, reuse, ex­
change, and sell seeds and other propagation material conserved on their farms.
For a more in-depth understanding of the implications of the debate, a few central 
points are considered below.
7.3.1 Intellectual Property Rights and Discoveries/Inventions
IPRs exclude third parties from use of inventions that are new, possess an inven­
tive step, and have industrial application, which excludes discoveries. Genetic and 
biological resources in their natural state are not subject to protection by means of
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IPRs. Therefore, to talk about privatization of biodiversity by means of patents for 
living matter is inexact. An altered biological entity fulfills protection requirements 
for patents without affecting sovereign right over the original entity. However, the 
types and interpretation that biotechnology patents have been acquiring in devel­
oped nations, especially the United States, appear to erase the difference between 
invention and discovery.
Nor is the situation clear regarding unmodified living substances. In the United 
States and the European Union protection can be given to the holders of unmodified 
genes and microorganisms, provided that they are isolated from their environment, 
their existence has not been known, and their usefulness has been determined. 
With this interpretation, the distinction becomes thinner and thus the claims for 
appropriation of matter existing in nature increase.
As Correa (1999) states, “In the United States, according to the principles devel­
oped for chemical patents, an isolated and purified form of a natural product is 
patentable. The requirement of ‘new’ does nor mean ‘preexisting’ but ‘novel’ in 
relation to the state of the art, so the unknown but natural existence of a product 
cannot exclude it from patentable subject matter. As a result of this interpreta­
tion, the dividing line between discoveries and inventions is very thin in the United 
States. ( . . . )  This principle and the approach described above have made it possi­
ble for the patenting of cells and genes, among other substances, to be preexisting 
or modified. In the United States, for instance, genes produced by mutagenesis or 
genetic engineering techniques, and even those whose natural existence was previ­
ously unknown, are patentable. The usual in these cases is that claims refer to an 
isolated D NA  sequence, D N A  constructions and new derived transformed plants, 
although they also often include natural sequences of D N A  without limitations.” 
One case of a claim per se is that of the glyphosate-resistant synthetase gene, 
which protects from the action of herbicides. Here is the text of one of the pertinent 
claims. “A  D N A  sequence of less than 5 kb with a structural gene that codifies 
glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate synthase” (Correa, 1999).
In relation to plants it should be considered that patents can be applied to a wide 
variety of biological material and procedures, among them:
-  Isolated D NA  sequences that codify for certain proteins
-  Isolated or purified proteins
-  Seeds
-  Plant cells and plants
-  Plant varieties, including parental lines
-  Processes to genetically modify plants
-  Processes to obtain hybrids
In January 2000, the United States Appeals Court ruled that patents for sexually 
reproduced varieties of plants were valid and rejected the argument that plant breed­
ing rights were only appropriate to protect new varieties. In Europe the situation 
has been rather confusing, even though recently the “Enlarged Board of Appeal” 
of the European Patents Office accepted the patentability of claims on more than 
one variety. This provision is consistent with the adoption by the Administrative
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Council of the Office of new “implementation rules” (June 16, 1999), which reflect 
the provisions of the European Patents Directive, which are accepted with sup­
plementary means of interpretation. It would definitely seem that acceptance of 
patent protection for plant varieties largely depends on “lawyers’ verbal skills” 
(Llewelyn, 2000).
The development of genomics also gives rise to controversy. Genomics (the study 
of species’ genes and their interaction) is one of the most powerful tools for research 
and development of agricultural and pharmaceutical products. “Access to and con­
trol of complex genomic information is now perceived as the cornerstone for the 
future development of transgenic plants, and the leaders of the agroindustrial genetic 
complex have entered a race for being the first to identify -  and hopefully own -  the 
genes involved in the regulation of commercially interesting traits and their interac­
tions” (Correa, 1999). The advances of structural (gene mapping and sequencing), 
functional (identification of the function of genes, when, how, and what genes act 
together to generate a characteristic) genes and bioinformatics (management and 
analysis of data resulting from genetic sequences) are another source of controversy 
due to the possibility that its access and utilization are controlled by IPRs. The cost 
and capabilities required can increase the lag and dependence of the developing 
countries.
In regard to this topic, protection of databases is important. However, the W IPO  
Treaty on copyright and the developments in different legislations and legislations of 
regional blocs, such as the European Union, only establish database appropriation 
rights, not the data in themselves. In other words, genomics information can be 
stored and consulted at a price, but this does not establish rights over sequences and 
genes, unless they are subject to independent patents.
7.3.2 Sovereignty over Genetic Resources
Whereas the sovereignty of States refers to genetic resources (including biochemi­
cal ones), application of IPRs to modifications that meet the basic requirements of 
protection will not affect rights over unmodified living matter. But if the definition 
of sovereignty includes synthesized or derivative products (i.e., the Common Access 
Regime of the Andean Pact), these become the object of IPRs, which could create a 
conflict due to the extension of the concept of sovereignty beyond genetic resources 
(Article 2 of CBD). It is probably necessary to distinguish derivative products (such 
as biochemical resources) subject to the access regime of those that consist of final 
or synthesized products (see Glowka, 1998). In any event, the latter could well be the 
object of negotiations for benefit sharing, in the case of products based on genetic 
and biochemical resources.
7.3.3 Protection of Microorganisms; Definition of Essentially 
Biological and Microbiological Processes30
The obligation to protect microorganisms can be conflictive due to the lack of def­
inition of the "microorganism" concept, so in certain nations a broad interpretation
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makes it possible to protect sub-cellular material such as genes, genetic sequences, 
and plasmids. According to the European Patents Office, the term “microorgan­
ism” includes not only bacteria and yeasts but also fungi, algae, cells, protozoans, 
plasmids, and viruses.
However, countries can decide to protect only modified microorganisms 
(Brazilian law on industrial property), interpret the concept in a restricted man­
ner (excluding genes and genetic sequences), or limit the scope of the patent to a 
specific use of the product, which would be compatible with TRIPS.
The TRIPS Agreement stipulates protection of microorganisms but does not 
mention genes or genetic sequences, at the same time as it admits granting patents 
in all areas of technology, which would seem to permit protection of the latter. The 
thesis would seem to uphold that D N A  is only a chemical structure. For example, 
there would be no legal problem on patenting D N A  sequences produced in laborato­
ries, which are different from natural ones and some sections of the molecule would 
have been eliminated in the process. There are arguments against this. For example, 
the elimination of junk D N A  is obvious to an “expert in the art” for the techniques 
of isolation and purification of D N A  are common use. Patents for genes and genetic 
sequences should be analyzed first from the point of view of the impossibility of 
granting them if the product does not have a known function31 And second, the 
option of protecting sequences, that is, parts of genes, entails a dangerous fragmen­
tation of the patentable subject matter which can increase the number of holders 
whose permits are necessary, if not for research, then to place a product on the 
market, with the negative consequences for research and development.32
Finally, defining and setting the limits on essentially biological processes, micro­
biological, and non-microbiological (chemical, etc.) ones are not easy to do, 
especially in biotechnology, nor do uniform solutions exist in the world.
It is not altogether clear how far the theory that propounds the impossibility of 
patenting recipes from nature (Gollin, 1994) is being transgressed by new legal 
interpretations and rules and whether these affect national sovereignty.
7.3.4 Patented Traits Present in Natural Form
It is advisable to consider the effects of intellectual property systems on biological 
resources. If a patented trait (the gene and the protein for which it codifies) is mani­
fested in natural form and it is possible to incorporate it into plants by conventional 
improvement methods, there would be a not altogether clear interface between the 
patent holder and the traditional improver (Correa, 1999). Barton (1997a) states that 
in this case the patent holder is protected against use of the gene by another biotech­
nologist but leave third parties free to use and improve organisms that naturally 
contain the gene.
Although it is not a similar antecedent, it is worth citing the lawsuit of the 
Monsanto Company against the Canadian farmer Percy Schmeiser, sued for using 
soy resistant to glyphosate. Schmeiser argued in his defense that his crops were 
contaminated with transgenic soy from neighboring crops, by accidental spillage
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or carried by the wind, and he never used it intentionally, even though he had it 
in his possession. The Court ruled in favor of Monsanto under the argument that 
Schmeiser lacked the right to use the gene protected by patent law without authoriza­
tion, even if it was naturally deposited on his land. The effects of this jurisprudence 
(now under appeal) on the farmer’s civil responsibility in fields with transgenic and 
non-transgenic crops have yet to be seen, but they could entail major risks for those 
who, even without using genetically altered varieties, could be subject to costly and 
long judicial proceedings (Louwars and Minderhoud, 2001).
7.3.5 Effects on Traditional Uses
There is concern over patents that cover an active component of a plant tradition­
ally used by local or indigenous communities. The effect of such protection could 
restrict the possibility of peoples to export the plant to the country that protects it, 
even for different or unrelated medicinal uses. This issue has become more rele­
vant due to complaints that the patents system is a mechanism for appropriation 
of traditional knowledge and genetic resources without fair and equitable benefit- 
sharing and without informed consent. The above has been denounced as biopiracy 
on resources and knowledge, as in the cases of neem, curcuma, quinoa, Mexican 
bean, ayahuasca, nuna bean and yacon. In these and other hypotheses, preexist­
ing biological resources with minor modifications and broadly disclosed traditional 
knowledge (which would cancel out the novelty of the invention, at least in the­
ory) have been the basis for applying for IPRs without meeting the requirements 
of inventive level and without the prior informed consent of the peoples, commu­
nities, or countries. Some of these patents have been revoked, thus accepting that 
they should never have been granted. In other cases it has been argued that IPRs 
have been used to appropriate genetic material under the custody of international 
agricultural research centers, as has been denounced against 147 IPR applications 
on plants. In one third of the cases the materials were obtained from other countries 
without evidence of improvement and another 16 involve germplasm under custody, 
to which no protection should be granted (IDRC, 1994).
7.3.6 Functional Patents
Functional patents, those that cover all possible means of solving a problem (Correa,
1999), such as granted to Agracetus, which excludes third parties from any genetic 
manipulation of cotton and soy, or patents on the use of BT technology,33 which 
hinder practically any process involving the use of this substance, have given rise 
to problems for agricultural research, one of the ends that IPRs should contribute to 
attaining.
In order to limit the pernicious effects of functional patents, the International 
Plant Genetic Resources Institute (IPGRI, 1999) proposes, among others:
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i) Antimonopoly laws.
ii) That the burden of proof on the functioning of claims should fall on the patent 
applicant and not on its challengers.
iii) Rigorously apply the requirements of inventive level and industrial application.
iv) Establish mechanisms that balance the claims of initial and subsequent 
innovators.
v) Limit or prohibit the use of functional claims.
7.3.7 IPRs and Traditional Practices of Reuse 
and Exchange of Seeds
Article 10 of CBD  promotes customary practices of use of biological resources, one 
of which is keeping seeds for reuse and sale. When it has not been possible to pro­
tect this practice by technical means (as in the case of hybrids which, although they 
can be reused, lose their vigor), efforts have been made to restrict it by legal means, 
especially through patents, plant breeding rights and contracts. Protection prevents 
seeds from being reused, a practice considered essential by some to conserve biodi­
versity and the way of life of farmers themselves, and therefore its restriction should 
be seen as an infringement of Article 10 c and the principles of CBD.
Some reports and decisions of United Nations agencies warn of the possible 
implications of these tendencies, indicating risks and impacts on human rights and 
development (UNDP, Report on Human Development, 1999). In August 2000, the 
Sub-commission for the Protection of Minorities of the Commission on Human 
Rights adopted a Resolution on Intellectual Property Rights and Human Rights 
that points to current or potential conflicts such as obstacles in the application of 
IPRs for technology transfer to developing countries; the consequences of IPRs on 
genetically modified organisms and the basic right to food security; reduction of 
communities’ control over their genetic resources, their cultural values and the pos­
sibilities of biopiracy; and restrictions on access to patented medicines and their 
implications on the basic right to health. The Resolution requests W TO  to take 
human rights into consideration during the TRIPS negotiations.
7.3.8 IPRs and Genetic Erosion
A  concern for those related to genetic improvement, agricultural production, and 
food security is the conservation of plant and animal genetic resources as a reserve 
for creating new varieties, seeds, and crops. Plant genetic resources have been 
defined as essential for agricultural development, increasing production, alleviating 
poverty, and promoting economic growth (Cooper et al., 1994). The phenomenon 
of genetic erosion has therefore been denounced as a threat to food security. Recent 
trends regarding protection of plants and animals by means of patents and new plant 
variety rights could reduce genetic diversity. This would occur when modern and 
homogeneous varieties (the homogeneity and stability of varieties is a requirement 
for obtaining their protection), on being used massively by farmers, would displace
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local varieties (much more diverse) and create dependence on a narrow genetic base 
(Cooper et al., 1994). This dependence and homogeneity entails a risk for crops 
because of their susceptibility to pests and diseases.
Genetic erosion is a significant threat for agricultural production, but its relation­
ship with the requirements of IPR has not been demonstrated. The causes of loss of 
genetic diversity and the threats to agricultural diversity in general are varied and 
complex, and it is difficult to isolate the behavior of a specific factor such as the 
one mentioned and assign it a general consequence. Several studies on activities 
and processes affecting diversity in general and agricultural diversity in particular 
do not mention IPRs at all (Dutfield, 2000).
In spite of this, one should consider Reid’s stance,34 who points out a strong 
connection between IPRs and the direction of agricultural scientific research, which 
ultimately has a bearing on agrobiodiversity. Reid maintains that whereas IPRs on 
varieties and plants foster the development of agricultural research aimed at uni­
form, homogeneous crops, they discourage research on agroecological conditions, 
which are more adapted to local needs and conditions.
While IPRs foster the development of seeds and varieties with wide demand 
to recover costs, companies will seek to focus their research on high-value crops 
and develop varieties that can be cultivated as much as possible. This entails the 
dissemination of highly homogeneous commercial varieties to be distributed and 
commercialized. Critics point to the tendency of IPRs to indirectly create systems 
of mono-cultivation, the consequence of which will be a reduction in biological 
diversity.
Other factors play more important roles in this problem. According to a study 
submitted by the Secretariat of CBD to the Third Conference of the Parties in 
1996, among the policies that can foster the use of new varieties and the loss 
of local varieties are credits, subsidies, and other forms of governmental agri­
cultural extension, policies and programs of international agencies and donors, 
control of corporations over research, distribution of pesticides and agrobiotech­
nologies, marketing and research, and development policies of transnationals 
enterprises.
It is difficult to argue that IPRs give rise to perverse incentives to develop tech­
nologies that reduce biological diversity (creating genetic erosion and increasing the 
use of chemicals, among others). Nonetheless, a document issued by the Secretariat 
of CBD35 identifies the following categories of impacts of IPRs on the objectives of 
the Convention:
a) Impact on the traditional knowledge, innovations, and practices of local and 
indigenous communities.
b) Impact on indirect incentives that affect conservation and sustainable use.
c) Impact on benefit-sharing through the development of technologies that use 
genetic resources.
d) Impact on transfer of or access to technological and scientific information.
e) Impact of IPRs on mechanisms of exchange of information established in the 
Convention.
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7.3.9 IPRs and Benefit-Sharing
IPR systems have not considered benefit-sharing derived from the use of traditional 
knowledge or biological resources incorporated into or used by the resulting inno­
vations. Actually it is a question of two approaches that are different rather than 
contradictory. In any event, the question on the possibility of using IPRs to protect 
biodiversity remains and can be made as long as IPRs create value for biodiver­
sity by allowing the use of genetic and biochemical resources in biotechnological 
research.
“It is important to understand that intellectual property rights create value 
because they provide a protected market for products generated by biodiversity. 
Pharmaceuticals, cosmetics and similar indirectly create value due to the incorpora­
tion of the raw materials of biodiversity (Lesser, 1991). This notwithstanding, it is 
worth asking whether IPRs are appropriated to claim that value. The answer is nega­
tive, for IPRs are not conceived to protect non-marketable materials (Lesser, 1991), 
in addition to other theoretical and practical inconveniences. Nevertheless, if these 
rights are accompanied by benefit-sharing agreements they could have a positive 
impact on distribution.
Some maintain that IPRs could indirectly provide more value to traditional 
knowledge and to genetic and biological resources if patents were authorized for 
products based on biological resources, especially in the area of biotechnology, or 
if it were possible at least to use the different types of intellectual property to pro­
tect that knowledge, innovations, and practices when IPRs involve agreements on 
benefit-sharing.
7.4 Conclusions
Intellectual property rights are linked to national and international policies and leg­
islations related to sustainable development, conservation, and fair and equitable 
distribution of the benefits derived from the use of genetic resources. It is neces­
sary for the modifications to IPR systems, including those stipulated in free trade 
agreements, to consider the implications that such rights will have on these issues.
Diverse points of contact make it necessary to proceed in this way, par­
ticularly those relative to the manner of synergic implementation of IPR sys­
tems and the obligations established in agreements such as the Convention on 
Biological Diversity, the FAO International Treaty, and the discussions of the 
Intergovernmental Committee of WIPO. Mechanisms such as disclosure of ori­
gin and the design of juridical systems for protection of traditional knowledge, 
among others, should be explored and, if appropriated, implemented to address the 
questions on the compatibility o f IPRs with other development objectives.
Only through proper consideration of these needs and the search for synergies 
will it be possible to incorporate the new obligations assumed with regard to IPRs 
into the processes of sustainable development, which entail the conservation and use 
of biodiversity and protection of traditional knowledge.
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Notes
1. Among other forums, the Council of the Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) of the World Trade Organization (WTO), Committee on Trade and 
Environment of that Organization, Convention on Biological Diversity, and World Intellectual 
Property Organization (WIPO).
2. See ICTSD-UNCTAD (2003) and Commission on Intellectual Property Rights (2002) on the 
implications of IPRs on development, biodiversity, and food security. Both documents pro­
vide detailed and objective analyses of the implications and tendencies of IPRs on agriculture 
and access to genetic resources, traditional knowledge, and benefit sharing.
3. The Bonn Guides establish that the Parties with users of genetic resources should consider 
measures to support compliance with the prior informed consent of the Party providing the 
same and the mutually agreed terms under which access takes place. These measures include: 
fostering disclosure of the country of origin of the resources and of the traditional knowledge 
in IPR applications.
4. Although the language of the Summit refers to benefit sharing, the meeting of the Working 
Programme of the Convention (Montreal, March 2003) recommended that the Working 
Group consider, at its second meeting, the process, nature, sphere, elements, and types of 
an international regime of access to genetic resources and benefit sharing.
5. On the evolution of and activities carried out by the Commission on Genetic Resources, see 
Mekour (2002) (www.fao/ag/cgrfa) and Cooper (2002).
6. Decision II-7 of the Second Conference of the Parties in 1995 had already recognized the 
distinctive characteristics of Agricultural Genetic Resources.
7. The Treaty entered into effect on 29 July 2004 with ratification No. 50.
8. The Preamble stipulates that the rights recognized by the Treaty to conserve, use, exchange, 
and sell seeds and other propagation material conserved in farms is fundamental to the validity 
of farmers’ rights.
9. On principle, for even if  the product is patented, broad exceptions could be applied with regard 
to research. And if it is not, access to the material could be restricted by means of contracts.
10. Other aspects related to disclosure of origin are also discussed in the Standing Committee on 
the Law of Patents (Substantive Treaty on Law of Patents) and in the Working Group for the 
Reform of the Patent Cooperation Treaty, both of WIPO.
11. See other details at www.wipo.int/tk/en/igc/
12. At its last session, the Committee limited itself to taking note of the documents and proposals 
for decision that it reviewed, without taking any substantive decision with regard to the topics 
of genetic resources and intellectual property, traditional knowledge, and folklore.
13. The European Union’s proposal on disclosure of origin for genetic resources and associ­
ated traditional knowledge in patent applications (November 16, 2004) includes compulsory 
requirement to reveal country of origin or source in patent applications, valid for national, 
regional, and international applications; the applicant must declare the country of origin or 
the source to which the inventor had physical access; the invention must be based directly 
on genetic resources; the requirement would apply to traditional knowledge, a concept that 
requires further study; not process applications that are not accompanied by the required 
information; provide for effective, proportional, and dissuasive sanctions, outside patent 
rights, for those who turn in incorrect or incomplete information; notification procedure in 
charge of the Patent Offices to advise the country of origin of the respective application.
14. India has proposed that the Committee on Genetic Resources should meet with the Committee 
on Law of Patents.
15. Cfr. WIPO, “Intellectual Property and Traditional Knowledge”, Booklet No 2.
16. The Committee has developed a draft o f objectives and principles on traditional cultural 
expressions or Folklore, which can be part of protection of traditional knowledge in the broad 
sense of the word. The Committee distinguishes protection in the strict sense (traditional 
knowledge) and broad sense (traditional cultural expressions).
17. The forum for dealing with topics related to intellectual property had traditionally been 
WIPO. Nevertheless, due to its lack of effective dispute settlement mechanisms, GATT was 
considered the most viable alternative for changing the forum for negotiations and establish­
ing minimum standards. As a result of the negotiation of the Substantive Patent Law Treaty 
(SPLT), WIPO has once again been supported as the main regulator on the matter. See Correa 
and Mussungu (2002).
18. Basically it is required that the variety be homogenous, stable, new, different (in the 
commercial sense), and have a denomination.
19. UPOV is considered neither necessary nor sufficient to comply with such a provision because 
a) it is not required by Article 27.3.b and b) it is not sufficient, since the mandate of TRIPS 
requires as different system from that of UPOV1991. For example, the granting of National 
Treatment only to UPOV members (based on the principle of reciprocity) would be in viola­
tion of TRIPS. Furthermore, UPOV permits initial protection of a limited amount of varieties, 
whereas TRIPS includes them all.
20. In a case taken before WTO, the Panel concluded that any exception that substantially reduces 
the holder’s rights would be inconsistent with Article 30 of WTO. This implies that even in 
the case of patents as a means of solution for the case of varieties, the exceptions of the Right 
of New Plant Varieties could be incompatible with Article 30 of the TRIPS Agreement (case 
of the Canadian Patents Law of 2000).
21. Although the TRIPS Agreement does not mention the rights of plant breeders, in one case 
brought before WTO the Appeals Panel, on analyzing Section 211 of the 1998 United States 
Omnibus Act, expressed that the sui generis rights of Article 27.3.b were a form of intellectual 
property admitted by TRIPS.
22. At the time of the review there were significant divergences regarding its scope. For the 
developed countries, the system should center on implementation aspects. Most of the devel­
oping countries advocated a substantive review that would conclude in amendments to 
the text. See the documents submitted by the countries and those prepared by the TRIPS 
Council at www.wto.org and at International Center for Trade and Sustainable Development, 
www.ictsd.org.
23. On technical and legal aspects concerning disclosure of origin, see WIPO (2005); Sarnoff, 
Joshua and Correa (2006); Rojas et al. (2005); Sarnoff (2006); Ho (2003); and Hoare (2006).
24. For an analysis of the proposals submitted until February 2006, see “The relationship between 
the TRIPS Agreement and the Convention on Biological Diversity.” Summary of issues raised 
and points made. Note by the Secretariat. Document IP/C/W//368/Re\.l, February 2006, and 
IP  Quarterly Update, South Centre and CIEL, First Quarter, 2006.
25. The main promoters of these proposals are the Group of African countries by means of the 
document entitled “Taking Forward the Review of Article 27.3.b of the TRIPS Agreement” 
and a Group of Developing Countries, some of the megadiverse, headed by Brazil and 
India (plus Bolivia, Cuba, Ecuador, Dominican Republic, Peru, Thailand, and Venezuela). 
See http://docsonline.wto.org/DDFDocuments. Although the proposals differ in language 
and certain legal considerations, in general they seek to introduce the requirement of dis­
closure of origin and proof of legality of access in the patents system. See a summary in 
IP/C/W/273/Rev., February 2003. In early 2004 some developing countries submitted a Check 
List of the issues that should be discussed, which has been useful in orienting the discussions.
26. The Deputy Director has initiated negotiations on the basis of a document that contains 11 
questions to be answered by the Members.
27. WT/GC/W/564, May 31, 2006.
28. The WIPO questionnaire WIPO/GRTKF/IC/1/ of April 6, 2001, which compiles information 
from various countries on practices of protection of biotechnological inventions, cites as top­
ics of interest: the possibility of patenting or not plants and animals if they meet the basic 
requirements; extension of denial to do so (plants and animals per se, varieties, breeds, etc); 
protection of new uses of biological material, of microorganisms, and microbiological pro­
cesses, including those isolated from essentially biological and genetic sequence processes, 
even those identical to the ones existing in nature, etc.
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29. This research does not deal with the ethical, legal, and economic implications of disclosure 
of the human genoma in February 2001 by two research teams and published in N a tu re  mag­
azine. This topic and the appropriability of the results by means of IPR are of major interest 
for plant genomics. The description of the Arabidopsis genoma and the works under way on 
corn and rice makes it likely that there will also be debate in this field.
30. According to Tansey (1999), the expressions of Article 27 of TRIPS subject to interpretation 
are plants, animals, microorganisms, essentially biological, non-biological, microbiological 
procedures, plant varieties, efficacious, and su i g en er is .
31. In the case of human genes, fragments, without known use, are called “expressed sequence 
tags.” As Bergel (1997) states, “Granting patents on these DNA fragments, that is to say, 
monopolizing in their inventors almost all the subsequent technical advances (complete 
sequence of DNA, products that codify and uses of these products) would contravene the basic 
principle that the scope of protection of a patent should be proportional to the contribution of 
the invention to the state of the art.
32. In 2000, 355,000 sequences were patented, an increase of 5,000% over 1990. It is likely that 
the trend will increase.
33. Technology for creating transgenic plants that express the gene of the Bacillus Turingensis 
or BT, which allows these to eliminate, by the expression of a substance, pests such as 
lepidoptera.
34. Cited by Dutfield (2000).
35. Secretariat of the Convention on Biological Diversity (UNEP/CBD/COP/3/22).
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Chapter 8
In t e lle c t u a l P r o p e r t y  in  L iv i n g  O r g a n is m s . 
C u r r e n t  S it u a t io n ,  T r e n d s  a n d  C h a lle n g e s
César Morales
8.1 Introduction
This chapter analyzes and studies the situation and perspectives of intellectual 
property protection of living organisms from the standpoint of the interests of the 
development countries in general and the Latin American region specially. It is a 
rather complex issue on which there are considerably different positions between the 
developed and the developing countries, companies linked to genetic engineering, 
universities, research centers, and development agencies.
The complexities are not new, but have deepened with the advances in genetic 
engineering and recombinant D N A  techniques, which have made the production 
of transgenic organisms a reality and increased the value of genetic sequences of 
plants, animals, bacteria, and fungi with characteristics of commercial value.
The very definition of living organisms is accompanied by difficulties and the 
need to specify. Although it would seem obvious that all organisms are living by 
definition, in viruses this is not always so. These acellular entities, o f major impor­
tance for the production of plant and animal transgenic organisms, are on the border 
between living beings and what is defined as inert and are, moreover, o f great impor­
tance for the production of plant and animal transgenic organisms.1 This fact can 
have important implications from the viewpoint of intellectual protection.
Viruses are sub-microscopic entities capable of feeding themselves, growing, 
reproducing themselves, and dying, by parasitizing a cell and using its genetic mate­
rial. Without them they cannot carry out any of these functions and can crystallize 
like minerals, remaining inert for indefinite periods.2
Added to the above is the fact that scientific development has succeeded in artifi­
cially producing organisms which nature would never have been able to produce and
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which combine their genetic material with parts of completely alien and unrelated 
organisms, such as plants, animals, bacteria, fungi, and viruses.
The difficulty in managing the economic aspect of these advances lies in the fact 
that the interests of those who possess the technologies to commercially develop 
these modified organisms do not coincide with those of the countries that have the 
necessary biodiversity to develop them, that is, plants, animals, and other organ­
isms with commercially desirable characteristics. This has given rise to conflicts of 
interest and opposed points of view.
The different regulatory frameworks add a little more complexity to the existing 
picture. In force at multilateral level are the Agreement on Trade-Related Aspects of 
Intellectual Property (TRIPS) and the Convention on Biological Diversity (CBD), 
which coexist with the sui generis systems of diverse countries within the frame­
work of the International Convention for the Protection of New Varieties of Plants, 
which is administered by the International Union for the Protection of New Varieties 
(UPOV), as well as different autonomous national laws.
There is a major controversy regarding the possibility of patenting living 
organisms. This goes back many years, but the scenario has undoubtedly been com­
plicated by the development of genetic engineering and the possibility of industrially 
developing products based on the use of modified living organisms.
World Trade Organization (W TO ), through the TRIPS Agreement, has put for­
ward criteria on the possibility of granting intellectual protection to biotechnological 
innovations. According to Article 27.3(b) of TRIPS, plants and animals other 
than microorganisms are patentable subject-matter, as are essentially biological 
processes for the production of plants or animals other than non-biological and 
microbiological processes.
However, TRIPS also stipulates that Members shall provide for the protection 
of plant varieties either by patents or by an effective sui generis system or by any 
combination thereof and that such provisions shall be reviewed 4 years after the date 
of entry into force of the W TO  Agreement.
Article 27.3(b) is one of the most controversial in the TRIPS Agreement since 
on the one hand it describes patentable subject-matter, and on the other hand, it 
obliges Members to protect microorganisms and certain biological processes. The 
above reflects the strong conflict of interests between developed countries desiring 
to obtain protection for their biotechnological innovations, the differences between 
various countries on the scope of protection, and the concern of the developing 
countries about patents on life forms (UNCTAD-ICTSD, 2005).
8.2 Protection and Regulatory Frameworks:
Some Conceptual Aspects
8.2.1 Intellectual Property Protection
The types of protection applicable to living organisms or parts of them are the 
following: technical protection, industrial secret, patents, and plant breeders’ rights.
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8.2.1.1 Technical Protection
This type has to do with the nature of the process or product and is assigned when 
it is impossible, very difficult or very costly to copy the innovation. The degree 
of protection, that is, how difficult it would be to imitate the product or process, 
depends on to the extent that the innovation is incorporated into the product. There 
are two cases in point:
(i) When it is impossible to recover the innovation as of the product or process and
(ii) when the innovation is fully recoverable as of the product of process.
Between the two cases there are infinite possibilities. Hybrid seeds3 correspond 
to the first case, since their characteristics cannot be reproduced in the offspring, 
which cannot even be obtained in many cases. Among the industrial crops repro­
duced on the basis of hybrids are corn, sunflower, and sorghum. The opposite case 
is that of the new varieties of autogamous plants,4 whose technical protection is 
impossible or very limited, as it is possible to obtain “copies” from their seed. It is 
said that in this case the seed completely “embodies” the innovation. Autogamous 
plants cultivated industrially are soy, wheat, oats, and barley.
8.2.1.2 Industrial Secret
This type of protection is associated with seeds of hybrids and with processes that 
confer desirable characteristics on commercial plants. It is used a step prior to an 
application for a patent or to recognition of the producer of new plant varieties. 
In contrast to other types of intellectual protection, the industrial secret does not 
confer exclusive rights and is not conditioned to registers, or to proof of novelty or 
inventive step.
8.2.1.3 Patents
Patents can be granted to processes and products such as new varieties of hybrid 
plants, transgenic plants, processes to endow them with desired characteristics, 
vaccines, agricultural machinery. In such cases it is necessary to demonstrate 
that the invention is novel and meets the requirements of inventive step and 
industrial application, a concept that includes uses in agriculture. There are 
differences among countries on the patentability of microorganisms, cell lines, 
genes, and genetic sequences and on the importance assigned to the product or 
process used.
8.2.1.4 Utility Models
This modality can be applied to the holders of rights on equipment and agricul­
tural machinery, their parts and pieces, including their configuration or external
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design. In general, their requirements and duration are less than those demanded for 
patents.
8.2.1.5 Plant Breeders’ Rights
Cover the plant varieties resulting from plant breeding, as long as they meet the 
requirements of novelty and are distinguishable, stable, and uniform. The require­
ment of novelty means that the new variety should not have been commercialized 
or offered for sale by the plant breeder in the country of application. It is also 
demanded that one or more of its characteristics should be clearly distinguishable 
from other commonly known ones. It has likewise been established that new vari­
eties should maintain their characteristics and essential traits stable in time after 
repeated propagations.
8.2.2 International Regulation
8.2.2.1 Paris Convention for the Protection of Industrial Property
It was signed in 1883 and has been the object of various revisions. It applies to 
patents, trademarks, geographical indications, industrial designs and models, and 
unfair competition.
8.2.2.2 Patent Cooperation Treaty (PCT)
It facilitates the application for and registration of patents abroad for the signatory 
countries.
8.2.2.3 International Convention for the Protection 
of New Varieties of Plants (UPOV)
It was signed in 1961 and was amended in 1978 and 1991. It establishes the crite­
ria for protecting plant varieties by means of “plant breeders’ rights.” The 1991 
amendments stipulate strengthening the rights of plant breeders over the multi­
plication, commercialization, exportation, and importation of the material to be 
propagated, including improvements to the potential protection of all genres and 
species of plants. These provisions were incorporated into the European Union’s 
Plant Varieties Law in 1995.
UPOV also introduced the concept of “essentially derived varieties” to allow 
plant breeders to control the use of random mutations. Understood as such are vari­
eties “it is predominantly derived from the initial variety, or from a variety that 
is itself predominantly derived from the initial variety, while retaining the expres­
sion of the essential characteristics that result from the genotype or combination of 
genotypes of the initial variety” (UNCTAD -ICTSD , 2005).
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Thus the rights of plant breeders who would otherwise lose the value of their 
intellectual property in a short time are protected (as would often occur when 
a plant breeder made “cosmetic” changes to a previous variety without paying 
for it).
Other UPOV stipulations recognize the right of farmers to keep seeds for the 
next sowing cycle without the need to ask permission and that “small farm­
ers” are exempt from payment of royalties and may keep particular varieties for 
7 years.
Despite these flexibilities, the 1991 UPOV revision brought the regime of plant 
breeders’ rights closer to that of patents. The Convention extends the coverage of 
intellectual property rights to imports, exports, and harvested crops; broadens the 
duration of plant breeders’ rights, aligning them with that of patents; restricts free 
access to protected varieties (although it maintains it for purposes of reproduction of 
new varieties); and extends plant breeders’ rights to all varieties considered “essen­
tially derived” from the protected variety, limiting the use of new varieties that are 
developed. Although the new norms allow using protected varieties for research pur­
poses, any improvement obtained should show significant changes in the phenotype. 
Otherwise, the variety is not considered “new” and will continue to be the property 
of the first plant breeder. Furthermore, the right to use formerly permitted, such 
as the accumulation and reproduction of varieties protected in “gene banks” aimed 
at preserving genetic diversity, is restricted. Finally, farmers’ privilege of keeping 
seeds for later sowing seasons is eliminated.
8.2.2.4 Madrid Agreement
Deals with repression with illegitimate use of indications in products.
8.2.2.5 TRIPS
This agreement stems from an agreement signed at the Uruguay Round in April 
1994. It provides minimum standards of protection in practically all aspects of intel­
lectual property (patents, copyright, trademarks, industrial designs, geographical 
indications, integrated circuits, and business secrets). According to the transitory 
articles, the developing countries had 5 years as of January 1, 1995 (until January 1, 
2000) to implement them. The period was extended to 11 years for the less devel­
oped countries. For products which at the time of signing the agreement were not 
patentable, the term was extended until January 1, 2005.
The TRIPS Agreement also provides new rules for patents on pharmaceutical and 
biotechnological products, extends their protection to 20 years, eliminates or limits 
the requirement of local exploitation of inventions, and strengthens the mechanisms 
for enforcement of rights (IICA, 2000). TRIPS is an expansion on a world scale 
of the criteria adopted in the 1980s, especially in the United States, to have more 
vigorous and uniform laws to protect inventions.
Despite the agreements, important differences among the Members persist, even 
among the developed countries with respect to plants and animals and the processes
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to produce them. Thus, for example, the member countries of the European Patents 
Convention do not recognize patents on plant varieties. To save this situation, the 
TRIPS Agreement recognizes the authority of W TO  Members to exclude from 
patents plants and animals that are not microorganisms and essentially biological 
processes for the production of plants or animals.
In any event, the countries should take the necessary measures to protect plant 
varieties by means of patents, sui generis systems, or a combination thereof. 
According to this provision and in the absence of greater accuracy, animals and 
plants as such, animal breeds and species of plants and animals may be excluded 
from patents.
Although TRIPS does not make it compulsory to adopt a regime identical to 
that of UPOV or adhere to it, many countries have established the obligation 
to protect plant varieties in accordance with plant breeders’ rights and adhesion 
to UPOV. DR-CAFTA includes the obligation to sign UPOV 1991, thus forgo­
ing each country’s option to create its own sui generis system. Other developing 
countries, by contrast, are discussing sui generis regimes different from those 
of UPOV.
In sum, intellectual property protection may be obtained on innovations, whether 
plants, parts of the latter or new varieties. This is possible according to the regimes 
set forth below:
i) Plant breeders’ rights. Applicable to new plant varieties (UPOV).
ii) Invention patents. Applicable to plants or parts thereof, that is, cells, genes, 
seeds, procedures for the transformation of plants and transformation vectors 
and, in some countries, to plant varieties and hybrids (TRIPS).
In regard to the second point, European norms do not consider patentable plant 
varieties, animal breeds, and essentially biological plant or animal breeding proce­
dures since they are independent from human technical intervention. However, they 
admit that the patentability of inventions that coincide with products from nature 
when they have been obtained through technical procedures is feasible. Thus, “bio­
logical material isolated from its natural environment and produced by means of a 
technical procedure could be the object of an invention, even when it already existed 
previously in a natural state” (UNCTAD -ICTSD , 2005; IICA 2000).
Thus, it is possible to patent D N A  sequences, microorganisms, and other beings 
the same as those pre-existent in nature. What is important is that said inventions 
should be structurally or morphologically identical to a product from nature, have 
been isolated from their natural environment, or produced by some technical pro­
cedure, which guarantees the possibility of industrial production. Accordingly, the 
fact that the biological matter is in its natural state does not hinder its patentabil­
ity (requirement of novelty), but its invention may be obvious (lack of inventive 
activity) or lack industrial application.
Box 8.1 summarizes the main characteristics of the regimes of UPOV and the 
Paris Convention.
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Box 8.1 Protection of biological materials: plant breeders’ 
rights and patents
Regime UPOV Paris Convention
Rights Plant breeders’ rights Patents
Material that can 
be protected
Plant varieties Plant varieties, plants, or parts of 
plants such as seeds, cells, and 
genes. In some countries 
(United States), genes 
produced by means of genetic 
engineering can he patented
Protection
requirements
a) Novelty: that the variety has 
not been sold in the country 
where protection is requested 





a) Novelty: no prior publication 
or execution of the invention 





Materialization Applicable to existing varieties That the invention can he carried 





Exception of the plant breeder, 
who permits use of the 
protected variety for 
subsequent development
Depending on countries, 
exceptions arc admitted for 
scientific research
Duration 20-25 years 20 years
Territorial ity Only in the country where the 
right was obtained
Only in the country where 
protection was obtained (and in 
the countries affiliated to PCT 
if the interested country is a 
member)
Accumulation It is possible to accumulate plant 
breeder's rights and patents on 
the same variety. Such is the 
case of transgenics
Use of plant material as a source 
of germplasm is not permitted 
for other developments
Source: Correa. C. ( 1999). “Normativa Nacional. Regional e Internacional sobre Propiedad 
Intelectual, su aplicación en los INIAS del Cono Sur."
8.3 Patents and Innovation
The relationship between the forms of protection of innovations has been under 
discussion for a long time. The granting of monopolies by means of intellectual 
property rights for a specific number of years is associated with fair retribution to
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the innovator for the investment made, until the innovation in question is out on the 
market.
In most cases, especially in cutting-edge technology, investments to create 
an innovation are very considerable. Added to the expenses deriving from basic 
research are others no less considerable to finance the tests (test data) demanded by 
the respective authority so that the product circulates in the market.
These demands are greater for pharmaceuticals, food products, and substances 
with the risk of significantly affecting the environment. Finally there are the 
expenses derived from the waiting time for approval of the product by the con­
sumer. It is estimated that the average total time is 10-16 years for new varieties 
of plants and medicines. In view of the amount of the investments, it comes as no 
surprise that the largest and most solvent companies present the most applications 
for patents.
It is estimated that putting a new drug on the market entails a cost of around 
400 million dollars. In view of the high investments at play, companies in the 
pharmaceutical-biotechnological sector are under pressure to improve their produc­
tivity and the rate of introduction of new products into the market. It is estimated that 
to achieve 10% growth in earnings from sales, a new drug needs to be introduced 
into the market every 6 months. At present, despite the advances in the matter, the 
major companies launch a new drug onto the market every 27 months on an average. 
One reason for these long periods is the time demanded by the tests to which drugs 
and biotechnological products must be subjected, especially as regards their effects 
on health, side effects, and effects on the environment.
The costs and time frames of agricultural biotechnological products are simi­
lar. Discovering a new gene can cost several million dollars, but inserting it in a 
germplasm costs only some 200,000 dollars, depending on the crop (Lichtenberg,
2000). These are costs prior to crop tests for their approval by government agencies 
(in the United States this involves the Department of Agriculture, the Environmental 
Protection Agency, the Food and Drug Administration, and others).
It is estimated that the costs of preparing the basic background material for 
biological tests for the effects on human health, on other organisms, and toxicity 
reach almost 2 million dollars. The respective spending for chemical pesticides is 
higher. In addition to this there are other costs which increase the figure to almost 
double. The Monsanto Company estimates that the costs of preparing informa­
tion required by tests on insect-resistant transgenic maize reaches some 3.8 million 
dollars (Lichtenberg, 2000, Appendix A).
At present there is an enormous quantity of patents registered in the offices of all 
countries and in the specialized international agencies, and this tendency is accel­
erating. In the United States, since the creation of the Patents Office (USPTO), to 
date more than six million patents have been granted, more than half of them since 
1988, and there are applications for a similar number or more. Except in the case 
of the green revolution, which gave rise to innovations that were defined as public 
goods, important scientific discoveries have always brought new technologies that 
significantly increase the number of applications. However, the increase in patents 
and applications in the field of genetics since the last decade, especially as of the 
end of the human genome project, has no comparable precedents.
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This context redefines the long-standing controversy on the relationship between 
protection of intellectual property rights and innovation. On the one hand there are 
those who maintain that protection by means of patents is a basic condition to assure 
the generation of innovations and, on the other hand, those who affirm that patents 
tend rather to raise barriers to the entry of other innovators and induce companies to 
move for speculative reasons.5 Nonetheless, it tends to be accepted that patenting is 
a “proxy” o f innovation.
In regard to the proportion of patents that reach the market incorporated in prod­
ucts, there are few studies due to the difficulties in following their route. In any case, 
although the existence of important sectoral differences can be presumed,6 the well- 
known consulting firm Ernst &  Young estimates that no more than 10% of patents 
on biotechnological innovations are finally incorporated into commercial products. 
Follow-up on the matter by the Patent and License Exchange coincides with the 
above estimate (Platt, 2001).
The fact that 90% of the patents obtained do not reach the market incorporated 
in products suggests that there are hidden factors that have a bearing on patenting 
activity and that there is a need for appropriate mechanisms so that more patents 
finally reach the market.
With regard to the first point, it is possible that many patent registers have no 
other purpose than to block the entry of other innovators. As for the second, the 
development of an explicit secondary market for patent transactions could help 
transform more patents into marketable innovations. In market terms, there is a high 
lack of liquidity in the “primary market” for patents as a consequence of the risk 
and uncertainty these entail.
8.4 Barriers to Entry
Initially conceived to encourage innovation, the patents mechanism tends to turn 
into an instrument for preservation of monopolies obtained thus and into bar­
riers to entry for other innovators. In fact, protection of innovation ensures 
exclusivity for the patent holders and collection of royalties and licenses for 
their use. According to W IPO and other agencies, in the mid-1990s half of 
the royalties and license payments favored large United States’ corporations and 
around 70% of them corresponded to transactions between their own subsidiaries 
and other related companies. According to U N D P ’s 2000 Human Development 
Report, 85% of advanced technology patents are in the hands of the major 
conglomerates.7
The resources generated by intellectual property rights are of such magnitude and 
have such growth dynamics that the regulatory framework is seen by some as more 
appropriate for protecting this source of earnings than for encouraging innovation. 
It is estimated that in 1990 total earnings from royalties and licenses for the use 
of patents brought in 15 billion dollars for their owners. In just 8 years this figure 
increased to 100 billion dollars and it was estimated that in 2005 it would reach 
5 trillion dollars (Mooney, 2000).
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Another barrier to the entry of new stakeholders, especially smaller ones, is the 
high costs of lawsuits on patents due to the complexity and specialization they entail. 
In 1999 alone 8,200 proceedings were instituted on the matter in the United States, 
a figure 10 times higher than 4 years before. This profusion of litigation suggests 
that the regulatory framework, rather than encouraging innovation, encourages the 
interests of large corporations and dissuades smaller firms, institutions, universities, 
and innovators without large amounts of resources.
Control by the large corporations over almost the entirety of innovations in 
cutting-edge technology makes it more difficult for new agents to enter the inno­
vation process. Only three large conglomerates of private companies linked to the 
Human Genome Project have made three million patent applications on parts of 
genes, DNA, and cell lines from 2000 to date. The complexity of the applications 
and their enormous number make it very difficult for patent offices to assess their 
pertinence and they relegate the right for their applications to be processed to third 
parties.
Genetic codification of biological barriers is added to these barriers. The first 
generation of these technologies, known as Terminator, consists of a protein that 
kills the seed embryo once the seed has fulfilled its productive cycle. Thus its reuse is 
prevented in new sowing seasons, obliging the farmer to acquire them for each cycle. 
More recent technologies codify the seed’s sensitivity to particular agrochemicals 
that sterilize it externally or make it lose its commercial properties.8
Paradoxically, these innovations can lose importance as mechanisms to ensure 
complete appropriation of their benefits. Satellite technology for the control of agri­
cultural activities has reached a level of sophistication such that it can make it less 
costly for biotechnological and transformation companies to ensure through pro­
duction contracts with farmers the use of the anticipated technological inputs (seeds 
and agrochemicals) for the time agreed and in the required form. In this way it 
will be possible to control reuse of seeds without authorization from the supply­
ing companies and demand the use and application of particular pesticides and 
treatments.
8.5 Application and Granting of Patents
8.5.1 Background
In 1873 the United States Patents and Trademarks Office (USPTO ) granted patent 
No. 141,172 to Louis Pasteur for yeast free of disease germs, considering it a man­
ufacture. It was subsequently decided not to continue along that line, with some 
exceptions (a breed of bacteria in 1977). The criterion that prevailed was con­
sidering that living organisms were not patentable because they were regarded as 
products of nature, or because they were not subject to sufficient written description, 
as demanded by the patents system. This excluded bacteria and fungi that produced 
antibiotics, for which reason prior to 1980 most patents were granted to processes,
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mainly those that used bacteria to treat wastewater or produce chemical substances, 
antibiotics, etc.
In 1930 the United States Congress approved the Plant Patent Act, which permit­
ted protection for asexually reproduced plants with the exclusive right to propagate 
the plant for 17 years (Solleiro et al., 1996). To date the USPTO has granted around
6,000 patents for plant holders, mainly fruit trees, flowers, ornamental trees, grapes, 
and other horticultural species.
In 1961 the International Convention for the Protection o f New Varieties o f Plants 
(UPOV) was signed in Paris. It has been submitted to three revisions, the last one 
in 1991.
In 1970 the United States introduced an adapted version o f the UPOV System 
o f Plant Breeders’ Rights into its legislation to protect new sexually reproduced 
varieties o f plants.
In Europe, after the signing o f UPOV, several countries recognized protection 
titles for new plant varieties. Nevertheless, in 1973 the European Patent Convention 
in Munich excluded the patenting of plant varieties and the essentially biological 
procedures for their production (Correa, 2002).
In 1977 the first patent on a breed o f bacteria was granted in the United States, but 
it was not until 1980 that the first major changes were made to intellectual property 
regulations.
In 1972 microbiologist Chakrabarty filed a patent application for 36 claims 
related to the invention o f a genetically designed bacterium o f the Pseudomonas 
species, capable o f degrading the multiple components o f crude petroleum. The 
application was rejected, but Chakrabarty appealed, and on June 16, 1980, the 
United States Supreme Court decided in a historic ruling that the said bacterium 
was a “manufacture” or “composition o f matter” which met the criteria o f novelty (inexistent as such in nature and not obvious for science at the time) was derived 
from an inventive step (it had been produced in a laboratory by transfer o f plas­
mids) and met the requirement o f usefulness (its purpose was to use it in oil spill 
clean-up work).
The ruling included the following phrase: patents can be granted “to anything 
under the sun that is made by man.” Thus the objection to patents on living 
beings for the simple fact o f being living was eliminated. The Budapest Treaty 
(1977, in force since 1980) establishes as a requirement for patent applications on 
microorganisms the deposit o f cultures in well-known collections to that effect.
This decision marked an important change on the subject and led to modifica­
tions o f the regulatory framework for Intellectual Property Rights in the United 
States. The perception o f deterioration o f the United States’ comparative advantages 
in the technology-intensive industry brought about significant changes in forms of 
protection o f intellectual property rights (Hunt, 1999).
The loss of competitiveness was attributed to the fact that the system was geared 
to basic research, was weak, and rather inefficient in producing results for firms, 
whereas the results o f research were easily appropriable by competitors due to lack 
of protection (Coriat and Orsi, 2001).
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One important modification was the one that habilitated universities and scientific 
teams to patent their innovations, including those financed with public resources. 
As o f that time the innovative activities o f the main universities were significantly 
unleashed, giving rise in the process to small biotechnological companies made up 
o f scientific personnel from the same universities. Subsequently, most o f these firms 
were acquired by large corporations in the field through mergers and acquisitions.
In 1985 the Board o f Patents Appeals and Interferences granted Kenneth Hibbert 
the first utility patent for a plant that could be sexually propagated and genetically 
manipulated: a variety o f maize enriched with Tryptophan o f the firm Molecular 
Genetics & Development. Utility patents protect not only the plant but also parts of 
it, the seeds and genes, so they justify multiple claims according to applications of 
the innovation in different products, processes, and species. Two years later it was 
the turn o f an inferior animal: a polyploid oyster.
In 1988 Harvard University obtained a patent on a genetically modified mouse, 
precursor o f a transgenic breed, carrier of a human oncogene that makes it suscepti­
ble to developing tumors. After heated debate, on April 12, 1988, it was granted 
patent No. 4,736,866. The year before, the Commissioner of Patents had estab­
lished that the United States could concede patents to “multicellular non-human 
living organisms, including animals, which do not occur in nature. There have 
been hundreds o f applications to patent transgenic animals but very few have been 
granted.”
In 1990 the United States Supreme Court admitted the patent rights of the 
University o f California regarding a line o f cells that could be cultivated in vitro 
against the pretensions o f Mr. Moore (Moore v. University o f California).
In 1991 and 1992 the United States National Institutes o f Health applied for 
patents for thousands o f DNA segments with unknown function, obtained as copies 
by reverse-transcription o f RNAm. The long dispute on patenting o f DNA and genes 
was beginning.
Since that time and together with the impressive advances in decoding the human 
genome, the debate on the protection of intellectual property has become enor­mously complicated. Novelty and inventive step, discovery, and invention become 
more diffuse factors as progress is made on increasingly complex ground.9 Thus, for 
example, in 1991 Dr. Craig Venter presented patent applications to USPTO for 337 
partial human gene sequences. In 1992 the application was extended to 2,700 new 
fragments which due to the manner of obtainment were called expressed sequence 
tags (EST).
These applications gave rise to an intense debate which still has not concluded. Many biologists were directly opposed to these intentions because they could curb 
basic research and technology transfer in very promising spheres o f genetics. For 
different reasons, associations o f biotechnological companies also requested that 
data on sequences o f the National Institutes of Health (NIH) should be made 
publicly available (Iañez, 2001). In 1997 the USPTO admitted that under certain 
conditions, ESTs were patentable. The first was granted to Incyte Pharmaceuticals 
on October 6 ,1998 . However, new applications and the rather unclear conditions of 
authorization have further kindled the debate.
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Faced with this panorama, the Biotechnological Industries Organization (BIO) 
requested the intervention o f USPTO to clarify the issue and distinguish between 
applications for patents for EST with sufficient utility and EST with rather unclear 
utility. In 1998 USPTO issued some provisional guidelines that led to establishing 
the definitive provisions (“Revised Utility Examination Guidelines”) in December 
1999. These indicate that the invention “should have a specific and substantial 
utility” that “excludes ‘unimportant,’ ‘insubstantial,’ or ‘unspecific’ utilities.”
From then on the situation has become increasingly complex, for unforeseen 
problems appear which have led some specialists to maintain that there is a gap 
between advances in sciences and intellectual property regulations.
The year o f the turning-point in this process was 1980, when USPTO granted 
around 60,000 patents. In 2001 the figure rose to 166,000. Since its independence 
as a country over 200 years ago, the United States has recognized more than six 
million patents, and the number o f unanswered applications is very high. On genetic 
materials alone there are more than three million pending applications.
8.5.2 Regulatory Levels and Frameworks
Patents can be applied for and obtained at national, regional, and international 
level. For the first level there are the specialized national offices, for the sec­
ond the regional authority (e.g., the European Patent Office), and for the third the 
International Patent Cooperation Treaty (PCT) administered by WIPO, under which 
valid patents can be registered in all the signatory countries.
Patents do not grant the same rights in all countries, for each one has its 
own law. For the same reason, authorizations may have different coverage, so 
that comparisons with information from different countries and systems entail 
difficulties.
USPTO, the European Patent Office (EPO), and the Japan Patent Office (JPO) 
are the ones that receive the most applications and authorize the largest number 
o f patents. The agents that apply for and obtain patents are usually classified into 
companies, individuals and government, nationals, and foreigners. It is also possible 
for patents registered abroad to be applied for by the head office in some cases and 
by subsidiaries in others.
8.5.3 Patenting Trends
According to available data, applications for patents grew from 2.3 million in 1994 
to more than 8 million in 2001 and more than 12 million in 2004 throughout the 
world. Applications under the Patent Cooperation Treaty show a similar growth 
rate, from just over 1.1 million to 5 million during the period.
As for the fields in which patents are applied for, there are some differences 
between USPTO and EPO. According to the international classification, in USPTO
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17% of applications fall under the category “Human Needs,” which include foods, 
food production, and transgenics. In EPO the most important category is chemicals 
and metallurgy, although not much more than others.
A research project with USPTO information for the past 10 years shows that the 
United States is the most active country, since between 1980 and 2000 the number 
of patents authorized more than doubled, and between 2000 and 2004 these grew 
60%.
Although the innovating agents that patent the most are individuals and national 
firms, as well as governments, foreigners are the most dynamic.
Japan, Germany, the United Kingdom, France, and Canada are the most active 
countries within the United States, the country that concentrates the most foreign 
patents. One outstanding fact is the high concentration o f patenting activities in few  
countries. Japan is the country that patents the most in the United States, for it holds 
452,737 patents, more than four times the number o f the United Kingdom (101,330) 
and almost 20 times more than the Chinese province o f Taiwan (24,646).
Latin America and the Caribbean are in a very marginal position. M exico is in 
first place with position 24th in the world and 1,907 patents. Fairly far behind is 
Brazil (place 28th with 1,263 patents), Argentina (32nd place with 904 patents), 
and Venezuela (36th with 557 patents).
At the corporate level, IBM o f the United States occupies first place, followed by 
Canon and Toshiba o f Japan and Samsung o f the Republic o f Korea.
The most dynamic fields for patenting in the United States are biotechnol­
ogy and molecular microbiology, pharmaceuticals and compounds, electronics, and 
optic systems (Box 8.2). In the field o f biotechnology, transgenics and associated 
processes, genes, and gene sequences are outstanding.
Box 8.2 Main patenting agents
Biotechnology Agricultural biotechnology
Dow Chemical Monsanto Group (5.9% o f  total patents)
Basf Dupont Pioneer Group (0.2%)
Ciba Geigy Singenta(13.8%)
Monsanto Aventis (15.7%)
United States Government Universities under contract with the above-mentioned




Source: Prepared by the author from USPTO databases.
In transgenics and advanced biotechnology applications on plants, research with 
USPTO data indicated that so far, 4,609 patents have been obtained, of which 902
Table 8.1 United States: patents obtained on transgenics and new plant varieties
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Category No. o f  patents
Total 4,609
Higher cultivable plants, seed plants, or parts 902



















Source: Prepared by the author from USPTO databases.
correspond to higher cultivable plants, seed plants, or parts of plants (Angiosperms 
and gymnosperms); 501 patents for transgenic soy; 423 for pathogen-resistant transgenics; and 336 for transgenics with male sterility (see Table 8.1).With regard to genes and gene sequences, the ranking is as follows:
a) United States Government
b) University of California
c) Smith Kline Beecham Incyte Pharmaceuticals Inc.
8.6 The Challenges
Latin America and the Caribbean as well as many other developing countries pos­
sess an enormous biodiversity and its native inhabitants have for centuries developed 
knowledge and learning on how to utilize that enormous wealth in a sustainable 
manner. One hectare o f Latin America’s tropical forest possesses more biodiversity 
than the entire European continent. Thanks to the work o f the original peoples of 
the region, humanity has foods such as maize and potatoes, among many others. 
The region also has an important base o f scientists and technicians in agricultural 
innovation, but it benefits little from their knowledge. Conservative estimates indi­
cate that in Latin America and the Caribbean more than 150 million people live in 
the rural area, and a significant part o f them in conditions o f poverty and indigence.
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The major challenges for the region in terms o f intellectual property and 
innovation fall within this general picture. The consolidation o f the new reg­
ulatory frameworks o f TRIPS can increase the gap between developing and 
developed countries, unless the former take the necessary measures to rein­
force their scientific development and protect their heritage and their creations 
simultaneously.
The linkage o f these agreements with the free trade agreements points up the need 
for the countries to articulate their efforts to co-ordinate both aspects, particularly 
biodiversity.
The region has an important amount of scientific advances without intellectual 
protection. Many o f them have been generated in institutes and public universities 
with the involvement o f private parties. In view o f the investments made and their 
capabilities, it is a question o f subject-matters that can and should be addressed 
from a public-policy perspective.
Innovative efforts in the field o f scientific and technological development require 
economic scales that the region itself can provide, for instance in agriculture and 
in the protection and utilization o f biodiversity, where a critical mass of quali­
fied scientists is available, whose coordination could be the object o f multinational 
efforts.
In this regard, public policy should consider elements such as the following:
1) Creation o f a regulatory framework that favors care and sustainable use o f biodi­
versity and recognition and protection o f the traditional learning and knowledge 
of indigenous peoples and peasants. This involves making national laws com­
patible with agreements between countries on biodiversity, the fight against 
biopiracy, and norms on bioprospecting contracts.
2) National and regional innovation policies that make possible the sustainable use 
of the region’s capabilities, protection o f locally generated knowledge, adop­
tion o f new technologies with regard to biodiversity and the environment, and 
the entry o f new national innovators. In keeping with the above, establish reg­ulatory measures to prevent monopolistic or almost monopolistic control of 
knowledge.
3) In line with the above, establish measures to neutralize or at least counter 
the control o f complete productive chains via genetic coding o f seeds and the 
exclusion of small farmers.
Notes
1. Organisms are considered transgenic when they are the result o f  genetic manipulation whose 
genome combines genetic materials o f  other organisms with which they have no sexual affinity. 
With current techniques, a transgenic carries its own genetic material and others from viruses 
and bacteria, from plants, and/or animals.
2. Viruses’ position on the border between the living and the inert poses the problem o f their 
origin. For many scientists viruses would be the first beings in the evolution between inert and 
living, effectively combining the functions o f replication, transcription, and translation. They 
would thus be the least evolved organisms (es.wikipedia.org/wiki/Virus).
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3. Hybrids are produced from plants that reproduce by cross-pollination between to sexually 
different individuals. In this case, the seed can only be used for a certain time, for subse­
quently it loses its commercial characteristics. They are plants that have biological or technical 
protection. Farmers must buy the seeds for every crop.
4. Crops with autogamous plants correspond to those that reproduce by self-fertilization and in 
which hybridizing is commercially impossible. In this case the seed can be used for more than 
one cultivation period and it is therefore not possible to count on protection on the basis o f the 
biology o f the plant or on technical protection.
5. The first line o f  argument includes academic media and large corporations and the second, 
some recent papers by Cimoli (2002) and Katz (2005).
6. In pharmaceutical chemistry it is estimated that between 30 and 60% o f patented innovations 
can become marketable products.
7. Human Development Report and Globalization (2000), Sustainable Development Topics, 
Number 2, UNDP, page 39: “ .. .only ten countries accounted for 84% o f world spending 
on research and development, and they controlled 95% o f United States patents in the last 
two decades. Moreover, more than 80% o f patents granted in developing countries belong to 
residents o f industrialized countries.”
8. Novartis recently patented a technology o f  this type which uses a derivative o f aspirin to control 
the growth o f seeds and plant characteristics.
9. Patent law rejects the patentability o f discoveries. The reason is that discoveries do not involve 
a technical contribution and are not the product o f  human ingenuity, which are characteris­
tics o f  the concept o f invention. Nevertheless, as highlighted by the Communication from 
the Administrative Council o f  the European Patent Office o f  July 1, 1999, the importance o f  
biotechnological inventions is ever greater. Since the 1980s more than 15,000 applications for 
biotechnological patents have been deposited in the European Patent Office, o f  which 1,500 are 
for transgenic plants, 600 for transgenic animals, and 2,000 for D N A  sequences. Some 3,000 
have been granted.
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Gabriela Dutrénit
9.1 Introduction
There is growing consensus that a close relationship between science, technology, 
innovation, and growth exists; the creation and dissemination o f knowledge are basic 
factors o f innovation, sustainable economic growth, and the well-being o f nations. 
This idea has already been highlighted by Solow (1957), who suggested that basic 
science is a determining factor o f economic progress.
There are, however, different approaches to the premises of the most appropriate 
science, technology, and innovation policies (STIP), the aims they should follow, the 
actors that should participate in their definition, what institutions will put them into 
practice, and the desirable relationships between science, technology, economics, 
and society.
In M exico’s case, STIP have been changing since the early 1990s, from a supply- 
side approach of support for science to one oriented toward promoting innovation of 
the private sector in market conditions. The change has intensified in recent years, 
shaping the emergence of an innovation policy, which is made up o f a combination 
of instruments gathered from other experiences, such as those o f Brazil, Chile, and 
the OECD.
However, spending on research and development (R&D) has not increased since 
the 1990s (currently 0.4% of GDP), the private sector’s share o f total spending on 
R&D continues to be reduced, the country’s competitive position dropped from 
33rd place in 2000 to 56th in 2004 (according to the International Institute for 
Management Development) and, in general, the innovative behavior o f the play­
ers is limited. Many stakeholders in academia, industry, and civil society perceive 
that there have been no substantial changes in innovation capacity or in national 
technological capabilities as a whole. In fact, there are many aspects to reflect on 
and discuss before arriving at a clear STIP.
This chapter aims to contribute to this discussion with two objectives in mind: 
first, to examine the premises of the design o f STIP, particularly innovation policy, of
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the different agents in Mexico, and second, to discuss the design o f the combination 
o f instruments according to the systemic approach. The method combines theoret­
ical discussion o f the STIP premises with empirical analysis o f the results from 
some of the instruments used. The sources o f information are national statistics on 
the matter and the National Innovation Survey.
Section 9.2 discusses some of the STIP premises and argues the need to focus 
them in a perspective o f innovation system; Section 9.3 analyzes the scope and 
instruments o f innovation policies, as part o f the STIP; Section 9.4 presents dif­
ferent opinions o f Mexican agents on STIP; Section 9.5 studies the characteristics 
of national technological capabilities and the results of certain instruments of 
innovation policy; and Section 9.6 presents a few reflections.
9.2 The Science, Technology, and Innovation Policy 
From a Perspective of Innovation System
The perception on the process o f innovation and its interaction with science and 
technology has been shifting. There are at least five generations o f innovation mod­
els with implications for STIP (Rothwell, 1994). Moreover, it is possible to see the 
evolution of the policies following the conceptions on the innovation model.
The Linear Model, in its Technology Push version o f the fifties, assigned a central 
role in development and innovation activities to the supply o f science and technol­
ogy. According to this model, STIP should basically be oriented to investment in 
science. In the 1960s the Demand Pull Model emerged, in which the market and 
clients were the source o f new ideas, so that STIP should be oriented mainly toward 
identifying client needs and development activities. The Coupling Model (or inter­
active model) o f science, technology, and market followed in the 1970s and 1980s, 
which defines a set o f sequential stages, which nonetheless interact among them­
selves. In this model, STIP should stimulate both technology supply and market 
needs. In the 1980s the discussion on the Integrated Model was introduced, in which 
the functional stages are parallel and highly integrated. In the 1990s the emphasis 
on the Model o f Integration of Systems and Networks, which is an evolution of 
the Integrated Model, became generalized. In this model basic research ceases to 
be an exogenous transmitted knowledge to become closely related to economic and 
technological factors in “nodes o f a network” for the creation o f wider knowledge. 
Consequently, STIP should focus on balancing technology supply and market needs, 
fostering the creation o f networks.
The experiences o f successful STIP suggest that countries’ progress is closely  
associated with constant capacity building in science and technology to lay the 
foundations for knowledge-based development. Modern approaches o f STIP have 
overcome the linear model o f innovation and tend to adopt a frame o f reference 
closer to the model o f integration o f systems and networks and new forms o f pro­
duction o f knowledge in order to reach (1) a balance between supply of and demand 
for science and technology oriented to innovation, addressing economic and social 
needs, and (2) the development o f networks between agents.
Since knowledge is produced today in a context of application by means of 
multidisciplinary configurations, teamwork, and social responsibility, the idea has
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emerged that STIP should orient science and technology toward the solution o f eco­
nomic and social problems (Velho, 2005; Casas, 2005). For this it is necessary to 
place STIP within a perspective of national innovation system (NIS).
Given that NIS is a system o f players, interactions, and structural conditions (see 
Fig. 9.1 ), STIP should be oriented to improving the performance o f the system as 
a whole and not to solving possible market failures, for systems depend on factors 
that change slowly (culture, technological path, governance systems) (Laredo and 
Mustar, 2001; Smith, 2000).
Macroeconomic and 
regulatory context
Education and training _  ^ ' - ' 'G l o b a l  in n o v a tio n " '- -^  _ Communications
system networks inlrastiuctuic
\  National inno ration capacity
Country performance: Growth, job 
creation, competitiveness
Fig. 9.1 Dimensions related to National Innovation Systems. Source: OECD (1998)
The literature highlights the following objectives o f a modern STIP (Laredo and
Mustar, 2001; EC, 2003; Georghiou, 2004):
a) Identify national specificities, weaknesses, and strengths o f the NIS to design 
ad hoc science, technology, and innovation policies.
b) Design a set o f mixed, sustained, and co-ordinated policies between the different 
levels o f government.
c) Design long-term policies based on consensuses, association, and commitment 
among the key actors. Only long-term policies have cumulative effects and bring 
about changes in the behavior o f the agents.
d) Support scientific development to generate knowledge, develop expertise, and consolidate the training o f human resources in science and technology.
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e) Promote close relations between the scientific community and other agents of 
the NIS to efficiently apply the knowledge generated to national needs.
f) Combine direct and indirect innovation policy instruments. The direct instru­
ments should combine demand side policies (of innovative products to encour­
age companies to develop R&D and stimulate the country’s leading innovation 
markets) and supply-side policies (to transfer resources and innovation capabili­
ties to companies from the government and related agents, universities, research 
centers) and instruments o f support when the conditions o f the milieu -  human 
resources, scientific base, regulatory framework, and policy coordination -  are 
critical.
g) STIP involves different levels o f government: local, regional, and national. The 
up-down relations o f politics tend to be incapable o f linking themselves to 
regional/local diversity. It is increasingly evident that in the regions and locali­
ties networks among companies, clients, suppliers, universities, and other agents 
involved in innovation activities are created. The relations within these net­
works are strongly influenced by the regional/local economic, political, social, 
and cultural setting. It is therefore necessary to combine up-down policies with 
down-up policies stemming from the regions and localities.
h) Support initiatives for the development o f clusters with infrastructure, educa­
tion, training, risk capital, spaces for consensus-seeking, etc. Cluster relations 
tend to be down-up, and informal communication and networks play a cen­
tral role.
i) Use the functions o f government to facilitate and spark changes in agents’ 
behavior and promote collective actions and learning processes instead o f sub­
sidizing the development o f previously selected companies and technologies.
j) Strike a balance between investment in the development o f national technologi­
cal capabilities o f high and medium intensity of knowledge and activities based 
on local knowledge and systems.
STIP studies show that policies are adaptations to the context in two ways:
(i) imitation of and inspiration from policies implemented in other countries, and
(ii) own diagnoses o f the problems and absorption o f other countries’ experiences 
(Sanz, 2005). There is increasing consensus regarding the fact that STIPs should 
be long term and should be based on the association and the commitment o f the 
key stakeholders in order to have cumulative effects and bring about changes in 
behavior.
9.3 Innovation Policy: Objective and Instruments
Innovation policy is related to that o f science and technology, but has its own 
objectives. The objectives of science and technology policy are to expand the bor­
ders o f knowledge, train human resources, and contribute to meeting social needs 
(environment, health, etc.) and to economic growth.
9 Premises and Instruments o f Innovation Policy 239
The main objective of innovation policy is applying knowledge to the devel­
opment o f new products, processes, and services. The innovative capacity of 
companies depends on the economic setting and the NIS. Innovation policies seek 
to remedy the deficiencies o f companies or o f the context in which they operate 
with the objective o f increasing the rate and the success o f the introduction o f prod­
ucts, processes, and services (EC, 2003). In this regard, innovation policies are also 
oriented toward supporting the creation and dissemination o f knowledge (strength­
ening NIS) and stimulating company spending on R&D. To this end they seek to 
ensure that companies recognize that investment in R&D will give them sustained 
returns. Private R&D and innovation are in turn linked to economic growth and an 
increase in productivity. Here innovation policy is decisive in improving the dynam­
ics o f NIS, but is not limited to promoting R&D, it includes innovation activities 
related to organization, marketing, etc. (Malkin, 2005).1
Innovation policy is related to other economic policies (competition, industrial, 
labor, financial market, e-commerce, investment, educational). A set o f direct and 
indirect instruments o f innovation policy can be identified to increase the rate and 
the success o f the introduction o f new products, processes, and services. Most o f the 
instruments are direct and are grouped as shown in Box 9.1 (EC, 2003).
Box 9.1 Direct instruments of innovation policy
Supply-side policies -<
Oriented to transferring resources and capabilities for 
innovation to firms from the government and related 
agents (universities, research centers, etc.)
fo rce  o f  support when the conditions o f  the setting 
(human resources, scientific base, regulatory 
framework) and policy coordination are critical 
conditions.
Demand-side policies -<
Oriented to increasing demand for innovating products 
and thus to increasing firms' incentives to develop 
R& D .
Seek to stimulate leading markets in the country's 
innovating activity that can direct the changes required.
In relation to the context in which companies and institutions operate, the 
literature identifies four types o f deficiencies and the most common innova­tion policy instruments to overcome them (Metcalfe and Georghiou, 1998; EC, 
2003). Such deficiencies usually entail resources, incentives, capabilities, and 
opportunities.
Deficiency o f resources means that sufficient resources for carrying out R&D 
are unavailable without public funds. This situation comes about particularly in 
academic research, private R&D in conditions o f considerable uncertainty and in
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cases in which social returns demand an investment that the private sector can­
not or is unwilling to carry out. With regard to incentives, the deficiencies refer 
to the fact that research institutions or the market do not provide the incentives 
for socially desirable behavior (e.g., academia-company linkage). The deficiency in 
capabilities occurs when organizations lack the key capabilities to innovate (e.g., 
abilities to develop business plans or access risk capital). Finally, the deficiency 
of opportunities refers to situations in which there is difficulty in creating inno­
vation opportunities. This deficiency is one o f the main justifications o f public 
science.
Box 9.2 lists a set o f policy instruments and the deficiencies they contribute to 
overcoming. As may be seen, each instrument deals with specific deficiencies and 
can contribute to overcoming one or more, although it can also have a contradictory 
influence, positive in some and negative in others. Therefore innovation policies 
should foresee measures to counteract negative effects.
Box 9.2 Innovation policy instrumentsand deficiencies dealt with
Supply-side measures Resources Incentives Capabilities Opportunities
Support for basic research
Support for public research aimed at 
productive sector
Support for training and the mobility 
o f  researchers
Donations, subsidies, supports and 
prizes for industrial R&D
Tax incentives for R&D
Initial financing for risk capital
Co-localization measures
Support for information and 
intermediation between agents
Measures for the creation o f  networks
Demand for new goods or services
Systemic policies
Source: Based on EC (2003) and Georghiou (2004).
The design and implementation o f innovation policies to induce greater spending 
on R&D and thus expand the rate o f introduction o f new products and processes into 
the market is part o f the agenda o f policy designers in almost all countries (Teubal, 
2002; Bartzokas and Teubal, 2001).
Progress has been made at international level in the building and use o f a set 
of indicators to measure innovation capacity, such as 1) generation of knowledge 
(public-sector R&D, researchers in the public sector, basic research and scien­
tific publications); 2) Science/industry links (private financing o f public research,
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scientific publications cited in patents); 3) industrial innovation (private R&D as per­
centage o f GDP, private researchers for every 10,000 employees, number o f patents 
[triadic] proportion of innovating companies [Oslo Manual]), and 4) organizational 
investment (information and communication, training, value chains). Efforts are 
being made in M exico to gather and systematize information in line with these 
indicators.
The evidence from successful countries suggests that innovation policies should 
have characteristics such as the following:
1) Combine demand-side and supply-side policies to increase spending on R&D 
and improve competitiveness. Excessive emphasis on only one aspect could turn 
out to be useless or counterproductive.
2) Adopt an innovation system perspective.
3) Involve and co-ordinate different levels of government: local, regional, and 
national.
4) Assure sustained investments to create technological capabilities in companies 
and reinforce certain areas o f knowledge in universities and research centers.
Argentina, Brazil, and Chile have some successful experiences o f innovation, 
but lack the NIS approach and continue to have difficulties in creating links among 
agents (Chudnovsky, Niosi, and Bercovich, 2000; Vonortas, 2002; Furtado et al., 
1999; Velho, 2005; Mani, 2004). Mani (2004) argues that the fine-tuning o f financial 
instruments for R&D is not enough and should be complemented with non-fiscal 
instruments, particularly human resources training policies. The success o f such 
instruments depends, among other factors, on the existence o f a sufficient number of 
technicians with capabilities that can be incorporated into R&D activities. A more 
systematic and thorough evaluation is needed, and greater documentation of the experiences.
9.4 Different Perceptions on the Innovation Model
and the Approach to Science, Technology, and Innovation 
Policy in Mexico
The evidence shows that in M exico there is a certain degree of consensus 
among agents on various premises of STIR Box 9.3 shows these and adds the 
divergences.2
Box 9.3 Perceptions on the stip approach in Mexico
Premises agreed on
•  Need for a macroeconomic context that is stable and favors public 
intervention in science, technology, and innovation (STI).
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•  STI contribute to social development and to the building o f a knowledge- 
based society
•  Importance o f scientific research to increase society’s cultural heritage, 
train human resources (generation o f talent), and generate knowledge for 
technological development and innovation.
•  Need to articulate science, technology, and innovation policy with a
balance that solves any redistributive conflicts that may arise.
•  Interactivity as the hub o f policies and creation o f links among disci­
plines and fields o f knowledge, between areas o f knowledge, sectors and
state and regional problems, between local/regional and national policies), 
concurrence o f stakeholders and creation o f networks to build and orient 
science, technology and innovation capabilities.
•  Approach to solve economic and social problems.
Other points in the agreement
•  Reach long-term agreements among the three major actors (government, 
academia, and business sector) to influence who takes the decisions in 
public policies and budgets.
•  Ensure the participation o f  different sectors o f society, considering that 
financing comes from citizens and therefore there should be accountability.
•  Since there are different actors involved in the conception o f SU P, mech­
anisms arc needed so that universities, firms, national institutes, public 
research centers, regional science and technology councils, scientific com­
munities, associations o f producers, public officials and other stakeholders 
set forth their objectives, interests, and demands for knowledge. There 
should be multidirectional communication mechanisms among the same 
and participation o f the stakeholders in discussing STIP follow-up and 
evaluation mechanisms.
•  Advance toward a society based on knowledge that solves priority socioe­
conomic problems and ensures greater social access and transfer o f  
knowledge to improve the quality o f life o f the population. Since eco­
nomic and social problems demand the conjunction o f several disciplines, 
the approach o f the solutions should be multidisciplinary.
•  Distinguish between generation o f knowledge and “innovative applica­
tion o f knowledge,” which entails building bridges between science and 
technology. There is a need to train human resources to bring about the 
required change.
•  Make an agreed-on diagnosis o f national scientific and technological capa­
bilities and a proposal to the political parties that take different scenarios 
into account. Consider the existence o f different traditions, rhythms and 
logics in the production o f knowledge among disciplines, research groups, 
and other stakeholders (universities, public research centers, etc.).
•  Identify sectors and areas in which international technological leadership 
can be exercised and support them with new careers and research centers
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•  Place STIP within a strategy o f consistent national development and in 
an NIS perspective, where learning plays a central role. Analyze systemic 
relations between STIPs and other systems (financial markets, labor mar­
kets, fiscal policy, etc.) and design a comprehensive policy that links the 
policies (STIP, industrial, competition, labor, etc.).
•  Scientific and technological development requires financial resources, and 
it is therefore necessary to assure sustained investments.
•  STIP involves different levels o f government: local, regional, and national. 
The up-down dimension of the policy cannot include regional/local diver­
sity. It is necessary to combine it with down-up policies stemming from 
the regions and localities.•  Policy design responds to a structure o f bodies that legislate and organs 
responsible for the design. The different stakeholders should participate 
but not replace existing structures.
Diverging opinions
•  On political will on the topic o f science and technology.
—  As an argument in favor o f the existence o f political will the approval o f  
the science and technology law by a congress with diversity o f opinions 
was mentioned.
-  As an argument against, it was stated that there was neither clar­
ity on the role of science and technology in development nor policy 
articulation.
•  To what extent there are structural conditions to take a leap in technologi­
cal, economic, and social development.
-  Arguments in favor: a regulatory framework has been created, the sci­
entific and technological community has grown, there is macro stability, 
there is a certain political stability and the interest rate has dropped.
-  Arguments against: loss o f competitiveness as a country (drop to place 
number 56-60  in the IMD) and lack o f articulation among the three 
major actors (government, academia, and business sector) in policy 
design.
•  With regard to the adequate institutional framework to formulate these 
policies, the options appear to be: continue with CONACYT, create a 
Ministry o f Science and Technology, or separate decisions on science and 
technology on one hand, and innovation on the other hand. Nor is there any 
agreement on whether an integrated STIP should be defined or a specific 
policy for each one o f these activities has to be designed.
•  It is not clear how investment in science and technology can have a 
bearing on better living conditions. There is no agreement on the way o f
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identifying basic economic and social needs/problems, or mechanisms to 
orient science in terms o f the kind o f country that is desired.
•  What rationale should prevail: one that is economic and business oriented, 
or a social one? In this regard, there is no agreement on the main policy 
model: academic, economic, or social oriented. There is a perception that 
emphasis was placed on the first since the 1970s; emphasis on the second 
in the last decade and that little attention has been paid to the third.
•  Which should be the functions o f government: some consider that these 
are facilitating and acting as a catalyst for the changes in behavior o f the 
actors; others that they are to chose and subsidize company development 
and specific technologies.
Source; Foro Consultivo Científico y Tecnológico (2005).
The differences o f opinion come from different theoretical-conceptual frame­
works on the model o f innovation, the relationship between STIP and economic 
and social development, and the outline o f activity (academia, industry, and govern­
ment) and institutions ascribed to diverse political positions. Beyond the differences, 
it is necessary to build consensuses in key aspects to achieve a more harmonious 
implementation o f the policies.
9.5 Toward an Assessment of Innovation Policy in Mexico
9.5.1 Evidence o f National Technological Capabilities
Over time, economic growth is the result o f the interaction among a set of 
incentives -  related to each country’s institutional framework -  and its domes­
tic capabilities. Domestic technological capabilities include the ability to make 
effective use o f knowledge to produce goods and services satisfying social needs.
Table 9.1 summarizes some indicators of the technological capabilities o f four 
Latin American countries, including Mexico. It introduces information on the 
Republic o f Korea as a point o f comparison.
The information indicates that Latin America’s endowment o f human resources 
in the 1980s was fairly low in comparison with the Republic of Korea’s, even though 
spending on education as a percentage o f Gross Domestic Product (GDP) and the net 
rate of enrolment in secondary and tertiary education were not much smaller. This 
suggests that the Latin American countries have made an important effort to develop 
their human capital in recent decades, but that the results in terms of quality have 
not been as significant as those o f the Republic o f Korea. This result suggests that 
there are institutional aspects o f the organization o f educational activities that could 
explain these results. First, the indicator for Expenditure in Experimental Research 
and Development (EERD, or GIDE for its Spanish acronym) shows very low values 
in most o f the countries, which evince that the Latin American countries’ efforts in
'O
Table 9.1 Indicators o f  national technological capabilities in some Latin American countries
Republic o f Korea Argentina Brazil Chile Mexico
A. Economic performance
1. GDP billions o f dollars 605.7 126.7 492.2 72.1 620
(2003)a
2. Per capita GDP dollars (2003)a 12,638 3,300 2,757 4,548 6,008
3. Competitiveness ranking3
-2000 29 42 38 30 33
-2004 35 59 53 26 56
B. Human capital
1. Central government spending on education (%  G D P)b
- 1980 3.5 (1990) 1.9 0.7 4.1 3.1
-2001 3.6 4.6 4 3.9 5.1
2. Net enrolment rate (% )b
- Primary (1990) 104 94 86 88 100
- Primary (2002) 101 108 97 89 101
- Secondary (1990) 86 66.5(1985)° 15 55 46
- Secondary (2002) 89 81 72 75 60
- Post-secondary education ( 1980)c - 22.2 12 10.8 14.9
- Post-secondary education (1998)° - - 12.6 31.4 17.6
3. Students in post-secondary education in sciences, 34 30 23 43 31
mathematics and engineering, percentage o f total 













Republic o f Korea Argentina Brazil Chile Mexico
C. Efforts in science and technology
1. Patents granted to residents per million inhabitants, 
2002b
2. EERDd
490 4 0 2 1
- 1996 2.6 0.42 0.77 0.58 0.41
-2001
3. EERD by source o f fundingd
2.91 0.42 0.87 0.57 0.4
- Government (2002) 25.4 70.2 60.2 (2000) 50.5 (2003) 55.5
- Business (2002) 72.2 24.3 38.2 (2000) 35.2 (2003) 34.7
- Others (2002)




- 1996 2,193 651 - 358 215
-2001 2,880 684 323
-2 ,00
419 434
5. PhDs in sciences and engineering obtained by 
foreigners in the United States by citizenship 
o f  origin, 2001e
862 69 141 205
aIM D  (2004); bUNDP (2004); CECLAC (2003); dC O N AC YT (2005); UNESCO (2004), and OECD (2004a); eOECD (2004b). Data on researchers in R&D 
and EERD for the Republic o f  Korea were taken from the World Bank (2004).
Notes: The net enrolment rate corresponds to school-age children with respect to the total population o f  that age. Rates that exceed 100% in the table reflect 
discrepancies o f  information for both categories.
Patents granted were calculated on the basis o f information on patents granted to residents in W IPO  (2004).
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science and technology are still weak. Brazil shows the highest level o f EERD (dou­
ble that o f most Latin American countries), but lower than the Republic o f Korea. 
Second, the EERD by financing source shows that the greatest effort is that o f gov­
ernments, whereas firms do not show a high level of commitment to R&D activities. 
By contrast, Korean firms contribute with a significant percentage o f EERD. Third, 
there are important differences between Latin America and the Republic o f Korea 
with regard to number of researchers and human resources involved in science and 
technology activities.
This evidence suggests that Mexico and other Latin American countries have 
made efforts to increase their domestic technological capabilities through the train­
ing o f human resources, but the resulting educational quality is still poor. In contrast, 
efforts in science and technology fall way behind international standards. Both 
factors contribute to explaining the slow evolution and weakness of technological 
capabilities in recent decades.
9.5.2 Some Characteristics o f R&D Activity and Innovation 
of Mexican Firms
The 2001 National Innovation Survey (1999-2000 data) showed that 33% of firms 
operating in Mexico are innovative, that is, they introduced new products or pro­
cesses into the market during the period. Some 47.5% of innovating firms stated 
that they carried out R&D activities.
Innovating firms follow strategies similar to those of latecomer countries, that 
is, they carry out R&D to differentiate technologies and products, mainly on the 
basis o f machinery and equipment. Their strategies include creation of technology 
for their own use, although they also make great efforts to adapt and assimilate. 
Chart 9.1 shows firms’ main strategies.
Three indicators are used at international level to obtain an approximate measure­
ment o f innovation inputs: intensity of R&D, intensity of spending on innovation, 
and technological intensity. Table 9.2 presents the levels o f these indicators in 
Mexico, which show that a) spending on R&D is not high, the firms that carry out 
R&D spend an average o f 0.7% of their sales on this item (in Spain they spend 
1.8%); b) the companies that carry out R&D tend to make greater efforts in inno­
vation; and c) a high percentage o f spending on innovation refers to machinery and 
equipment, which is an international tendency.
Firms combine internal and external sources o f knowledge. The internal sources 
are important, but the more intense the R&D activities, the greater the use o f external 
sources. However, there is little cooperation for innovation with universities and 
public research centers, which reflects deficient articulation o f the Mexican NIS.
In terms of the results of innovation activities, new products represent 16.2% of 
sales in firms that carry out R&D, a slightly greater percentage than the companies 
that do not carry it out (see Chart 9.2).
This differentiated behavior is greater when we consider the degree of novelty of 
innovations. Chart 9.3 shows that the majority o f innovations introduced by all o f the
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Chart 9.1 Focus o f  the technological strategy o f  innovating firms. Source: Encuesta Nacional de 
Innovación (2001)







Intensity o f  R&D 0.7 0 1.8
Intensity o f  spending on innovation 3.4 2.2 2.4
Technological intensity 30.8 0 33.4
Source: National Innovation Survey (2001).
firms analyzed are only novel for the firms themselves or for the country. But among 
the firms that carry out R&D, a much higher percentage o f innovations translate into 
new products in the international market in relation to the firms that do not carry out 
R&D, 27.4 and 14.5%, respectively. This means that R&D activities are associated 
with better innovative results, sales o f new products represent a higher percentage of firms’ sales, and these tend to introduce a larger amount o f novel products into 
the international market.
9.5.3 Assessment o f Instruments o f Innovation Policy
Over the last few years an innovation policy has been integrated, which in 2005 
translated into a structured set o f instruments which address different deficiencies, 
as described in Box 9.2 (resources, incentives, capabilities, and opportunities). Its
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Chart 9.2 Results o f innovative activity: percentage o f new products in sales. Source: Encuesta 
Nacional de Innovación (2001)
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implementation has been slow and many of the instruments were not implemented 
until the end o f the 2000-2006 six-year presidential term.
9.5.3.1 Combination of Innovation Policy Instruments
Most o f the instruments are supply side, that is, they are oriented to transferring 
to companies the necessary resources and capabilities for innovation from the gov­
ernment and related agents (universities, research centers, etc.). They have been 
designed as supports when the conditions o f the setting (human resources, scientific 
base, regulatory framework) and policy coordination are critical conditions. The
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instruments and the deficiencies they address are shown in Table 9.3. A detailed 
description is included in the work by Daniel Villavicencio in this book.
There are three major articulators o f innovation policy with different degrees of 
maturity: a) CONACYT3 funds, b) fiscal incentives, and c) AVANCE4.
The CONACYT funds are defined in the Science and Technology Law under 
the regime of trust fund. They allow the Council to interact with State ministries, 
state governments, federal entities, academic and scientific institutions, and private 
enterprises. There are three types of funds: a) sectoral, b) joint, and c) institutional.
The Sectoral Funds are trust funds that the Federal Public Administration and 
CONACYT constitute to allocate resources to scientific research and technological 
development.
The Joint Funds5 are supports for state and municipal government to scientific 
and technological development by means o f a trust fund made up of contribu­
tions from the State or Municipal Government and the federal government through 
CONACYT. Their objective is to empower the state and municipal governments 
to allocate resources to scientific research and technological development in order 
to solve strategic problems identified by the State itself; promote the develop­
ment and consolidation of the scientific and technological capabilities o f the 
states/municipalities; and channel resources to help the state’s comprehensive devel­
opment. There are currently 29 co-ordinated state joint funds and one municipal one. 
An evaluation o f their performance is presented further ahead.
The Institutional Funds support the development o f quality scientific research, 
the training of professionals with a high academic level at all grades (with emphasis 
on strategic areas and new, emerging and lagging fields) and the consolidation of 
international-level interdisciplinary research groups that promote national scientific 
development.
Fiscal Incentives for R&D are a program of federal fiscal benefits for taxpayers 
who invest in R&D in order to develop new products, materials, or processes. The 
objective is to reinforce the spending and annual investment made by the firms on 
projects carried out or in process to develop new products, processes, or services. 
The incentives, in force as o f 2001, consist o f tax credits o f 30% of the spending 
and investment under this heading and in training of specialized personnel essential 
for the attainment o f the previously established objectives. This instrument is aimed 
at remedying deficiencies in resources and incentives and is evaluated further on in 
this chapter.Finally, the AVANCE (High Value Added in Business with Knowledge and 
Entrepreneurs by it Spanish acronym) subprogram, assigned to the Program for 
Promotion o f Innovation and Technological Development, whose objectives are to 
promote the creation o f organizations with high value added based on scientific and 
technological knowledge and design and implement and operate seed risk capital 
schemes for the financing o f technology. It is made up o f three instruments: the 
first is “Last Mile,” designed to convert mature scientific and technological devel­
opments into investment prospects that give rise to high value added businesses 
or new lines o f business. The second is the “CONACYT-NAFIN Entrepreneurs 
Program” to support capital investment by firms that develop new high value added
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Table 9.3 Innovation policy instruments in M exico and deficiencies dealt with
Policy measures
Instruments in 
M exico Resources Incentives Capabilities Opportunities Year started
Supports for basic 
research
SEP-
CON A C YT 
basic science 
fund
Continuation o f 




2002 in this form
Support for oriented 
research
Various sectoral 
and jo in t funds
2002
Support for training 






Process 200 5 a




Process only in 2003
Donations, 
subsidies, supports 
and prizes for 
industrial R& D .
A vance-last mile May 2003, call 2004- 
1
Avance- 













Fiscal incentives for 
R& D
Fiscal incentives 










At the design stage
Avance-










AVA N CE tools)






Measures for the 
creation o f 
networks






Source: Author’s analysis o f  the PLASC data.
aCompetitive Grant Process refers to a yearly process called in Spanish “ convocatorias” .
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lines o f business based on scientific and technological knowledge at the commercial 
development stage. The third is the “CONACYT-NAFIN Guarantee Fund,” which 
facilitates access to lines o f credit by means o f guarantees and preferential financing 
to companies that develop new lines o f business.
Furthermore, the instrument “Innovation promotion funds (seed capital)” is 
linked to the AVANCE subprogram with seed capital funds for incipient businesses 
and firms based on the exploitation o f scientific discoveries or technological devel­
opments. As a whole, the AVANCE subprogram mainly addresses deficiencies of 
resources and incentives.
An assessment o f the impact o f some instruments on the increase in private R&D 
should measure inputs, products, and behavior o f additionality. There is evidence 
that certain supports, particularly those associated with the program o f collaboration 
in R&D, do not necessarily generate additional contributions from the firms on the 
resources received (Georghiou, 2002). In Mexico this is especially important for tax 
incentives, sectoral funds, joint funds and consortia, but a study o f additionality is 
not the object o f this chapter.
9.5.3.2 Analysis of Joint Funds and Fiscal Incentives6
These instruments were designed and implemented from the beginning o f the 2000-  
2006 administration so they have a certain maturity and it is now possible to evaluate 
some results.
i) The joint funds. Table 9.4 shows the evolution o f the total amount allocated to the 
joint funds. Charts 9 .4 ,9 .5  and 9.6 show the results o f the 1,425 projects approved and financed in 111 competitive grant processes during the period 2 002-  
2005.
Table 9.4 Evolution o f  joint funds (millions o f  current dollars)
2002 2003 2004 2005
Joint funds 19.4 20.2 18.7 27.3
Source: Prepared by the author based on official C O N A C YT  data on 
the financial situation o f the funds.
An analysis o f the information shows that
•  the state funds in operations and the total amount allocated to financing projects 
have grown constantly;
•  projects have been aimed at scientific research and technological development;
•  the knowledge areas with the highest percentage o f projects approved are engi­
neering and industry (22.6%), biotechnology and agricultural sciences (20.3%), 
and social sciences and economy (16.2%);
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Creation and Creation and Integrated projects 
infrastructure consolidation o f 
strengthening research groups and 
networks
Chart 9.4 Types o f  joint funds, 2002-2005 (projects). Source: Prepared by the author based on 
official C O N A C YT  data on the joint funds
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Engineering and Biotechnology Social and
industry and agriculture econom ics
Biology and Humanities and M edicine and Physics, 
chemistry behavioural health mathematics and 
sciences geosciences
Chart 9.5 Supports by areas o f  knowledge (projects). Source: Prepared by the author based on 
official C O N A C YT  data on the joint funds
•  although the joint funds are oriented toward applied research (82%), a smaller 
percentage of the projects can be classified as technological development (14.5%) 
and basic science (3.5%);
•  the institutions benefited are mainly state higher education institutions (66%), the 
CONACYT research centers (16%), and, to a lesser extent, firms (9.6%);
•  the bias toward state universities contributes to greater decentralization of federal 
resources allocated to science and technology.
ii) Fiscal incentives. This instrument was one o f the most successful o f the 2001-2006 administration. Between 2001 and 2005 both the amount o f fiscal 
incentives authorized and the firms benefited increased. The universe o f firms 
that carry out R&D in Mexico is made up of micro, small, medium, and large 
enterprises in different sectors of activity. This heterogeneity is reflected in fiscal 
incentives, as can be seen in Tables 9.5 and 9.6.
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Chart 9.6 Sponsored institutions (projects). Source: Prepared by the author based on official 
C O N A C YT  data on the joint funds
Table 9.5 Evolution o f the amount o f  fiscal incentives (millions o f  current dollars)
2001 2002 2003 2004 2005
Amount 37.8 45.1 45.5 90.9 272.7
Source: Prepared by the author based on official C O N A C YT  data, 
le 9.6 Evolution o f  the projects submitted by firm size (millions o f current doll
Firm size 2001 2002 2003 2004 2005
Large 31.5 52.5 63.5 85.4 124.9
Medium 22.7 29.3 29.4 38.5 52.4
Small 5.3 9.9 12.8 12.8 21.7
Micro 2.3 5.4 3.2 9.5 15.6
Source: Prepared by the author based on official C O N A C YT  data.
Firms o f all sizes have submitted projects with an increase in micro and small 
ones. A more detailed analysis at firm level shows that o f the 621 firms benefited 
during the period, 327 applied for incentives for the first time in 2005. Moreover, 
the majority o f the incentives were concentrated in few companies. As shown in 
Table 9.7, of the 505 firms benefited up to 2004, 26 obtained 54% of the incentives 
granted throughout the period. Outstanding among them are automotive companies
Table 9.7 Fiscal incentives of the main firms, 2001-2004 (thousands of dollars)
Firm name
Amount
2001 2002 2003 2004 2001-2004 Total amount (% )
Volkswagen de México, S. A. de C. V. 0 0 0 1,390 14,117 6.44
Controladora General Motors de México, S. A . de C. V. 2,679 2,247 3,578 4,490 12,995 5.93
Delphi Automotive Systems, S. A  de C. V. 0 2,818 4,431 3,677 10,927 4.98
Hewlett Packard de México, S. A. de C. V. 2,690 1,876 2,047 2,811 9,424 4.3
Nemak, S. A. 1,789 1,730 1,558 1,514 6,591 3.01
Vitro S. A. de C. V., several 1,909 1,761 1,025 1,478 6,172 2.81
Du Pont México, S. A . de C. V. 2,240 2,084 669 1,043 6,036 2.75
Tip de México, S. de R. L. de C. V. 0 0 640 3,399 4,039 1.84
Tubos de Acero de México, S. A. 386 3,198 443 0 4,027 1.84
Hylsa, S, A . de C. V. 988 926 1,219 451 3,584 1.63
Phi México, S. A. de C. V. 0 1,103 1,050 1,272 3,425 1.56
Daimler Chrysler de México, S. A. de C. V. 0 0 0 3,238 3,238 1.48
Centro de Ingeniería Avanzada en Turbomáquinas, S. de R. L. C. V. 1,100 0 929 1,068 3,096 1.41
Alestra, S. de R, L. de C. V. 2,863 151 35 0 3,048 1.39
Sigma Alimentos several, S. A. de C. V. 615 960 547 826 2,948 1.34
Ford Motor Company, S. A. de C. V. o . , . :- 0 0 2,607 2,607 1.19
Centro de Investigación de Polímeros, S. A . de C. V. 0 874 950 761 2,585 1.18
Galvak, S. A . de C. V. 233 56 652 1,590 2,532 1.15
Investigación ide Tecnología Avanzada, S. A. de C. V. 398 274 98 1,660 2,430 1.11
Mabe México, S. de R. L. de C. V. 0 0 1,695 715 2.410 1.1
Toyota Motor Manufacturing de Baja California, S. de R. L. de C. V. 0 0 0 2,326 2,326 1.06
Metalsa, S. de R. L. 0 847 372 1,086 2,305 1.05
Transmisiones y Equipos Mecánicos, S. A. de C. V. 339 499 537 890 2,265 1.03
Laboratorios Silanes, S. A . de C. V. 564 0 699 911 2,174 0.99
Ganaderos Productores de Leche pura, S. A. de C. V. 0 709 878 585 2,172 0.99
Probiomed, S. A . de C. V. 650 513 504 196 1,863 0.85











Table 9.8 Reported spending on research (millions o f dollars)
Firm size 2001 2002 2003 2004
Micro 4.0 3.6 2.7 9.0
Small 9.5 22.3 29.6 39.3
Medium 49.0 175.4 104.4 115.0
Large 4.0 3.6 2.7 9.0
Source: Esteva Maraboto (2005).
Table 9.9 Project size (dollars)
Incentive applied for Number o f  projects
More than 1 million dollars 35
Between 100,000 and 1 million dollars 347
Between 10,000 and 100,000 dollars 938
Less than 10,000 dollars 286
Source: Esteva Maraboto (2005).
and companies with Mexican capital that carry out R&D activities (Vitro, Nemak, 
Hylsa, Metalsa, Probiomed, etc.).
In parallel to the duplication o f the number o f firms benefiting from fiscal incen­
tives, reported spending on R&D has quadrupled (see Table 9.8). This evolution 
can be partly explained by the firms’ increase in spending in the 4 years (General 
Motors; Hewlett Packard; Investigación de Tecnología Avanzada, Galvak, Metalsa) 
and partly by the inclusion o f new firms with high expenditures (Volkswagen, Tip 
de México; Daimler Chrysler; Sigma, Ford Motor Co., etc.).
As appreciated in Table 9.9, the average value o f the projects is small, since the 
majority of them report spending between 10,000 and 100,000 dollars, and there are 
only 35 projects with spending above 1 million dollar.
The innovations reported are technological applications based on packages of 
existing knowledge (customizing), identification and development o f opportunities 
to improve costs or quality, development of improvements, design adaptation of ele­
ments for local supply, and development o f systems and other back-up instruments 
to improve business administration.
In general terms, fiscal incentives reveal certain characteristics: firms o f all sizes 
have received them, although one third were applied for by large companies. The 
number o f firms that have obtained fiscal incentives by their R&D spending has 
increased, which shows greater dissemination o f the instrument. However, only 26 
firms received 54% of the benefits, among them various subsidiaries o f multinational 
corporations explain a high percentage of the incentives granted. Furthermore, the 
average value o f the projects is small, for most o f them reported spending o f between
10,000 and 100,000 dollars. Finally, the low average amount o f the projects and 
the objectives and nature of the innovations generated seem to indicate that R&D 
is aimed more at bringing about incremental improvements than new products or 
processes.
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The projects have different objectives, from disperse and random actions for 
improvement by individuals or temporary groups, professionals or technicians dedi­
cated to other functions who carry out isolated tasks to seek improvements, product 
of factory engineering groups with time and resources assigned to research, to 
groups dedicated to R&D in an exclusive or preferential manner. This result is con­
sistent with the data reported by the National Innovation Survey on the formality 
of R&D activities and the personnel dedicated to these activities. Only 64% of the 
companies that carry out R&D have a laboratory, and many firms do not report personnel dedicated to these activities.
The high share o f automotive assembly plants in the total o f fiscal incentives 
assigned is noteworthy, since they do not have a tradition o f carrying out R&D 
activities in Mexico. A  more detailed study o f this instrument is required in order 
to evaluate to what extent the incentives have supported spending on R&D, and 
basically experimentation, instead o f development, which entails identifying the 
activities reported by the beneficiaries.
9.6 Final Reflections
International experience shows that innovation policies are important in improv­
ing the dynamism o f national innovation systems and countries’ competitiveness in 
products with high value added. But success appears to depend on the combination 
of instruments on the demand and supply sides sustained over the long term.
A number o f studies have documented that Mexico, like various Latin American 
countries, is weak in the design o f the STIR Although some policies applied over the 
last few decades have resulted in the creation o f an infrastructure o f human capital research and development, the same cannot be said about companies’ technological 
behavior. Due to the macroeconomic turbulence that these countries have confronted 
in recent decades, firms have developed a defensive behavior that has negatively 
affected the option to invest with a long-term outlook.
M exico has a great deal to do so that STI contribute to economic development. 
International evidence shows that sustained policies are needed in order to advance. 
In view o f the differences in opinions on different aspects o f STIP, it is necessary to 
encourage the necessary consensus to guarantee the design and implementation of 
a sustainable strategy over the long term.
An initial approximation to the analysis o f STIP in the 2000-2006 administra­tion suggests that beyond the efforts made, design and implementation weaknesses 
persist:
1) A long-term approach based on the consensus and commitment o f the key play­
ers is lacking, which counteracts the cumulative effects and the expected change 
in the behavior o f the agents.
2) Certain changes in the instruments employed in the period gave rise to confusion 
among the players, which does not contribute to altering their behavior.
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3) A systematic and sustained NIS approach is lacking. STIP has been more geared 
to solving market failures than to solving those o f the system as a whole.
4) Different conceptions on the innovation model persist, and many policy makers 
seem to assume the old idea o f the linear model.
5) Beyond decentralization efforts, an up-down approach persists which is imposed 
on the down-up proposals that emerge from the regions.
The study of innovation policy showed that
1) The approach to the STIP until the end o f the 1980s was basically supply side. 
An innovation policy was gradually designed in the 2000-2006 administration.
2) Combining demand and supply innovation policies has been lacking. The 
measures continue to be basically direct on the supply side. Various novel 
instruments have begun to be implemented or have been designed but not 
implemented, which weakens STIP as a whole.
3) Policy instruments in M exico tend to be changed every 6 years by the incom­
ing government, which hinders cumulative effects to change the behavior o f the 
agents. It is likely that this practice will be maintained.
4) The design o f the innovation policy has been articulated around three instru­
ments with different degrees o f maturity: a) the CONACYT funds, b) the fiscal 
incentives, and 3) AVANCE.
5) This chapter studied the joint funds and the fiscal incentives. Significant progress 
can be observed in the impact o f these instruments. The joint funds have 
increased substantially and have contributed to greater decentralization o f the 
resources allocated to science and technology. The number o f enterprises using 
fiscal incentives has also increased. The literature points up that there are firms 
that become captives o f this type o f instruments, which makes it necessary to 
measure the additionality to have a clearer evaluation o f their impact.
The STIP is not sufficient to induce sustained growth in the industrial sec­tor. It is necessary to articulate it with industrial policies oriented to productive 
development (Pères, 1997; Katz, 2000) and with competition policies designed to 
change the conditions in which different types o f firms compete (Tavares and Tineo, 
1999). Furthermore, there is a need to design and implement a combination of 
horizontal and vertical policies that integrate the down-up-down dimension o f activ­
ities. In other words, there is a need for joint, sustained, and co-ordinated policies 
between the different levels o f government and long-term strategies, consensuses, 
association, and commitment of the key stakeholders.
Notes
1. OECD and EC focus on innovation policies instead o f STIP. In the case o f developing countries, 
which have limited scientific and technological capabilities, it seems that is more appropriate to 
focus on STIP.
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2. Foro Consultivo Científico y Tecnológico (2005).
3. C O N A C YT  is the Spanish acronym form the Mexican National Commission o f Science and 
Technology ( www.conacyt.gob.mx).
4. AVANCE is the Spanish acronym for the program High Value Added in Business with 
Knowledge and Entrepreneurs.
5. In Spanish, Fondos Mixtos (FO M IX )
6. See Dutrénit et al. (2006) for a detailed study o f  the 2000-2006 science and technology program 
in Mexico.
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Chapter 10
R e c e n t  C h a n g e s  in  S c i e n c e  a n d  T e c h n o l o g y  
P o l i c y  in  M e x i c o :  I n n o v a t i o n  I n c e n t i v e s
Daniel Villavicencio
10.1 Introduction
In the current context o f trade liberalization we can see the development and co­
existence o f novel processes and dynamics which suggest new ways of designing 
and implementing policies to foster firm production and innovation. For instance, 
trademark exploitation (franchises) and production methods for durable goods for 
personal and domestic use (apparel, footwear, domestic appliances, and even cars) 
reinforce the tendency toward worldwide standardization. Moreover, there is a trend 
toward economic specialization in regions and countries. Production processes have 
gradually been segmented into links in worldwide production chains in regions, 
which has promoted specialization in firms manufacturing parts and components 
and product assembly. The subsidiaries o f multinational corporations and national 
companies participate in this trend in different ways, irrespective o f size.
At world level, we see the forming o f clusters and chains o f production with 
particular forms of coordination and hierarchical relations, which depend on the 
complexity of the components manufactured or assembled, on knowledge and 
human capital and on the capacity o f companies to obtain the inputs and services 
necessary to create value and keep up the productivity standards demanded by the 
global chain.
The national and regional offer o f intellectual capital, services to production and 
to trade, incentives to productivity and innovation, as well as political and macroe­conomic stability determine the attraction for investment and the establishment of 
links in global production chains.
The regulatory action o f the State by means o f public policy programs must 
contribute to creating room for companies to take advantage o f the opportunities 
and counteract the negative effects o f the trade opening. To what extent have the
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industrial and technological development policies in effect in M exico contributed 
to creating supports in keeping with productivity, innovation, and competitive 
needs within the framework o f global market dynamics and transnational chains 
of production and creation o f value?
The purpose o f this chapter is to analyze transformations in the design and exe­
cution o f industrial and technological policy in recent years in M exico as o f the 
different programs implemented by CONACYT and other institutions.1
Section 10.2 contains a general reflection on the changes in industrial and tech­
nological policies (hereinafter ITP) at world level. Section 10.3 includes a brief 
outline o f the evolution and distinctive features of the policies to promote indus­
trial development in Mexico. Section 10.4 presents the main characteristics o f the 
general pattern and functioning o f institutions, programs, and mechanisms imple­
mented in the last few years in M exico based on certain amendments to the Science 
and Technology Law and on program design.
10.2 The New Premises of Industrial and Technological Policy
This section introduces the main transformations in the conception and design 
o f industrial and technological policy (ITP) on the argument that the world 
scenario characterized by globalization has particular effects on industrial sectors 
and regions, so that the design o f the new ITPs responds to the demands o f the 
“current technical-economic paradigm” (Freeman and Pérez, 1988). This paradigm 
compels firms to increase their productivity and competitiveness based on new 
technological and organizational competences, greater use o f knowledge and new 
institutional links.
Another important aspect is the role of public policy in the promotion o f compa­
nies’, sectors’, regions’, and even countries’ innovation. In this regard and from 
the perspective o f the evolving economy, Edquist (2002) states that public pol­
icy does not mean solving market “failures,” but market “problems.” This idea is closely linked to the neo-institutionalist approach, which highlights the function o f 
institutions as a framework for company operations and relations in the market.
The point to underscore is the role o f the State and public policy in the design 
and implementation o f market regulation mechanisms. Under the premise o f the rationale and limited action o f stakeholders in the market, it is clear that the attain­
ment o f companies’ objectives and interests is possible in the space established by 
the interests and actions o f the other stakeholders. Tensions and conflicts between 
them are settled within the framework o f the laws governing trade, investment, labor 
markets, intellectual property, etc.
Now, the market is built by the action o f firms and other institutions at the macro, 
meso, and micro levels. Those actions in turn give rise to new specific forms o f co­
operation, but also to tensions (competition, for example) which must be settled by 
the laws, programs, and related public institutions (problem-solving policy).
The third aspect is the prevailing concept o f the meaning and dimensions o f inno­
vation. Innovation is a process o f knowledge creation based on existing knowledge,
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exploration, and exploitation o f new opportunities. It requires learning processes 
and acquisition o f cumulative technological, productive, and organizational capa­
bilities which result in better and/or new processes and products in the market (Dosi 
et al., 1988). In these processes, companies develop capabilities to articulate their 
internal technological and organizational experiences, both individual and collec­
tive, with those obtained in their interaction with the environment (Villavicencio 
and Arvanitis, 1994).
Innovation occurs in firms, not in an isolated manner, but in interaction with 
other firms or public and private Research and Development (R&D) agencies and 
universities. Moreover, the ideas of where, how, and when to innovate not only 
come from entrepreneurs, engineers, and researchers from R&D laboratories but 
also come from interaction with suppliers, clients, and even from the actions of 
competitors.
The creation o f technological knowledge has increasing, varied time-frames and 
processes and is distributed among more and more stakeholders, and therefore 
the forms of interaction between these and the speed of circulation o f knowledge 
become central aspects of innovation. Therefore, production chains, sectoral clus­
ters, and innovation networks take on importance to the extent that they offer less 
costly knowledge dissemination mechanisms, becoming collective stakeholders that 
foster co-operative innovation.
The learning of new technological capabilities, the acquisition and capitalization 
of knowledge, and the capacity to translate it into new processes and products have 
been the central element o f firms’ innovation strategies since the end o f the 1980s. 
The learning process and the use o f knowledge are linked to the size and financial 
capacity o f firms, as well as to the characteristics o f the sectors in which these 
operate, including the immediate (regional) institutional setting (Malerba, 2003).Thus, technological knowledge demands firms to develop innovation strategies 
that integrate commercialization, services, organizational changes, use o f patents, 
and others (Nyholm et al., 2002).
For many years technology was conceived as a “material” good (machines 
and techniques) available on the market for all companies. Thus, industrial and 
technological strategies were basically conceived as fund distributors to acquire 
“material” technology and thus increase firms’ economic performance. These poli­
cies, which we can call “sole-instrument” (Lipsey, 1998), did not distinguish 
sectoral dynamics and firm characteristics, namely size, market, products, techno­
logical intensity of productive processes, organizational and technological capacity 
(Villavicencio, 1993).
Nowadays, ITP design and decision makers assign an important role to technol­
ogy due largely to the thrust and dissemination of microelectronics, new materials, 
and information and communication technologies, which have shown a growing 
capacity to overcome company productivity and adaptability to markets since the 
1980s. The introduction o f these technologies has been accompanied by substantial 
changes in organization o f labor and of the firm as a whole.
Toward the end o f the 1980s a combination o f approaches and conceptual pro­
posals on the content of the new technologies appeared. Research projects during
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those years underscored that technology was more than a strictly technical “mate­
rial” artifact, for it included intangible and organizational aspects relative to the 
use o f information, the appropriation o f knowledge, and interaction and cooperation 
with multiple agents. This expansion o f the concept made it possible to clarify two 
issues:
1) It is not enough to acquire technological goods to increase productivity or 
economic performance, but to acquire the information necessary to use them, 
develop operational abilities, implement mechanisms for the dissemination of 
knowledge, etc.
2) Firms are social institutions with economic ends; they are the product o f relations 
and rules built by individuals possessing diverse backgrounds and purposes. 
They are also heterogeneous entities with different capabilities to acquire and use 
technology, and they therefore take advantage o f market opportunities through 
different strategies.
Such considerations form part o f the OECD (1994, 1996) recommendations for 
the design o f countries’ industrial and technological policies. Recent studies place 
emphasis on an important change o f conception and implementation of these poli­
cies on the basis o f the characteristics o f real economic stakeholders, considering 
their different productive capacities, technological competences, market strategies, 
etc. (Niosi and Bellon, 1995; Eliasson, 1998; Archibugi and Iammarino, 2003; 
Laredo and Mustar, 2001).
This change is also reflected in the types o f financing o f technological develop­
ment and innovation, which used to be extended as loans and direct credits for firm 
projects. Without abandoning these types completely, financing today is granted 
indirectly as tax deductions or scholarships to professionals for research stays that 
make it possible for firms to have highly qualified personnel available at low cost.2
Another type is the promotion and joint financing o f research and innovation 
networks, such as jointly sponsored projects or with risk capital for R&D in asso­ciation with universities and basic and applied research laboratories (Amitav, 1990; 
Bellandi, 1992; Arvanitis, 1996). This type makes it possible to save on costs, 
especially for companies without the financial capacity and infrastructure required 
by R&D projects. For academic and research institutions, association with com­
panies enables them to obtain resources for research and productive expansion of 
innovations and even obtain the respective patents.
The promotion o f co-operative innovation networks has been accompanied by 
the strengthening o f intellectual property instruments (licensing, patents, etc.), espe­
cially as concerns emerging technologies, with the object o f assuring protection of 
knowledge, appropriation o f its benefits, and control o f its dissemination.
The redefinition o f ITPs in the last decade involves public and private insti­
tutions in the design o f objectives, mechanisms, and instruments; distribution of 
resources and financing; and even evaluation o f results. The purpose o f these new 
policies is to support firms in acquiring and improving technologies (hard and 
soft), increase R&D activities, and take the opportunities to innovate (Metcalfe
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and Georghiou, 1998). In this regard, policies are not only aimed at redefining 
the framework for solving market problems but to take advantage o f opportu­
nities (opportunity-creating policy) generated by technology, dissemination and 
appropriation o f knowledge, etc. (Edquist, 2002).
10.3 Heritage and Evolution of Industrial and Technological 
Policies in Mexico
M exico’s industrial policy has been linked to the import substitution model which 
prevailed for over 40 years. This model brought with it a combination o f features 
that forged the heritage o f industrial and technological development and o f firms’ 
actions, features which the current globalization and technological competitiveness 
have obliged to modify substantially. We can distinguish at least two stages in the 
alternative industrialization model. The first, from the fifties to the end o f the 1960s, 
was characterized by stable economic growth; the second, as o f the 1980s decade, 
imposed limits on the model and began a transition to the mid-1990s. As of that 
time a new regulatory framework began to be put in place, in which technology, 
innovation, and the markets’ global-regional dynamics acquired an essential role 
for the economic performance o f enterprises and the country as a whole.
However, it was not until the first years o f this decade when more horizontal and 
selective policies were adopted which fostered innovation, favoring private joint 
financing and cooperation with academic institutions and public R&D centers.
10.3.1 Period o f Import Substitution
The first stage in the import substitution period was characterized by attraction 
o f foreign capital to boost national industrialization. It was a period when large 
transnational corporations’ investment in the most dynamic sectors (engineering, 
chemical and pharmaceutical, automotive, and household appliances) predomi­
nated. For some authors, the strategy during this stage was simply to welcome any 
investment aimed at manufacturing goods in the country (Halty-Carrère, 1986).
More selective industrial policies were established in the 1970s, favoring invest­
ment o f domestic capital with laws for the protection o f strategic industries and 
stricter regulation of foreign investment and technology transfer. It was a defensive 
strategy to reduce the economic influence o f foreign corporations and strengthen 
domestic industrial groups to create jobs and new markets, make more efficient 
use o f natural resources, etc. Nonetheless, the protection mechanisms, price insta­
bility, and the shortage of inputs did not favor an improvement in technological 
capabilities, much less the strategies o f entrepreneurial innovation.
Box 10.1 summarizes the general characteristics o f the context, the industrial 
policy o f the times, and companies’ behavior. The distinctive trait is companies’ lack 
of interest in technological development in a context o f relative economic growth 
and growing demand for low-cost, standardized products. Entrepreneurial actions
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were oriented to establishing political agreements with the elites in power with the 
aim of obtaining spaces for free play to obtain earnings to the detriment of their 
productive and technological capacities (Tirado, 1994; Luna, 1995; Mújica, 1997; 
Pérez, 1996; Alba, 1997).
Box 10.1 ITP during the period of import substitution, 1950s-1970s
General context
Characteristics o f  
firms’ behavior
Institutional actors o f 
industrial policy and o f  science and technology
General policy 
objectives
Instruments types of 
financing
Economic stability and relative growth
-  Industrialization dominated by strategies of 
multinational corporations
-  Almost exclusive use o f public resources by large 
domestic enterprises
-  Deficient industrial infrastructure
-  High cost o f R&D
-  Little dissemination o f technological information
Save cost of factors and increase productive capacity
-  Little vertical integration, few chains o f production
-  Dependence on suppliers o f foreign equipment and 
technology
-  Adaptive learning and reverse engineering with 
high costs
-  Copies o f products and process improvements, 
lack o f innovation
Lack o f coordination among instruments, agents, 
and services of technological and industrial 
development
-  Diverse public institutions contribute to policy 
formulation (SPP, SECOFI, NAFIN, SEP, CONACYTa) which operate in an isolated manner 
and repeat patterns
Increase in infrastructure for productive capacities 
and employment
-  Effort to increase and improve human resources
-  Financial support projects for large firms’ 
technological development projects
Programs to finance infrastructure and productive 
capacity projects
-  Export information services-  Subsidies, trust funds, direct credits under 
guarantees that only large firms cap comply with
-  Public financing, exclusively,;
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Characteristics of 
policy operation
Implications for firms' 
learning and innovation 
capacities
Vertical and direct policies
-  Offer o f supports for short-term projects
-  No quality evaluation of results
-  Red tape in procedures and selection
-  Nature of firms, sectors, and regions not 
discriminated
Firms are passive and not very receptive
-  It is hoped that policies will replace firms’ 
shortcomings
-  Some firms succeed in improving their productive 
capacity
-  Technological dependence on foreign suppliers is 
not overcome
-  Innovation is sporadic and only in large firms
-  Few firms benefit from the policies
Source: Prepared on the basis ol Villavicencio (2000).
"For their Spanish acronyms: SPP. Secretariat o f  Programming and Budget: SECOFI. 
Secretariat o f Trade and Industrial Development; NAFIN , development banking institution 
(Nacional Financiera); SF.P, Secretariat o f education; C O NACYT, National Commission o f 
Science and Technology
Prominent in Mexican industrial policy is the creation o f public institutions 
which, at times repeating inherited objectives, granted subsidies and direct financing 
to short-term projects aimed at job creation, almost the only objective o f industrial 
policy. Finally, it should be noted that the supply o f services and public benefits 
was only useful to large companies that were capable o f meeting the guarantees and 
conditions to obtain and reimburse the financing (Villavicencio, 2000).
10.3.2 Transition Period as o f the 1980s
The second period, the transition, initiated in the early 1980s, was character­
ized by a set o f structural problems associated with the energy crisis o f the 1970s, 
its late impact on the Mexican economy, and by the obstacles inherited from the 
previous model, which became evident in the face o f the new world trends. The 
structural problems were reflected by high costs deriving from inefficient production 
and marketing o f goods (transportation and communications problems), monop­
olistic positions in some sectors, protectionist barriers to international trade, and 
little pressure to raise productivity and competitiveness, which was reflected by few 
incentives for innovation.
In the second half o f the 1980s changes began to be introduced into the regulatory 
framework o f the economy in general and trade, industry, and services in particular,
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which were expressed in opening up to international trade, liberalization of for­
eign investment, elimination of state subsidies, promotion of exports, and policies 
to increase the productivity of national industries.
A  notable change during this period, which was prolonged into the mid-nineties, 
was the role assigned to the technological dimension of productive processes by 
means of policies and programs to promote a culture of quality and technology and 
encourage technological modernization. The rules for public financing for scien­
tific and technological activities were reformed, a new industrial property law was 
enacted and specialized agencies for the certification and metrology of productive 
processes were created.
Box 10.2 summarizes the general characteristics of the period and shows that 
despite the changes in the general conception of ITPs and the problem of tech­
nological modernization of firms, institutional inertias from the preceding period 
prevailed, with after effects on instruments and objectives, as well as on the behavior 
o f firms.
Box 10.2 ITP in the transition period from the 1980s to the mid-1990s
Contraction of markets and increase in 
international competition 
General context -  Need to modify production structures
-  Economic and financial crises (1982,1987, 
1994)
-  High mortality of firms
-  Shortage o f public resources
-  Deficient industrial infrastructure and 
scarce R&D
-  Increase in investment in maquiladora 
industry
Optimize resources, technological 
modernization, and search for productive 
efficiency
-  Little vertical integration, few chains of 
production
-  Lack of liquidity ánd investment
-  Dependence on suppliers o f foreign 
equipment and technology
-  Adaptive learning and reverse engineering
-  Improvements in products and processes to 
remain in the market and little innovation
Characteristics of 
firms’ behavior
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Institutional actors of 









Lack of coordination among instruments, 
agents, and services for technological and 
industrial development
-  Science and technology policies under 
CONACYT supervision compete with 
those of other agencies (SECOFI, NAFIN, 
BANCOMEXT®)
-  Decentralized agents emerge to promote 
links between public and private actors
Promotion o f firms ' technological 
modernization
-  Continuation of many objectives of the 
previous period
-  Creation of infrastructure and services for 
metrology and certification
-  Efforts to increase the participation of 
private agents in technological 
development
-  Financing to obtain technological 
information, access export markets, 
training
Programs to finance projects for 
infrastructure and productive capacity
-  New rules for direct and indirect public 
financing
-  Predominance of public financing
-  Information services for exporting, finding 
suppliers, metrology, technological 
training
-  Subsidies, trust funds, funds for risk 
projects
-  Deregulation to encourage private 
financing
Reconversion policies
-  Aim of simplifying procedures
-  Lack of evaluation of result quality and of 
institutional coordination
-  Promotion o f the participation of private 
agents and of links between universities 
and companies







Competition obliges firms to seek 
competitiveness strategies
-  Credits and technological modernization 
instruments enable some companies to 
improve their technological infrastructure
-  Some companies carry out R&D to 
improve products and processes
-  Some domestic firms (large and medium) 
succeed in being innovative
-  Networks of firms emerge to externalize 
technological development
Source: Prepared on the basis o f  Casalet et al. (1995) and Villavicencio D. (2000). 
“Acronyms as indicated in Box 10.1. BANCOM EXT, Bank o f  Foreign Trade.
There have been few studies on the action of entrepreneurs and business insti­
tutions such as chambers and their role in the construction of relations with the 
State favorable to the country’s industrialization. Several authors coincide on point­
ing out the importance of the political links between business organizations and 
the successive governments (Story, 1990). For Mújica (1997), for example, busi­
ness chamber acted historically as support and corporate negotiation in the building 
of the State, which had an influence on the unequal development of economic 
sectors. Attention to entrepreneurial demands used to occur under circumstan­
tial pressures, which did not favor the development of a competitive industry, 
either.
Thus, while public institutions in charge of designing and implementing ITP 
were modernizing, companies and business chambers kept up old habits o f emi­
nently political interlocution with the State, with a lack of demands for instruments 
in keeping with the process of productive and industrial restructuring of the period. 
The very supply of ITP instruments and entrepreneurial proposals was limited to 
demands to reduce costs of raw materials, services, taxes, etc.
10.3.3 The Period o f Opening
It was not until the second half of the 1990 that a new framework for the design of 
industrial and technological policy was introduced, which coincided with a currency 
depreciation crisis and a deep but brief recession.
The patterns of monopolistic behavior and technological autarchy of many com­
panies, inherited from the import-substitution model, were combined with lack of
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liquidity, increase in debts and, for the same reason, lack of investment, increase 
in the costs of foreign technology and services to production. At the same time, 
a period of accelerated competition not only in high technology and value added 
goods but also in products from traditional sectors and mature technology with 
countries with lower labor costs such as those o f south-east Asia and China. The 
mortality of small and medium-sized enterprises (SMEs) increased and many large 
domestic firms were obliged to reduce their supply of products and establish agree­
ments and strategic alliances with foreign firms in order to survive and remain in the 
domestic market.3
The process experienced by the industrial sector during the first half of the 1990s 
constitutes, in our view, the reference point for the modernization of ITPs. Many 
institutions restructured their policies, seeking greater coordination with other agen­
cies and trying to avoid overlapping of objectives and instruments. The main aspect 
of the new policies is based on the need to increase productivity and the qual­
ity and competitiveness of firms to satisfy the domestic market faced with foreign 
competitors and to increase firms’ exports.
Another important feature of the new ITPs is the promotion of association 
and cooperation among firms in order to integrate the smallest and weakest into 
sectoral chains to avoid the reduction of the productive plant and employment. 
Sub-contracting exchanges, programs of technological incubators and programs of 
university-company linkage received more attention with the aim of saving firms’ 
specific costs such as those associated with technological development and invest­
ment in machinery. The implementation of ITPs tended to decentralize, regional and 
sectoral agencies were created, promoted by state governments, and regional insti­
tutions emerged that relied on public financing, but with autonomy to design and 
implement entrepreneurial promotion programs, especially SMEs.
Entrepreneurial agencies, for their part, began to show greater interest in tak­
ing part in the conception of ITP. In some cases, business chambers acted as 
regional consultative bodies and co-operated with public institutions to design and 
operate programs of their interest. Box 10.3 summarizes the main aspects of this 
period.
Box 10.3 Description of ITP in the period of opening 1995-2000
Unstable macroeconomic scenario and shortage of 
financial resources
General context -  Increase in demand and adaptation of foreign
technology with competitiveness in mind
-  Macroeconomic stability
-  Industrial structure dominated by strategies of large 
multinational and domestic firms
-  Insufficient domestic R&D
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Characteristics of firm 
behavior
Institutional actors of 
industrial policy and of 
Science and 
Technology
General objectives of 
the policies




Efforts to improve production processes, quality 
and economies of scale, and learning oriented to 
increasing productivity
-  Lack of liquidity
-  Technological modernization processes and 
productive efficiency
-  Strategic alliances and chains of production
-  Tendency to specialization in products
^ Proliferation of the “maquiladora" companies 
scheme in many sectors
-  Some innovations of products and processes
Emergence of public and private bridge 
institutions
-  CONACYT acquires the status of institution for 
the promotion o f Science and Technology 
policies
-  Creation of regional and sectoral agencies that 
implement support programs for science and 
technology on the initiative of local governments
Promotion of technological capacities, 
productivity, and quality. Continuation of 
objectives of the previous period
-  High-risk and shared-risk project financing
-  Financing at regional level
-  Financing for the integration of chains of 
production and exports
-  Promotion of incubators, development of 
suppliers, productive associations
Programs to finance technological development 
programs and innovation
-  Trust funds, public funds for risk projects
-  Information for technological exports, suppliers, 
certification, metrology, technological training
-  Scarce private financing for technological 
development
More inducive horizontal policies
-  Creation of quantitative assessment mechanisms
-  Insufficient institutional coordination
-  Simplification of procedures
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-- Promotion of cooperation and networks
-  Search for profitable projects and incentives 
to innovation projects
-  SMEs receive more attention
Some firms active, others defensive
-  Firms try to maintain market positions 
through prices (niches) and in some cases 
through technological advantages
-  Firms’ technological capabilities are used to 
substitute machinery and equipment due to 
the difficulty in accessing foreign 
technological markets
-  High costs of access to information and to 
tech nologicalknowledge
-  Many firms use their innovation potential for 
marketing activities
-  Innovation networks (firms, institutions, etc.) 
arc weak
Source: Prepared on the basis o f  Casalet (2000) and Villavicencio (2001 ).
10.4 Recent Changes in Science and Technology Policy 
in Mexico and the New Programs to Foster 
Innovation
The entry into force of Mexico’s free trade agreements with countries o f North 
America, Latin America, the European Union, and others since the mid-1990s coin­
cided with the process of macroeconomic and financial stabilization, conditions 
which favored greater certainty for domestic and foreign investment, savings, trade, 
and productive activities in general.
At the same time, these changes allowed a greater presence of global corpora­
tions in the domestic market, which altered the conditions of competition through 
the introduction of greater technological and innovation capacities. In some sec­
tors there were mergers and acquisitions o f national firms by foreign competitors 
(chemical industry, for example). In others, processes of productive specialization 
were introduced and some firms became suppliers o f parts and components in global 
chains of production, such as the automotive and electronics industries. In the com­
modity production sectors there was a high firm mortality rate due to international 
competition.
In 2000 there was a change of government which, among other things, promoted 
legal reforms and created instruments for the country’s scientific and technolog­
ical development (Casalet, 2005). Among the most important changes were the
Results and
implications




Science and Technology Law (2002), the Organic Law o f CONACYT, and the 
Special Program for Science and Technology (PECYT by its Spanish acronym). 
PECYT establishes three objectives: (1) adopt a policy o f State in science and tech­
nology; (2) increase the country’s scientific and technological capacity, and (3) raise 
competitiveness and firms’ innovative spirit.
PECYT’s strategies to attain its objectives are the following:
1 ) Structure the National Science and Technology System.
2) Adapt the Organic Law of CONACYT so that it satisfies the attributions 
assigned to it by the Law for the Promotion o f Scientific and Technological 
Research (LFICyT by its Spanish acronym).
3) Promote areas o f strategic knowledge for the country’s development.
4) Decentralize scientific and technological activities.
5) Increase the scientific-technological culture o f Mexican society.
6) Increase the national budget for scientific and technological activities.
7) Increase the middle- and high-level technical personnel and scientific and 
technological personnel with postgraduate studies.
8) Promote basic scientific and technological research and the strengthening of 
applied and technological research.
9) Expand the national scientific and technological infrastructure, including basic, 
middle, and higher education.
10) Strengthen international cooperation in science and technology.
11) Increase private investment in research and development.
12) Promote technological management in firms.
13) Promote the incorporation o f high-level scientific-technological personnel in 
firms.
14) Strengthen infrastructure aimed at supporting firms’ competitiveness and 
innovation.
In contrast to previous programs, PECYT tresses the need to foster innovation, 
bring supply and demand for science and technology closer, and induce greater 
participation o f the private sector in financing and innovation activities, including 
SMEs. Decentralization o f programs and resources and assessment o f performance 
and operation o f the instruments4 also constitute substantial changes in this regard. 
Private strategies underscore an increase in infrastructure, the education o f human 
resources, and inter-institutional cooperation by means of basic and applied research 
networks and consortia.
PECYT identifies strategic areas o f promotion of research from a sectoral per­
spective. These areas are related, on the one hand, to leading-edge technology 
and, on the other hand, to aspects that concern national development: informatics, 
computer science, biotechnology, communications, materials, construction, petro­
chemicals, manufacturing processes, natural resources (maritime and land), water 
problems, technology transfer, and health.
PECYT gave rise to a set o f new programs that came to light as o f 2001 with the 
participation of other government agencies.5 These are
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1) institutional funds administered by CONACYT such as Risk Capital, AVANCE 
(High Value Added in Business with Knowledge and Entrepreneurs by its 
Spanish acronym), and Fiscal Incentives,6 among others;
2) sectoral funds with financing shared with CONACYT, State ministries, and other 
parastate agencies;
3) international cooperation funds (NSF, EU, etc.); and
4) Joint Funds for shared financing with state governments.
In contrast to previous periods, when many government agencies related to strate­
gic areas (energy, natural resources, health, etc.) established their own scientific 
and technological development programs in parallel with CONACYT, the PECYT 
funds were an effort to establish public policy coordination mechanisms in strategic 
sectors.
Below we will analyze the characteristics o f some o f these programs in order to 
interpret the nature o f the institutional changes in relation to policy strategies and 
the new realities of the national economy.
10.4.1 The Sectoral Funds
In concert with other public agencies, CONACYT has created 17 sectoral funds 
to foster applied research and technological development. All o f them have been 
implemented with resources from CONACYT and federal agencies related to the 
sector in question. Some were created for the first time and others are improved 
versions of earlier programs.
Each fund convokes a yearly competitive process and establishes areas o f demand 
or sectoral priorities for research projects. The projects selected receive financing for 
the acquisition o f machinery and equipment, improvement o f infrastructure, thesis 
scholarships for graduate and postgraduate studies, travel expenses and per diems, 
and operating costs o f the project itself (research assistants, logistics, surveys, lab­
oratory tests, etc.). Depending on the characteristics of the areas, some funds favor 
support for research group projects, including inter-institutional groups, to foster 
co-operative research and generate more knowledge.
The amounts of resources for projects have varied from year to year depending 
on availability. One important aspect is that in projects proposed by enterprises, 
these should contribute at least the same amount as the resources requested with 
the intention o f increasing the productive sector’s share o f spending on R&D and 
applied research. Table 10.1 lists the existing sectoral funds, they date they were 
launched and the number o f convocations issued to December 2007.
10.4.2 The Joint Funds
The Joint Funds (Fondos Mixtos, FOMIX by its Spanish acronym) are jointly 
administered by CONACYT and state government agencies to decentralize the
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Number o f 
competitive 
processes to 
the end o f 
2007
Sectoral Research Fund for Airport Development and A ir 
Navigation ASA -C O N A C YT
2003 5
Sectoral Fund for Research and Technical Development in Energy 
CFE-CONACYT
2004 4
Sectoral Research and Development Fund on Water 
C N A -C O N AC YT
2004 4
Sectoral Fund for Research, Development and Technical 
Innovation in Forestry CO NAFO R-CO NACYT
2002 9
Fund for Scientific and Technological Development for the 
Promotion o f  Production and Financing o f  Housing and Growth 
o f  the Housing Sector, CO NAFO VI-G O NACYT
2002 4
Sectoral Science and Technology Fund for Economic 
Development ECO N O M ÍA-C O N AC YT
2002 6
Sectoral Research and Development Fund 
INM UJERES-CONACYT
2003 2
Sectoral Fund for Research in Agriculture, Livestock, 
Aquaculture, Agrobiotechnology and Plant Genetic Resources 
SAG ARPA-CO N ACYT
2002 5
Sectoral Research Fund for Social Development 
SEDESOL-CONACYT
2002 4
Research and Development Fund SEGOB-CONACYT 2004 2
Sectoral Furtd for Research and Development in Naval Sciences 
SEM AR-CO NACYT
2002 5
Sectoral Environmental Research Fund SEM ARNAT-CO NACYT 2002 3
Sectoral Research Fund for Education SEP-CONACYT (2002-to 
date); initially Competition for Support for Basic Research 
Projects (2001) and before “Competition for Support for 
Research Projects 1999-2000”
2002 10
Sectoral Fund for Research in Health and Social Security 
SSA/IMSS/1SSSTE-CONACYT
2003 10
Source: Prepared by the author based on information from www.conacyt.mx.
financing of scientific and technological development. The first 16 FOMIX were 
set up in 2001 and 9 more in 2002. By December 2005, 28 state FOMIX had been 
created, plus 1 municipal (in Ciudad Juárez, Chihuahua).
The states’ contribution has varied according to the agreements and especially 
the capacity o f the federative entities to finance scientific and technological devel­
opment activities. Some entities contribute the same amount as CONACYT and 
others that contribute half or less.
In the majority o f cases, CONACYT’s counterpart is represented by the State 
Science and Technology Council o f each state. When there is no similar agency, 
Joint Funds are administered by the State Economic Development Secretariat or the 
Education Secretariat.
According to the structure o f the FOMIX, there are priority areas, although 
these do not appear systematically in each yearly competitive granting process. In 
some Joint Funds’ competitive processes have been opened for more specific areas. 
Table 10.2 shows the number o f projects approved by area and year.
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Table 10.2 Projects supported by Joint Funds in areas o f demand
Number o f projects approved
Area 2001 2002 2003 2004 2005 Total
Total 44 286 484 369 346 1,529
Agricultural food chain 10 54 66 53 60 243
Health 4 37 33 40 33 147
Social and educational 15 59 95 96 46 311
development
Urban and rural 4 26 25 24 35 114
development
Industrial development 8 46 126 112 64 356
Environment and natural 3 64 139 44 108 358
resources
Issuance o f  competitive I 19 23 18 24 85
processes
Source: Prepared by the author based on documents that appear in www.conacyt.mx
As can be seen in Table 10.2, the number o f projects supported in 2003 was 
higher than in other years. This is because the issuance competitive grant process 
and project approval lasts an average o f 5 months and because there are Joint Funds 
that issue two competitive processes a year and others that issue them less often according to available resources. The larger number o f project approvals in 2003 is 
due to the conjunction of various factors: a) greater availability o f resources in some 
federative entities in 2003,7 b) greater number o f competitive grant processes issued in late 2002 which were added to those o f 2003, and c) accumulation o f applications 
by researchers, companies, and other agencies as the Joint Funds took root.
Table 10.3 also shows that the greater proportion o f projects supported cor­
responds to the areas o f environment, industrial development, and social and 
educational development. This situation is partly due to the fact that these three 
areas have appeared in the competitive grant process o f all the Joint Funds every 
year. Moreover, the number of projects approved in these areas reflects the capability 
o f applied research, the interest o f the communities o f scientists and technologists 
in them, and firms’ participation in industrial development.
In addition to the areas of demand, there are five types that specify the kinds of 
projects to support and the results desired. Thus the majority correspond to projects 
o f type A, which groups together more than half o f the projects, followed by type 
B, which refers to technological development (see Table 10.3).
The project approval rate in 2002 was 39.3%, that is, for every 10 projects almost 
4 were approved; in 2003, the rate was 42% and in 2004, 39.7%. Thus, the conclu­
sion can be drawn from Table 10.3 that there is an appreciable supply o f applied
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Table 10.3 Projects approved by type in the Joint Funds
Number o f  projects approved
Type 2002 2003 2004 Total
Total 330 484 377 1,191
a) Scientific research 270 200 223 693
b) Technological development 29 101 88 218
c) Creation and consolidation o f  research 4 13 18 35
groups and networks
d) Creation and strengthening o f 17 32 15 64
infrastructure
e) Dissemination and information 6 50 33 89
activities
Various modalities 4 - - -
Not available - 88 - 88
Source: Prepared by the author based on information from www.conacyt.mx
research projects, as every year approximately 1,000 applications are turned in. 
This situation contrasts with the 1990s, when the programs were administered by 
centralized federal agencies.
Most o f the competitive grant processes present specific demands depending on 
real and potential users, so the expected results are ones that have an impact on the 
entity’s needs or problems. Projects last an average o f 2 years, and therefore some 
research projects from the first competitive grant process have just concluded or are 
about to conclude. However, CONACYT has not so far presented an estimate of the 
qualitative impact o f the results or their benefits in terms o f social and economic 
development.
10.4.3 The Science and Technology Sectoral Fund fo r Economic 
Development
The aim o f this fund is to promote R&D and innovation in the production sector 
by means of resources for firm projects. Firms proposing projects must contribute 
a sum o f economic resources equal to those requested, not necessarily o f domestic 
capital, so the subsidiaries o f transnational corporations can also compete.
There are three types o f firm projects: a) innovation and technological devel­
opment; b) creation and consolidation of R&D groups; and c) creation and 
strengthening o f the firm’s or the industrial sector’s technological infrastructure.8 
More than 80% of the projects approved to date are type “i” followed by type “iii” 
(about 15%).
According to the information available on the CONACYT web page, in the first 
3 years o f the Fund’s operation 177 projects were sponsored, one third o f the total of 
applications (see Table 10.4). In terms of national industry and the total number of
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Table 10.4 Projects approved in the convocations
Year Projects requested Projects approved Percentage approval
2002 295 56 19
2003 209 ( 129)a 63 48.4
2004 209 58 27.8
Total 703 177
Source: Prepared by the author based on documents that appear in 
www.conacyt.mx
“That year the modality o f  pre-proposals was used, with only 129 projects 
viable for assessment being selected. This is why the percentage approval 
appears greater, since it is calculated on 129 and not 209.
existing firms, these data are not very significant. However, if we consider that over 
the past 20 or 30 years new products and new technologies came mainly from abroad 
and that few domestic companies developed R&D, we can conclude that the sectoral 
fund tends to modify the patterns o f technological development and innovation in 
the country, not only because o f the very nature o f the projects it finances but also 
because it fosters private investment in R&D.
Since it was set up, the Fund has encouraged industrial firms to create or improve 
their technological capabilities, to develop prototypes, and to provide the domes­
tic market with new processes and products. In this regard, every year specific 
areas have been convoked, taking into account their economic and technological 
dynamism and, above all, the possible substitution o f inputs, the generation o f qual­
ified jobs and the capacity to insert firms in chains o f production with high value added. Box 10.4 lists the industrial areas that have appeared in competitive grant 
processes. As may be seen, there is a certain continuity from 1 year to the next 
in particular areas, such as the automotive and auto parts, electric and electronic, 
food, and pharmaceutical industries, which appear in all the competitive grant 
processes.
If we take into account all the periods that issued competitive grant processes 
and the continuity o f the areas of the sectoral fund, the projects o f the automo­
tive and auto parts and electrical and electronic sectors are the ones that have 
received most approvals, which reflects their technological dynamism, which since 
the signing o f NAFTA9 have been a pillar o f the growth of domestic manufac­
turing production, especially in the industrial areas o f the north and center o f the 
country.
As an interpretation o f the way in which the fund is contributing to favoring 
innovation dynamics in the country, we can prepare a classification o f the projects 
in four categories that enable us to understand the state o f development o f firms’ 
productive and technological capacities in relation to their innovation strategies. 
Thus, there are projects to improve the R&D infrastructure to develop prototypes, 
to create R&D centers, and to improve or carry out new products and productive 
processes.
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Box 10.4 Continuity o f  the areas o f  demand o f  the sectoral fund
Industrial area o r  o f  demand o f  competitive 
grant processes 2002 2003 2004 2005 2006
Food industry (processed foods)




Chemical and petrochemical industry





Electrical and electronics industry
Aeronautics and aerospace
Nanotechnology: applied to materials, *
electronics, health, among others
Advanced materials: ceramics, compounds, *
polymers, etc.
Products for design and advanced *
manufacture
Electronics and telecommunications: *
devices, sensors, circuit design, etc.
Information technologies: information *
systems, biometrics, simulation, informatics
security, embedded software, etc.
Biotechnology environmental, food and *
health.
Source: Prepared by the author based on documents that appear in www.conacyt.mx 
* Areas o f knowledge created in the 2005 competitive grant process
From the point of view o f firms’ technological learning paths and their relation 
to the competitiveness strategies, it may be said that the more knowledge is accu­
mulated, the more complex the productive and organizational routines tend to be. 
In this regard, the firms that find themselves in the initial phases o f a specific path
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or with technologies that have received little dissemination in the market devote 
themselves to improving processes and products. In the stages that follow, firms are engaged in developing prototypes for new products, create infrastructure and 
even R&D centers which operate as autonomous business units capable o f provid­
ing technological knowledge to other companies o f the industrial group or sell R&D 
projects to external companies.10
Table 10.5 shows the projects approved per year according to the above classi­
fication. It can be seen that the largest proportion o f projects is in the category of 
new or improved processes and products, which in the 5 years reviewed exceeds 
40% of the projects approved followed by the category of prototypes, which repre­
sents more than one third. By contrast, projects to create R&D centers or improve 
infrastructure account for the lowest proportion.
Two hypotheses can be put forward regarding the last aspect a) that many firms 
have sufficient R&D infrastructure, and therefore they do not require financing for 
improving it or creating centers and b) that many firms do not have R&D centers 
or departments because they lack the financial, organizational, and human resource 
capacity.
The second hypothesis seems more plausible, since until the mid-1990s, the 
industrial sector was experiencing a process o f productive and organizational 
restructuring in which many firms disappeared, others became specialized and 
others established relations o f subcontracting or strategic alliances. Some had to 
make their production processes more efficient and modernize their technology to 
meet needs such as quality, price, and quick market response and, in cases such 
as the chemical and pharmaceutical industries, adapt to pollution reduction stan­
dards. This process o f forced modernization in the first years o f the trade opening, 
which meant putting finances on a sound footing, correcting errors, improving productive efficiency, and reducing production costs had to use productive and tech­
nological capabilities accumulated during the period o f import substitution, to the 
detriment o f their use to develop competitiveness strategies based on R&D and 
innovation.
Some authors maintain that in the 1990s there was a loss o f technological capa­
bilities due to the trade opening and the productive restructuring (Katz, 2000). But 
these factors could merely evidence the obsolescence o f the accumulated capabili­
ties, as global productivity and competitiveness patterns had changed considerably 
through the introduction of new technologies, new materials, and new uses o f tech­
nological knowledge. In this process, some companies in technologically dynamic 
sectors kept up their competitive positions due to their capacity to enter global 
productive chains.
Table 10.6 shows the distribution o f projects approved by the Fund in 200311 
in relation to industrial sectors and the taxonomy used. It is worth noting that half 
of the projects are for new or improved processes and products and that only the 
automotive, electrical and electronics, and pharmaceutical sectors develop projects 
to create or strengthen R&D infrastructure. We can also see that most o f the projects 
aimed at developing prototypes are from the automotive, electrical, and electronics 
sectors.












Projects % Projects % Projects % Projects % Projects %
Total 56 100 63 100 58 100 74 100 33 100
Infrastructure for R&D 4 7.1 7 11.1 8 13.8 9 12.2 — —
New or better products and 26 46.4 30 47.6 29 50.0 35 47.3 14 42.4
processes
Creation o f  R&D centers 3 5.4 7 11.1 3 5.2 14 18.9 9 27.3
Prototypes 23 41.1 19 30.2 18 31.0 16 21.6 10 30.3






Table 10.6 Classification o f projects by industrial sector (competitive grant process 2003)
R&D Infrastructure
New products and 
processes
Creation o f  R&D 
centers Prototypes
Projects % Projects % Projects % Projects % Total
Total 7 100 30 100 7 100 19 100 63
Aeronautics and aerospace 1 3.3 1
Biotechnology 5 16.7 1 5.3 6
Electrical and electronics 3 42.9 4 13.3 4 21.1 11
industry
Food industry 5 16.7 2 28.6 1 5.3 8
Automotive and auto parts 3 42.9 9 30.0 5 71.4 7 36.8 24
industry
Pharmaceutical industry 1 14.3 1 3.3 1 5.3 3
Other areas 3 10.0 3 15.8 6
Information and 2 6.7 2 10.5 4
communication
technologies (ICTs)












The above can be explained by the importance that these sectors have taken 
on in industry and the national economy as a result o f the signing o f NAFTA. 
In fact, during the 1990s there were major investments by foreign corporations in 
these sectors in order to increase the number o f plants producing parts and compo­
nents and final assembly on the country’s northern border. The investments coincide 
with the strategies o f many transnational corporations to articulate global produc­
tive chains, setting up plants in Mexican territory and forming networks o f local 
suppliers.
However, participation by firms in the global chains o f transnational or Mexican 
automotive, electrical, and electronics industries (large or SMEs) implies using and 
maintaining global standards o f manufacture, logistics, and exchange o f pieces 
and parts, as well as responding swiftly to the constant changes in product and 
equipment design. On account o f the type o f projects it supports, the sectoral fund 
makes it possible to complement firms’ strategies in applied research and technolog­
ical development in the most technologically dynamic sectors such as the electronics 
and auto parts industries.
NAFTA and the growing trade with the United States and Canada have boosted 
the development of trade, services, infrastructure, and qualified labor platforms in 
the large industrial population centers on the country’s northern border, thus assur­
ing a favorable territory for production needs. The result has been the forming of 
spaces for learning and institutional dynamics that represent settings with con­
ditions and opportunities to raise the competitiveness of high technology sectors 
(Villavicencio and Casalet, 2005).
So far no information is available on the effects o f the sectoral fund’s supports 
on firms’ technological learning capabilities, the strength o f R&D centers, and the 
impact o f new and improved products on the domestic market. However, the Fund 
enables firms in technologically dynamic sectors to carry out adaptation and inno­
vation activities and thus respond to the demands for competitiveness o f global 
chains of production and for trade exchanges within the framework of NAFTA. 
In this regard, the Fund contributes to the country’s technological development by 
combining public and private investment.
10.5 By Way of Conclusion
This chapter has made a brief description o f the main changes in the country’s indus­
trial and technological policies, as well as their effects on firms’ behavior, with 
emphasis on the period that began with the trade liberalization and the signing of 
NAFTA.
We have seen how, as o f the 2001-2006 administration, institutional changes 
were introduced that laid new foundations for the design and implementation of 
programs. In contrast to the models applied until the end o f the 1990s, characterized 
by a heterogeneous supply o f instruments lacking coordination, the policies o f the 
last period tend to be more horizontal, decentralized and autonomous, for they seek, 
among other aspects:
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1 ) Greater coordination between CONACYT and other government agencies.
2) Greater participation by the productive sector in the supply of programs and in 
the use of resources for R&D and innovation.
3) Greater sectoral orientation of applied research.
4) Greater regional orientation of the instruments.
5) Creation of infrastructure for technological development and R&D.
6) Incentives to co-operative forms of carrying out applied research and technolog­
ical development through the financing of networks, consortia, and university- 
firm linkage.
The process of implementation and evaluation of the results of public poli­
cies requires long terms, especially in policies that aim to be innovative in design 
and implementation. The current policies reveal interesting quantitative results (for 
instance, the growth of projects approved) and have fostered growing participation 
by enterprises and academic institutions in the Joint and Sectoral Funds, thus fulfill­
ing the assignment of meeting the demands of the various stakeholders, bearing in 
mind the specificity of regions, areas, and priority areas.
However, it is still early to assess the performance and the impact of instruments 
on firms’ innovation capacity or the quality of applied research carried out by univer­
sities and public research centers. Many projects financed by the sectoral and Joint 
Funds are only just about to conclude, and in many cases, the results expected corre­
spond to prototypes or generic knowledge that will require the design of instruments 
for their validation and dissemination.
Today’s policies should set their sights on complementary objectives, take advan­
tage of sectoral specialization and the technological and productive advantages 
inherited from the period of productive restructuring and foster the development of 
innovation areas in the “windows of opportunity” opened by emerging technologies. 
Furthermore, instruments and incentives should be combined in order to increase 
the technological capabilities of the greatest number of capabilities in all sectors 
of production and services, but also to select “winners” capable of expanding the 
technological frontier in strategic sectors.
One decisive condition for obtaining positive results over the medium and long 
terms is to maintain the country’s macroeconomic stability to guarantee the positive 
results of policies and programs. Otherwise, financial or political crises could pre­
vent not only implementing the policies altogether (Cimoli, 2005) but also taking 
advantage of technological opportunities and consolidating firms catching-up and 
innovation strategies.
Notes
1. Here we show information consulted at www.conacyt.mx
2. See the comparative study o f  programs implemented by different countries in Europe and 
Latin America in Casalet et al. (1995).
3. A  study o f  the transformations during this period can be found in the compilation by Cimoli 
(2001) on the Mexican Innovation System.
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4. Article 52, section IV, subparagraph b) o f the Decree for the Expenditures Budget o f 
the Federation for each Fiscal Year provides that “ Programs subject to rules o f  operation 
shall present the evaluation o f  results o f  each program to the Budget and Public Accounts 
Committee o f  the Chamber, to the Ministry and to the Public Administration no later than 30 
September, so that the results are considered in the process o f analysis and approval o f  the 
Expenditures Budget o f  the Federation for the following fiscal year.”
5. Programs in effect for more than 30 years, such as those for training o f  human resources, are
maintained.
6. Reformed version o f  a program initiated in the mid-1990s.
7. The total amount approved for projects in 2003 was almost double that o f  2002. See
www.conacyt.mx
8. These modalities existed until 2005, the year in which it appears as “ i”  Firm association 
schemes for technological innovation, and what was previously considered as “ ii”  and “ iii”  
were merged.
9. The North American Free Trade Agreement (Canada, United States, and M exico) entered into 
effect in 1994.
10. Roussel et al. (1991) make an interesting analysis o f  the evolution o f  R& D  activities in the last 
few decades and observes a process o f diversification o f  units or departments.
11. The data for 2002 and 2004 reflect a similar distribution.
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11.1 Introduction
Before addressing the topic of scientific and technological policy in Mexico and 
its relation to intellectual property, it is important to review some aspects that 
have contributed to the establishment and evolution of what we know today as the 
“intellectual property system.”
These facts make it easier to understand why industrial property is currently con­
sidered as an essential ingredient of countries’ economic, industrial, technological, 
and intellectual development and growth.
The first known instance of “intellectual property” took place in the 15th century, 
in 1421 in Florence, when the State granted architect Filippo Brunelleschi a tempo­
rary privilege to make exclusive use for 3 years of a design of a barge to transport 
marble to Florence Cathedral, at that time under construction (IMPI, 1997).
Thus, intellectual property is not a recently created right, but has been the basis 
for the generation of knowledge, instruments, artistic creations, methods, and pro­
cesses that have given rise to innovations and technical solutions to diverse problems 
and the benefits of which are reflected in better living standards in communities.
This is why many countries have adopted schemes and institutions to foster 
knowledge of the implications of the use of the intellectual property system.
Examples of this are the intellectual property and technology transfer units of 
some of the world’s most prestigious universities. These units carry out various 
activities, among them analysis of technical information on patents in order to pro­
vide advisory assistance to those responsible for research projects; identification of 
latent needs to develop projects to meet those needs; identification of the portfo­
lio of industrial property assets to be protected; steps taken before the authorities 
for the protection of such assets; and negotiation of technology transfer licenses or 
contracts.
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Mexico has not remained on the sidelines of these schemes. Since its establish­
ment in 1993, the Mexican Industrial Property Institute (IMPI) has worked closely 
with public and private universities and research centers, as well as with national and 
foreign public agencies to make known the existence of the Institute and the means 
of accessing the system of protection offered by the Law on Industrial Property.
Going back to the historical antecedent mentioned above, by recognizing 
Brunelleschi’s effort to solve the problem of transporting marble to Florence 
Cathedral, inventive activity was stimulated in the rest of his community to provide 
solutions to existing problems. But recognition and authorization of the exclusive 
period of use granted by the State demand in exchange documented information on 
the problem in question. The technical information contained in patents documents 
is an endless source of new knowledge that will serve as the groundwork for the 
development of new inventions.
Moreover, when the inventions or the products and services derived from them 
reach the consumer or end user they will need an image and a distinctive name or 
trademark. These names or marks are added to the portfolio of industrial property 
assets on which technological development relies and contribute to providing greater 
protection and legal certainty to the holders.
So far we have used the terms intellectual property and industrial property indis­
tinctly, but the latter is one of the two major branches of the former. The other is 
copyright.
The authority in charge of registering copyright in Mexico is the National 
Copyright Institute, an agency that is answerable to the Ministry of Public 
Education; the authority in charge of registration and protection of industrial 
property is IMPI.
11.2 Universe of Intellectual Property
The juridical concepts overseen by IMPI are grouped into two sections: inventions 
and distinctive signs. The former include patents, utility models, industrial designs 
(which are in turn divided into industrial blueprints and industrial models), layout 
designs of integrated circuits, and industrial secrets. The latter include trademarks, 
collective marks, trade names and notices, and denominations of origin.
So, what is understood by industrial property?
Briefly, industrial property consists of a set of exclusive rights that the State 
grants to the creators of new products, procedures, or designs that will be offered 
on the market and will be accompanied by indications of a commercial nature to 
facilitate their identification to the consumer or user faced with products from com­
petitors. These rights allow the holders to exploit industrially or commercially their 
inventions or distinctive signs exclusively for a particular period.
Protection by the system of industrial property is limited to the territory of the 
country in which the application for registration was filed. This responds to the fact 
that each industrial property office has its own regulatory framework that typifies the
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juridical concepts of protection, the term of the rights, and the applicable procedures 
of examination and opinion.
The time frame for marks, notices, and trade names in Mexico is 10 years as 
of the date of presentation of the application, extendable for periods of 10 years, 
successively.
The term for inventions, which is also counted as of the date of filing of the 
application, changes depending on the concepts protected and is not extendable. 
Thus, the protection period for patents and industrial designs is 20 and 15 years, 
respectively, whereas the period for utility models and layout designs for integrated 
circuits is 10 years.1
The legal protection afforded by the Law on Industrial Property through IMPI 
contributes to promoting investment in scientific and technological research and 
development activities that can have a bearing on our country’s economic growth.
OECD studies show that investment in science and technology makes itself felt 
by up to 25% in the growth of the developing countries and at least by 50% in the 
developed countries.
Spending on science and technology in Mexico in 2003 reached 0.39% of GDP, 
a proportion that is considered insufficient. It is worth mentioning, furthermore, that 
more than half of the investment in scientific and technological activities is financed 
by the government.
11.2.1 Investment in Science and Technology
Evidence of the importance of investing in research and scientific development 
activities is the impact these have on productivity. It is estimated that productivity 
can increase 0.17% for each percentage point that investment increases in research 
and development activities in developing countries.
Another indicator that complements the above statement is the annual average 
growth rate of spending on research and development, which it estimated should be 
18% to reach the level of self-sufficiency. This indicator did not rise above 3% in 
the 2000-2004 period.
Investment in research and development in Mexico has increased very little in 
comparison with other countries since 1970. In Brazil, whose development is sim­
ilar to Mexico’s, it grew five times, whereas in Mexico it only grew two times. 
(Table 11.1).
Another angle of appreciation of this item is the quantity of patent applications 
by the nationals of these countries in their respective industrial property offices. 
The Korean Intellectual Property Office (KIPO) received 139,198 patent applica­
tions in 2004, of which 75.6% corresponded to Korean applicants (105,198) (KIPO, 
2005), whereas IMPI received 13,194 patent applications, only 4% (565) of which 
corresponded to Mexican applicants in the same period (IMPI, 2006).
Investment in research and development also has a direct relation to countries’ 
competitiveness and the per capita income of their populations.
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Table 11.1 Investment in research and development
Country Growth o f  investment
Patent applications 
by nationals (2004)
Republic o f  Korea 9.6 times 105,198
Spain 6.5 times 2,864
Brazil 5 times 3,098a
Mexico 2 times 565
Source: Prepared by the author based on official information. 
“Data to 2002.
A study of these variables in eight countries, among them Mexico, clearly shows 
that the more the investment made in scientific and technological research activities, 
the better the competitive position and the greater the per capita income that can be 
attained.
11.2.2 Investment in Research and Development
The United States invests almost 2.69% of GDP in scientific and technological activ­
ities, which enables it to occupy first place in competitiveness and obtain a per capita 
income of around 37,000 dollars. In Mexico, where investment in scientific and 
technological activities barely reaches 0.39% of GDP, per capita income is less than 
6,000 dollars and the country is in 41st place in competitiveness.2
The participation of the above-mentioned countries in the international patent 
application mechanism through the Patent Cooperation Treaty (PCT) shows a simi­
lar situation. The United States is also the country that presents the largest quantity 
of international PCT applications (more than 42,000), whereas Mexico only presents 
0.10%.3
In the case of the United States there seems to be a direct relation between invest­
ment in scientific and technological activities, utilization of the PCT mechanism and 
its competitive position as a nation.
We can see, then, that investment in science and technology, with the consequent 
development of innovations in products and processes, leads to protection of intel­
lectual property rights not only in the country of origin but also in others, giving 
rise to competitive advantages and consolidating the market position of innovating 
companies.
In Mexico’s case, strong impetus has been given in recent years to the National 
Researchers’ System (SNI), which increased the base of researchers registered in 
the period 1995-2003 by 73.6%. This has resulted in an increase of 98.3% in the 
publication of scientific and technological articles. However, patent applications by 
Mexicans registered only an 8.3% variation during the period.
This is due to the fact that the National Researchers’ System favors the publi­
cation of scientific articles over the filing of patent applications for the results of 
research carried out (see Table 11.2). Moreover, it is much simpler for researchers 
to publish articles than undertake the process to obtain a patent, around 4 years, the
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Table 11.2 Scientific production in Mexico
Year Researchers (SN I) Articles
Patent applications 
by Mexicans
Total Does not apply 39,001 4,105
1995 5,868 2,916 432
1996 6,969 3,282 386
1997 6,278 3,587 420
1998 6,742 4,057 453
1999 7,252 4,531 455
2000 7,466 4,633 431
2001 8,018 4,999 534
2002 9,200 5,213 526
2003 10,189 5,783 468
Source: IMPI (2005).
standard time for the study and report on patent applications at international level 
and in Mexico.
It is important to mention that the publication of the advances of research can 
endanger protection of the results that may be obtained, since the advances are incor­
porated into what is known as the “state of the art,” which harms the requirement of 
novelty of a possible invention.
As mentioned earlier, patent applications by Mexicans presented for study before 
IMPI barely reached 4% of the total in the 2004 fiscal year (IMPI, 2005).
An interesting fact that can be seen in Chart 11.1 is that patent applications from 
abroad increased gradually following Mexico’s accession to the PCT, which entered 
into effect on 1 January 1995.
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
l'orcigners 7,659 9.446 4.961 6,365 10.111 10.440 11,655 12.630 13,032 12.536 11.739 12.629
Mexicans 553 498 432 386 420 453 455 431 534 526 468 565
Chart 11.1 Patent applications filed before IMPI Mexicans-foreigners 
Source: IMPI (2005).
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Nevertheless, it should be mentioned that although patent applications by 
Mexicans have not increased significantly, their relative share of the total of appli­
cations received has diminished due to the constant increase in foreign applications.
In 1970, Mexico and the Republic of Korea had similar levels o f investment 
in science and technology, competitiveness, and per capita income; in 1984 both 
countries had a similar number of patents granted by USPTO (Chart 11.2).
— ■— Rep.ofKorea 29 38 45 84 97 159 225 4(12 538 765 943 1.161 1.4931.8913.2593.5623,3143,5383.7863.944
- -*■ -Mexico 42 32 37 49 44 39 32 28 39 50 52 45 42 45 57 76 76 81 94 84
Chart 11.2 Patents granted by USPTO comparison Mexico-Republic o f  Korea 
Source: IM PI (2005).
The gap between the two began to widen during the second half of the 1980s 
until it became very wide in 2003. While Mexico doubled its investment in sci­
ence and technology, the patents granted to Mexicans by USPTO rose by 100%. In 
the Republic of Korea, by contrast, investment in science and technology increased 
almost 10 times, while the patents granted to Koreans by USPTO registered an 
increase of 13,500%.
These data reinforce earlier statements to the effect that investment in scientific 
and technological research has a direct bearing on industrial property and therefore, 
on nations’ competitiveness.
The consequence of patents on the economy and industrial development of coun­
tries can also be appreciated by relating it to the labor force. This gives an idea of 
the innovating effort of the productive plant and its technological level.
On analyzing the trend in Mexico, Latin America, and the Caribbean during the 
period 1960-2000, it is noteworthy that Mexico has registered a decreasing patent 
rate per million workers, in contrast to the rest of Latin America and the Caribbean, 
which, as of 1970, are above Mexico (Chart 11.3).4
The Republic of Korea once again stands out when comparing it directly with the 
rest of the countries of East Asia and Mexico, Latin America, and the Caribbean.
In the 1970s, Mexico, Latin America, the Caribbean, and the countries of East 
Asia were above the Republic of Korea, a situation that was reverted as of the period 
1990-1994, when the Republic of Korea reached almost 20 patents per million
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Source: Lederman, Maloney and Serven (2005).
workers, whereas Mexico, Latin America, and the Caribbean registered an average 
of almost three patents per million workers.
By the period 1995-2000 this gap had widened significantly, for the Republic of 
Korea exceeded 70 patents per million workers, whereas Mexico, Latin America, 
and the Caribbean barely reached 4.5 per million workers.
The 2005 General Report on the Status of Science and Technology of the 
National Science and Technology Council (CONACYT) documents that 55% 
of investment in science and technology in Mexico is made directly by the 
State, whereas the remaining 45% comes from private initiative (CONACYT, 
2005).
In this regard, the five main Mexican patent holders for the period 2002-2005 
are public institutions. The first three contribute 76.9,72.5, and 55.5%, in that order. 
It should be mentioned that in the 3 years under study, the Mexican Petroleum 
Institute remained in first position with more than double the number of patents 
than the institution or enterprise that occupies second place (IMPI, 2005) (see 
Table 11.3).
If we analyze the five main countries holding patents in Mexico for fiscal year 
2004 (Germany, United States, France, Japan, United Kingdom and Switzerland), 
we can see that no government institutions feature in any of them (IMPI, 2005) 
(see Table 11.4). The majority are private enterprises that protect their technological 
innovations in industries such as electronics, chemicals, and pharmaceuticals.
It should be noted that five of the six countries included in Table 11.4 focus 
particularly on research and protection of chemical and pharmaceutical innovations 
and developments, while Japan is oriented toward the electronic field.
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Table l l J  Main Mexican holders o f  patents granted by IM PI, 2002-2004 
Mexico 2002
Instituto Mexicano del Petróleo 
Universidad Nacional Autónoma de México 
Grupo Bimbo, S. A. de C. V.
Universidad Autónoma Metropolitana 
Comercial Acros Whirlpool, S. A. de C. V.
M exico 2003
Instituto Mexicano del Petróleo 
Universidad Nacional Autónoma de México 
Grupo Bimbo, S. A. de C. V.
Servicios Condumex, S. A . de C. V.
Universidad Autónoma Metropolitana
M exico 2004
Instituto Mexicano del Petróleo 
Grupo PI Mabe, S. A . de C. V.
Helvex, S. A. de C. V.
Instituto de Investigaciones Eléctricas 
Servicios Condumex, S. A. de C. V.
Source: IM PI (2005).
Table 11.4 Main holders o f  patents granted by IM PI in 2004 by country o f origin
Germany United States
BASF Corporation 97 The Procter &  Gamble Company 184
Bayer, Inc. 95 Kimberly Clark Worldwide, Inc. 140
Aventis Pharma, S.A. 49 Pfizer Inc. 97
Boehringer Ingelheim International 28 E.I. Du Pont de Nemours and Company, 65
GMBH Inc.
Merck &  Co., Inc. 16 Qualcomm, Inc. 57
France Japan
Thomson Consumer Electronics, Inc. 107 Matsushita Electric Industrial Co., Ltd. 28
L ’Oréal 56 Sony Corporation 19
SANO FI-SYNTH ELABO 30 Mitsubishi Denki Kabushiki Kaisha 13
Aventis Pharma, S.A. 28 Alps Electric Co., Ltd. 9
LES Laboratoires Servier 16 Shionogi &  Co., Ltd 9
United Kingdom Switzerland
Glaxo Group Limited 14 F. Hoffman-La Roche AG 51
Smithkline Beecham PLC 11 CIBA Specialty Chemicals Holding Inc. 47
Switched Reluctance Drives Limited 7 Société des Produits Nestlé S.A. 28
AstraZeneca UK  Limited 5 Novartis AG 18
BP Chemicals Limited 5 Tetra Laval Holdings &  Finance S.A. 14
Source: Prepared by the author with IM PI information.
Having taken a quick look at the factors that have a bearing on countries’ tech­
nological development and competitiveness and their relation to industrial property, 
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to contribute to building a culture of respect and protection for industrial property 
rights and thus promote the incorporation of this discipline into Mexico’s scien­
tific and technological policy through educational and research and development 
institutions.
First of all, emphasis should be placed on the hard work carried out by IMPI 
with higher education and public and private research institutions to educate and 
train human resources in the field of industrial property. The result has been the 
creation of “Patenting Centers,” the object of which is to act as advisory and/or pro­
motion units within their respective institutions in order to identify projects that are 
subject to not only protection but also commercialization by means of the licensing 
or transfer of the industrial property rights acquired.
11.2.3 Creation of Patenting Centers
To date, IMPI has set up 12 patenting centers in institutions carrying out scientific 
and technological research activities. Most of them are in institutions in the states 
of the country, so in addition to their substantive advisory work, they have become 
extensions of IMPI in promoting and disseminating the advantages and benefits of 
the industrial property system.
Under this scheme, IMPI acquires the commitment to train the group of advisors 
who will be in charge of the patenting center, while the host institution contributes 
the infrastructure for its functioning and operation. Likewise, IMPI provides access 
to the technical information databases on patents, consultation of which is essential 
for advisory assistance.
In order to foster applications for patents by Mexicans, the Industrial Property 
Law provides for a 50% discount on the corresponding rates and on the search for 
technical information on patents carried out by IMPI’s Technological Information 
Center. This discount only applies for independent inventors, micro entrepreneurs, 
research centers, and Mexican higher education institutions.
IMPI has also developed training programs and schemes on topics related to 
industrial property, such as the annual program of courses given weekly on its 
premises, as well as the participation of the Institute’s officers in conferences, 
workshops, diploma courses, and seminars organized by diverse public and private 
institutions.
Since IMPI’s participation in this type of activities increases year by year (716 
in 2004 and 866 in 2005) (IMPI, 2005 and 2006), the need has arisen to provide 
schemes for formal education. To that end the creation of an Academy of Intellectual 
Property is under study, which would be in charge of the design of study plans in 
the formal education system for users of the industrial property system (lawyers, 
technologists, entrepreneurs, researchers, etc.), and well as for personnel from the 
institute itself. The academy would also undertake research projects and/or studies 
in diverse topics in this discipline.
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The idea has been studied to situate the academy as a higher education institu­
tion within Mexico’s National Education System so that it imparts updating and 
continuous education programs at the postgraduate level by means of diploma 
courses and organizes congresses with the possibility of teaching master’s degree 
courses and doctorates in industrial property in the future.
The establishment of the academy would be in three stages, listed in 
Box 11.1.
Box 11.1 Stages of the project for the creation 
of the academy of intellectual property in Mexico
First stage: project design (fiscal year 2006)




3) Academic structure -  administrative
4) Functioning of academic life
5) Regulatory framework and academic policy guidelines
6) Administrative structure







9) Work program 2006: launching of the IMPI Academy 
10) Start of operations
Second stage: implementation of the project (fiscal years 2007-2009)
1) Building of curriculum
2) Hiring of academic-administrative staff
3) Training of staff in teaching and public-speaking skills
4) Registration o f accreditation and certification processes
5) Building of the premises
6) Start of operations on the new premises
7) Definition of lines of research
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Third stage: evaluation of the project (fiscal year 2010)
1) Evaluation of study programs
2) Evaluation o f  user satisfaction
3) Evaluation of administrative processes
Source: Prepared by the author with IMPI information.
11.2.4 Public Domain Patents Portal
With the aim of promoting the technological modernization of enterprises, espe­
cially small and medium ones, IMPI developed in conjunction with the Under 
Ministry for Small and Medium Enterprises of the Ministry of Economy and 
the Mexico-United States Foundation for Science (FUMEC), a Public Domain 
Patents Portal with access to technical information contained in patent documents 
(published patent applications and patents granted).
The ultimate aim of this portal is for companies to consult it and take advan­
tage of the available technological alternatives for their incorporation into existing 
productive processes or as the groundwork for the creation and development of 
technological innovations.
The portal would place at the disposal of interested parties a large quantity of 
patent documents from different parts the world that did not request protection 
in our country or that are no longer protected and are therefore free to use in 
Mexico.
The information ranges from traditional technological sectors to new fields of 
knowledge such as biotechnology, nanotechnology, mecatronics, pharmaceuticals, 
genetic engineering.
The portal is designed with a technological alert system in the form of traffic 
lights for easy understanding (see Fig. 11.1).
The red light indicates technologies protected in Mexico with the possibility of 
their being licensed by their patent holders. The amber light means technologies 
that can be used in Mexico. And the green light indicates technologies that are not 
protected in Mexico and can therefore be used freely.
The portal is made up of the following sections: search, FAQs, discussion forums, 
sites of interest, and support for companies.
A search can be carried out in different ways:
a) simple, in which terms are located in English, French, and Spanish;
b) classified, using the International Patents Classification, which is made up of 
eight sections;
c) advanced, in which words in English or French and the logic operators are used; 
and
d) localization in fields of the catalogue card, i.e., by biographical data.
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Fig. 11.1 Technological alert 
traffic lights.
Source: Public Domain 
Patents Portal
TECHNOLOGICAL ALERT TRAFFIC LIGHTS
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Source: Public Domain Patents Portal.
In this portal SMEs have a point of liaison with general topics of interest to users. 
The sites of interest section offer direct links to other industrial property offices in 
the world and to international agencies. The area of support to companies is a link 
to national institutions that offer support to SMEs, inventors, researchers, and other 
users.
In its 12 years of existence IMPI has identified a number of obstacles that hinder 
micro entrepreneurs, researchers, independent inventors, higher education institu­
tions, and research centers in using the industrial property system to protect their 
technological developments.
One of them is the investment required for filing applications for protection 
and/or registration of innovations. Earlier we informed of the discount offered to 
foster the filing of applications by Mexicans. But the investment needed for the fil­
ing of applications through the Patent Cooperation Treaty (PCT) amounts to several 
thousand dollars, an investment that most inventors and micro entrepreneurs are 
unable to make.
This is why IMPI has been studying various options with CONACYT and other 
agencies to assess the legal and financial viability of creating a support fund for 
projects with possibilities of commercial success that need to be protected in Mexico 
and abroad through PCT.
One concern that arises at the time of requesting protection for inventions is that 
of remuneration of the people involved in their development.
This is a problem whose solution depends on the labor contracts that researchers 
may have signed with the institution responsible. If the contract does not establish 
any remuneration as regards royalties derived from exploitation of the invention, the
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researcher(s) involved will not have access to any additional financial benefit to the 
salary they earn.
One possible solution to this problem in the case of researchers who are mem­
bers of CONACYT’s National Researchers’ System (SNI)5 would be for the SNI 
to privilege the filing of patent applications and their obtainment over the publica­
tion of scientific articles, which, as has been mentioned, can put the novelty of the 
invention at risk.
For researchers who do not form part of SNI a remuneration scheme could be 
established in terms of the profits derived from commercialization of the invention.
However, the solution to this issue does not depend directly on IMPI, but on other 
agencies or organizations in the public and private sectors.
In addition to the areas in which IMPI is working, other projects are summarized 
below by way of final notes.
a) Electronic payments portal. In order to facilitate and streamline the filing 
of applications for protection and/or registration of inventions and distinc­
tive signs, the corresponding payments can be made through a Portal as of 
19 September 2006. This is in keeping with the strategies and specifications 
for the development of Electronic Government established by the 2001-2006 
administration.
Although this is a major step forward for the simplification of the procedures 
that users must follow to request protection of their industrial property rights, the 
project is only just in its first phase. It is foreseen that future phases will facilitate 
the presentation of applications for distinctive signs and inventions electronically. 
These phases will be made known during the course of 2007.
Use of the portal’s services does not entail additional costs for users. The only 
requirement is registration, which is carried out only once to have access 24 h a day 
365 days a year throughout the country, being subject to the policies of the affili­
ated banks. Attendance online will make it possible to adequately select the current 
items and rates, including calculations for the payment of annual installments on 
patents.
Similarly, IMPI’s internal management systems, accounting and treasury sys­
tems are empowered to interact with the portal, thus guaranteeing the continuity of 
operations and simplifying processes within IMPI.
In order to guarantee the security and confidentiality of users’ operations, the 
payments portal is endowed with security and encrypting elements validated by 
certifying entities recognized worldwide. Likewise, the service complies with the 
current guidelines regarding protection of personal data in accordance with the 
Federal Law on Transparency and Access to Information.
This does not mean that the portal will be the only means of access to services. 
IMPI will maintain the services payment scheme by means of the use of printed 
formats to cater to users who do not have electronic media and also as a contingency 
in the face of failure of online services.
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b) Archive storage. Due to the fact that IMPFs physical archives grow by the day, 
the construction of a building has been provided for with the necessary facilities 
for their proper handling, control, storage, and conservation.
c) Technological Information Center. Construction has been foreseen for a new 
building for IMPI’s Technological Information Center, whose functions are 
essential for the promotion and dissemination of the information contained in 
patent documents. Currently it has more than 25 million documents that require 
storage, control, reproduction, and consultation. The present installations are 
insufficient. Hence more suitable installations have been provided for.
It is hoped that the points addressed in this document will be useful for under­
standing the relationship between scientific and technological policy and industrial 
property, and consequently, with nations’ competitiveness and economic well-being.
At IMPI we work with the conviction of the importance of the institution and 
industrial property for Mexico’s economic, technological, and industrial develop­
ment, and we are working daily to disseminate and promote the use and integration 
of the industrial property system into the national science and technology policy and 
its linkage to the productive sectors.
Notes
1. Law on Industrial Property, “Amendment o f  26 January 2004.”
2. International Institute o f Management Development.
3. W IPO  Statistics -  PCT Statistical Indicators Report, 2005.
4. Lederman, Maloney and Serven (2005).
5. The National Researchers’ System was created in 1984 to recognize and encourage the work 
o f  persons devoted to producing scientific knowledge and technology. The recognition grants 
the appointment o f  national researcher and corresponding financial incentives.
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G e n e r a l  C o n c l u s i o n s :  T h e  C h a l l e n g e s  
f o r  D e v e l o p m e n t
This book is made up of 11 academically solid chapters, based on relevant empir­
ical sources and on contributions by experts in the field of economic and political 
decision making. By way of conclusion we recall the main findings and recom­
mendations for the developing countries and identify the topics currently under 
discussion regarding countries’ technical and innovation capabilities in relation 
to sustainable economic growth and well-being and the links between forms of 
protection of intellectual property and the promotion of innovation.
Since the late 1980s, the Latin American countries in general and the smallest 
ones in particular have sought actively to enter the world economy’s main tendencies 
by opening up their economies, looking for new trading partners, and attracting 
foreign direct investment.
The rates and strategies for entry are diverse, but the first step taken by all the 
countries was unilateral trade liberalization based on tariff-reduction programs. The 
second step was participation in the multilateral negotiations of the Uruguay Round 
and accession to the General Agreement on Tariffs and Trade (GATT). The third 
step was the negotiation and signing of bilateral and regional trade agreements 
(Martinez-Piva and Padilla, 2007).
All of this has resulted in a new development model whose strategy is to attract 
foreign investment helping to complement investment needs, so that external mar­
kets boost growth through the demand for domestic products and so that the supply 
of new products stimulates production and technology transfer.
The signing of free trade agreements with the United States is a natural step of 
the trade policy adopted by various countries of Latin America, among them those 
of Central America, Chile, Colombia, Dominican Republic Mexico, Panama, and 
Peru. These countries assign a central role to foreign investment and international 
trade in their development model, in which the United States is a very significant 
trading partner and an important source of foreign investment.
Prior to the signing of the free trade agreements, a large part of the Central 
American and Andean exports to the United States benefited from diverse 
preferential-treatment schemes whose unilateral nature gave rise to uncertainty as 
to their renewal (Pacheco and Valerio, 2007). These and other considerations led to 
the negotiation and signing of free trade agreements that eliminate the uncertainty, 
but include strict intellectual property rules.
J.M. Martinez-Piva (ed.), Knowledge Generation and Protection, 
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Despite the dynamic growth of exports in some of the countries of Latin America 
and their diversification toward manufactures -  especially Central America, the 
Caribbean, and Mexico -  including those of high and medium technology, the value 
added of exports continues to be low on account of their considerable dependence 
on imported intermediate inputs. Thus, the growth of exports has been accompanied 
by an increase in imports, particularly in technology-based industries such as elec­
tronics, whose inputs are largely imported. This gap highlights the need to create 
productive links between the manufacturing export industry and the rest of the local 
economy (Martinez-Piva and Padilla, 2007).
The current productive specialization of most of the Latin American countries, 
like the majority of the developing countries, concentrates on links in the global 
value chain that are less knowledge intensive, such as assembly and large-scale 
manufacture. This type of integration, characterized by the temporary importation of 
intermediate goods for their subsequent exportation, is limited as regards the devel­
opment of technological capabilities. This means that in order to raise productivity, 
improve workers’ income and achieve dynamic competitiveness, it is necessary to 
have public policies that promote escalation on the production value chain.
In their contribution, Cimoli and Primi show a parallel between “North-South” 
asymmetry in patenting activities and technological capabilities, and the “North- 
South” asymmetry in technological intensity of production structures and patterns 
of specialization. Although patenting is not the only indicator of countries’ tech­
nological capability, its dynamics reflects the structural differences between them. 
The industrialized countries have production structures that are more specialized in 
activities and sectors that are knowledge and technology intensive, and invest more 
resources in research and development, so it is not surprising that they are leaders 
in the number, diversity, and rate of patents applied for and granted.
If the technological capabilities of the developing countries determine their 
condition on the periphery, their transition toward a position of leadership in the 
international market makes it necessary to emphasize the policies on diffusion and 
access to knowledge, innovation, and creation of technology. Trade policies and 
policies to reinforce intellectual property rights do not in themselves make it pos­
sible to move toward economies capable of escalating on the national production 
value chain.
Free trade has favored a dynamic rate of technological change in the develop­
ing countries, but it is furthered by imports of capital goods with different degrees 
of technological intensity. This has determined that most of the advanced national 
companies undertake little research in the conventional sense, although they take 
pains to imitate and develop adaptive and incremental innovations. In view of their 
dependence on imports of capital goods with incorporated technology and their 
lack of significant advanced scientific and technological infrastructure, it will be 
difficult for developing countries to take the path of innovation without previously 
implementing the appropriate policies.
Mexico signed the North American Free Trade Agreement and created the 
Mexican Industrial Property Institute in 1993. This Institute has made important 
efforts to promote patenting and the use of its stock of information to strengthen
General Conclusions: The Challenges for Development 307
innovation in that country. Paradoxically, the register of Mexican patents dropped 
12%, whereas that of foreign patents doubled between 1995 and 2005, even though 
spending on scientific and technological activities also doubled during the period. 
Spending on research and development in Mexico rose from 0.2 to 0.4% as a per­
centage of GDP, but it continues to be very low in comparison with the United 
States, which invests almost 2.69% of GDP under this heading. The coefficient of 
investment in science and technology in Mexico is five times lower than the OECD 
average.
The rest of Latin America is not doing much better. The countries that invest 
the most in research and development fail to reach 1% of GDP: Brazil (0.99%) and 
Chile (0.57%). The region as a whole registers an average level of around 0.5% of 
GDP, which definitely does not contribute to reducing the technological gap with the 
developed countries: in the United States, for instance, this indicator has remained 
at around 2.5% of GDP for several years (Lugones, 2007).
1 Trips Plus
For the majority of the Latin American countries, the United States is their most 
important trading partner. This country has pushed for trade agreements with mar­
ket access rules and processes that are convenient for its partners, but at the same 
time it has obtained their consent to adopt stricter and more comprehensive intel­
lectual property regulations. This is largely explained by the political economy of 
the United States’ trade negotiations, which are encouraged by powerful interest 
groups that support trade agreements as long as they include the strengthening of 
intellectual property rights. The signing of trade agreements with the United States 
entails the obligation to adopt stricter intellectual property rules than those of TRIPS 
Agreement.
Prior to the free trade agreements recently signed by the United States and the 
European Union with developing countries, the latter assumed that TRIPS was the 
ceiling as regards standards and demands concerning observance of intellectual 
property rights. Nevertheless, most of these agreements, mainly those signed with 
the United States and the European Union, establish stricter standards, which is why 
they have rightly been called TRIPS Plus. The new rules reduce TRIPS’ margins of 
flexibility in patentable subject matter and its corresponding exceptions, compulsory 
licensing, access to medicines by consumers, and access to generic pharmaceuticals 
by companies in developing countries (see Andrés Moncayo’s contribution in this 
volume).
In other areas the demands for protection have also gone beyond the demands 
of TRIPS; such is the case of protection of undisclosed test data relative to agro­
chemicals and pharmaceutical products in latest-generation free trade agreements. 
This poses additional problems, since unless adequate regulation is provided for at 
the national level, the exclusivity of undisclosed test data can make the process of 
approval of pharmaceutical or agrochemical products more costly, and can -  in the
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absence of adequate national regulations -  make it more difficult, if not impossible, 
to grant the compulsory licenses provided for in the TRIPS Agreement.
The concerns voiced by the developing countries refer mainly to the reduction in 
leeway for the exercise of public policies in important areas for economic develop­
ment and social well-being. Many hold the view that the TRIPS Plus requirements 
will prevent countries from recurring to the flexibilities of TRIPS and implementing 
industrial policies with laxer intellectual property rights, as the developed countries 
themselves and newly industrialized countries such as the Republic of Korea and the 
Chinese province of Taiwan utilized to strengthen their technological capabilities 
(see the contribution by Pedro Roffe).
In the face of these inconveniences, new trade negotiations would be expected 
to strike a balance between intellectual property regimes, earnings expectations by 
corporate patent holders and greater access to external markets by the developing 
countries. But even more important than the above-mentioned balance should be 
expectations for expansion and the type of growth hoped for over the long term. In 
this regard, many people are right when they state that the economic success of trade 
agreements lies in the complementary agendas of public-policy combinations that 
help make the most of the opportunities afforded by such agreements.
Public policies must now adjust to the obligations acquired under the new trade 
agreements, but this does not stand in the way of legislating on important issues 
for the Latin American countries and most of the developing countries. Such issues 
are linked to the sectors that have significant weight in the economy: agriculture, 
medicines and health, biological diversity, and the creative industries in general. It 
is equally important not to be limited to a static analysis of traditionally impor­
tant sectors, but to promote new sectors, which will certainly have increasing 
knowledge-intensive components.
In the area of medicines it is very important for the countries to update their intel­
lectual property and health laws, in such a way as to regulate, make transparent, and 
streamline procedures related to consumer rights. In this regard there is a pending 
task regarding use of the Bolar clause, granting of compulsory licenses, regulation 
of parallel imports, and revocation of patents. It is important to bear in mind that 
compulsory licensing, although it is little used, the mere threat of its use can prove 
positive. At the same time, work should be undertaken in prevention of intellectual 
property rights abuses by their holders, in the creation or improvement of competi­
tion regulations and practices and opposition proceedings to the granting of a patent. 
It is no less important to analyze and regulate the possibilities of special clauses in 
order to take measures to protect public health (see contribution by Fabiana Jorge).
Just as health and medicines are matters of public interest, so is agriculture for 
the protection of biodiversity. In Latin America and the Caribbean more than 150 
million people live in the rural milieu and many of them are poor. At the same time, 
rural areas are the depositories of an enormous biodiversity and traditional knowl­
edge. There should therefore be a legal framework and public policies that favor 
the care and sustainable utilization of the region’s biodiversity and recognition and 
protection of traditional know-how and knowledge. This involves addressing issues
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such as the relationship between national laws and international agreements on bio­
diversity, the fight against bio-piracy, and standards for contracts on bio-prospecting 
(see César Morales’ contribution).
National laws should regulate sustainable development and in particular conser­
vation, sustainable use and fair and equitable distribution of the benefits derived 
from the use of their biodiversity, including genetic resources and protection of tra­
ditional knowledge. This opens up leeway to make intellectual property regimes 
compatible with the stipulations of international treaties, such as the Convention on 
Biological Diversity and the FAO International Treaty on Plant Genetic Resources 
for Food and Agriculture. Resources such as disclosure of origin and the design 
of standards for protection of traditional knowledge, among others, should be 
explored and implemented to bring intellectual property rights into line with other 
development objectives (see the contribution by Jorge Cabrera).
In addition to protection of traditional sectors and their major development poten­
tial, it is important to promote new, knowledge-intensive sectors. There is consensus 
in the Latin American region that the main challenge is building economies that are 
more intensive in knowledge, innovation, and learning capacity. In order for the 
strengthening of intellectual property regulations to contribute to and not hinder 
progress in this direction, there is a need for careful implementation and the devel­
opment of a complementary agenda focusing on innovation, diffusion of knowledge, 
competition, and consumer rights.
2 The Importance of Research, Development, and Innovation
The capacity to generate research, create knowledge, and translate it into new tech­
nologies is the basis for the wealth of the most developed nations and goes a long 
way toward explaining their economic growth. Equally important is the capacity to 
appropriate themselves of the rents generated by research and technology, but in 
order to arrive at this state it is necessary to go through previous processes of inno­
vation, considering that rigorous intellectual property rules do not in themselves 
encourage innovation.
The regime of protection of intellectual property rights stimulates the creation of 
production capacities once the industry has developed its own technological capa­
bilities in the highest links in the value chain. Specialization in knowledge-intensive 
sectors favors technical change, increases the absorption capacity of the production 
sector, and demands more knowledge in a typical process of cumulative circular 
causation. It is as of the time when certain technological capabilities have accumu­
lated that the productive system requires a regime of intellectual property rights and 
benefits from it (see contribution by Mario Cimoli and Annalisa Primi).
The experience of the developed countries and more recently that of India, 
China, and Brazil shows that the expansion of research and development activi­
ties preceded the strengthening of intellectual property rights. Many countries, like 
the United States, had for a long time “weak” intellectual property regimes that
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facilitated the absorption of foreign technological knowledge without paying for 
the corresponding licenses. As these countries’ innovation dynamics expanded and 
their investments abroad grew, the tendency toward the strengthening of intellectual 
property rights increased (see the contribution by Álvaro Díaz).
Since a rigorous intellectual property rights regime will not in itself encourage 
research and development and, on the contrary, could even hinder technological 
innovation, in that it could hamper and raise the cost of imitative, adaptive and 
incremental innovation, efforts should concentrate on science and technology public 
policies that counteract such stumbling blocks.
In the intellectual property regimes considered TRIPS Plus, the room for maneu­
ver for implementing science and technology policies has been reduced. Some 
provisions lengthen patents’ years of protection, restrict the use of pharmaceuti­
cal and agrochemical products’ undisclosed test data, prohibit reverse engineering, 
broaden patentable subject-matter, and reduce access to the same for research 
purposes. A new science and technology policy for developing countries should 
maximize the flexibilities of TRIPS and other international agreements.
In short, the future of the Latin American nations that have signed free trade 
agreements with the United States will be defined by the public policies they design 
after ratification of the respective agreements. Such policies will build up their 
economic development.
These policies should design a balanced system of institutions in which at 
the same time as an increase in protection of intellectual property rights, the 
available flexibilities are used, protection of competition and consumer rights are 
strengthened, access to information and knowledge are developed, and science and 
technology policies oriented toward innovation and technological learning are pro­
moted. In his contribution, Álvaro Díaz points out that the developing countries that 
have signed agreements with TRIPS Plus rules face a threefold challenge:
First, implementing intellectual property legislation which complies with the 
provisions of the trade agreements, but which also uses all possible flexibilities 
to achieve a balance between incentives to innovation and facilities for access to 
knowledge and the cultural heritage, which protects human health and provides 
access at reasonable cost to the goods and services protected by intellectual property.
Second, developing a complementary agenda that reinforces public policies and 
enacts laws favorable to innovation, education, competition policy, and consumer 
rights.
Third, considering intellectual property as a field of public policy that requires 
solving coordination faults within governments. Intellectual property rights are not 
the exclusive competence of the agencies in charge of their protection. They should 
also be a matter of concern to ministries of health, innovation, and science and tech­
nology. It is equally important to develop an institutional framework that facilitates 
expression of interests, both for the holders of intellectual property rights and for 
consumers or users of goods protected by such rights. This involves a balanced 
system of public institutions, transparent and legally endorsed.
The processes of trade opening can give rise to a significant expansion of interna­
tional trade and foreign direct investment. In some cases, such as Central America,
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the process led to a change in the export structure, from raw materials to manufac­
tures, mainly in apparel and, in recent years, high technological intensity industries 
such as electronics and medical equipment. However, the indicators for efforts and 
technological results leave much to be desired, which shows that the trade opening, 
although accompanied in some cases by export-promotion and investment-attraction 
programs, has not favored the development of local technological capabilities.
The efforts of the Latin American countries, especially those that have recently 
signed trade agreements with the United States, are weak in science, technology, 
and innovation policies. Overcoming this problem does not occupy an important 
place in most countries’ agenda, and the financial and human resources of existing 
programs are insufficient.
The above shows that the pending domestic tasks are major ones, irrespective 
of whether or not trade rules have strengthened intellectual property standards. The 
basic efforts -  public spending on education, spending on research and develop­
ment, use of licenses, among others -  are insufficient and, as expected, the results -  
number of patents, number of scientific publications, economic internationalisation 
pattern, etc. -  are poor.
Due to the trade strategy of many Latin American countries, it is very important 
to establish a positive relationship between international trade, foreign direct invest­
ment, and technological change. The trade strategy under way is an opportunity 
to encourage technological learning by means of activities related to exportation 
and importation and with interaction with foreign subsidiaries. For this to happen 
the countries have to be capable of absorbing the new technologies, which in turn 
demands specific technological capabilities of acquisition and use of the technolog­
ical knowledge thus transferred. The capacity to absorb technology is developed in 
long processes of human capital formation, investments in process and product inno­
vation, and linkage to external sources of technology (Martinez-Piva and Padilla, 
2007). This opens up a wide field for countries’ public policies, not for policies 
directly related to intellectual property, but for the creation of capacities that will 
subsequently demand intellectual property rights.
Finally, in industrial policy there are also spaces that the countries can occupy. 
In many cases, export products and related production processes, even in industrial 
sectors considered of medium and high technology, tend to remain unlinked from 
the development of local technological capabilities. This happens especially in the 
maquiladora industry, where in general such firms participate in parts of the value 
chain that are not knowledge intensive. In the case of high-technology exports, their 
success is not based on a solid domestic industrial and technological structure, but 
on the productive strategies of transnational corporations.
The experience of Ireland, Republic of Korea, Singapore, and others shows that 
orientation toward external markets has the potential of creating virtuous circles of 
development of technological capabilities. In this regard, ECLAC (Martinez-Piva 
and Padilla, 2007) has pointed to three central elements on which public policy can 
focus:
First of all, capital formation at all levels, especially in knowledge-intensive 
activities, such as design and research and development, that is, university and
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postgraduate education. Also, there should be more on-the-job training due to its 
advantage of rapid adaptation to new technologies in accordance with the specific 
knowledge demanded by firms. This is independent of basic education coverage, 
whose insufficiency continues to be enormous in most Latin American countries.
Second, there is a need to develop and strengthen innovation systems, which is a 
complex task. One of the first steps is to strengthen public institutions and organi­
zations in charge of the formulation, implementation, and coordination of science, 
technology and innovation policy. Likewise, resources should be allocated to the 
strengthening and interaction of the other components of the system by increas­
ing research and development activities in universities, research centers, and in the 
private sector itself.
Third, even though it may appear obvious, it is necessary to design and exe­
cute policies related to the trade opening, such as promoting exports with higher 
value added, attracting transnational corporations that offer greater technological 
and economic spillovers, programs to strengthen the capacities of local firms so that 
they supply the transnationals corporations established in the country, and initia­
tives to strengthen links between transnationals corporations, universities, and local 
research centers, among others.
In the relationship between international trade, TRIPS Plus rules and economic 
development, not everything centers on intellectual property. Many actions can be 
undertaken on the sidelines with direct effects on technological and innovation capa­
bilities. The combination and balance of public policy measures that may be taken 
will be determining factors in intensifying a particular development path or in sur­
passing it with economic structures based on knowledge and greater technological 
capacity.
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